HITId,original_text,key_strokes,datetime,summary,copied
38Z7YZ2SB3N12WW16H4JJFMLWAMQIO,"Comparison of Weight-Loss Diets with Different Compositions of Fat, Protein, and Carbohydrates

The possible advantage for weight loss of a diet that emphasizes protein, fat, or carbohydrates has not been established, and there are few studies that extend beyond 1 year.

We randomly assigned 811 overweight adults to one of four diets; the targeted percentages of energy derived from fat, protein, and carbohydrates in the four diets were 20, 15, and 65%; 20, 25, and 55%; 40, 15, and 45%; and 40, 25, and 35%. The diets consisted of similar foods and met guidelines for cardiovascular health. The participants were offered group and individual instructional sessions for 2 years. The primary outcome was the change in body weight after 2 years in two-by-two factorial comparisons of low fat versus high fat and average protein versus high protein and in the comparison of highest and lowest carbohydrate content.

At 6 months, participants assigned to each diet had lost an average of 6 kg, which represented 7% of their initial weight; they began to regain weight after 12 months. By 2 years, weight loss remained similar in those who were assigned to a diet with 15% protein and those assigned to a diet with 25% protein (3.0 and 3.6 kg, respectively); in those assigned to a diet with 20% fat and those assigned to a diet with 40% fat (3.3 kg for both groups); and in those assigned to a diet with 65% carbohydrates and those assigned to a diet with 35% carbohydrates (2.9 and 3.4 kg, respectively) (P) 0.20 for all comparisons). Among the 80% of participants who completed the trial, the average weight loss was 4 kg; 14 to 15% of the participants had a reduction of at least 10% of their initial body weight. Satiety, hunger, satisfaction with the diet, and attendance at group sessions were similar for all diets; attendance was strongly associated with weight loss (0.2 kg per session attended). The diets improved lipid-related risk factors and fasting insulin levels.
",Backspace Delete,"['2023-05-29T22:30:57.844Z', '2023-05-29T22:31:23.058Z', '2023-05-29T22:31:30.693Z', '2023-05-29T22:31:40.132Z', '2023-05-29T22:31:46.134Z', '2023-05-29T22:31:48.042Z']","Because carbs usually provide over half of calories consumed, the main reason for weight loss on the Atkins Diet is lower overall calorie intake from eating less carbs. Some studies suggest that there are other reasons for weight loss with the Atkins Diet. You may shed pounds because your food choices are limited. And you eat less since the extra protein and fat keep you feeling full longer. Both of these effects also contribute to lower overall calorie intake. The Atkins Diet says that its eating plan can prevent or improve serious health conditions, such as metabolic syndrome, diabetes, high blood pressure and heart disease. In fact, almost any diet that helps you shed excess Some very low carb diets also restrict carbs so much that they cause you not to have enough nutrients or fiber. This can cause such health problems as constipation, diarrhea and nausea. Eating carbs that are high fiber, whole grain and high in nutrients can improve the health profile of programs like the Atkins Diet, though eight can reduce or even reverse risk factors for heart disease and diabetes. 

",False
38Z7YZ2SB3N12WW16H4JJFMLWAMQIO,"Comparison of Weight-Loss Diets with Different Compositions of Fat, Protein, and Carbohydrates

The possible advantage for weight loss of a diet that emphasizes protein, fat, or carbohydrates has not been established, and there are few studies that extend beyond 1 year.

We randomly assigned 811 overweight adults to one of four diets; the targeted percentages of energy derived from fat, protein, and carbohydrates in the four diets were 20, 15, and 65%; 20, 25, and 55%; 40, 15, and 45%; and 40, 25, and 35%. The diets consisted of similar foods and met guidelines for cardiovascular health. The participants were offered group and individual instructional sessions for 2 years. The primary outcome was the change in body weight after 2 years in two-by-two factorial comparisons of low fat versus high fat and average protein versus high protein and in the comparison of highest and lowest carbohydrate content.

At 6 months, participants assigned to each diet had lost an average of 6 kg, which represented 7% of their initial weight; they began to regain weight after 12 months. By 2 years, weight loss remained similar in those who were assigned to a diet with 15% protein and those assigned to a diet with 25% protein (3.0 and 3.6 kg, respectively); in those assigned to a diet with 20% fat and those assigned to a diet with 40% fat (3.3 kg for both groups); and in those assigned to a diet with 65% carbohydrates and those assigned to a diet with 35% carbohydrates (2.9 and 3.4 kg, respectively) (P) 0.20 for all comparisons). Among the 80% of participants who completed the trial, the average weight loss was 4 kg; 14 to 15% of the participants had a reduction of at least 10% of their initial body weight. Satiety, hunger, satisfaction with the diet, and attendance at group sessions were similar for all diets; attendance was strongly associated with weight loss (0.2 kg per session attended). The diets improved lipid-related risk factors and fasting insulin levels.
",Control Control Control Control c c Control c c c Control c c c Control v Control v Control c c c c c Control c c c,"['2023-05-29T20:58:29.931Z', '2023-05-29T20:58:30.425Z', '2023-05-29T20:58:30.460Z', '2023-05-29T20:58:30.495Z', '2023-05-29T20:58:30.500Z', '2023-05-29T20:58:30.723Z', '2023-05-29T20:58:51.003Z', '2023-05-29T20:58:51.278Z', '2023-05-29T20:58:51.515Z', '2023-05-29T20:58:51.694Z', '2023-05-29T20:59:46.124Z', '2023-05-29T20:59:46.338Z', '2023-05-29T20:59:46.564Z', '2023-05-29T20:59:46.694Z', '2023-05-29T21:00:15.099Z', '2023-05-29T21:00:15.356Z', '2023-05-29T21:00:24.867Z', '2023-05-29T21:00:25.259Z', '2023-05-29T21:04:54.651Z', '2023-05-29T21:04:55.085Z', '2023-05-29T21:04:55.356Z', '2023-05-29T21:04:55.533Z', '2023-05-29T21:04:55.667Z', '2023-05-29T21:04:55.822Z', '2023-05-29T21:05:40.582Z', '2023-05-29T21:05:40.860Z', '2023-05-29T21:05:41.068Z', '2023-05-29T21:05:41.228Z']","A study was conducted to compare the effectiveness of different weight-loss diets with varying compositions of fat, protein, and carbohydrates. The study involved 811 overweight adults who were randomly assigned to one of four diets. The diets had different percentages of energy derived from fat, protein, and carbohydrates. Participants received group and individual instructional sessions over a period of two years. The primary outcome was the change in body weight after two years. After six months, participants in each diet group lost an average of 6 kg, but weight regain started after 12 months. After two years, the weight loss remained similar across the different diet groups. Satiety, hunger, satisfaction with the diet, and attendance at group sessions were similar for all diets. The diets also improved lipid-related risk factors and fasting insulin levels. Overall, the study found no significant advantage for weight loss among the different diet compositions tested over a two-year period.",True
38Z7YZ2SB3N12WW16H4JJFMLWAMQIO,"Comparison of Weight-Loss Diets with Different Compositions of Fat, Protein, and Carbohydrates

The possible advantage for weight loss of a diet that emphasizes protein, fat, or carbohydrates has not been established, and there are few studies that extend beyond 1 year.

We randomly assigned 811 overweight adults to one of four diets; the targeted percentages of energy derived from fat, protein, and carbohydrates in the four diets were 20, 15, and 65%; 20, 25, and 55%; 40, 15, and 45%; and 40, 25, and 35%. The diets consisted of similar foods and met guidelines for cardiovascular health. The participants were offered group and individual instructional sessions for 2 years. The primary outcome was the change in body weight after 2 years in two-by-two factorial comparisons of low fat versus high fat and average protein versus high protein and in the comparison of highest and lowest carbohydrate content.

At 6 months, participants assigned to each diet had lost an average of 6 kg, which represented 7% of their initial weight; they began to regain weight after 12 months. By 2 years, weight loss remained similar in those who were assigned to a diet with 15% protein and those assigned to a diet with 25% protein (3.0 and 3.6 kg, respectively); in those assigned to a diet with 20% fat and those assigned to a diet with 40% fat (3.3 kg for both groups); and in those assigned to a diet with 65% carbohydrates and those assigned to a diet with 35% carbohydrates (2.9 and 3.4 kg, respectively) (P) 0.20 for all comparisons). Among the 80% of participants who completed the trial, the average weight loss was 4 kg; 14 to 15% of the participants had a reduction of at least 10% of their initial body weight. Satiety, hunger, satisfaction with the diet, and attendance at group sessions were similar for all diets; attendance was strongly associated with weight loss (0.2 kg per session attended). The diets improved lipid-related risk factors and fasting insulin levels.
",ArrowLeft Backspace ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft Alt Backspace Control v,"['2023-05-30T02:49:46.401Z', '2023-05-30T02:49:46.407Z', '2023-05-30T02:49:46.996Z', '2023-05-30T02:49:47.027Z', '2023-05-30T02:49:47.058Z', '2023-05-30T02:49:47.106Z', '2023-05-30T02:49:47.137Z', '2023-05-30T02:49:47.167Z', '2023-05-30T02:49:47.200Z', '2023-05-30T02:49:47.230Z', '2023-05-30T02:49:47.263Z', '2023-05-30T02:49:47.292Z', '2023-05-30T02:49:47.324Z', '2023-05-30T02:49:47.370Z', '2023-05-30T02:49:47.401Z', '2023-05-30T02:49:47.433Z', '2023-05-30T02:49:47.464Z', '2023-05-30T02:49:47.495Z', '2023-05-30T02:49:47.526Z', '2023-05-30T02:49:47.557Z', '2023-05-30T02:49:47.589Z', '2023-05-30T02:49:47.620Z', '2023-05-30T02:49:47.666Z', '2023-05-30T02:49:47.699Z', '2023-05-30T02:49:47.729Z', '2023-05-30T02:49:47.761Z', '2023-05-30T02:49:47.792Z', '2023-05-30T02:49:47.825Z', '2023-05-30T02:49:47.854Z', '2023-05-30T02:49:47.885Z', '2023-05-30T02:49:47.916Z', '2023-05-30T02:49:47.963Z', '2023-05-30T02:49:47.995Z', '2023-05-30T02:49:48.026Z', '2023-05-30T02:49:48.057Z', '2023-05-30T02:49:48.088Z', '2023-05-30T02:49:48.124Z', '2023-05-30T02:49:48.155Z', '2023-05-30T02:49:48.187Z', '2023-05-30T02:49:48.217Z', '2023-05-30T02:49:48.249Z', '2023-05-30T02:49:48.280Z', '2023-05-30T02:49:48.311Z', '2023-05-30T02:49:48.357Z', '2023-05-30T02:49:48.389Z', '2023-05-30T02:49:48.420Z', '2023-05-30T02:49:48.452Z', '2023-05-30T02:49:48.483Z', '2023-05-30T02:49:48.514Z', '2023-05-30T02:49:48.545Z', '2023-05-30T02:49:48.576Z', '2023-05-30T02:49:48.611Z', '2023-05-30T02:49:48.642Z', '2023-05-30T02:49:48.689Z', '2023-05-30T02:49:48.720Z', '2023-05-30T02:49:48.752Z', '2023-05-30T02:49:48.783Z', '2023-05-30T02:49:48.815Z', '2023-05-30T02:49:48.845Z', '2023-05-30T02:49:48.877Z', '2023-05-30T02:49:48.908Z', '2023-05-30T02:49:48.939Z', '2023-05-30T02:49:48.986Z', '2023-05-30T02:49:49.017Z', '2023-05-30T02:49:49.049Z', '2023-05-30T02:49:49.080Z', '2023-05-30T02:49:49.111Z', '2023-05-30T02:49:49.142Z', '2023-05-30T02:49:49.173Z', '2023-05-30T02:49:49.205Z', '2023-05-30T02:49:49.236Z', '2023-05-30T02:49:49.283Z', '2023-05-30T02:49:49.314Z', '2023-05-30T02:49:49.346Z', '2023-05-30T02:49:49.376Z', '2023-05-30T02:49:49.408Z', '2023-05-30T02:49:49.438Z', '2023-05-30T02:49:49.471Z', '2023-05-30T02:49:49.501Z', '2023-05-30T02:49:49.533Z', '2023-05-30T02:49:49.579Z', '2023-05-30T02:49:49.611Z', '2023-05-30T02:49:49.643Z', '2023-05-30T02:49:49.674Z', '2023-05-30T02:49:49.704Z', '2023-05-30T02:49:49.735Z', '2023-05-30T02:49:49.766Z', '2023-05-30T02:49:49.799Z', '2023-05-30T02:49:49.830Z', '2023-05-30T02:49:49.876Z', '2023-05-30T02:49:49.908Z', '2023-05-30T02:49:49.939Z', '2023-05-30T02:49:49.970Z', '2023-05-30T02:49:50.001Z', '2023-05-30T02:49:50.032Z', '2023-05-30T02:49:50.064Z', '2023-05-30T02:49:50.095Z', '2023-05-30T02:49:50.126Z', '2023-05-30T02:49:50.173Z', '2023-05-30T02:49:50.204Z', '2023-05-30T02:49:50.236Z', '2023-05-30T02:49:50.267Z', '2023-05-30T02:49:50.298Z', '2023-05-30T02:49:50.330Z', '2023-05-30T02:49:50.361Z', '2023-05-30T02:49:50.392Z', '2023-05-30T02:49:50.424Z', '2023-05-30T02:49:50.470Z', '2023-05-30T02:49:50.501Z', '2023-05-30T02:49:50.533Z', '2023-05-30T02:49:50.564Z', '2023-05-30T02:49:50.595Z', '2023-05-30T02:49:50.627Z', '2023-05-30T02:49:50.658Z', '2023-05-30T02:49:50.689Z', '2023-05-30T02:49:50.720Z', '2023-05-30T02:49:50.767Z', '2023-05-30T02:49:50.799Z', '2023-05-30T02:49:50.830Z', '2023-05-30T02:49:50.860Z', '2023-05-30T02:49:50.892Z', '2023-05-30T02:49:50.923Z', '2023-05-30T02:49:50.954Z', '2023-05-30T02:49:50.985Z', '2023-05-30T02:49:51.032Z', '2023-05-30T02:49:51.063Z', '2023-05-30T02:49:51.095Z', '2023-05-30T02:49:51.126Z', '2023-05-30T02:49:51.157Z', '2023-05-30T02:49:51.188Z', '2023-05-30T02:49:51.220Z', '2023-05-30T02:49:51.251Z', '2023-05-30T02:49:51.282Z', '2023-05-30T02:49:51.329Z', '2023-05-30T02:49:51.363Z', '2023-05-30T02:49:51.394Z', '2023-05-30T02:49:51.428Z', '2023-05-30T02:49:51.460Z', '2023-05-30T02:49:51.491Z', '2023-05-30T02:49:51.522Z', '2023-05-30T02:49:51.553Z', '2023-05-30T02:49:51.578Z', '2023-05-30T02:49:51.625Z', '2023-05-30T02:49:51.657Z', '2023-05-30T02:49:51.688Z', '2023-05-30T02:49:51.720Z', '2023-05-30T02:49:51.751Z', '2023-05-30T02:49:51.782Z', '2023-05-30T02:49:51.809Z', '2023-05-30T02:49:51.856Z', '2023-05-30T02:49:51.887Z', '2023-05-30T02:49:51.919Z', '2023-05-30T02:49:51.950Z', '2023-05-30T02:49:51.981Z', '2023-05-30T02:49:52.012Z', '2023-05-30T02:49:52.044Z', '2023-05-30T02:49:52.088Z', '2023-05-30T02:49:52.119Z', '2023-05-30T02:49:52.150Z', '2023-05-30T02:49:52.181Z', '2023-05-30T02:49:52.213Z', '2023-05-30T02:49:52.244Z', '2023-05-30T02:49:52.275Z', '2023-05-30T02:49:52.317Z', '2023-05-30T02:49:52.349Z', '2023-05-30T02:49:52.380Z', '2023-05-30T02:49:52.411Z', '2023-05-30T02:49:52.444Z', '2023-05-30T02:49:52.475Z', '2023-05-30T02:49:52.506Z', '2023-05-30T02:49:52.537Z', '2023-05-30T02:49:52.579Z', '2023-05-30T02:49:52.611Z', '2023-05-30T02:49:52.644Z', '2023-05-30T02:49:52.667Z', '2023-05-30T02:49:52.715Z', '2023-05-30T02:49:52.748Z', '2023-05-30T02:49:52.779Z', '2023-05-30T02:49:52.811Z', '2023-05-30T02:49:52.841Z', '2023-05-30T02:49:52.874Z', '2023-05-30T02:49:52.897Z', '2023-05-30T02:49:52.944Z', '2023-05-30T02:49:52.976Z', '2023-05-30T02:49:53.007Z', '2023-05-30T02:49:53.038Z', '2023-05-30T02:49:53.069Z', '2023-05-30T02:49:53.101Z', '2023-05-30T02:49:53.132Z', '2023-05-30T02:49:53.173Z', '2023-05-30T02:49:53.209Z', '2023-05-30T02:49:53.240Z', '2023-05-30T02:49:53.271Z', '2023-05-30T02:49:53.304Z', '2023-05-30T02:49:53.334Z', '2023-05-30T02:49:53.366Z', '2023-05-30T02:49:53.397Z', '2023-05-30T02:49:53.428Z', '2023-05-30T02:49:53.468Z', '2023-05-30T02:49:53.500Z', '2023-05-30T02:49:53.531Z', '2023-05-30T02:49:53.562Z', '2023-05-30T02:49:53.593Z', '2023-05-30T02:49:53.624Z', '2023-05-30T02:49:53.671Z', '2023-05-30T02:49:53.704Z', '2023-05-30T02:49:53.735Z', '2023-05-30T02:49:53.766Z', '2023-05-30T02:49:53.797Z', '2023-05-30T02:49:53.831Z', '2023-05-30T02:49:53.863Z', '2023-05-30T02:49:53.894Z', '2023-05-30T02:49:53.924Z', '2023-05-30T02:49:53.956Z', '2023-05-30T02:49:53.987Z', '2023-05-30T02:49:54.034Z', '2023-05-30T02:49:54.066Z', '2023-05-30T02:49:54.097Z', '2023-05-30T02:49:54.128Z', '2023-05-30T02:49:54.160Z', '2023-05-30T02:49:54.190Z', '2023-05-30T02:49:54.237Z', '2023-05-30T02:49:54.253Z', '2023-05-30T02:49:54.300Z', '2023-05-30T02:49:54.330Z', '2023-05-30T02:49:54.365Z', '2023-05-30T02:49:54.398Z', '2023-05-30T02:49:54.430Z', '2023-05-30T02:49:54.461Z', '2023-05-30T02:49:54.492Z', '2023-05-30T02:49:54.523Z', '2023-05-30T02:49:54.555Z', '2023-05-30T02:49:54.588Z', '2023-05-30T02:49:54.619Z', '2023-05-30T02:49:54.651Z', '2023-05-30T02:49:54.682Z', '2023-05-30T02:49:54.713Z', '2023-05-30T02:49:54.761Z', '2023-05-30T02:49:54.791Z', '2023-05-30T02:49:54.828Z', '2023-05-30T02:49:54.859Z', '2023-05-30T02:49:54.890Z', '2023-05-30T02:49:54.922Z', '2023-05-30T02:49:54.953Z', '2023-05-30T02:49:54.984Z', '2023-05-30T02:49:55.015Z', '2023-05-30T02:49:55.047Z', '2023-05-30T02:49:55.079Z', '2023-05-30T02:49:55.110Z', '2023-05-30T02:49:55.157Z', '2023-05-30T02:49:55.187Z', '2023-05-30T02:49:55.219Z', '2023-05-30T02:49:55.252Z', '2023-05-30T02:49:55.282Z', '2023-05-30T02:49:55.314Z', '2023-05-30T02:49:55.345Z', '2023-05-30T02:49:55.375Z', '2023-05-30T02:49:55.407Z', '2023-05-30T02:49:55.455Z', '2023-05-30T02:49:55.485Z', '2023-05-30T02:49:55.516Z', '2023-05-30T02:49:55.547Z', '2023-05-30T02:49:55.579Z', '2023-05-30T02:49:55.610Z', '2023-05-30T02:49:55.643Z', '2023-05-30T02:49:55.674Z', '2023-05-30T02:49:55.705Z', '2023-05-30T02:49:55.737Z', '2023-05-30T02:49:55.783Z', '2023-05-30T02:49:55.815Z', '2023-05-30T02:49:55.847Z', '2023-05-30T02:49:55.877Z', '2023-05-30T02:49:55.909Z', '2023-05-30T02:49:55.940Z', '2023-05-30T02:49:55.971Z', '2023-05-30T02:49:56.002Z', '2023-05-30T02:49:56.034Z', '2023-05-30T02:49:56.081Z', '2023-05-30T02:49:56.112Z', '2023-05-30T02:49:56.143Z', '2023-05-30T02:49:56.174Z', '2023-05-30T02:49:56.206Z', '2023-05-30T02:49:56.237Z', '2023-05-30T02:49:56.268Z', '2023-05-30T02:49:56.299Z', '2023-05-30T02:49:56.331Z', '2023-05-30T02:49:56.378Z', '2023-05-30T02:49:56.409Z', '2023-05-30T02:49:56.439Z', '2023-05-30T02:49:56.472Z', '2023-05-30T02:49:56.502Z', '2023-05-30T02:49:56.534Z', '2023-05-30T02:49:56.564Z', '2023-05-30T02:49:56.597Z', '2023-05-30T02:49:56.630Z', '2023-05-30T02:49:56.661Z', '2023-05-30T02:49:56.699Z', '2023-05-30T02:49:56.731Z', '2023-05-30T02:49:56.762Z', '2023-05-30T02:49:56.793Z', '2023-05-30T02:49:56.835Z', '2023-05-30T02:49:56.867Z', '2023-05-30T02:49:56.898Z', '2023-05-30T02:49:56.933Z', '2023-05-30T02:49:56.964Z', '2023-05-30T02:49:56.995Z', '2023-05-30T02:49:57.026Z', '2023-05-30T02:49:57.058Z', '2023-05-30T02:49:57.104Z', '2023-05-30T02:49:57.136Z', '2023-05-30T02:49:57.155Z', '2023-05-30T02:49:57.194Z', '2023-05-30T02:49:57.225Z', '2023-05-30T02:49:57.256Z', '2023-05-30T02:49:57.287Z', '2023-05-30T02:49:57.334Z', '2023-05-30T02:49:57.365Z', '2023-05-30T02:49:57.397Z', '2023-05-30T02:49:57.428Z', '2023-05-30T02:49:57.458Z', '2023-05-30T02:49:57.491Z', '2023-05-30T02:49:57.522Z', '2023-05-30T02:49:57.553Z', '2023-05-30T02:49:57.600Z', '2023-05-30T02:49:57.630Z', '2023-05-30T02:49:57.663Z', '2023-05-30T02:49:57.694Z', '2023-05-30T02:49:57.725Z', '2023-05-30T02:49:57.756Z', '2023-05-30T02:49:57.787Z', '2023-05-30T02:49:57.829Z', '2023-05-30T02:49:57.860Z', '2023-05-30T02:49:57.892Z', '2023-05-30T02:49:57.923Z', '2023-05-30T02:49:57.954Z', '2023-05-30T02:49:57.985Z', '2023-05-30T02:49:58.017Z', '2023-05-30T02:49:58.048Z', '2023-05-30T02:49:58.079Z', '2023-05-30T02:49:58.126Z', '2023-05-30T02:49:58.157Z', '2023-05-30T02:49:58.188Z', '2023-05-30T02:49:58.220Z', '2023-05-30T02:49:58.251Z', '2023-05-30T02:49:58.282Z', '2023-05-30T02:49:58.314Z', '2023-05-30T02:49:58.345Z', '2023-05-30T02:49:58.392Z', '2023-05-30T02:49:58.423Z', '2023-05-30T02:49:58.455Z', '2023-05-30T02:49:58.486Z', '2023-05-30T02:49:58.517Z', '2023-05-30T02:49:58.550Z', '2023-05-30T02:49:58.581Z', '2023-05-30T02:49:58.612Z', '2023-05-30T02:49:58.643Z', '2023-05-30T02:49:58.691Z', '2023-05-30T02:49:58.721Z', '2023-05-30T02:49:58.754Z', '2023-05-30T02:49:58.784Z', '2023-05-30T02:49:58.816Z', '2023-05-30T02:49:58.846Z', '2023-05-30T02:49:58.879Z', '2023-05-30T02:49:58.908Z', '2023-05-30T02:49:58.940Z', '2023-05-30T02:49:58.986Z', '2023-05-30T02:49:59.017Z', '2023-05-30T02:49:59.049Z', '2023-05-30T02:49:59.080Z', '2023-05-30T02:49:59.112Z', '2023-05-30T02:49:59.142Z', '2023-05-30T02:49:59.173Z', '2023-05-30T02:49:59.205Z', '2023-05-30T02:49:59.238Z', '2023-05-30T02:49:59.283Z', '2023-05-30T02:49:59.315Z', '2023-05-30T02:49:59.346Z', '2023-05-30T02:49:59.378Z', '2023-05-30T02:49:59.408Z', '2023-05-30T02:49:59.441Z', '2023-05-30T02:49:59.471Z', '2023-05-30T02:49:59.504Z', '2023-05-30T02:49:59.534Z', '2023-05-30T02:49:59.580Z', '2023-05-30T02:49:59.611Z', '2023-05-30T02:49:59.643Z', '2023-05-30T02:49:59.674Z', '2023-05-30T02:49:59.705Z', '2023-05-30T02:49:59.737Z', '2023-05-30T02:49:59.767Z', '2023-05-30T02:49:59.797Z', '2023-05-30T02:49:59.837Z', '2023-05-30T02:49:59.868Z', '2023-05-30T02:49:59.900Z', '2023-05-30T02:49:59.931Z', '2023-05-30T02:49:59.962Z', '2023-05-30T02:49:59.993Z', '2023-05-30T02:50:00.040Z', '2023-05-30T02:50:00.074Z', '2023-05-30T02:50:00.104Z', '2023-05-30T02:50:00.136Z', '2023-05-30T02:50:00.166Z', '2023-05-30T02:50:00.198Z', '2023-05-30T02:50:00.228Z', '2023-05-30T02:50:00.260Z', '2023-05-30T02:50:00.291Z', '2023-05-30T02:50:00.339Z', '2023-05-30T02:50:00.370Z', '2023-05-30T02:50:00.401Z', '2023-05-30T02:50:00.432Z', '2023-05-30T02:50:00.463Z', '2023-05-30T02:50:00.496Z', '2023-05-30T02:50:00.526Z', '2023-05-30T02:50:00.557Z', '2023-05-30T02:50:00.588Z', '2023-05-30T02:50:00.636Z', '2023-05-30T02:50:00.666Z', '2023-05-30T02:50:00.699Z', '2023-05-30T02:50:00.729Z', '2023-05-30T02:50:00.761Z', '2023-05-30T02:50:00.791Z', '2023-05-30T02:50:00.823Z', '2023-05-30T02:50:00.853Z', '2023-05-30T02:50:00.899Z', '2023-05-30T02:50:00.932Z', '2023-05-30T02:50:00.962Z', '2023-05-30T02:50:00.994Z', '2023-05-30T02:50:01.026Z', '2023-05-30T02:50:01.056Z', '2023-05-30T02:50:01.088Z', '2023-05-30T02:50:01.121Z', '2023-05-30T02:50:01.150Z', '2023-05-30T02:50:01.198Z', '2023-05-30T02:50:01.228Z', '2023-05-30T02:50:01.262Z', '2023-05-30T02:50:01.290Z', '2023-05-30T02:50:01.324Z', '2023-05-30T02:50:01.354Z', '2023-05-30T02:50:01.386Z', '2023-05-30T02:50:01.416Z', '2023-05-30T02:50:01.448Z', '2023-05-30T02:50:01.495Z', '2023-05-30T02:50:01.525Z', '2023-05-30T02:50:01.557Z', '2023-05-30T02:50:01.588Z', '2023-05-30T02:50:01.620Z', '2023-05-30T02:50:01.650Z', '2023-05-30T02:50:01.681Z', '2023-05-30T02:50:01.713Z', '2023-05-30T02:50:01.744Z', '2023-05-30T02:50:01.791Z', '2023-05-30T02:50:01.822Z', '2023-05-30T02:50:01.844Z', '2023-05-30T02:50:07.580Z', '2023-05-30T02:50:08.853Z', '2023-05-30T02:50:09.133Z']","This two-year study found that diets varying in terms of fat, protein, and carbohydrates composition had similar effectiveness for weight-loss and improvement of cardiovascular health factors. 811 overweight adults participated in the study and were assigned to one of four diets containing different proportions of fat, protein, and carbohydrates.",True
3SBX2M1TKD87UPXMLS2FPEC2RSM4QO,"Effect of Screening Mammography on Breast-Cancer Mortality in Norway

A challenge in quantifying the effect of screening mammography on breast-cancer mortality is to provide valid comparison groups. The use of historical control subjects does not take into account chronologic trends associated with advances in breast-cancer awareness and treatment.

The Norwegian breast-cancer screening program was started in 1996 and expanded geographically during the subsequent 9 years. Women between the ages of 50 and 69 years were offered screening mammography every 2 years. We compared the incidence-based rates of death from breast cancer in four groups; two groups of women who from 1996 through 2005 were living in counties with screening (screening group) or without screening (nonscreening group); and two historical-comparison groups that from 1986 through 1995 mirrored the current groups.

We analyzed data from 40,075 women with breast cancer. The rate of death was reduced by 7.2 deaths per 100,000 person-years in the screening group as compared with the historical screening group (rate ratio, 0.72; 95% confidence interval (CI), 0.63 to 0.81) and by 4.8 deaths per 100,000 person-years in the nonscreening group as compared with the historical nonscreening group (rate ratio, 0.82; 95% CI, 0.71 to 0.93; P (0.001 for both comparisons), for a relative reduction in mortality of 10% in the screening group (P = 0.13). Thus, the difference in the reduction in mortality between the current and historical groups that could be attributed to screening alone was 2.4 deaths per 100,000 person-years, or a third of the total reduction of 7.2 deaths.

The availability of screening mammography was associated with a reduction in the rate of death from breast cancer, but the screening itself accounted for only about a third of the total reduction.
",Control c Control v Control a Delete Control v Control c Control c Control c Control c,"['2023-05-29T20:23:32.104Z', '2023-05-29T20:23:32.395Z', '2023-05-29T20:30:54.669Z', '2023-05-29T20:30:55.004Z', '2023-05-29T20:35:13.568Z', '2023-05-29T20:35:13.819Z', '2023-05-29T20:35:15.098Z', '2023-05-29T20:35:16.216Z', '2023-05-29T20:35:16.618Z', '2023-05-29T20:35:49.715Z', '2023-05-29T20:35:52.354Z', '2023-05-29T20:36:33.345Z', '2023-05-29T20:36:33.602Z', '2023-05-29T20:36:56.801Z', '2023-05-29T20:36:57.092Z', '2023-05-29T20:38:11.746Z', '2023-05-29T20:38:12.025Z', '2023-05-29T20:39:12.130Z', '2023-05-29T20:39:12.379Z']","Effect of Screening Mammography on Breast-Cancer Mortality in Norway

A challenge in quantifying the effect of screening mammography on breast-cancer mortality is to provide valid comparison groups. two groups of women who from 1996 through 2005 were living in counties with screening (screening group) or without screening (non screening group); The rate of death was reduced by 7.2 deaths per 100,000 person-years in the screening group as compared with the historical screening group (rate ratio, 0.72; 95% confidence interval (CI), 0.63 to 0.81) and by 4.8 deaths per 100,000 person-years in the non screening group as compared with the historical non screening group (rate ratio, 0.82; Thus, the difference in the reduction in mortality between the current and historical groups that could be attributed to screening alone was 2.4 deaths per 100,000 person-years, or a third of the total reduction of 7.2 deaths.

The availability of screening mammography was associated with a reduction in the rate of death from breast cancer, but the screening itself accounted for only about a third of the total reduction.",True
3SBX2M1TKD87UPXMLS2FPEC2RSM4QO,"Effect of Screening Mammography on Breast-Cancer Mortality in Norway

A challenge in quantifying the effect of screening mammography on breast-cancer mortality is to provide valid comparison groups. The use of historical control subjects does not take into account chronologic trends associated with advances in breast-cancer awareness and treatment.

The Norwegian breast-cancer screening program was started in 1996 and expanded geographically during the subsequent 9 years. Women between the ages of 50 and 69 years were offered screening mammography every 2 years. We compared the incidence-based rates of death from breast cancer in four groups; two groups of women who from 1996 through 2005 were living in counties with screening (screening group) or without screening (nonscreening group); and two historical-comparison groups that from 1986 through 1995 mirrored the current groups.

We analyzed data from 40,075 women with breast cancer. The rate of death was reduced by 7.2 deaths per 100,000 person-years in the screening group as compared with the historical screening group (rate ratio, 0.72; 95% confidence interval (CI), 0.63 to 0.81) and by 4.8 deaths per 100,000 person-years in the nonscreening group as compared with the historical nonscreening group (rate ratio, 0.82; 95% CI, 0.71 to 0.93; P (0.001 for both comparisons), for a relative reduction in mortality of 10% in the screening group (P = 0.13). Thus, the difference in the reduction in mortality between the current and historical groups that could be attributed to screening alone was 2.4 deaths per 100,000 person-years, or a third of the total reduction of 7.2 deaths.

The availability of screening mammography was associated with a reduction in the rate of death from breast cancer, but the screening itself accounted for only about a third of the total reduction.
","CapsLock A CapsLock s t u d y i n CapsLock N CapsLock o r w a y f o u n d t h a t s c r e e n i n g m a m m o g r a p h y w a s a a Backspace s s o c i a t e Backspace d w i t h a r e d u c t i o n i n t h e r a t e o f d e a t h f r e o b r e a s t Backspace m c a n c e r . CapsLock T CapsLock h e s t u d y f o u n d t h a t t h e a v a i l a v i l i t y o f s c r e e n i n g m a m m o g r a p h y w a s a s s o c i a t e Backspace d w i t h a 1 0 Shift Shift Shift Shift Shift Shift Shift Shift Shift % r e d u c t i o n i n m p o Backspace Backspace o r t a i l i t y Backspace Backspace f r o m b r e a s t c e n c e r Backspace a . Backspace Shift T Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Enter Shift H o w e v e r Backspace , t h e s t u d y a l s o f o u n d t h g Backspace e s c r e e n i n g i t s e l f o n l y s Backspace a c c o u n t e d f o r a b o u t a t h i r d o f t h e t o t a l r e d u c t i o n i n m o r t a i l y Backspace i t .","['2023-05-29T18:40:24.249Z', '2023-05-29T18:40:24.518Z', '2023-05-29T18:40:24.831Z', '2023-05-29T18:40:25.125Z', '2023-05-29T18:40:25.518Z', '2023-05-29T18:40:25.894Z', '2023-05-29T18:40:26.174Z', '2023-05-29T18:40:26.429Z', '2023-05-29T18:40:26.830Z', '2023-05-29T18:40:27.126Z', '2023-05-29T18:40:27.606Z', '2023-05-29T18:40:27.902Z', '2023-05-29T18:40:28.118Z', '2023-05-29T18:40:29.183Z', '2023-05-29T18:40:29.486Z', '2023-05-29T18:40:29.735Z', '2023-05-29T18:40:30.030Z', '2023-05-29T18:40:35.789Z', '2023-05-29T18:40:36.182Z', '2023-05-29T18:40:36.376Z', '2023-05-29T18:40:36.797Z', '2023-05-29T18:40:37.102Z', '2023-05-29T18:40:42.389Z', '2023-05-29T18:40:42.862Z', '2023-05-29T18:40:43.221Z', '2023-05-29T18:40:43.782Z', '2023-05-29T18:40:44.206Z', '2023-05-29T18:40:44.461Z', '2023-05-29T18:40:44.742Z', '2023-05-29T18:40:44.965Z', '2023-05-29T18:40:45.221Z', '2023-05-29T18:40:45.645Z', '2023-05-29T18:40:45.958Z', '2023-05-29T18:40:53.537Z', '2023-05-29T18:40:53.776Z', '2023-05-29T18:40:54.047Z', '2023-05-29T18:40:54.335Z', '2023-05-29T18:40:54.495Z', '2023-05-29T18:40:54.984Z', '2023-05-29T18:40:55.767Z', '2023-05-29T18:40:56.167Z', '2023-05-29T18:40:56.455Z', '2023-05-29T18:40:56.752Z', '2023-05-29T18:41:08.120Z', '2023-05-29T18:41:08.423Z', '2023-05-29T18:41:08.751Z', '2023-05-29T18:41:08.919Z', '2023-05-29T18:41:09.255Z', '2023-05-29T18:41:10.031Z', '2023-05-29T18:41:10.616Z', '2023-05-29T18:41:10.942Z', '2023-05-29T18:41:11.655Z', '2023-05-29T18:41:12.047Z', '2023-05-29T18:41:12.294Z', '2023-05-29T18:41:12.625Z', '2023-05-29T18:41:20.728Z', '2023-05-29T18:41:20.951Z', '2023-05-29T18:41:21.190Z', '2023-05-29T18:41:21.422Z', '2023-05-29T18:41:21.702Z', '2023-05-29T18:41:21.911Z', '2023-05-29T18:41:23.041Z', '2023-05-29T18:41:23.647Z', '2023-05-29T18:41:23.863Z', '2023-05-29T18:41:24.383Z', '2023-05-29T18:41:24.807Z', '2023-05-29T18:41:25.166Z', '2023-05-29T18:41:25.406Z', '2023-05-29T18:41:25.623Z', '2023-05-29T18:41:25.918Z', '2023-05-29T18:41:26.113Z', '2023-05-29T18:41:32.759Z', '2023-05-29T18:41:33.230Z', '2023-05-29T18:41:34.534Z', '2023-05-29T18:41:46.662Z', '2023-05-29T18:41:47.157Z', '2023-05-29T18:41:47.533Z', '2023-05-29T18:41:47.950Z', '2023-05-29T18:41:48.214Z', '2023-05-29T18:41:48.437Z', '2023-05-29T18:41:48.694Z', '2023-05-29T18:41:54.120Z', '2023-05-29T18:41:54.319Z', '2023-05-29T18:41:54.664Z', '2023-05-29T18:41:54.912Z', '2023-05-29T18:41:55.560Z', '2023-05-29T18:41:55.856Z', '2023-05-29T18:41:56.327Z', '2023-05-29T18:41:56.544Z', '2023-05-29T18:41:56.857Z', '2023-05-29T18:41:57.088Z', '2023-05-29T18:42:03.271Z', '2023-05-29T18:42:03.823Z', '2023-05-29T18:42:04.040Z', '2023-05-29T18:42:04.343Z', '2023-05-29T18:42:04.600Z', '2023-05-29T18:42:04.953Z', '2023-05-29T18:42:05.176Z', '2023-05-29T18:42:05.712Z', '2023-05-29T18:42:05.927Z', '2023-05-29T18:42:06.176Z', '2023-05-29T18:42:06.407Z', '2023-05-29T18:42:06.583Z', '2023-05-29T18:42:06.975Z', '2023-05-29T18:42:07.663Z', '2023-05-29T18:42:07.911Z', '2023-05-29T18:42:08.231Z', '2023-05-29T18:42:08.439Z', '2023-05-29T18:42:08.664Z', '2023-05-29T18:42:09.033Z', '2023-05-29T18:42:09.312Z', '2023-05-29T18:42:09.663Z', '2023-05-29T18:42:16.646Z', '2023-05-29T18:42:16.863Z', '2023-05-29T18:42:17.055Z', '2023-05-29T18:42:17.347Z', '2023-05-29T18:42:17.622Z', '2023-05-29T18:42:18.263Z', '2023-05-29T18:42:18.587Z', '2023-05-29T18:42:18.815Z', '2023-05-29T18:42:19.189Z', '2023-05-29T18:42:19.432Z', '2023-05-29T18:42:19.731Z', '2023-05-29T18:42:20.037Z', '2023-05-29T18:42:24.238Z', '2023-05-29T18:42:27.630Z', '2023-05-29T18:42:32.807Z', '2023-05-29T18:42:33.062Z', '2023-05-29T18:42:33.494Z', '2023-05-29T18:42:34.047Z', '2023-05-29T18:42:34.270Z', '2023-05-29T18:42:34.456Z', '2023-05-29T18:42:35.366Z', '2023-05-29T18:42:48.590Z', '2023-05-29T18:43:26.217Z', '2023-05-29T18:43:26.824Z', '2023-05-29T18:43:27.497Z', '2023-05-29T18:43:27.874Z', '2023-05-29T18:43:28.504Z', '2023-05-29T18:43:28.857Z', '2023-05-29T18:43:30.376Z', '2023-05-29T18:43:30.904Z', '2023-05-29T18:43:31.264Z', '2023-05-29T18:43:31.696Z', '2023-05-29T18:43:32.664Z', '2023-05-29T18:43:32.984Z', '2023-05-29T18:43:33.487Z', '2023-05-29T18:43:33.888Z', '2023-05-29T18:43:34.159Z', '2023-05-29T18:43:34.696Z', '2023-05-29T18:43:35.056Z', '2023-05-29T18:43:35.377Z', '2023-05-29T18:43:43.464Z', '2023-05-29T18:43:44.402Z', '2023-05-29T18:43:44.664Z', '2023-05-29T18:43:44.999Z', '2023-05-29T18:43:45.295Z', '2023-05-29T18:43:45.647Z', '2023-05-29T18:43:45.895Z', '2023-05-29T18:43:46.120Z', '2023-05-29T18:43:46.383Z', '2023-05-29T18:43:55.431Z', '2023-05-29T18:43:55.815Z', '2023-05-29T18:43:56.712Z', '2023-05-29T18:43:56.960Z', '2023-05-29T18:43:57.311Z', '2023-05-29T18:43:57.535Z', '2023-05-29T18:43:57.936Z', '2023-05-29T18:43:58.322Z', '2023-05-29T18:43:58.627Z', '2023-05-29T18:43:58.866Z', '2023-05-29T18:43:59.233Z', '2023-05-29T18:43:59.761Z', '2023-05-29T18:44:00.106Z', '2023-05-29T18:44:16.017Z', '2023-05-29T18:44:16.465Z', '2023-05-29T18:44:17.001Z', '2023-05-29T18:44:17.288Z', '2023-05-29T18:44:18.352Z', '2023-05-29T18:44:18.833Z', '2023-05-29T18:44:24.505Z', '2023-05-29T18:44:24.880Z', '2023-05-29T18:44:25.080Z', '2023-05-29T18:44:28.017Z', '2023-05-29T18:44:28.320Z', '2023-05-29T18:44:28.616Z', '2023-05-29T18:44:28.880Z', '2023-05-29T18:44:29.168Z', '2023-05-29T18:44:39.024Z', '2023-05-29T18:44:39.336Z', '2023-05-29T18:44:39.760Z', '2023-05-29T18:44:40.377Z', '2023-05-29T18:44:41.240Z', '2023-05-29T18:44:41.721Z', '2023-05-29T18:44:42.048Z', '2023-05-29T18:44:42.313Z', '2023-05-29T18:44:42.816Z', '2023-05-29T18:44:43.248Z', '2023-05-29T18:44:43.496Z', '2023-05-29T18:44:43.807Z', '2023-05-29T18:44:48.527Z', '2023-05-29T18:44:48.704Z', '2023-05-29T18:44:48.895Z', '2023-05-29T18:44:49.225Z', '2023-05-29T18:44:49.592Z', '2023-05-29T18:44:51.616Z', '2023-05-29T18:44:51.800Z', '2023-05-29T18:44:52.687Z', '2023-05-29T18:44:53.145Z', '2023-05-29T18:44:53.480Z', '2023-05-29T18:44:53.736Z', '2023-05-29T18:44:54.225Z', '2023-05-29T18:44:54.480Z', '2023-05-29T18:44:54.713Z', '2023-05-29T18:45:21.129Z', '2023-05-29T18:45:23.033Z', '2023-05-29T18:45:23.850Z', '2023-05-29T18:45:24.673Z', '2023-05-29T18:45:25.178Z', '2023-05-29T18:45:25.576Z', '2023-05-29T18:45:25.873Z', '2023-05-29T18:45:26.145Z', '2023-05-29T18:45:26.417Z', '2023-05-29T18:45:26.650Z', '2023-05-29T18:45:27.049Z', '2023-05-29T18:45:27.409Z', '2023-05-29T18:45:33.705Z', '2023-05-29T18:45:34.211Z', '2023-05-29T18:45:34.244Z', '2023-05-29T18:45:34.274Z', '2023-05-29T18:45:34.306Z', '2023-05-29T18:45:34.337Z', '2023-05-29T18:45:34.369Z', '2023-05-29T18:45:34.402Z', '2023-05-29T18:45:34.431Z', '2023-05-29T18:45:34.456Z', '2023-05-29T18:45:38.537Z', '2023-05-29T18:45:39.880Z', '2023-05-29T18:45:40.089Z', '2023-05-29T18:45:40.400Z', '2023-05-29T18:45:40.841Z', '2023-05-29T18:45:41.232Z', '2023-05-29T18:45:41.545Z', '2023-05-29T18:45:41.993Z', '2023-05-29T18:45:42.209Z', '2023-05-29T18:45:42.793Z', '2023-05-29T18:45:43.016Z', '2023-05-29T18:45:49.809Z', '2023-05-29T18:45:50.105Z', '2023-05-29T18:45:50.321Z', '2023-05-29T18:45:50.536Z', '2023-05-29T18:45:50.793Z', '2023-05-29T18:45:50.803Z', '2023-05-29T18:45:52.902Z', '2023-05-29T18:45:53.552Z', '2023-05-29T18:45:54.320Z', '2023-05-29T18:45:54.936Z', '2023-05-29T18:45:55.193Z', '2023-05-29T18:45:55.513Z', '2023-05-29T18:45:56.097Z', '2023-05-29T18:45:56.392Z', '2023-05-29T18:45:56.626Z', '2023-05-29T18:45:57.001Z', '2023-05-29T18:45:57.209Z', '2023-05-29T18:45:57.512Z', '2023-05-29T18:46:06.737Z', '2023-05-29T18:46:13.610Z', '2023-05-29T18:46:15.514Z', '2023-05-29T18:46:15.729Z', '2023-05-29T18:46:16.194Z', '2023-05-29T18:46:16.602Z', '2023-05-29T18:46:16.825Z', '2023-05-29T18:46:17.219Z', '2023-05-29T18:46:17.602Z', '2023-05-29T18:46:17.825Z', '2023-05-29T18:46:18.073Z', '2023-05-29T18:46:18.354Z', '2023-05-29T18:46:18.593Z', '2023-05-29T18:46:18.857Z', '2023-05-29T18:46:19.161Z', '2023-05-29T18:46:19.650Z', '2023-05-29T18:46:19.906Z', '2023-05-29T18:46:20.329Z', '2023-05-29T18:46:20.521Z', '2023-05-29T18:46:20.715Z', '2023-05-29T18:46:21.002Z', '2023-05-29T18:46:24.714Z', '2023-05-29T18:46:25.001Z', '2023-05-29T18:46:35.457Z', '2023-05-29T18:47:54.705Z', '2023-05-29T18:47:55.298Z', '2023-05-29T18:47:55.569Z', '2023-05-29T18:47:58.481Z', '2023-05-29T18:47:58.697Z', '2023-05-29T18:47:58.937Z', '2023-05-29T18:47:59.161Z', '2023-05-29T18:47:59.410Z', '2023-05-29T18:47:59.681Z', '2023-05-29T18:48:00.274Z', '2023-05-29T18:48:03.922Z', '2023-05-29T18:48:04.321Z', '2023-05-29T18:48:06.289Z', '2023-05-29T18:48:06.641Z', '2023-05-29T18:48:07.115Z', '2023-05-29T18:48:08.035Z', '2023-05-29T18:48:08.579Z', '2023-05-29T18:48:09.035Z', '2023-05-29T18:48:09.580Z', '2023-05-29T18:48:10.003Z', '2023-05-29T18:48:10.435Z', '2023-05-29T18:48:10.796Z', '2023-05-29T18:48:11.178Z', '2023-05-29T18:48:11.836Z', '2023-05-29T18:48:28.658Z', '2023-05-29T18:48:29.153Z', '2023-05-29T18:48:29.201Z', '2023-05-29T18:48:29.233Z', '2023-05-29T18:48:29.263Z', '2023-05-29T18:48:29.294Z', '2023-05-29T18:48:29.326Z', '2023-05-29T18:48:29.357Z', '2023-05-29T18:48:29.390Z', '2023-05-29T18:48:29.419Z', '2023-05-29T18:48:29.466Z', '2023-05-29T18:48:29.496Z', '2023-05-29T18:48:29.528Z', '2023-05-29T18:48:29.563Z', '2023-05-29T18:48:29.591Z', '2023-05-29T18:48:29.622Z', '2023-05-29T18:48:29.653Z', '2023-05-29T18:48:29.660Z', '2023-05-29T18:48:31.307Z', '2023-05-29T18:48:31.594Z', '2023-05-29T18:48:31.970Z', '2023-05-29T18:48:32.426Z', '2023-05-29T18:48:32.842Z', '2023-05-29T18:48:33.706Z', '2023-05-29T18:48:33.915Z', '2023-05-29T18:48:34.114Z', '2023-05-29T18:48:34.467Z', '2023-05-29T18:48:40.330Z', '2023-05-29T18:48:41.370Z', '2023-05-29T18:48:43.330Z', '2023-05-29T18:48:43.593Z', '2023-05-29T18:48:43.833Z', '2023-05-29T18:48:44.058Z', '2023-05-29T18:48:47.907Z', '2023-05-29T18:48:54.434Z', '2023-05-29T18:48:54.778Z', '2023-05-29T18:48:55.169Z', '2023-05-29T18:48:55.417Z', '2023-05-29T18:48:55.874Z', '2023-05-29T18:48:56.164Z', '2023-05-29T18:48:56.722Z', '2023-05-29T18:48:57.322Z', '2023-05-29T18:48:57.521Z', '2023-05-29T18:48:57.834Z', '2023-05-29T18:48:58.186Z', '2023-05-29T18:48:59.098Z', '2023-05-29T18:48:59.634Z', '2023-05-29T18:48:59.956Z', '2023-05-29T18:49:00.570Z', '2023-05-29T18:49:00.913Z', '2023-05-29T18:49:01.098Z', '2023-05-29T18:49:07.801Z', '2023-05-29T18:49:08.081Z', '2023-05-29T18:49:08.089Z', '2023-05-29T18:49:09.900Z', '2023-05-29T18:49:10.131Z', '2023-05-29T18:49:10.396Z', '2023-05-29T18:49:10.941Z', '2023-05-29T18:49:11.299Z', '2023-05-29T18:49:11.636Z', '2023-05-29T18:49:11.940Z', '2023-05-29T18:49:12.100Z', '2023-05-29T18:49:12.579Z', '2023-05-29T18:49:12.916Z', '2023-05-29T18:49:13.251Z', '2023-05-29T18:49:13.948Z', '2023-05-29T18:49:14.267Z', '2023-05-29T18:49:21.963Z', '2023-05-29T18:49:22.323Z', '2023-05-29T18:49:22.684Z', '2023-05-29T18:49:22.971Z', '2023-05-29T18:49:23.331Z', '2023-05-29T18:49:23.819Z', '2023-05-29T18:49:24.059Z', '2023-05-29T18:49:24.411Z', '2023-05-29T18:49:25.090Z', '2023-05-29T18:49:25.379Z', '2023-05-29T18:49:25.862Z', '2023-05-29T18:49:26.130Z', '2023-05-29T18:49:39.451Z', '2023-05-29T18:49:40.347Z', '2023-05-29T18:49:40.570Z', '2023-05-29T18:49:40.971Z', '2023-05-29T18:49:41.138Z', '2023-05-29T18:49:41.644Z', '2023-05-29T18:49:41.956Z', '2023-05-29T18:49:42.482Z', '2023-05-29T18:49:42.851Z', '2023-05-29T18:49:43.067Z', '2023-05-29T18:49:43.323Z', '2023-05-29T18:49:43.594Z', '2023-05-29T18:49:48.962Z', '2023-05-29T18:49:49.292Z', '2023-05-29T18:49:49.691Z', '2023-05-29T18:49:49.978Z', '2023-05-29T18:49:50.218Z', '2023-05-29T18:49:50.627Z', '2023-05-29T18:49:51.019Z', '2023-05-29T18:49:51.291Z', '2023-05-29T18:49:51.594Z', '2023-05-29T18:49:51.882Z', '2023-05-29T18:49:59.971Z', '2023-05-29T18:50:00.338Z', '2023-05-29T18:50:00.746Z', '2023-05-29T18:50:01.010Z', '2023-05-29T18:50:01.514Z', '2023-05-29T18:50:01.850Z', '2023-05-29T18:50:02.106Z', '2023-05-29T18:50:02.371Z', '2023-05-29T18:50:08.009Z', '2023-05-29T18:50:08.484Z', '2023-05-29T18:50:08.740Z', '2023-05-29T18:50:09.092Z', '2023-05-29T18:50:09.332Z', '2023-05-29T18:50:09.548Z', '2023-05-29T18:50:09.740Z', '2023-05-29T18:50:10.044Z', '2023-05-29T18:50:10.596Z', '2023-05-29T18:50:11.195Z', '2023-05-29T18:50:11.430Z', '2023-05-29T18:50:11.852Z', '2023-05-29T18:50:12.107Z', '2023-05-29T18:50:17.316Z', '2023-05-29T18:50:17.524Z', '2023-05-29T18:50:17.827Z', '2023-05-29T18:50:18.091Z', '2023-05-29T18:50:18.443Z', '2023-05-29T18:50:18.692Z', '2023-05-29T18:50:19.196Z', '2023-05-29T18:50:19.411Z', '2023-05-29T18:50:19.684Z', '2023-05-29T18:50:19.892Z', '2023-05-29T18:50:27.125Z', '2023-05-29T18:50:27.404Z', '2023-05-29T18:50:27.620Z', '2023-05-29T18:50:28.139Z', '2023-05-29T18:50:28.419Z', '2023-05-29T18:50:28.867Z', '2023-05-29T18:50:29.363Z', '2023-05-29T18:50:29.635Z', '2023-05-29T18:50:29.971Z', '2023-05-29T18:50:30.285Z', '2023-05-29T18:50:30.667Z', '2023-05-29T18:50:30.940Z', '2023-05-29T18:50:40.283Z', '2023-05-29T18:50:43.226Z', '2023-05-29T18:50:55.227Z', '2023-05-29T18:50:57.563Z']","A study in Norway found that screening mammography was associated with a reduction in the rate of death from breast cancer .The availability of screening mammography was associated with a 10% reduction in mortality from breast cancer .
However, the study also found the screening itself only accounted for about a third of the total reduction in mortality .",False
3SBX2M1TKD87UPXMLS2FPEC2RSM4QO,"Effect of Screening Mammography on Breast-Cancer Mortality in Norway

A challenge in quantifying the effect of screening mammography on breast-cancer mortality is to provide valid comparison groups. The use of historical control subjects does not take into account chronologic trends associated with advances in breast-cancer awareness and treatment.

The Norwegian breast-cancer screening program was started in 1996 and expanded geographically during the subsequent 9 years. Women between the ages of 50 and 69 years were offered screening mammography every 2 years. We compared the incidence-based rates of death from breast cancer in four groups; two groups of women who from 1996 through 2005 were living in counties with screening (screening group) or without screening (nonscreening group); and two historical-comparison groups that from 1986 through 1995 mirrored the current groups.

We analyzed data from 40,075 women with breast cancer. The rate of death was reduced by 7.2 deaths per 100,000 person-years in the screening group as compared with the historical screening group (rate ratio, 0.72; 95% confidence interval (CI), 0.63 to 0.81) and by 4.8 deaths per 100,000 person-years in the nonscreening group as compared with the historical nonscreening group (rate ratio, 0.82; 95% CI, 0.71 to 0.93; P (0.001 for both comparisons), for a relative reduction in mortality of 10% in the screening group (P = 0.13). Thus, the difference in the reduction in mortality between the current and historical groups that could be attributed to screening alone was 2.4 deaths per 100,000 person-years, or a third of the total reduction of 7.2 deaths.

The availability of screening mammography was associated with a reduction in the rate of death from breast cancer, but the screening itself accounted for only about a third of the total reduction.
",Enter,['2023-05-29T18:23:15.814Z'],"The Norwegian breast-cancer screening program was started in 1996 and expanded geographically during the subsequent 9 years. Women between the ages of 50 and 69 years were offered screening mammography every 2 years. We compared the incidence-based rates of death from breast cancer in four groups; two groups of women who from 1996 through 2005 were living in counties with screening (screening group) or without screening (nonscreening group); and two historical-comparison groups that from 1986 through 1995 mirrored the current groups.

",False
38DCH97KHHNXX7G7OZPJVG1L9PBQJ0,"First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children

An ongoing phase 3 study of the efficacy, safety, and immunogenicity of candidate malaria vaccine RTS, S/AS01 is being conducted in seven African countries.

From March 2009 through January 2011, we enrolled 15,460 children in two age categories - 6 to 12 weeks of age and 5 to 17 months of age - for vaccination with either RTS, S/AS01 or a non-malaria comparator vaccine. The primary end point of the analysis was vaccine efficacy against clinical malaria during the 12 months after vaccination in the first 6000 children 5 to 17 months of age at enrollment who received all three doses of vaccine according to protocol. After 250 children had an episode of severe malaria, we evaluated vaccine efficacy against severe malaria in both age categories.

In the 14 months after the first dose of vaccine, the incidence of first episodes of clinical malaria in the first 6000 children in the older age category was 0.32 episodes per person-year in the RTS, S/AS01 group and 0.55 episodes per person-year in the control group, for an efficacy of 50.4% (95% confidence interval (CI), 45.8 to 54.6) in the intention-to-treat population and 55.8% (97.5% CI, 50.6 to 60.4) in the per-protocol population. Vaccine efficacy against severe malaria was 45.1% (95% CI, 23.8 to 60.5) in the intention-to-treat population and 47.3% (95% CI, 22.4 to 64.2) in the per-protocol population. Vaccine efficacy against severe malaria in the combined age categories was 34.8% (95% CI, 16.2 to 49.2) in the per-protocol population during an average follow-up of 11 months. Serious adverse events occurred with a similar frequency in the two study groups. Among children in the older age category, the rate of generalized convulsive seizures after RTS, S/AS01 vaccination was 1.04 per 1000 doses (95% CI, 0.62 to 1.64).

The RTS, S/AS01 vaccine provided protection against both clinical and severe malaria in African children.
","Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace , f r o m Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift M a r c h 2 0 0 9 t h r o u g h Shift J a n u a r y 2 0 1 1 Shift ( Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace . Control z Backspace .","['2023-05-29T18:24:22.677Z', '2023-05-29T18:24:22.825Z', '2023-05-29T18:24:23.049Z', '2023-05-29T18:24:23.209Z', '2023-05-29T18:24:23.385Z', '2023-05-29T18:24:23.561Z', '2023-05-29T18:24:23.705Z', '2023-05-29T18:24:23.897Z', '2023-05-29T18:24:24.041Z', '2023-05-29T18:24:24.233Z', '2023-05-29T18:24:24.409Z', '2023-05-29T18:24:24.649Z', '2023-05-29T18:25:25.514Z', '2023-05-29T18:26:55.913Z', '2023-05-29T18:26:56.122Z', '2023-05-29T18:26:56.441Z', '2023-05-29T18:26:56.729Z', '2023-05-29T18:26:56.825Z', '2023-05-29T18:26:57.017Z', '2023-05-29T18:26:57.273Z', '2023-05-29T18:26:58.138Z', '2023-05-29T18:26:58.638Z', '2023-05-29T18:26:58.671Z', '2023-05-29T18:26:58.704Z', '2023-05-29T18:26:58.737Z', '2023-05-29T18:26:58.770Z', '2023-05-29T18:26:58.803Z', '2023-05-29T18:26:58.836Z', '2023-05-29T18:26:58.869Z', '2023-05-29T18:26:58.902Z', '2023-05-29T18:26:58.935Z', '2023-05-29T18:26:58.968Z', '2023-05-29T18:26:59.001Z', '2023-05-29T18:26:59.034Z', '2023-05-29T18:26:59.049Z', '2023-05-29T18:26:59.657Z', '2023-05-29T18:26:59.881Z', '2023-05-29T18:27:00.345Z', '2023-05-29T18:27:00.473Z', '2023-05-29T18:27:01.225Z', '2023-05-29T18:27:02.026Z', '2023-05-29T18:27:02.457Z', '2023-05-29T18:27:02.601Z', '2023-05-29T18:27:03.386Z', '2023-05-29T18:27:05.337Z', '2023-05-29T18:27:05.817Z', '2023-05-29T18:27:05.930Z', '2023-05-29T18:27:06.169Z', '2023-05-29T18:27:06.361Z', '2023-05-29T18:27:07.673Z', '2023-05-29T18:27:07.833Z', '2023-05-29T18:27:07.977Z', '2023-05-29T18:27:08.937Z', '2023-05-29T18:27:09.577Z', '2023-05-29T18:27:09.753Z', '2023-05-29T18:27:10.042Z', '2023-05-29T18:27:10.154Z', '2023-05-29T18:27:10.442Z', '2023-05-29T18:27:10.729Z', '2023-05-29T18:27:12.009Z', '2023-05-29T18:27:12.170Z', '2023-05-29T18:27:12.713Z', '2023-05-29T18:27:14.570Z', '2023-05-29T18:27:14.857Z', '2023-05-29T18:27:15.081Z', '2023-05-29T18:27:15.257Z', '2023-05-29T18:27:32.953Z', '2023-05-29T18:27:33.290Z', '2023-05-29T18:27:33.561Z', '2023-05-29T18:27:51.850Z', '2023-05-29T18:27:52.345Z', '2023-05-29T18:28:38.282Z', '2023-05-29T18:28:38.782Z', '2023-05-29T18:28:38.815Z', '2023-05-29T18:28:38.848Z', '2023-05-29T18:28:38.881Z', '2023-05-29T18:28:38.914Z', '2023-05-29T18:28:38.947Z', '2023-05-29T18:28:38.980Z', '2023-05-29T18:28:39.013Z', '2023-05-29T18:28:39.046Z', '2023-05-29T18:28:39.079Z', '2023-05-29T18:28:39.112Z', '2023-05-29T18:28:39.145Z', '2023-05-29T18:28:39.178Z', '2023-05-29T18:28:39.211Z', '2023-05-29T18:28:39.244Z', '2023-05-29T18:28:39.498Z', '2023-05-29T18:28:39.674Z', '2023-05-29T18:28:39.850Z', '2023-05-29T18:28:40.026Z', '2023-05-29T18:28:40.202Z', '2023-05-29T18:28:40.458Z', '2023-05-29T18:28:42.090Z', '2023-05-29T18:28:45.754Z', '2023-05-29T18:28:45.978Z', '2023-05-29T18:30:23.354Z', '2023-05-29T18:30:23.946Z']","Exciting news from a study on a malaria vaccine called RTS,S/AS01 in African children. They enrolled over 15,000 kids in seven African countries, split into two age groups, from March 2009 through January 2011. The vaccine showed positive results! In the older age group, it had a 50.4% success rate in preventing regular malaria cases for a whole year after vaccination. When it came to severe malaria, the vaccine had a 45.1% success rate in one group and 47.3% in another. Combining both age groups, it still managed a 34.8% success rate against severe malaria. Good news for safety too - serious side effects were rare. However, there were some cases of convulsive seizures, but they were infrequent. Overall, this vaccine shows promise in protecting African children from malaria. ",False
38DCH97KHHNXX7G7OZPJVG1L9PBQJ0,"First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children

An ongoing phase 3 study of the efficacy, safety, and immunogenicity of candidate malaria vaccine RTS, S/AS01 is being conducted in seven African countries.

From March 2009 through January 2011, we enrolled 15,460 children in two age categories - 6 to 12 weeks of age and 5 to 17 months of age - for vaccination with either RTS, S/AS01 or a non-malaria comparator vaccine. The primary end point of the analysis was vaccine efficacy against clinical malaria during the 12 months after vaccination in the first 6000 children 5 to 17 months of age at enrollment who received all three doses of vaccine according to protocol. After 250 children had an episode of severe malaria, we evaluated vaccine efficacy against severe malaria in both age categories.

In the 14 months after the first dose of vaccine, the incidence of first episodes of clinical malaria in the first 6000 children in the older age category was 0.32 episodes per person-year in the RTS, S/AS01 group and 0.55 episodes per person-year in the control group, for an efficacy of 50.4% (95% confidence interval (CI), 45.8 to 54.6) in the intention-to-treat population and 55.8% (97.5% CI, 50.6 to 60.4) in the per-protocol population. Vaccine efficacy against severe malaria was 45.1% (95% CI, 23.8 to 60.5) in the intention-to-treat population and 47.3% (95% CI, 22.4 to 64.2) in the per-protocol population. Vaccine efficacy against severe malaria in the combined age categories was 34.8% (95% CI, 16.2 to 49.2) in the per-protocol population during an average follow-up of 11 months. Serious adverse events occurred with a similar frequency in the two study groups. Among children in the older age category, the rate of generalized convulsive seizures after RTS, S/AS01 vaccination was 1.04 per 1000 doses (95% CI, 0.62 to 1.64).

The RTS, S/AS01 vaccine provided protection against both clinical and severe malaria in African children.
",Delete Delete Control v t h e 1 c h i s u s e d t o e v Control z Control z z z z z z z z z z z z z z z z e u t Backspace Backspace i t s Shift A w a s s h o w e n Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace s w e r e Backspace Backspace Backspace Backspace Backspace w e r e s h o w n f r o m t h e s t u d i e s . Backspace u n d e r w a y Backspace Backspace n a t i o n s Delete Delete Delete Delete Delete Delete Delete Delete d i f f e r Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace b a b i e s i n d i f f Backspace f e r e n t w e e k s o f a g e w a s e f f e c t i v e ArrowRight ArrowRight t h e t e s t s u b j e c t s Shift ( b o t h e Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace s p l a s e Backspace Backspace Backspace s e 4 Backspace 3 Backspace h ArrowLeft Delete Control c Control v Delete Control c Control v Enter Backspace Control v,"['2023-05-29T18:19:27.221Z', '2023-05-29T18:19:27.431Z', '2023-05-29T18:19:27.649Z', '2023-05-29T18:19:27.854Z', '2023-05-29T18:20:09.340Z', '2023-05-29T18:20:09.528Z', '2023-05-29T18:20:09.575Z', '2023-05-29T18:20:28.345Z', '2023-05-29T18:20:28.351Z', '2023-05-29T18:20:28.357Z', '2023-05-29T18:20:28.360Z', '2023-05-29T18:20:28.382Z', '2023-05-29T18:20:28.386Z', '2023-05-29T18:20:28.388Z', '2023-05-29T18:20:28.393Z', '2023-05-29T18:20:28.397Z', '2023-05-29T18:20:28.401Z', '2023-05-29T18:20:28.407Z', '2023-05-29T18:20:28.409Z', '2023-05-29T18:20:28.413Z', '2023-05-29T18:20:28.417Z', '2023-05-29T18:20:28.418Z', '2023-05-29T18:20:28.422Z', '2023-05-29T18:20:30.757Z', '2023-05-29T18:20:30.921Z', '2023-05-29T18:20:31.459Z', '2023-05-29T18:20:31.622Z', '2023-05-29T18:20:31.955Z', '2023-05-29T18:20:32.321Z', '2023-05-29T18:20:32.616Z', '2023-05-29T18:20:32.775Z', '2023-05-29T18:20:33.275Z', '2023-05-29T18:20:33.309Z', '2023-05-29T18:20:33.341Z', '2023-05-29T18:20:33.374Z', '2023-05-29T18:20:33.407Z', '2023-05-29T18:20:33.518Z', '2023-05-29T18:20:33.673Z', '2023-05-29T18:20:33.836Z', '2023-05-29T18:20:33.992Z', '2023-05-29T18:20:34.164Z', '2023-05-29T18:20:34.337Z', '2023-05-29T18:20:41.555Z', '2023-05-29T18:20:45.249Z', '2023-05-29T18:20:45.284Z', '2023-05-29T18:20:45.766Z', '2023-05-29T18:20:45.901Z', '2023-05-29T18:20:46.549Z', '2023-05-29T18:20:46.624Z', '2023-05-29T18:20:46.949Z', '2023-05-29T18:20:56.579Z', '2023-05-29T18:20:56.831Z', '2023-05-29T18:20:59.558Z', '2023-05-29T18:20:59.727Z', '2023-05-29T18:20:59.907Z', '2023-05-29T18:21:00.020Z', '2023-05-29T18:21:00.181Z', '2023-05-29T18:21:00.260Z', '2023-05-29T18:21:00.445Z', '2023-05-29T18:21:00.495Z', '2023-05-29T18:21:00.707Z', '2023-05-29T18:21:00.956Z', '2023-05-29T18:21:01.389Z', '2023-05-29T18:21:01.944Z', '2023-05-29T18:21:02.076Z', '2023-05-29T18:21:02.222Z', '2023-05-29T18:21:02.362Z', '2023-05-29T18:21:02.501Z', '2023-05-29T18:21:02.627Z', '2023-05-29T18:21:02.776Z', '2023-05-29T18:21:02.911Z', '2023-05-29T18:21:03.056Z', '2023-05-29T18:21:03.193Z', '2023-05-29T18:21:03.333Z', '2023-05-29T18:21:07.694Z', '2023-05-29T18:21:07.998Z', '2023-05-29T18:21:08.264Z', '2023-05-29T18:21:08.456Z', '2023-05-29T18:21:08.630Z', '2023-05-29T18:21:08.825Z', '2023-05-29T18:21:09.276Z', '2023-05-29T18:21:09.397Z', '2023-05-29T18:21:09.533Z', '2023-05-29T18:21:09.670Z', '2023-05-29T18:21:09.814Z', '2023-05-29T18:21:10.269Z', '2023-05-29T18:21:10.457Z', '2023-05-29T18:21:10.631Z', '2023-05-29T18:21:10.793Z', '2023-05-29T18:21:10.962Z', '2023-05-29T18:21:11.116Z', '2023-05-29T18:21:11.187Z', '2023-05-29T18:21:11.384Z', '2023-05-29T18:21:11.422Z', '2023-05-29T18:21:11.601Z', '2023-05-29T18:21:11.892Z', '2023-05-29T18:21:12.135Z', '2023-05-29T18:21:12.318Z', '2023-05-29T18:21:12.386Z', '2023-05-29T18:21:12.446Z', '2023-05-29T18:21:12.624Z', '2023-05-29T18:21:12.671Z', '2023-05-29T18:21:12.815Z', '2023-05-29T18:21:12.902Z', '2023-05-29T18:21:13.045Z', '2023-05-29T18:21:13.206Z', '2023-05-29T18:21:13.450Z', '2023-05-29T18:21:13.535Z', '2023-05-29T18:21:13.741Z', '2023-05-29T18:21:13.914Z', '2023-05-29T18:21:13.958Z', '2023-05-29T18:21:14.117Z', '2023-05-29T18:21:14.252Z', '2023-05-29T18:21:14.651Z', '2023-05-29T18:21:25.622Z', '2023-05-29T18:21:25.671Z', '2023-05-29T18:21:25.733Z', '2023-05-29T18:21:25.905Z', '2023-05-29T18:21:26.074Z', '2023-05-29T18:21:26.265Z', '2023-05-29T18:21:26.430Z', '2023-05-29T18:21:26.478Z', '2023-05-29T18:21:31.338Z', '2023-05-29T18:21:31.493Z', '2023-05-29T18:21:32.103Z', '2023-05-29T18:21:32.163Z', '2023-05-29T18:21:32.397Z', '2023-05-29T18:21:32.454Z', '2023-05-29T18:21:32.598Z', '2023-05-29T18:21:32.646Z', '2023-05-29T18:21:32.709Z', '2023-05-29T18:21:39.232Z', '2023-05-29T18:21:39.386Z', '2023-05-29T18:21:39.519Z', '2023-05-29T18:21:39.648Z', '2023-05-29T18:21:39.783Z', '2023-05-29T18:21:39.919Z', '2023-05-29T18:21:40.059Z', '2023-05-29T18:21:40.200Z', '2023-05-29T18:21:56.425Z', '2023-05-29T18:21:56.548Z', '2023-05-29T18:21:56.659Z', '2023-05-29T18:21:56.767Z', '2023-05-29T18:21:57.039Z', '2023-05-29T18:21:57.230Z', '2023-05-29T18:21:57.920Z', '2023-05-29T18:21:58.822Z', '2023-05-29T18:21:58.977Z', '2023-05-29T18:21:59.126Z', '2023-05-29T18:21:59.280Z', '2023-05-29T18:21:59.420Z', '2023-05-29T18:22:01.763Z', '2023-05-29T18:22:02.263Z', '2023-05-29T18:22:02.295Z', '2023-05-29T18:22:02.328Z', '2023-05-29T18:22:02.361Z', '2023-05-29T18:22:02.396Z', '2023-05-29T18:22:02.427Z', '2023-05-29T18:22:02.460Z', '2023-05-29T18:22:02.493Z', '2023-05-29T18:22:02.526Z', '2023-05-29T18:22:02.560Z', '2023-05-29T18:22:02.592Z', '2023-05-29T18:22:02.626Z', '2023-05-29T18:22:02.659Z', '2023-05-29T18:22:02.984Z', '2023-05-29T18:22:05.192Z', '2023-05-29T18:22:05.798Z', '2023-05-29T18:22:05.895Z', '2023-05-29T18:22:05.963Z', '2023-05-29T18:22:06.159Z', '2023-05-29T18:22:06.220Z', '2023-05-29T18:22:06.410Z', '2023-05-29T18:22:08.974Z', '2023-05-29T18:22:09.397Z', '2023-05-29T18:22:09.487Z', '2023-05-29T18:22:10.001Z', '2023-05-29T18:22:10.299Z', '2023-05-29T18:22:10.413Z', '2023-05-29T18:22:10.665Z', '2023-05-29T18:22:10.837Z', '2023-05-29T18:22:11.237Z', '2023-05-29T18:22:12.058Z', '2023-05-29T18:22:12.357Z', '2023-05-29T18:22:12.540Z', '2023-05-29T18:22:12.702Z', '2023-05-29T18:22:12.839Z', '2023-05-29T18:22:12.912Z', '2023-05-29T18:22:13.318Z', '2023-05-29T18:22:13.740Z', '2023-05-29T18:22:13.957Z', '2023-05-29T18:22:14.098Z', '2023-05-29T18:22:14.216Z', '2023-05-29T18:22:14.366Z', '2023-05-29T18:22:14.544Z', '2023-05-29T18:22:14.763Z', '2023-05-29T18:22:14.872Z', '2023-05-29T18:22:15.248Z', '2023-05-29T18:22:15.333Z', '2023-05-29T18:22:15.546Z', '2023-05-29T18:22:15.595Z', '2023-05-29T18:22:37.564Z', '2023-05-29T18:22:37.728Z', '2023-05-29T18:22:37.905Z', '2023-05-29T18:22:38.070Z', '2023-05-29T18:22:38.179Z', '2023-05-29T18:22:38.408Z', '2023-05-29T18:22:38.544Z', '2023-05-29T18:22:38.729Z', '2023-05-29T18:22:38.956Z', '2023-05-29T18:22:39.309Z', '2023-05-29T18:22:39.399Z', '2023-05-29T18:22:40.414Z', '2023-05-29T18:22:40.470Z', '2023-05-29T18:22:41.286Z', '2023-05-29T18:22:41.461Z', '2023-05-29T18:22:49.149Z', '2023-05-29T18:22:49.283Z', '2023-05-29T18:22:49.363Z', '2023-05-29T18:22:49.483Z', '2023-05-29T18:22:49.574Z', '2023-05-29T18:22:49.759Z', '2023-05-29T18:22:49.945Z', '2023-05-29T18:22:50.010Z', '2023-05-29T18:22:50.223Z', '2023-05-29T18:22:50.401Z', '2023-05-29T18:22:50.699Z', '2023-05-29T18:22:50.775Z', '2023-05-29T18:22:50.979Z', '2023-05-29T18:22:51.062Z', '2023-05-29T18:22:51.268Z', '2023-05-29T18:22:51.317Z', '2023-05-29T18:22:51.446Z', '2023-05-29T18:23:11.367Z', '2023-05-29T18:23:11.453Z', '2023-05-29T18:23:11.707Z', '2023-05-29T18:23:12.339Z', '2023-05-29T18:23:13.432Z', '2023-05-29T18:23:13.578Z', '2023-05-29T18:23:13.663Z', '2023-05-29T18:23:13.898Z', '2023-05-29T18:23:14.063Z', '2023-05-29T18:23:14.768Z', '2023-05-29T18:23:15.556Z', '2023-05-29T18:23:15.723Z', '2023-05-29T18:23:15.860Z', '2023-05-29T18:23:16.005Z', '2023-05-29T18:23:16.131Z', '2023-05-29T18:23:16.273Z', '2023-05-29T18:23:16.418Z', '2023-05-29T18:23:16.575Z', '2023-05-29T18:23:17.343Z', '2023-05-29T18:24:00.362Z', '2023-05-29T18:24:00.412Z', '2023-05-29T18:24:00.621Z', '2023-05-29T18:24:00.972Z', '2023-05-29T18:24:01.156Z', '2023-05-29T18:24:01.779Z', '2023-05-29T18:24:02.088Z', '2023-05-29T18:24:02.217Z', '2023-05-29T18:24:02.369Z', '2023-05-29T18:24:05.596Z', '2023-05-29T18:24:05.777Z', '2023-05-29T18:24:06.255Z', '2023-05-29T18:24:06.407Z', '2023-05-29T18:24:06.833Z', '2023-05-29T18:24:07.063Z', '2023-05-29T18:24:07.681Z', '2023-05-29T18:24:10.403Z', '2023-05-29T18:24:10.521Z', '2023-05-29T18:24:34.136Z', '2023-05-29T18:25:05.960Z', '2023-05-29T18:25:08.675Z', '2023-05-29T18:25:08.901Z', '2023-05-29T18:25:12.063Z', '2023-05-29T18:25:12.171Z', '2023-05-29T18:25:56.124Z', '2023-05-29T18:26:00.233Z', '2023-05-29T18:26:00.486Z', '2023-05-29T18:26:01.060Z', '2023-05-29T18:26:01.540Z', '2023-05-29T18:26:02.750Z', '2023-05-29T18:26:03.063Z', '2023-05-29T18:27:07.090Z', '2023-05-29T18:27:07.292Z']","A phase 3 study of the malaria vaccine RTS, S/AS01 was conducted in seven African countries from March 2009 to January 2011, enrolling 15,460 children in two age categories - 6 to 12 weeks of age and 5 to 17 months of age. The study aimed to evaluate the efficacy, safety, and immunogenicity of the vaccine. The primary endpoint of the analysis was vaccine efficacy against clinical malaria during the 12 months after vaccination in the first 6000 children 5 to 17 months of age at enrollment. The vaccine provided protection against both clinical and severe malaria in African children, with an efficacy of 50.4% against clinical malaria and 45.1% against severe malaria in the older age category. Serious adverse events occurred with similar frequency in the two study groups. Among children in the older age category, the rate of generalized convulsive seizures after RTS, S/AS01 vaccination was 1.04 per 1000 doses.",True
38DCH97KHHNXX7G7OZPJVG1L9PBQJ0,"First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children

An ongoing phase 3 study of the efficacy, safety, and immunogenicity of candidate malaria vaccine RTS, S/AS01 is being conducted in seven African countries.

From March 2009 through January 2011, we enrolled 15,460 children in two age categories - 6 to 12 weeks of age and 5 to 17 months of age - for vaccination with either RTS, S/AS01 or a non-malaria comparator vaccine. The primary end point of the analysis was vaccine efficacy against clinical malaria during the 12 months after vaccination in the first 6000 children 5 to 17 months of age at enrollment who received all three doses of vaccine according to protocol. After 250 children had an episode of severe malaria, we evaluated vaccine efficacy against severe malaria in both age categories.

In the 14 months after the first dose of vaccine, the incidence of first episodes of clinical malaria in the first 6000 children in the older age category was 0.32 episodes per person-year in the RTS, S/AS01 group and 0.55 episodes per person-year in the control group, for an efficacy of 50.4% (95% confidence interval (CI), 45.8 to 54.6) in the intention-to-treat population and 55.8% (97.5% CI, 50.6 to 60.4) in the per-protocol population. Vaccine efficacy against severe malaria was 45.1% (95% CI, 23.8 to 60.5) in the intention-to-treat population and 47.3% (95% CI, 22.4 to 64.2) in the per-protocol population. Vaccine efficacy against severe malaria in the combined age categories was 34.8% (95% CI, 16.2 to 49.2) in the per-protocol population during an average follow-up of 11 months. Serious adverse events occurred with a similar frequency in the two study groups. Among children in the older age category, the rate of generalized convulsive seizures after RTS, S/AS01 vaccination was 1.04 per 1000 doses (95% CI, 0.62 to 1.64).

The RTS, S/AS01 vaccine provided protection against both clinical and severe malaria in African children.
",Control v,"['2023-05-29T19:14:18.519Z', '2023-05-29T19:14:18.922Z']","A phase 3 trial of the RTS, S/AS01 malaria vaccine was conducted in seven African countries. The vaccine was found to be effective in preventing clinical malaria in children aged 5 to 17 months, with an efficacy of 50.4%. The vaccine was also effective in preventing severe malaria, with an efficacy of 45.1%. Serious adverse events occurred with a similar frequency in the two study groups. The rate of generalized convulsive seizures after RTS, S/AS01 vaccination was 1.04 per 1000 doses.

The RTS, S/AS01 vaccine is a promising new tool for the prevention of malaria in children. Further studies are needed to confirm the long-term efficacy and safety of the vaccine",True
3VI0PC2ZAY5V7F8GQQCGXKE05M8XON,"Azithromycin and the Risk of Cardiovascular Death

Although several macrolide antibiotics are proarrhythmic and associated with an increased risk of sudden cardiac death, azithromycin is thought to have minimal cardiotoxicity. However, published reports of arrhythmias suggest that azithromycin may increase the risk of cardiovascular death.

We studied a Tennessee Medicaid cohort designed to detect an increased risk of death related to short-term cardiac effects of medication, excluding patients with serious noncardiovascular illness and person-time during and shortly after hospitalization. The cohort included patients who took azithromycin (347,795 prescriptions), propensity-score - matched persons who took no antibiotics (1,391,180 control periods), and patients who took amoxicillin (1,348,672 prescriptions), ciprofloxacin (264,626 prescriptions), or levofloxacin (193,906 prescriptions).

During 5 days of therapy, patients taking azithromycin, as compared with those who took no antibiotics, had an increased risk of cardiovascular death (hazard ratio, 2.88; 95% confidence interval (CI), 1.79 to 4.63; P (0.001) and death from any cause (hazard ratio, 1.85; 95% CI, 1.25 to 2.75; P = 0.002). Patients who took amoxicillin had no increase in the risk of death during this period. Relative to amoxicillin, azithromycin was associated with an increased risk of cardiovascular death (hazard ratio, 2.49; 95% CI, 1.38 to 4.50; P = 0.002) and death from any cause (hazard ratio, 2.02; 95% CI, 1.24 to 3.30; P = 0.005), with an estimated 47 additional cardiovascular deaths per 1 million courses; patients in the highest decile of risk for cardiovascular disease had an estimated 245 additional cardiovascular deaths per 1 million courses. The risk of cardiovascular death was significantly greater with azithromycin than with ciprofloxacin but did not differ significantly from that with levofloxacin.

During 5 days of azithromycin therapy, there was a small absolute increase in cardiovascular deaths, which was most pronounced among patients with a high baseline risk of cardiovascular disease.
",Control Control Control Control Control Control Control Control Control Control v a t e,"['2023-05-29T21:20:34.138Z', '2023-05-29T21:20:34.632Z', '2023-05-29T21:20:34.665Z', '2023-05-29T21:20:34.697Z', '2023-05-29T21:20:34.730Z', '2023-05-29T21:20:34.763Z', '2023-05-29T21:20:34.797Z', '2023-05-29T21:20:34.829Z', '2023-05-29T21:20:34.862Z', '2023-05-29T21:20:34.895Z', '2023-05-29T21:20:34.899Z', '2023-05-29T21:20:37.899Z', '2023-05-29T21:20:38.475Z', '2023-05-29T21:20:39.027Z']","Azithromycin is a broad-spectrum macrolide antibiotic, marketed in the United States under the trade name Zithromax or Zmax/Z-pak, used to treat or prevent a range of common bacterial infections including upper and lower respiratory tract infections and certain sexually transmitted diseases. From a cardiac toxicity perspective, azithromycin has been considered the safest of the macrolide derivatives due to divergent pharmacokinetic properties (e.g. minimal CYP3A4 metabolism/inhibition) and limited in vitro blockade of the rapid delayed rectifier potassium current (IKr) conducted by human ether--go-go-related gene (hERG)-encoded Kv11.1 potassium channel at therapeutic concentrations (Table 1).14 As a result of its broad antibiotic spectrum and perceived favorable safety profile, azithromycin has become one of the top 15 most prescribed drugs and the best-selling antibiotic in the United States accounting for 55.4 million prescriptions in 2012, according to recent IMS Institute for Health Informatics market date",True
3VI0PC2ZAY5V7F8GQQCGXKE05M8XON,"Azithromycin and the Risk of Cardiovascular Death

Although several macrolide antibiotics are proarrhythmic and associated with an increased risk of sudden cardiac death, azithromycin is thought to have minimal cardiotoxicity. However, published reports of arrhythmias suggest that azithromycin may increase the risk of cardiovascular death.

We studied a Tennessee Medicaid cohort designed to detect an increased risk of death related to short-term cardiac effects of medication, excluding patients with serious noncardiovascular illness and person-time during and shortly after hospitalization. The cohort included patients who took azithromycin (347,795 prescriptions), propensity-score - matched persons who took no antibiotics (1,391,180 control periods), and patients who took amoxicillin (1,348,672 prescriptions), ciprofloxacin (264,626 prescriptions), or levofloxacin (193,906 prescriptions).

During 5 days of therapy, patients taking azithromycin, as compared with those who took no antibiotics, had an increased risk of cardiovascular death (hazard ratio, 2.88; 95% confidence interval (CI), 1.79 to 4.63; P (0.001) and death from any cause (hazard ratio, 1.85; 95% CI, 1.25 to 2.75; P = 0.002). Patients who took amoxicillin had no increase in the risk of death during this period. Relative to amoxicillin, azithromycin was associated with an increased risk of cardiovascular death (hazard ratio, 2.49; 95% CI, 1.38 to 4.50; P = 0.002) and death from any cause (hazard ratio, 2.02; 95% CI, 1.24 to 3.30; P = 0.005), with an estimated 47 additional cardiovascular deaths per 1 million courses; patients in the highest decile of risk for cardiovascular disease had an estimated 245 additional cardiovascular deaths per 1 million courses. The risk of cardiovascular death was significantly greater with azithromycin than with ciprofloxacin but did not differ significantly from that with levofloxacin.

During 5 days of azithromycin therapy, there was a small absolute increase in cardiovascular deaths, which was most pronounced among patients with a high baseline risk of cardiovascular disease.
",Backspace,['2023-05-29T19:23:20.766Z'],"During 5 days of therapy, patients taking azithromycin, as compared with those who took no antibiotics, had an increased risk of cardiovascular death (hazard ratio, 2.88; 95% confidence interval (CI), 1.79 to 4.63; P (0.001) and death from any cause (hazard ratio, 1.85; 95% CI, 1.25 to 2.75; P = 0.002). Patients who took amoxicillin had no increase in the risk of death during this period. Relative to amoxicillin, azithromycin was associated with an increased risk of cardiovascular death (hazard ratio, 2.49; 95% CI, 1.38 to 4.50; P = 0.002) and death from any cause (hazard ratio, 2.02; 95% CI, 1.24 to 3.30; P = 0.005), with an estimated 47 additional cardiovascular deaths per 1 million courses; patients in the highest decile of risk for cardiovascular disease had an estimated 245 additional cardiovascular deaths per 1 million courses. The risk of cardiovascular death was significantly greater with azithromycin than with ciprofloxacin but did not differ significantly from that with levofloxacin",False
3VI0PC2ZAY5V7F8GQQCGXKE05M8XON,"Azithromycin and the Risk of Cardiovascular Death

Although several macrolide antibiotics are proarrhythmic and associated with an increased risk of sudden cardiac death, azithromycin is thought to have minimal cardiotoxicity. However, published reports of arrhythmias suggest that azithromycin may increase the risk of cardiovascular death.

We studied a Tennessee Medicaid cohort designed to detect an increased risk of death related to short-term cardiac effects of medication, excluding patients with serious noncardiovascular illness and person-time during and shortly after hospitalization. The cohort included patients who took azithromycin (347,795 prescriptions), propensity-score - matched persons who took no antibiotics (1,391,180 control periods), and patients who took amoxicillin (1,348,672 prescriptions), ciprofloxacin (264,626 prescriptions), or levofloxacin (193,906 prescriptions).

During 5 days of therapy, patients taking azithromycin, as compared with those who took no antibiotics, had an increased risk of cardiovascular death (hazard ratio, 2.88; 95% confidence interval (CI), 1.79 to 4.63; P (0.001) and death from any cause (hazard ratio, 1.85; 95% CI, 1.25 to 2.75; P = 0.002). Patients who took amoxicillin had no increase in the risk of death during this period. Relative to amoxicillin, azithromycin was associated with an increased risk of cardiovascular death (hazard ratio, 2.49; 95% CI, 1.38 to 4.50; P = 0.002) and death from any cause (hazard ratio, 2.02; 95% CI, 1.24 to 3.30; P = 0.005), with an estimated 47 additional cardiovascular deaths per 1 million courses; patients in the highest decile of risk for cardiovascular disease had an estimated 245 additional cardiovascular deaths per 1 million courses. The risk of cardiovascular death was significantly greater with azithromycin than with ciprofloxacin but did not differ significantly from that with levofloxacin.

During 5 days of azithromycin therapy, there was a small absolute increase in cardiovascular deaths, which was most pronounced among patients with a high baseline risk of cardiovascular disease.
",Control c Control v,"['2023-05-29T22:11:31.928Z', '2023-05-29T22:11:32.001Z', '2023-05-29T22:14:19.408Z', '2023-05-29T22:14:19.469Z']","azithromycin is an antibiotic that doctors use and it is known for increasing a risk for cardiovascular diseases among people! The prescription competes well with other brand antibiotics and it is documented very thoroughly. There is a lot of research on therapy using azithromycin and it has been studied for multiple day trials, etc. It should be known that the rates are coming from multiple trial percentages that amassed through plenty of research along with multiple different antibiotics. Doctors researched the drug for 5 days and concluded that it will increase risk of heart and cardiovascular problems so they may be wary.",True
36BTXXLZ2VT76QCMY7RFU4M7NEO4RP,"Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects

The long-term effects of sibutramine treatment on the rates of cardiovascular events and cardiovascular death among subjects at high cardiovascular risk have not been established.

We enrolled in our study 10,744 overweight or obese subjects, 55 years of age or older, with preexisting cardiovascular disease, type 2 diabetes mellitus, or both to assess the cardiovascular consequences of weight management with and without sibutramine in subjects at high risk for cardiovascular events. All the subjects received sibutramine in addition to participating in a weight-management program during a 6-week, single-blind, lead-in period, after which 9804 subjects underwent random assignment in a double-blind fashion to sibutramine (4906 subjects) or placebo (4898 subjects). The primary end point was the time from randomization to the first occurrence of a primary outcome event (nonfatal myocardial infarction, nonfatal stroke, resuscitation after cardiac arrest, or cardiovascular death).

The mean duration of treatment was 3.4 years. The mean weight loss during the lead-in period was 2.6 kg; after randomization, the subjects in the sibutramine group achieved and maintained further weight reduction (mean, 1.7 kg). The mean blood pressure decreased in both groups, with greater reductions in the placebo group than in the sibutramine group (mean difference, 1.2 / 1.4 mm Hg). The risk of a primary outcome event was 11.4% in the sibutramine group as compared with 10.0% in the placebo group (hazard ratio, 1.16; 95% confidence interval (CI), 1.03 to 1.31; P = 0.02). The rates of nonfatal myocardial infarction and nonfatal stroke were 4.1% and 2.6% in the sibutramine group and 3.2% and 1.9% in the placebo group, respectively (hazard ratio for nonfatal myocardial infarction, 1.28; 95% CI, 1.04 to 1.57; P = 0.02; hazard ratio for nonfatal stroke, 1.36; 95% CI, 1.04 to 1.77; P = 0.03). The rates of cardiovascular death and death from any cause were not increased.

Subjects with preexisting cardiovascular conditions who were receiving long-term sibutramine treatment had an increased risk of nonfatal myocardial infarction and nonfatal stroke but not of cardiovascular death or death from any cause.
",Control v,"['2023-05-29T18:24:49.922Z', '2023-05-29T18:24:50.193Z']","Sibutramine is a weight loss drug that has been shown to be effective in reducing body weight in overweight and obese adults. However, the long-term effects of sibutramine on cardiovascular health have not been well studied.

In this study, researchers conducted a randomized controlled trial to assess the cardiovascular effects of sibutramine in overweight and obese adults with preexisting cardiovascular disease, type 2 diabetes mellitus, or both. The study included 10,744 participants who were randomly assigned to receive either sibutramine or placebo for 3.4 years.

The results of the study showed that sibutramine was associated with an increased risk of nonfatal myocardial infarction and nonfatal stroke. However, sibutramine was not associated with an increased risk of cardiovascular death or death from any cause.

Based on the results of this study, the researchers concluded that sibutramine should not be used in overweight and obese adults with preexisting cardiovascular disease.",True
36BTXXLZ2VT76QCMY7RFU4M7NEO4RP,"Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects

The long-term effects of sibutramine treatment on the rates of cardiovascular events and cardiovascular death among subjects at high cardiovascular risk have not been established.

We enrolled in our study 10,744 overweight or obese subjects, 55 years of age or older, with preexisting cardiovascular disease, type 2 diabetes mellitus, or both to assess the cardiovascular consequences of weight management with and without sibutramine in subjects at high risk for cardiovascular events. All the subjects received sibutramine in addition to participating in a weight-management program during a 6-week, single-blind, lead-in period, after which 9804 subjects underwent random assignment in a double-blind fashion to sibutramine (4906 subjects) or placebo (4898 subjects). The primary end point was the time from randomization to the first occurrence of a primary outcome event (nonfatal myocardial infarction, nonfatal stroke, resuscitation after cardiac arrest, or cardiovascular death).

The mean duration of treatment was 3.4 years. The mean weight loss during the lead-in period was 2.6 kg; after randomization, the subjects in the sibutramine group achieved and maintained further weight reduction (mean, 1.7 kg). The mean blood pressure decreased in both groups, with greater reductions in the placebo group than in the sibutramine group (mean difference, 1.2 / 1.4 mm Hg). The risk of a primary outcome event was 11.4% in the sibutramine group as compared with 10.0% in the placebo group (hazard ratio, 1.16; 95% confidence interval (CI), 1.03 to 1.31; P = 0.02). The rates of nonfatal myocardial infarction and nonfatal stroke were 4.1% and 2.6% in the sibutramine group and 3.2% and 1.9% in the placebo group, respectively (hazard ratio for nonfatal myocardial infarction, 1.28; 95% CI, 1.04 to 1.57; P = 0.02; hazard ratio for nonfatal stroke, 1.36; 95% CI, 1.04 to 1.77; P = 0.03). The rates of cardiovascular death and death from any cause were not increased.

Subjects with preexisting cardiovascular conditions who were receiving long-term sibutramine treatment had an increased risk of nonfatal myocardial infarction and nonfatal stroke but not of cardiovascular death or death from any cause.
",Control v,"['2023-05-29T18:23:35.088Z', '2023-05-29T18:23:35.392Z']","In a study of 10,744 overweight or obese subjects ages 55 and older with preexisting cardiovascular disease and/or type 2 diabetes mellitus, 9804 subjects underwent random assignment to either sibutramine or placebo treatment, in addition to participating in a weight management program, for a mean duration of 3.4 years. The sibutramine group achieved and maintained a mean weight reduction of 1.7 kg and experienced a small decrease in mean blood pressure. However, the risk of a primary outcome event (nonfatal myocardial infarction, nonfatal stroke, resuscitation after cardiac arrest, or cardiovascular death) was 11.4%, compared to 10.0% in the placebo group. Moreover, the sibutramine group had higher rates of nonfatal myocardial infarction and nonfatal stroke with a hazard ratio of 1.28 and 1.36, respectively. The rates of cardiovascular death and death from any cause were not increased. Therefore, the long-term effects of sibutramine treatment on cardiovascular outcomes in high-risk subjects were shown to result in an increased risk of nonfatal events.",True
36BTXXLZ2VT76QCMY7RFU4M7NEO4RP,"Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects

The long-term effects of sibutramine treatment on the rates of cardiovascular events and cardiovascular death among subjects at high cardiovascular risk have not been established.

We enrolled in our study 10,744 overweight or obese subjects, 55 years of age or older, with preexisting cardiovascular disease, type 2 diabetes mellitus, or both to assess the cardiovascular consequences of weight management with and without sibutramine in subjects at high risk for cardiovascular events. All the subjects received sibutramine in addition to participating in a weight-management program during a 6-week, single-blind, lead-in period, after which 9804 subjects underwent random assignment in a double-blind fashion to sibutramine (4906 subjects) or placebo (4898 subjects). The primary end point was the time from randomization to the first occurrence of a primary outcome event (nonfatal myocardial infarction, nonfatal stroke, resuscitation after cardiac arrest, or cardiovascular death).

The mean duration of treatment was 3.4 years. The mean weight loss during the lead-in period was 2.6 kg; after randomization, the subjects in the sibutramine group achieved and maintained further weight reduction (mean, 1.7 kg). The mean blood pressure decreased in both groups, with greater reductions in the placebo group than in the sibutramine group (mean difference, 1.2 / 1.4 mm Hg). The risk of a primary outcome event was 11.4% in the sibutramine group as compared with 10.0% in the placebo group (hazard ratio, 1.16; 95% confidence interval (CI), 1.03 to 1.31; P = 0.02). The rates of nonfatal myocardial infarction and nonfatal stroke were 4.1% and 2.6% in the sibutramine group and 3.2% and 1.9% in the placebo group, respectively (hazard ratio for nonfatal myocardial infarction, 1.28; 95% CI, 1.04 to 1.57; P = 0.02; hazard ratio for nonfatal stroke, 1.36; 95% CI, 1.04 to 1.77; P = 0.03). The rates of cardiovascular death and death from any cause were not increased.

Subjects with preexisting cardiovascular conditions who were receiving long-term sibutramine treatment had an increased risk of nonfatal myocardial infarction and nonfatal stroke but not of cardiovascular death or death from any cause.
",d i f f i c u l t,"['2023-05-29T20:57:30.826Z', '2023-05-29T20:57:31.327Z', '2023-05-29T20:57:31.889Z', '2023-05-29T20:57:32.063Z', '2023-05-29T20:57:32.537Z', '2023-05-29T20:57:33.126Z', '2023-05-29T20:57:33.656Z', '2023-05-29T20:57:33.952Z', '2023-05-29T20:57:34.366Z']",difficult,False
3M93N4X8HK89ANVKG3EOQGGMRDWSJR,"Exemestane for Breast-Cancer Prevention in Postmenopausal Women

Tamoxifen and raloxifene have limited patient acceptance for primary prevention of breast cancer. Aromatase inhibitors prevent more contralateral breast cancers and cause fewer side effects than tamoxifen in patients with early-stage breast cancer.

In a randomized, placebo-controlled, double-blind trial of exemestane designed to detect a 65% relative reduction in invasive breast cancer, eligible postmenopausal women 35 years of age or older had at least one of the following risk factors; 60 years of age or older; Gail 5-year risk score greater than 1.66% (chances in 100 of invasive breast cancer developing within 5 years); prior atypical ductal or lobular hyperplasia or lobular carcinoma in situ; or ductal carcinoma in situ with mastectomy. Toxic effects and health-related and menopause-specific qualities of life were measured.

A total of 4560 women for whom the median age was 62.5 years and the median Gail risk score was 2.3% were randomly assigned to either exemestane or placebo. At a median follow-up of 35 months, 11 invasive breast cancers were detected in those given exemestane and in 32 of those given placebo, with a 65% relative reduction in the annual incidence of invasive breast cancer (0.19% vs. 0.55%; hazard ratio, 0.35; 95% confidence interval (CI), 0.18 to 0.70; P = 0.002). The annual incidence of invasive plus noninvasive (ductal carcinoma in situ) breast cancers was 0.35% on exemestane and 0.77% on placebo (hazard ratio, 0.47; 95% CI, 0.27 to 0.79; P = 0.004). Adverse events occurred in 88% of the exemestane group and 85% of the placebo group (P = 0.003), with no significant differences between the two groups in terms of skeletal fractures, cardiovascular events, other cancers, or treatment-related deaths. Minimal quality-of-life differences were observed.

Exemestane significantly reduced invasive breast cancers in postmenopausal women who were at moderately increased risk for breast cancer. During a median follow-up period of 3 years, exemestane was associated with no serious toxic effects and only minimal changes in health-related quality of life.
",Control v,"['2023-05-29T18:26:30.599Z', '2023-05-29T18:26:30.902Z']","A randomized, placebo-controlled, double-blind trial of exemestane was conducted to investigate its potential for the primary prevention of breast cancer in postmenopausal women. The trial involved 4560 women who were 35 years of age or older with at least one risk factor for breast cancer - being 60 or older, having a Gail 5-year risk score of greater than 1.66%, having atypical ductal or lobular hyperplasia or lobular carcinoma in situ, or having ductal carcinoma in situ with mastectomy. During a median follow-up period of 3 years, those on exemestane experienced a 65% reduction in the annual incidence of invasive breast cancer (0.19% vs. 0.55%) and the annual incidence of invasive plus non-invasive (ductal carcinoma in situ) breast cancers was 0.35% compared to 0.77% in the placebo group. No serious toxic effects were observed and only minimal quality-of-life differences were reported. The findings suggest that exemestane can reduce the risk of breast cancer in postmenopausal women who are at an elevated risk of developing the disease.",True
3M93N4X8HK89ANVKG3EOQGGMRDWSJR,"Exemestane for Breast-Cancer Prevention in Postmenopausal Women

Tamoxifen and raloxifene have limited patient acceptance for primary prevention of breast cancer. Aromatase inhibitors prevent more contralateral breast cancers and cause fewer side effects than tamoxifen in patients with early-stage breast cancer.

In a randomized, placebo-controlled, double-blind trial of exemestane designed to detect a 65% relative reduction in invasive breast cancer, eligible postmenopausal women 35 years of age or older had at least one of the following risk factors; 60 years of age or older; Gail 5-year risk score greater than 1.66% (chances in 100 of invasive breast cancer developing within 5 years); prior atypical ductal or lobular hyperplasia or lobular carcinoma in situ; or ductal carcinoma in situ with mastectomy. Toxic effects and health-related and menopause-specific qualities of life were measured.

A total of 4560 women for whom the median age was 62.5 years and the median Gail risk score was 2.3% were randomly assigned to either exemestane or placebo. At a median follow-up of 35 months, 11 invasive breast cancers were detected in those given exemestane and in 32 of those given placebo, with a 65% relative reduction in the annual incidence of invasive breast cancer (0.19% vs. 0.55%; hazard ratio, 0.35; 95% confidence interval (CI), 0.18 to 0.70; P = 0.002). The annual incidence of invasive plus noninvasive (ductal carcinoma in situ) breast cancers was 0.35% on exemestane and 0.77% on placebo (hazard ratio, 0.47; 95% CI, 0.27 to 0.79; P = 0.004). Adverse events occurred in 88% of the exemestane group and 85% of the placebo group (P = 0.003), with no significant differences between the two groups in terms of skeletal fractures, cardiovascular events, other cancers, or treatment-related deaths. Minimal quality-of-life differences were observed.

Exemestane significantly reduced invasive breast cancers in postmenopausal women who were at moderately increased risk for breast cancer. During a median follow-up period of 3 years, exemestane was associated with no serious toxic effects and only minimal changes in health-related quality of life.
",Control v,"['2023-05-29T19:09:00.926Z', '2023-05-29T19:09:01.301Z']","Exemestane is an aromatase inhibitor that has been shown to reduce the risk of invasive breast cancer in postmenopausal women who are at moderately increased risk for the disease. In a randomized, placebo-controlled trial, exemestane was associated with a 65% relative reduction in the annual incidence of invasive breast cancer. The drug was also well-tolerated, with no significant differences in adverse events between the exemestane and placebo groups. These findings suggest that exemestane may be a safe and effective option for the prevention of breast cancer in postmenopausal women at moderate risk.",True
3M93N4X8HK89ANVKG3EOQGGMRDWSJR,"Exemestane for Breast-Cancer Prevention in Postmenopausal Women

Tamoxifen and raloxifene have limited patient acceptance for primary prevention of breast cancer. Aromatase inhibitors prevent more contralateral breast cancers and cause fewer side effects than tamoxifen in patients with early-stage breast cancer.

In a randomized, placebo-controlled, double-blind trial of exemestane designed to detect a 65% relative reduction in invasive breast cancer, eligible postmenopausal women 35 years of age or older had at least one of the following risk factors; 60 years of age or older; Gail 5-year risk score greater than 1.66% (chances in 100 of invasive breast cancer developing within 5 years); prior atypical ductal or lobular hyperplasia or lobular carcinoma in situ; or ductal carcinoma in situ with mastectomy. Toxic effects and health-related and menopause-specific qualities of life were measured.

A total of 4560 women for whom the median age was 62.5 years and the median Gail risk score was 2.3% were randomly assigned to either exemestane or placebo. At a median follow-up of 35 months, 11 invasive breast cancers were detected in those given exemestane and in 32 of those given placebo, with a 65% relative reduction in the annual incidence of invasive breast cancer (0.19% vs. 0.55%; hazard ratio, 0.35; 95% confidence interval (CI), 0.18 to 0.70; P = 0.002). The annual incidence of invasive plus noninvasive (ductal carcinoma in situ) breast cancers was 0.35% on exemestane and 0.77% on placebo (hazard ratio, 0.47; 95% CI, 0.27 to 0.79; P = 0.004). Adverse events occurred in 88% of the exemestane group and 85% of the placebo group (P = 0.003), with no significant differences between the two groups in terms of skeletal fractures, cardiovascular events, other cancers, or treatment-related deaths. Minimal quality-of-life differences were observed.

Exemestane significantly reduced invasive breast cancers in postmenopausal women who were at moderately increased risk for breast cancer. During a median follow-up period of 3 years, exemestane was associated with no serious toxic effects and only minimal changes in health-related quality of life.
","Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control = = Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control - - - Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control - - - h e r e t h e y d i s c u s s a b o u t h e t w o c a n c e r s Shift T a m o x i f e n a n d r a l o x i f e n e Backspace Backspace Backspace Backspace Backspace Backspace Backspace t m e m b e r s . t h e y a r e a c c e p t a n c e o f p r i m a r y p r e v e n t i o n o f b r e a s t c a n c e r . h e r e a r o m a t a s e i n h a v Backspace b i t o r d s Backspace s Backspace Backspace Backspace Backspace Backspace r s . = Backspace Backspace Backspace Backspace s i t c a u s e f e w e r s i d e e f f e c t s t h a n t a m o x i f e n i n p a t i e n t s w i t h e a r l y s t a g e b r e a s t c a n c e r . Tab Enter Enter p l a c e b o - c o n t r o l l e d , d o u b l e - b l i n d Control c Control Control v . . Enter Backspace Backspace Backspace Shift A Q t o t a l o f 4 5 6 0 w o m e n f o r w h o m t h e m e d i a n a g e w a s 6 2 . 5 y e a r s a n d t h e m e d i a n g a l i r i s k s c o r e w a s 2 . 3 Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift % w e r e r a n d o m l y a s s i g n e d . Control Control c Control v Backspace Backspace Backspace Backspace Backspace","['2023-05-29T18:35:17.459Z', '2023-05-29T18:35:17.926Z', '2023-05-29T18:35:17.956Z', '2023-05-29T18:35:17.986Z', '2023-05-29T18:35:18.017Z', '2023-05-29T18:35:18.047Z', '2023-05-29T18:35:18.079Z', '2023-05-29T18:35:18.108Z', '2023-05-29T18:35:18.143Z', '2023-05-29T18:35:18.166Z', '2023-05-29T18:35:18.227Z', '2023-05-29T18:35:18.265Z', '2023-05-29T18:35:18.275Z', '2023-05-29T18:35:18.307Z', '2023-05-29T18:35:18.362Z', '2023-05-29T18:35:18.363Z', '2023-05-29T18:35:18.404Z', '2023-05-29T18:35:18.470Z', '2023-05-29T18:35:18.471Z', '2023-05-29T18:35:18.471Z', '2023-05-29T18:35:18.513Z', '2023-05-29T18:35:18.537Z', '2023-05-29T18:35:18.543Z', '2023-05-29T18:35:18.719Z', '2023-05-29T18:35:20.459Z', '2023-05-29T18:35:20.959Z', '2023-05-29T18:35:20.990Z', '2023-05-29T18:35:21.020Z', '2023-05-29T18:35:21.049Z', '2023-05-29T18:35:21.080Z', '2023-05-29T18:35:21.109Z', '2023-05-29T18:35:21.148Z', '2023-05-29T18:35:21.170Z', '2023-05-29T18:35:21.201Z', '2023-05-29T18:35:21.235Z', '2023-05-29T18:35:21.268Z', '2023-05-29T18:35:21.291Z', '2023-05-29T18:35:21.336Z', '2023-05-29T18:35:21.351Z', '2023-05-29T18:35:21.383Z', '2023-05-29T18:35:21.410Z', '2023-05-29T18:35:21.440Z', '2023-05-29T18:35:21.471Z', '2023-05-29T18:35:21.500Z', '2023-05-29T18:35:21.534Z', '2023-05-29T18:35:21.573Z', '2023-05-29T18:35:21.595Z', '2023-05-29T18:35:21.620Z', '2023-05-29T18:35:21.669Z', '2023-05-29T18:35:21.700Z', '2023-05-29T18:35:21.711Z', '2023-05-29T18:35:21.741Z', '2023-05-29T18:35:21.770Z', '2023-05-29T18:35:21.800Z', '2023-05-29T18:35:21.831Z', '2023-05-29T18:35:21.887Z', '2023-05-29T18:35:21.889Z', '2023-05-29T18:35:21.920Z', '2023-05-29T18:35:21.950Z', '2023-05-29T18:35:21.981Z', '2023-05-29T18:35:22.011Z', '2023-05-29T18:35:22.040Z', '2023-05-29T18:35:22.070Z', '2023-05-29T18:35:22.117Z', '2023-05-29T18:35:22.136Z', '2023-05-29T18:35:22.161Z', '2023-05-29T18:35:22.198Z', '2023-05-29T18:35:22.223Z', '2023-05-29T18:35:22.251Z', '2023-05-29T18:35:22.283Z', '2023-05-29T18:35:22.314Z', '2023-05-29T18:35:22.342Z', '2023-05-29T18:35:22.372Z', '2023-05-29T18:35:22.402Z', '2023-05-29T18:35:22.434Z', '2023-05-29T18:35:22.473Z', '2023-05-29T18:35:22.492Z', '2023-05-29T18:35:22.523Z', '2023-05-29T18:35:22.551Z', '2023-05-29T18:35:22.582Z', '2023-05-29T18:35:22.611Z', '2023-05-29T18:35:22.645Z', '2023-05-29T18:35:22.832Z', '2023-05-29T18:35:22.994Z', '2023-05-29T18:35:35.850Z', '2023-05-29T18:35:36.351Z', '2023-05-29T18:35:36.382Z', '2023-05-29T18:35:36.411Z', '2023-05-29T18:35:36.445Z', '2023-05-29T18:35:36.471Z', '2023-05-29T18:35:36.502Z', '2023-05-29T18:35:36.530Z', '2023-05-29T18:35:36.563Z', '2023-05-29T18:35:36.591Z', '2023-05-29T18:35:36.623Z', '2023-05-29T18:35:36.651Z', '2023-05-29T18:35:36.684Z', '2023-05-29T18:35:36.710Z', '2023-05-29T18:35:36.742Z', '2023-05-29T18:35:36.771Z', '2023-05-29T18:35:36.802Z', '2023-05-29T18:35:36.832Z', '2023-05-29T18:35:36.862Z', '2023-05-29T18:35:36.892Z', '2023-05-29T18:35:36.924Z', '2023-05-29T18:35:36.984Z', '2023-05-29T18:35:37.011Z', '2023-05-29T18:35:37.041Z', '2023-05-29T18:35:37.072Z', '2023-05-29T18:35:37.102Z', '2023-05-29T18:35:37.131Z', '2023-05-29T18:35:37.162Z', '2023-05-29T18:35:37.192Z', '2023-05-29T18:35:37.222Z', '2023-05-29T18:35:37.251Z', '2023-05-29T18:35:37.281Z', '2023-05-29T18:35:37.312Z', '2023-05-29T18:35:37.513Z', '2023-05-29T18:35:37.654Z', '2023-05-29T18:36:37.853Z', '2023-05-29T18:36:38.095Z', '2023-05-29T18:36:38.334Z', '2023-05-29T18:36:38.525Z', '2023-05-29T18:36:38.754Z', '2023-05-29T18:36:40.385Z', '2023-05-29T18:36:40.606Z', '2023-05-29T18:36:40.791Z', '2023-05-29T18:36:40.936Z', '2023-05-29T18:36:41.196Z', '2023-05-29T18:36:41.447Z', '2023-05-29T18:36:41.646Z', '2023-05-29T18:36:41.886Z', '2023-05-29T18:36:42.447Z', '2023-05-29T18:36:42.678Z', '2023-05-29T18:36:42.977Z', '2023-05-29T18:36:43.162Z', '2023-05-29T18:36:43.319Z', '2023-05-29T18:36:43.619Z', '2023-05-29T18:36:43.810Z', '2023-05-29T18:36:44.198Z', '2023-05-29T18:36:44.338Z', '2023-05-29T18:36:44.634Z', '2023-05-29T18:36:44.878Z', '2023-05-29T18:36:45.409Z', '2023-05-29T18:36:45.639Z', '2023-05-29T18:36:45.830Z', '2023-05-29T18:36:49.292Z', '2023-05-29T18:36:49.892Z', '2023-05-29T18:36:50.052Z', '2023-05-29T18:36:50.363Z', '2023-05-29T18:36:50.642Z', '2023-05-29T18:36:50.832Z', '2023-05-29T18:36:51.033Z', '2023-05-29T18:36:51.392Z', '2023-05-29T18:36:51.663Z', '2023-05-29T18:36:51.872Z', '2023-05-29T18:36:52.084Z', '2023-05-29T18:44:12.020Z', '2023-05-29T18:44:13.249Z', '2023-05-29T18:44:13.361Z', '2023-05-29T18:44:13.708Z', '2023-05-29T18:44:15.178Z', '2023-05-29T18:44:15.747Z', '2023-05-29T18:44:16.107Z', '2023-05-29T18:44:16.347Z', '2023-05-29T18:44:16.746Z', '2023-05-29T18:44:16.956Z', '2023-05-29T18:44:17.256Z', '2023-05-29T18:44:17.516Z', '2023-05-29T18:44:18.634Z', '2023-05-29T18:44:18.964Z', '2023-05-29T18:44:19.264Z', '2023-05-29T18:44:19.464Z', '2023-05-29T18:44:20.314Z', '2023-05-29T18:44:21.603Z', '2023-05-29T18:44:22.123Z', '2023-05-29T18:44:22.361Z', '2023-05-29T18:44:22.792Z', '2023-05-29T18:44:24.770Z', '2023-05-29T18:44:25.240Z', '2023-05-29T18:44:25.519Z', '2023-05-29T18:44:25.719Z', '2023-05-29T18:44:25.909Z', '2023-05-29T18:44:26.199Z', '2023-05-29T18:44:46.211Z', '2023-05-29T18:44:46.415Z', '2023-05-29T18:44:46.610Z', '2023-05-29T18:44:47.131Z', '2023-05-29T18:44:47.319Z', '2023-05-29T18:44:47.919Z', '2023-05-29T18:44:48.159Z', '2023-05-29T18:44:52.202Z', '2023-05-29T18:45:12.577Z', '2023-05-29T18:45:12.880Z', '2023-05-29T18:45:13.082Z', '2023-05-29T18:45:13.645Z', '2023-05-29T18:45:13.866Z', '2023-05-29T18:45:14.110Z', '2023-05-29T18:45:14.266Z', '2023-05-29T18:45:14.436Z', '2023-05-29T18:45:17.882Z', '2023-05-29T18:45:18.722Z', '2023-05-29T18:45:57.875Z', '2023-05-29T18:45:58.164Z', '2023-05-29T18:45:58.388Z', '2023-05-29T18:45:58.624Z', '2023-05-29T18:45:58.804Z', '2023-05-29T18:45:59.178Z', '2023-05-29T18:45:59.454Z', '2023-05-29T18:45:59.783Z', '2023-05-29T18:45:59.972Z', '2023-05-29T18:46:00.254Z', '2023-05-29T18:46:00.531Z', '2023-05-29T18:46:00.731Z', '2023-05-29T18:46:00.912Z', '2023-05-29T18:46:01.224Z', '2023-05-29T18:46:01.393Z', '2023-05-29T18:46:01.780Z', '2023-05-29T18:46:02.020Z', '2023-05-29T18:46:02.213Z', '2023-05-29T18:46:02.622Z', '2023-05-29T18:46:02.841Z', '2023-05-29T18:46:03.019Z', '2023-05-29T18:46:03.340Z', '2023-05-29T18:46:03.689Z', '2023-05-29T18:46:03.851Z', '2023-05-29T18:46:04.199Z', '2023-05-29T18:46:04.888Z', '2023-05-29T18:46:05.048Z', '2023-05-29T18:46:05.268Z', '2023-05-29T18:46:05.387Z', '2023-05-29T18:46:05.677Z', '2023-05-29T18:46:05.827Z', '2023-05-29T18:46:06.117Z', '2023-05-29T18:46:08.096Z', '2023-05-29T18:46:08.384Z', '2023-05-29T18:46:08.654Z', '2023-05-29T18:46:08.834Z', '2023-05-29T18:46:09.064Z', '2023-05-29T18:46:09.301Z', '2023-05-29T18:46:09.572Z', '2023-05-29T18:46:09.793Z', '2023-05-29T18:46:09.894Z', '2023-05-29T18:46:10.163Z', '2023-05-29T18:46:10.382Z', '2023-05-29T18:46:11.336Z', '2023-05-29T18:46:11.601Z', '2023-05-29T18:46:11.791Z', '2023-05-29T18:46:11.980Z', '2023-05-29T18:46:12.399Z', '2023-05-29T18:46:12.520Z', '2023-05-29T18:46:12.708Z', '2023-05-29T18:46:12.962Z', '2023-05-29T18:46:13.162Z', '2023-05-29T18:46:13.398Z', '2023-05-29T18:46:13.687Z', '2023-05-29T18:46:13.857Z', '2023-05-29T18:46:14.068Z', '2023-05-29T18:46:14.467Z', '2023-05-29T18:46:14.648Z', '2023-05-29T18:46:14.796Z', '2023-05-29T18:46:15.288Z', '2023-05-29T18:46:15.788Z', '2023-05-29T18:47:09.973Z', '2023-05-29T18:47:10.220Z', '2023-05-29T18:47:10.414Z', '2023-05-29T18:47:10.603Z', '2023-05-29T18:47:10.832Z', '2023-05-29T18:47:11.185Z', '2023-05-29T18:47:12.741Z', '2023-05-29T18:47:13.799Z', '2023-05-29T18:47:15.140Z', '2023-05-29T18:47:15.440Z', '2023-05-29T18:47:15.616Z', '2023-05-29T18:47:15.837Z', '2023-05-29T18:47:16.022Z', '2023-05-29T18:47:16.152Z', '2023-05-29T18:47:16.476Z', '2023-05-29T18:47:18.235Z', '2023-05-29T18:47:18.453Z', '2023-05-29T18:47:18.811Z', '2023-05-29T18:47:19.042Z', '2023-05-29T18:47:19.255Z', '2023-05-29T18:47:19.811Z', '2023-05-29T18:47:20.293Z', '2023-05-29T18:47:20.511Z', '2023-05-29T18:47:20.961Z', '2023-05-29T18:47:21.240Z', '2023-05-29T18:47:21.462Z', '2023-05-29T18:47:21.782Z', '2023-05-29T18:47:21.790Z', '2023-05-29T18:47:22.628Z', '2023-05-29T18:47:22.910Z', '2023-05-29T18:47:23.427Z', '2023-05-29T18:47:24.086Z', '2023-05-29T18:47:24.296Z', '2023-05-29T18:47:24.489Z', '2023-05-29T18:47:24.685Z', '2023-05-29T18:47:25.268Z', '2023-05-29T18:47:26.223Z', '2023-05-29T18:47:32.027Z', '2023-05-29T18:47:32.857Z', '2023-05-29T18:47:33.945Z', '2023-05-29T18:47:34.603Z', '2023-05-29T18:47:35.932Z', '2023-05-29T18:47:36.460Z', '2023-05-29T18:47:36.670Z', '2023-05-29T18:47:36.841Z', '2023-05-29T18:47:37.033Z', '2023-05-29T18:47:38.389Z', '2023-05-29T18:47:38.608Z', '2023-05-29T18:47:45.029Z', '2023-05-29T18:47:45.320Z', '2023-05-29T18:47:45.499Z', '2023-05-29T18:47:45.848Z', '2023-05-29T18:47:46.080Z', '2023-05-29T18:47:46.417Z', '2023-05-29T18:47:46.617Z', '2023-05-29T18:47:46.820Z', '2023-05-29T18:47:47.189Z', '2023-05-29T18:47:48.624Z', '2023-05-29T18:47:48.924Z', '2023-05-29T18:47:49.144Z', '2023-05-29T18:47:49.353Z', '2023-05-29T18:47:49.593Z', '2023-05-29T18:47:50.352Z', '2023-05-29T18:47:51.304Z', '2023-05-29T18:47:51.521Z', '2023-05-29T18:47:51.880Z', '2023-05-29T18:47:52.104Z', '2023-05-29T18:47:52.280Z', '2023-05-29T18:47:52.490Z', '2023-05-29T18:47:52.670Z', '2023-05-29T18:47:52.850Z', '2023-05-29T18:47:53.057Z', '2023-05-29T18:47:53.420Z', '2023-05-29T18:47:53.599Z', '2023-05-29T18:47:53.958Z', '2023-05-29T18:47:54.158Z', '2023-05-29T18:47:55.908Z', '2023-05-29T18:47:56.086Z', '2023-05-29T18:47:56.255Z', '2023-05-29T18:47:56.544Z', '2023-05-29T18:47:56.827Z', '2023-05-29T18:47:58.013Z', '2023-05-29T18:47:58.254Z', '2023-05-29T18:47:59.760Z', '2023-05-29T18:48:00.132Z', '2023-05-29T18:48:00.758Z', '2023-05-29T18:48:01.100Z', '2023-05-29T18:48:01.637Z', '2023-05-29T18:48:01.856Z', '2023-05-29T18:48:02.056Z', '2023-05-29T18:48:03.135Z', '2023-05-29T18:48:03.776Z', '2023-05-29T18:48:03.984Z', '2023-05-29T18:48:04.254Z', '2023-05-29T18:48:04.531Z', '2023-05-29T18:48:04.873Z', '2023-05-29T18:48:05.411Z', '2023-05-29T18:48:05.661Z', '2023-05-29T18:48:05.941Z', '2023-05-29T18:48:06.800Z', '2023-05-29T18:48:06.994Z', '2023-05-29T18:48:08.559Z', '2023-05-29T18:48:09.579Z', '2023-05-29T18:48:09.806Z', '2023-05-29T18:48:10.209Z', '2023-05-29T18:48:10.356Z', '2023-05-29T18:48:11.347Z', '2023-05-29T18:48:12.115Z', '2023-05-29T18:48:12.553Z', '2023-05-29T18:48:12.805Z', '2023-05-29T18:48:13.386Z', '2023-05-29T18:48:13.702Z', '2023-05-29T18:48:14.033Z', '2023-05-29T18:48:15.609Z', '2023-05-29T18:48:15.838Z', '2023-05-29T18:48:15.999Z', '2023-05-29T18:48:16.179Z', '2023-05-29T18:48:16.447Z', '2023-05-29T18:48:16.767Z', '2023-05-29T18:48:17.975Z', '2023-05-29T18:48:18.325Z', '2023-05-29T18:48:18.434Z', '2023-05-29T18:48:18.614Z', '2023-05-29T18:48:18.794Z', '2023-05-29T18:48:19.023Z', '2023-05-29T18:48:19.343Z', '2023-05-29T18:48:19.942Z', '2023-05-29T18:48:20.152Z', '2023-05-29T18:48:20.374Z', '2023-05-29T18:48:20.763Z', '2023-05-29T18:48:20.962Z', '2023-05-29T18:48:21.109Z', '2023-05-29T18:48:21.620Z', '2023-05-29T18:48:21.819Z', '2023-05-29T18:48:25.713Z', '2023-05-29T18:48:27.640Z', '2023-05-29T18:48:34.728Z', '2023-05-29T18:48:34.907Z', '2023-05-29T18:48:35.147Z', '2023-05-29T18:48:35.486Z', '2023-05-29T18:48:35.727Z', '2023-05-29T18:48:37.373Z', '2023-05-29T18:48:37.673Z', '2023-05-29T18:48:39.082Z', '2023-05-29T18:48:39.639Z', '2023-05-29T18:48:39.808Z', '2023-05-29T18:48:40.098Z', '2023-05-29T18:48:40.448Z', '2023-05-29T18:48:40.767Z', '2023-05-29T18:48:41.006Z', '2023-05-29T18:48:41.229Z', '2023-05-29T18:48:41.411Z', '2023-05-29T18:48:41.715Z', '2023-05-29T18:48:42.104Z', '2023-05-29T18:48:42.423Z', '2023-05-29T18:48:44.629Z', '2023-05-29T18:48:44.960Z', '2023-05-29T18:48:48.325Z', '2023-05-29T18:48:48.482Z', '2023-05-29T18:48:48.662Z', '2023-05-29T18:48:49.042Z', '2023-05-29T18:48:49.500Z', '2023-05-29T18:48:49.799Z', '2023-05-29T18:48:50.071Z', '2023-05-29T18:48:52.189Z', '2023-05-29T18:48:52.504Z', '2023-05-29T18:48:52.764Z', '2023-05-29T18:48:53.106Z', '2023-05-29T18:48:53.304Z', '2023-05-29T18:48:53.582Z', '2023-05-29T18:48:54.064Z', '2023-05-29T18:48:54.300Z', '2023-05-29T18:49:12.956Z', '2023-05-29T18:49:13.327Z', '2023-05-29T18:49:15.236Z', '2023-05-29T18:49:15.982Z', '2023-05-29T18:49:16.262Z', '2023-05-29T18:49:16.590Z', '2023-05-29T18:49:19.496Z', '2023-05-29T18:49:19.934Z', '2023-05-29T18:50:14.744Z', '2023-05-29T18:50:15.481Z', '2023-05-29T18:50:15.900Z', '2023-05-29T18:50:20.479Z', '2023-05-29T18:50:21.087Z', '2023-05-29T18:50:22.004Z', '2023-05-29T18:50:22.303Z', '2023-05-29T18:50:22.525Z', '2023-05-29T18:50:22.558Z', '2023-05-29T18:50:22.952Z', '2023-05-29T18:50:23.851Z', '2023-05-29T18:50:24.040Z', '2023-05-29T18:50:24.568Z', '2023-05-29T18:50:24.769Z', '2023-05-29T18:50:25.098Z', '2023-05-29T18:50:25.487Z', '2023-05-29T18:50:26.964Z', '2023-05-29T18:50:27.190Z', '2023-05-29T18:50:27.481Z', '2023-05-29T18:50:29.426Z', '2023-05-29T18:50:29.637Z', '2023-05-29T18:50:29.874Z', '2023-05-29T18:50:30.154Z', '2023-05-29T18:50:30.824Z', '2023-05-29T18:50:35.570Z', '2023-05-29T18:50:35.721Z', '2023-05-29T18:50:35.965Z', '2023-05-29T18:50:36.139Z', '2023-05-29T18:50:36.368Z', '2023-05-29T18:50:36.657Z', '2023-05-29T18:50:37.944Z', '2023-05-29T18:50:38.143Z', '2023-05-29T18:50:38.308Z', '2023-05-29T18:50:38.522Z', '2023-05-29T18:50:38.982Z', '2023-05-29T18:50:39.182Z', '2023-05-29T18:50:39.411Z', '2023-05-29T18:50:39.743Z', '2023-05-29T18:50:40.338Z', '2023-05-29T18:50:41.189Z', '2023-05-29T18:50:41.385Z', '2023-05-29T18:50:41.605Z', '2023-05-29T18:50:41.804Z', '2023-05-29T18:50:42.861Z', '2023-05-29T18:50:43.131Z', '2023-05-29T18:50:43.429Z', '2023-05-29T18:50:43.728Z', '2023-05-29T18:50:43.939Z', '2023-05-29T18:50:44.198Z', '2023-05-29T18:50:44.377Z', '2023-05-29T18:50:44.614Z', '2023-05-29T18:50:44.896Z', '2023-05-29T18:50:45.098Z', '2023-05-29T18:50:45.355Z', '2023-05-29T18:50:46.785Z', '2023-05-29T18:50:47.452Z', '2023-05-29T18:50:47.702Z', '2023-05-29T18:50:47.888Z', '2023-05-29T18:50:48.357Z', '2023-05-29T18:50:48.648Z', '2023-05-29T18:50:49.813Z', '2023-05-29T18:50:50.845Z', '2023-05-29T18:50:51.191Z', '2023-05-29T18:50:55.857Z', '2023-05-29T18:50:56.176Z', '2023-05-29T18:50:56.345Z', '2023-05-29T18:50:57.454Z', '2023-05-29T18:50:57.712Z', '2023-05-29T18:50:58.091Z', '2023-05-29T18:51:01.461Z', '2023-05-29T18:51:01.701Z', '2023-05-29T18:51:01.950Z', '2023-05-29T18:51:02.102Z', '2023-05-29T18:51:02.410Z', '2023-05-29T18:51:02.622Z', '2023-05-29T18:51:02.860Z', '2023-05-29T18:51:03.148Z', '2023-05-29T18:51:04.872Z', '2023-05-29T18:51:05.204Z', '2023-05-29T18:51:05.472Z', '2023-05-29T18:51:05.820Z', '2023-05-29T18:51:06.060Z', '2023-05-29T18:51:06.328Z', '2023-05-29T18:51:06.678Z', '2023-05-29T18:51:08.331Z', '2023-05-29T18:51:08.512Z', '2023-05-29T18:51:08.712Z', '2023-05-29T18:51:08.923Z', '2023-05-29T18:51:09.292Z', '2023-05-29T18:51:10.438Z', '2023-05-29T18:51:10.657Z', '2023-05-29T18:51:10.896Z', '2023-05-29T18:51:11.187Z', '2023-05-29T18:51:11.598Z', '2023-05-29T18:51:13.163Z', '2023-05-29T18:51:13.393Z', '2023-05-29T18:51:13.750Z', '2023-05-29T18:51:13.969Z', '2023-05-29T18:51:14.213Z', '2023-05-29T18:51:14.509Z', '2023-05-29T18:51:15.675Z', '2023-05-29T18:51:15.884Z', '2023-05-29T18:51:16.127Z', '2023-05-29T18:51:16.353Z', '2023-05-29T18:51:18.048Z', '2023-05-29T18:51:18.257Z', '2023-05-29T18:51:18.536Z', '2023-05-29T18:51:18.756Z', '2023-05-29T18:51:19.543Z', '2023-05-29T18:51:20.040Z', '2023-05-29T18:51:20.071Z', '2023-05-29T18:51:20.100Z', '2023-05-29T18:51:20.130Z', '2023-05-29T18:51:20.163Z', '2023-05-29T18:51:20.195Z', '2023-05-29T18:51:20.230Z', '2023-05-29T18:51:20.261Z', '2023-05-29T18:51:20.291Z', '2023-05-29T18:51:20.320Z', '2023-05-29T18:51:20.350Z', '2023-05-29T18:51:20.381Z', '2023-05-29T18:51:20.411Z', '2023-05-29T18:51:20.440Z', '2023-05-29T18:51:20.472Z', '2023-05-29T18:51:20.500Z', '2023-05-29T18:51:20.530Z', '2023-05-29T18:51:20.559Z', '2023-05-29T18:51:20.589Z', '2023-05-29T18:51:20.620Z', '2023-05-29T18:51:20.649Z', '2023-05-29T18:51:20.681Z', '2023-05-29T18:51:20.709Z', '2023-05-29T18:51:20.738Z', '2023-05-29T18:51:20.769Z', '2023-05-29T18:51:20.805Z', '2023-05-29T18:51:20.829Z', '2023-05-29T18:51:20.859Z', '2023-05-29T18:51:20.888Z', '2023-05-29T18:51:20.918Z', '2023-05-29T18:51:20.948Z', '2023-05-29T18:51:20.978Z', '2023-05-29T18:51:21.008Z', '2023-05-29T18:51:21.042Z', '2023-05-29T18:51:21.068Z', '2023-05-29T18:51:21.099Z', '2023-05-29T18:51:21.129Z', '2023-05-29T18:51:21.158Z', '2023-05-29T18:51:21.195Z', '2023-05-29T18:51:21.232Z', '2023-05-29T18:51:21.258Z', '2023-05-29T18:51:21.289Z', '2023-05-29T18:51:21.319Z', '2023-05-29T18:51:21.350Z', '2023-05-29T18:51:21.381Z', '2023-05-29T18:51:21.408Z', '2023-05-29T18:51:21.438Z', '2023-05-29T18:51:21.468Z', '2023-05-29T18:51:21.498Z', '2023-05-29T18:51:21.528Z', '2023-05-29T18:51:21.558Z', '2023-05-29T18:51:21.587Z', '2023-05-29T18:51:21.617Z', '2023-05-29T18:51:21.660Z', '2023-05-29T18:51:21.677Z', '2023-05-29T18:51:21.707Z', '2023-05-29T18:51:21.738Z', '2023-05-29T18:51:21.767Z', '2023-05-29T18:51:21.797Z', '2023-05-29T18:51:21.828Z', '2023-05-29T18:51:21.856Z', '2023-05-29T18:51:21.887Z', '2023-05-29T18:51:21.917Z', '2023-05-29T18:51:21.946Z', '2023-05-29T18:51:21.976Z', '2023-05-29T18:51:22.006Z', '2023-05-29T18:51:22.036Z', '2023-05-29T18:51:22.066Z', '2023-05-29T18:51:22.097Z', '2023-05-29T18:51:22.126Z', '2023-05-29T18:51:22.157Z', '2023-05-29T18:51:22.191Z', '2023-05-29T18:51:22.226Z', '2023-05-29T18:51:22.255Z', '2023-05-29T18:51:22.286Z', '2023-05-29T18:51:22.317Z', '2023-05-29T18:51:22.345Z', '2023-05-29T18:51:22.376Z', '2023-05-29T18:51:22.405Z', '2023-05-29T18:51:22.437Z', '2023-05-29T18:51:22.465Z', '2023-05-29T18:51:22.496Z', '2023-05-29T18:51:22.525Z', '2023-05-29T18:51:22.556Z', '2023-05-29T18:51:22.616Z', '2023-05-29T18:51:22.648Z', '2023-05-29T18:51:22.675Z', '2023-05-29T18:51:22.705Z', '2023-05-29T18:51:22.734Z', '2023-05-29T18:51:22.766Z', '2023-05-29T18:51:22.794Z', '2023-05-29T18:51:22.825Z', '2023-05-29T18:51:22.857Z', '2023-05-29T18:51:22.885Z', '2023-05-29T18:51:22.914Z', '2023-05-29T18:51:22.945Z', '2023-05-29T18:51:22.974Z', '2023-05-29T18:51:23.004Z', '2023-05-29T18:51:23.035Z', '2023-05-29T18:51:23.064Z', '2023-05-29T18:51:23.097Z', '2023-05-29T18:51:23.126Z', '2023-05-29T18:51:23.161Z', '2023-05-29T18:51:23.192Z', '2023-05-29T18:51:23.226Z', '2023-05-29T18:51:23.256Z', '2023-05-29T18:51:23.284Z', '2023-05-29T18:51:23.313Z', '2023-05-29T18:51:23.344Z', '2023-05-29T18:51:23.373Z', '2023-05-29T18:51:23.404Z', '2023-05-29T18:51:23.434Z', '2023-05-29T18:51:23.463Z', '2023-05-29T18:51:23.493Z', '2023-05-29T18:51:23.522Z', '2023-05-29T18:51:23.553Z', '2023-05-29T18:51:23.612Z', '2023-05-29T18:51:23.614Z', '2023-05-29T18:51:23.644Z', '2023-05-29T18:51:23.673Z', '2023-05-29T18:51:23.703Z', '2023-05-29T18:51:23.733Z', '2023-05-29T18:51:23.763Z', '2023-05-29T18:51:23.792Z', '2023-05-29T18:51:23.822Z', '2023-05-29T18:51:23.853Z', '2023-05-29T18:51:23.883Z', '2023-05-29T18:51:23.912Z', '2023-05-29T18:51:23.941Z', '2023-05-29T18:51:23.971Z', '2023-05-29T18:51:24.003Z', '2023-05-29T18:51:24.032Z', '2023-05-29T18:51:24.062Z', '2023-05-29T18:51:24.092Z', '2023-05-29T18:51:24.126Z', '2023-05-29T18:51:24.151Z', '2023-05-29T18:51:24.187Z', '2023-05-29T18:51:24.222Z', '2023-05-29T18:51:24.253Z', '2023-05-29T18:51:24.283Z', '2023-05-29T18:51:24.312Z', '2023-05-29T18:51:24.340Z', '2023-05-29T18:51:24.371Z', '2023-05-29T18:51:24.401Z', '2023-05-29T18:51:24.432Z', '2023-05-29T18:51:24.463Z', '2023-05-29T18:51:24.502Z', '2023-05-29T18:51:24.522Z', '2023-05-29T18:51:24.550Z', '2023-05-29T18:51:24.585Z', '2023-05-29T18:51:24.611Z', '2023-05-29T18:51:24.641Z', '2023-05-29T18:51:24.672Z', '2023-05-29T18:51:24.700Z', '2023-05-29T18:51:24.731Z', '2023-05-29T18:51:24.771Z', '2023-05-29T18:51:24.790Z', '2023-05-29T18:51:24.821Z', '2023-05-29T18:51:24.849Z', '2023-05-29T18:51:24.882Z', '2023-05-29T18:51:24.912Z', '2023-05-29T18:51:24.942Z', '2023-05-29T18:51:24.971Z', '2023-05-29T18:51:25.000Z', '2023-05-29T18:51:25.030Z', '2023-05-29T18:51:25.058Z', '2023-05-29T18:51:25.092Z', '2023-05-29T18:51:25.119Z', '2023-05-29T18:51:25.150Z', '2023-05-29T18:51:25.184Z', '2023-05-29T18:51:25.221Z', '2023-05-29T18:51:25.248Z', '2023-05-29T18:51:25.278Z', '2023-05-29T18:51:25.309Z', '2023-05-29T18:51:25.339Z', '2023-05-29T18:51:25.368Z', '2023-05-29T18:51:25.398Z', '2023-05-29T18:51:25.429Z', '2023-05-29T18:51:25.467Z', '2023-05-29T18:51:26.376Z', '2023-05-29T18:51:29.428Z', '2023-05-29T18:51:29.577Z', '2023-05-29T18:51:29.756Z', '2023-05-29T18:51:29.937Z', '2023-05-29T18:51:30.843Z', '2023-05-29T18:51:33.228Z', '2023-05-29T18:51:33.466Z', '2023-05-29T18:51:33.765Z', '2023-05-29T18:51:34.244Z', '2023-05-29T18:51:34.474Z', '2023-05-29T18:51:34.713Z', '2023-05-29T18:51:34.912Z', '2023-05-29T18:51:35.261Z', '2023-05-29T18:51:35.560Z', '2023-05-29T18:51:37.325Z', '2023-05-29T18:51:37.677Z', '2023-05-29T18:51:37.838Z', '2023-05-29T18:51:38.233Z', '2023-05-29T18:51:38.992Z', '2023-05-29T18:51:39.213Z', '2023-05-29T18:51:39.541Z', '2023-05-29T18:51:39.768Z', '2023-05-29T18:51:39.997Z', '2023-05-29T18:51:44.853Z', '2023-05-29T18:51:57.530Z', '2023-05-29T18:51:58.028Z', '2023-05-29T18:51:58.054Z', '2023-05-29T18:51:59.474Z', '2023-05-29T18:51:59.783Z', '2023-05-29T18:52:20.002Z', '2023-05-29T18:52:26.455Z', '2023-05-29T18:55:23.356Z', '2023-05-29T18:55:29.970Z', '2023-05-29T18:58:48.684Z']","here they discuss about the two members  Tamoxifen and raloxifene .  they are acceptance of primary prevention of breast cancer. here aromatase inhabitors it cause fewer side effects than tamoxifen inpatients with early stage breast cancer.
placebo-controlled , double - blind  trial of exemestane designed to detect a 65% relative reduction in invasive breast cancer, eligible postmenopausal women 35 years of age or older had at least one of the following risk factors.AQ total of 4560 women for whom the median age was 62.5 years and the median gali risk score was 2.3 % were randomly assigned .At a median follow-up of 35 months, 11 invasive breast cancers were detected in those given exemestane and in 32 of those given placebo, with a 65% relative reduction in the annual incidence of invasive breast cancer . The annual incidence of invasive plus noninvasive  breast cancers was 0.35% on exemestane  . Adverse events occurred in 88% of the exemestane group and 85% of the placebo group , with no significant differences between the two groups in terms of skeletal fractures, cardiovascular events, other cancers, or treatment-related death
",True
3087LXLJ6M1T4CPCOB4J1CIB3EX0FA,"Effect of Three Decades of Screening Mammography on Breast-Cancer Incidence

To reduce mortality, screening must detect life-threatening disease at an earlier, more curable stage. Effective cancer-screening programs therefore both increase the incidence of cancer detected at an early stage and decrease the incidence of cancer presenting at a late stage.

We used Surveillance, Epidemiology, and End Results data to examine trends from 1976 through 2008 in the incidence of early-stage breast cancer (ductal carcinoma in situ and localized disease) and late-stage breast cancer (regional and distant disease) among women 40 years of age or older.

The introduction of screening mammography in the United States has been associated with a doubling in the number of cases of early-stage breast cancer that are detected each year, from 112 to 234 cases per 100,000 women - an absolute increase of 122 cases per 100,000 women. Concomitantly, the rate at which women present with late-stage cancer has decreased by 8%, from 102 to 94 cases per 100,000 women - an absolute decrease of 8 cases per 100,000 women. With the assumption of a constant underlying disease burden, only 8 of the 122 additional early-stage cancers diagnosed were expected to progress to advanced disease. After excluding the transient excess incidence associated with hormone-replacement therapy and adjusting for trends in the incidence of breast cancer among women younger than 40 years of age, we estimated that breast cancer was overdiagnosed (i.e., tumors were detected on screening that would never have led to clinical symptoms) in 1.3 million U.S. women in the past 30 years. We estimated that in 2008, breast cancer was overdiagnosed in more than 70,000 women; this accounted for 31% of all breast cancers diagnosed.

Despite substantial increases in the number of cases of early-stage breast cancer detected, screening mammography has only marginally reduced the rate at which women present with advanced cancer. Although it is not certain which women have been affected, the imbalance suggests that there is substantial overdiagnosis, accounting for nearly a third of all newly diagnosed breast cancers, and that screening is having, at best, only a small effect on the rate of death from breast cancer.
",Control a Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control v,"['2023-05-29T19:08:13.500Z', '2023-05-29T19:08:13.877Z', '2023-05-29T19:08:14.318Z', '2023-05-29T19:08:14.828Z', '2023-05-29T19:08:14.860Z', '2023-05-29T19:08:14.890Z', '2023-05-29T19:08:14.922Z', '2023-05-29T19:08:14.952Z', '2023-05-29T19:08:14.984Z', '2023-05-29T19:08:15.015Z', '2023-05-29T19:08:15.046Z', '2023-05-29T19:08:15.077Z', '2023-05-29T19:08:15.124Z', '2023-05-29T19:08:15.155Z', '2023-05-29T19:08:15.186Z', '2023-05-29T19:08:15.218Z', '2023-05-29T19:08:15.251Z', '2023-05-29T19:08:15.283Z', '2023-05-29T19:08:15.311Z', '2023-05-29T19:08:15.343Z', '2023-05-29T19:08:15.373Z']","The introduction of screening mammography in the United States has been associated with a doubling in the number of cases of early-stage breast cancer that are detected each year. However, only 8 of the 122 additional early-stage cancers diagnosed were expected to progress to advanced disease. This suggests that there is substantial overdiagnosis of breast cancer, accounting for nearly a third of all newly diagnosed breast cancers. Screening mammography is having, at best, only a small effect on the rate of death from breast cancer.

In conclusion, while screening mammography has led to an increase in the number of early-stage breast cancer diagnoses, it is not clear that this has led to a corresponding decrease in the number of breast cancer deaths. Further research is needed to determine the true impact of screening mammography on breast cancer mortality.",True
3087LXLJ6M1T4CPCOB4J1CIB3EX0FA,"Effect of Three Decades of Screening Mammography on Breast-Cancer Incidence

To reduce mortality, screening must detect life-threatening disease at an earlier, more curable stage. Effective cancer-screening programs therefore both increase the incidence of cancer detected at an early stage and decrease the incidence of cancer presenting at a late stage.

We used Surveillance, Epidemiology, and End Results data to examine trends from 1976 through 2008 in the incidence of early-stage breast cancer (ductal carcinoma in situ and localized disease) and late-stage breast cancer (regional and distant disease) among women 40 years of age or older.

The introduction of screening mammography in the United States has been associated with a doubling in the number of cases of early-stage breast cancer that are detected each year, from 112 to 234 cases per 100,000 women - an absolute increase of 122 cases per 100,000 women. Concomitantly, the rate at which women present with late-stage cancer has decreased by 8%, from 102 to 94 cases per 100,000 women - an absolute decrease of 8 cases per 100,000 women. With the assumption of a constant underlying disease burden, only 8 of the 122 additional early-stage cancers diagnosed were expected to progress to advanced disease. After excluding the transient excess incidence associated with hormone-replacement therapy and adjusting for trends in the incidence of breast cancer among women younger than 40 years of age, we estimated that breast cancer was overdiagnosed (i.e., tumors were detected on screening that would never have led to clinical symptoms) in 1.3 million U.S. women in the past 30 years. We estimated that in 2008, breast cancer was overdiagnosed in more than 70,000 women; this accounted for 31% of all breast cancers diagnosed.

Despite substantial increases in the number of cases of early-stage breast cancer detected, screening mammography has only marginally reduced the rate at which women present with advanced cancer. Although it is not certain which women have been affected, the imbalance suggests that there is substantial overdiagnosis, accounting for nearly a third of all newly diagnosed breast cancers, and that screening is having, at best, only a small effect on the rate of death from breast cancer.
","Shift T o r e d u c e i m m o r t a l i t y , Backspace Backspace End c a n c e r s c r e e i n g Backspace Backspace Backspace Backspace n i n g p r o g r a m s n Backspace i n c r e a s e c a n c e r i n c i d e n Backspace c e a t e a r l y s t a g e a n d d e c r e a s e a t l a t e s t a g e . Shift A s p e r r e p o r t f r o m 1 9 7 6 t o 2 0 0 8 , 4 0 y e a r s o l d w m e n Backspace Backspace Backspace o m e n Backspace Backspace Backspace a g e d a n d a b o v e End h a d b o t h e a r l y a n d l a t e s t a g e b r e a s t c a n c e r . Backspace Shift S c r e e n i n g m a o Backspace m m o g r a p h y i n CapsLock U . S CapsLock r e d u c e d t h e l a t e s t a g e c a n c e r s b y 8 Shift % a n d c a s e s a Backspace 1 . 3 m i l l i o n o m Backspace Backspace w o m e n d i a g n o s e d i n p a s t 3 0 y e a r s a n d 3 3 1 Shift % o f b Backspace Backspace Backspace o f a l l b r e a s t c a n c e r s d i a g n o s e d . i n t r o d u c e d w h i c h Backspace","['2023-05-29T20:22:57.964Z', '2023-05-29T20:22:58.099Z', '2023-05-29T20:22:58.778Z', '2023-05-29T20:22:59.052Z', '2023-05-29T20:22:59.267Z', '2023-05-29T20:22:59.397Z', '2023-05-29T20:22:59.707Z', '2023-05-29T20:22:59.897Z', '2023-05-29T20:23:00.074Z', '2023-05-29T20:23:00.306Z', '2023-05-29T20:23:00.426Z', '2023-05-29T20:23:00.890Z', '2023-05-29T20:23:00.978Z', '2023-05-29T20:23:01.850Z', '2023-05-29T20:23:02.041Z', '2023-05-29T20:23:02.242Z', '2023-05-29T20:23:02.929Z', '2023-05-29T20:23:03.082Z', '2023-05-29T20:23:03.356Z', '2023-05-29T20:23:03.553Z', '2023-05-29T20:23:04.059Z', '2023-05-29T20:23:04.306Z', '2023-05-29T20:23:04.731Z', '2023-05-29T20:23:04.962Z', '2023-05-29T20:23:13.306Z', '2023-05-29T20:23:13.530Z', '2023-05-29T20:23:14.201Z', '2023-05-29T20:24:19.049Z', '2023-05-29T20:24:19.217Z', '2023-05-29T20:24:19.562Z', '2023-05-29T20:24:19.833Z', '2023-05-29T20:24:20.083Z', '2023-05-29T20:24:20.305Z', '2023-05-29T20:24:20.625Z', '2023-05-29T20:24:20.833Z', '2023-05-29T20:24:21.217Z', '2023-05-29T20:24:21.601Z', '2023-05-29T20:24:21.808Z', '2023-05-29T20:24:22.010Z', '2023-05-29T20:24:23.114Z', '2023-05-29T20:24:23.361Z', '2023-05-29T20:24:23.530Z', '2023-05-29T20:24:23.666Z', '2023-05-29T20:24:24.298Z', '2023-05-29T20:24:24.528Z', '2023-05-29T20:24:24.713Z', '2023-05-29T20:24:24.872Z', '2023-05-29T20:24:25.969Z', '2023-05-29T20:24:26.201Z', '2023-05-29T20:24:26.386Z', '2023-05-29T20:24:26.553Z', '2023-05-29T20:24:26.672Z', '2023-05-29T20:24:26.817Z', '2023-05-29T20:24:26.970Z', '2023-05-29T20:24:27.345Z', '2023-05-29T20:24:27.585Z', '2023-05-29T20:24:27.873Z', '2023-05-29T20:24:27.993Z', '2023-05-29T20:24:28.221Z', '2023-05-29T20:24:28.386Z', '2023-05-29T20:24:28.538Z', '2023-05-29T20:25:52.176Z', '2023-05-29T20:25:53.057Z', '2023-05-29T20:25:53.664Z', '2023-05-29T20:25:53.880Z', '2023-05-29T20:25:54.084Z', '2023-05-29T20:25:54.360Z', '2023-05-29T20:25:54.511Z', '2023-05-29T20:25:54.608Z', '2023-05-29T20:25:54.864Z', '2023-05-29T20:25:54.984Z', '2023-05-29T20:25:55.328Z', '2023-05-29T20:26:00.952Z', '2023-05-29T20:26:09.319Z', '2023-05-29T20:26:10.080Z', '2023-05-29T20:26:10.391Z', '2023-05-29T20:26:11.015Z', '2023-05-29T20:26:11.201Z', '2023-05-29T20:26:11.504Z', '2023-05-29T20:26:11.768Z', '2023-05-29T20:26:12.296Z', '2023-05-29T20:26:12.514Z', '2023-05-29T20:26:12.672Z', '2023-05-29T20:26:12.808Z', '2023-05-29T20:26:13.048Z', '2023-05-29T20:26:13.232Z', '2023-05-29T20:26:14.536Z', '2023-05-29T20:26:15.263Z', '2023-05-29T20:26:15.511Z', '2023-05-29T20:26:15.807Z', '2023-05-29T20:26:16.216Z', '2023-05-29T20:26:19.588Z', '2023-05-29T20:26:19.808Z', '2023-05-29T20:26:19.951Z', '2023-05-29T20:26:20.089Z', '2023-05-29T20:26:20.216Z', '2023-05-29T20:26:20.455Z', '2023-05-29T20:26:20.632Z', '2023-05-29T20:26:21.128Z', '2023-05-29T20:26:21.279Z', '2023-05-29T20:26:21.472Z', '2023-05-29T20:26:21.704Z', '2023-05-29T20:26:21.960Z', '2023-05-29T20:26:22.280Z', '2023-05-29T20:26:22.496Z', '2023-05-29T20:26:22.751Z', '2023-05-29T20:26:22.928Z', '2023-05-29T20:26:23.129Z', '2023-05-29T20:26:23.244Z', '2023-05-29T20:26:23.369Z', '2023-05-29T20:26:23.496Z', '2023-05-29T20:26:23.728Z', '2023-05-29T20:26:24.000Z', '2023-05-29T20:26:24.247Z', '2023-05-29T20:26:24.360Z', '2023-05-29T20:26:24.504Z', '2023-05-29T20:26:24.735Z', '2023-05-29T20:26:24.848Z', '2023-05-29T20:26:25.248Z', '2023-05-29T20:26:36.458Z', '2023-05-29T20:26:36.690Z', '2023-05-29T20:26:36.801Z', '2023-05-29T20:26:36.992Z', '2023-05-29T20:26:37.187Z', '2023-05-29T20:26:38.030Z', '2023-05-29T20:26:38.145Z', '2023-05-29T20:26:38.505Z', '2023-05-29T20:26:39.024Z', '2023-05-29T20:26:39.328Z', '2023-05-29T20:26:39.510Z', '2023-05-29T20:26:39.721Z', '2023-05-29T20:26:39.889Z', '2023-05-29T20:26:40.065Z', '2023-05-29T20:26:40.274Z', '2023-05-29T20:28:07.311Z', '2023-05-29T20:28:07.431Z', '2023-05-29T20:28:07.646Z', '2023-05-29T20:28:07.863Z', '2023-05-29T20:28:08.064Z', '2023-05-29T20:28:08.238Z', '2023-05-29T20:28:08.367Z', '2023-05-29T20:28:08.615Z', '2023-05-29T20:28:08.775Z', '2023-05-29T20:28:08.838Z', '2023-05-29T20:28:09.070Z', '2023-05-29T20:28:09.455Z', '2023-05-29T20:28:09.663Z', '2023-05-29T20:28:09.911Z', '2023-05-29T20:28:10.103Z', '2023-05-29T20:28:10.223Z', '2023-05-29T20:28:10.430Z', '2023-05-29T20:28:10.542Z', '2023-05-29T20:28:10.727Z', '2023-05-29T20:28:10.846Z', '2023-05-29T20:28:11.063Z', '2023-05-29T20:28:11.447Z', '2023-05-29T20:28:11.910Z', '2023-05-29T20:28:12.735Z', '2023-05-29T20:28:12.946Z', '2023-05-29T20:28:13.159Z', '2023-05-29T20:28:13.286Z', '2023-05-29T20:28:13.408Z', '2023-05-29T20:28:13.566Z', '2023-05-29T20:28:13.718Z', '2023-05-29T20:28:13.903Z', '2023-05-29T20:28:14.136Z', '2023-05-29T20:28:15.958Z', '2023-05-29T20:28:16.223Z', '2023-05-29T20:28:16.494Z', '2023-05-29T20:28:16.671Z', '2023-05-29T20:28:16.775Z', '2023-05-29T20:28:17.102Z', '2023-05-29T20:28:17.126Z', '2023-05-29T20:28:17.271Z', '2023-05-29T20:28:17.399Z', '2023-05-29T20:28:18.150Z', '2023-05-29T20:28:18.424Z', '2023-05-29T20:28:19.047Z', '2023-05-29T20:28:19.296Z', '2023-05-29T20:28:19.422Z', '2023-05-29T20:28:19.550Z', '2023-05-29T20:28:19.750Z', '2023-05-29T20:28:20.519Z', '2023-05-29T20:28:20.702Z', '2023-05-29T20:28:20.901Z', '2023-05-29T20:28:22.103Z', '2023-05-29T20:28:22.295Z', '2023-05-29T20:28:22.478Z', '2023-05-29T20:28:23.615Z', '2023-05-29T20:28:23.806Z', '2023-05-29T20:28:23.910Z', '2023-05-29T20:28:24.071Z', '2023-05-29T20:28:37.247Z', '2023-05-29T20:28:37.455Z', '2023-05-29T20:28:37.615Z', '2023-05-29T20:28:38.959Z', '2023-05-29T20:28:39.201Z', '2023-05-29T20:28:39.409Z', '2023-05-29T20:28:39.666Z', '2023-05-29T20:29:01.903Z', '2023-05-29T20:29:02.135Z', '2023-05-29T20:29:02.248Z', '2023-05-29T20:29:02.375Z', '2023-05-29T20:29:02.559Z', '2023-05-29T20:29:03.143Z', '2023-05-29T20:29:03.368Z', '2023-05-29T20:29:03.544Z', '2023-05-29T20:29:03.798Z', '2023-05-29T20:29:04.032Z', '2023-05-29T20:29:05.551Z', '2023-05-29T20:29:22.785Z', '2023-05-29T20:29:23.191Z', '2023-05-29T20:29:23.318Z', '2023-05-29T20:29:23.512Z', '2023-05-29T20:29:23.688Z', '2023-05-29T20:29:23.871Z', '2023-05-29T20:29:24.014Z', '2023-05-29T20:29:24.175Z', '2023-05-29T20:29:24.359Z', '2023-05-29T20:29:24.950Z', '2023-05-29T20:29:25.063Z', '2023-05-29T20:29:25.304Z', '2023-05-29T20:29:25.584Z', '2023-05-29T20:29:25.767Z', '2023-05-29T20:29:26.038Z', '2023-05-29T20:29:27.096Z', '2023-05-29T20:29:27.239Z', '2023-05-29T20:29:27.463Z', '2023-05-29T20:29:27.544Z', '2023-05-29T20:29:27.680Z', '2023-05-29T20:29:27.799Z', '2023-05-29T20:29:27.943Z', '2023-05-29T20:29:28.174Z', '2023-05-29T20:29:28.368Z', '2023-05-29T20:29:28.944Z', '2023-05-29T20:29:29.207Z', '2023-05-29T20:29:29.454Z', '2023-05-29T20:29:30.247Z', '2023-05-29T20:29:30.462Z', '2023-05-29T20:29:30.711Z', '2023-05-29T20:29:31.688Z', '2023-05-29T20:29:31.832Z', '2023-05-29T20:29:32.086Z', '2023-05-29T20:29:32.216Z', '2023-05-29T20:29:32.448Z', '2023-05-29T20:29:32.663Z', '2023-05-29T20:29:32.806Z', '2023-05-29T20:29:33.038Z', '2023-05-29T20:29:33.206Z', '2023-05-29T20:29:33.327Z', '2023-05-29T20:29:33.566Z', '2023-05-29T20:29:33.687Z', '2023-05-29T20:29:33.943Z', '2023-05-29T20:29:34.167Z', '2023-05-29T20:29:34.390Z', '2023-05-29T20:29:34.600Z', '2023-05-29T20:29:37.119Z', '2023-05-29T20:29:38.495Z', '2023-05-29T20:32:33.677Z', '2023-05-29T20:32:33.804Z', '2023-05-29T20:32:34.148Z', '2023-05-29T20:32:34.437Z', '2023-05-29T20:32:34.644Z', '2023-05-29T20:32:34.803Z', '2023-05-29T20:32:35.077Z', '2023-05-29T20:32:35.260Z', '2023-05-29T20:32:35.428Z', '2023-05-29T20:32:35.573Z', '2023-05-29T20:32:40.940Z', '2023-05-29T20:32:41.429Z', '2023-05-29T20:32:41.627Z', '2023-05-29T20:32:42.188Z', '2023-05-29T20:32:42.899Z', '2023-05-29T20:32:43.301Z', '2023-05-29T20:32:43.492Z', '2023-05-29T20:32:43.724Z', '2023-05-29T20:32:44.221Z', '2023-05-29T20:32:44.588Z', '2023-05-29T20:32:44.813Z', '2023-05-29T20:32:45.149Z', '2023-05-29T20:32:46.107Z', '2023-05-29T20:32:46.420Z', '2023-05-29T20:33:42.796Z', '2023-05-29T20:33:43.116Z', '2023-05-29T20:33:43.300Z', '2023-05-29T20:33:43.445Z', '2023-05-29T20:33:44.176Z', '2023-05-29T20:33:44.260Z', '2023-05-29T20:33:44.564Z', '2023-05-29T20:33:44.788Z', '2023-05-29T20:33:45.079Z', '2023-05-29T20:33:46.356Z', '2023-05-29T20:33:46.836Z', '2023-05-29T20:33:46.932Z', '2023-05-29T20:33:47.325Z', '2023-05-29T20:33:47.507Z', '2023-05-29T20:33:47.756Z', '2023-05-29T20:33:48.004Z', '2023-05-29T20:33:48.253Z', '2023-05-29T20:33:48.509Z', '2023-05-29T20:33:49.140Z', '2023-05-29T20:33:49.323Z', '2023-05-29T20:33:49.387Z', '2023-05-29T20:33:49.588Z', '2023-05-29T20:34:02.251Z', '2023-05-29T20:34:02.364Z', '2023-05-29T20:34:02.644Z', '2023-05-29T20:34:02.730Z', '2023-05-29T20:34:02.915Z', '2023-05-29T20:34:03.220Z', '2023-05-29T20:34:03.428Z', '2023-05-29T20:34:04.172Z', '2023-05-29T20:34:04.420Z', '2023-05-29T20:34:04.596Z', '2023-05-29T20:34:04.773Z', '2023-05-29T20:34:04.956Z', '2023-05-29T20:34:05.084Z', '2023-05-29T20:34:05.276Z', '2023-05-29T20:34:05.381Z', '2023-05-29T20:34:05.644Z', '2023-05-29T20:34:05.803Z', '2023-05-29T20:34:06.034Z', '2023-05-29T20:34:06.875Z', '2023-05-29T20:34:07.187Z', '2023-05-29T20:34:07.419Z', '2023-05-29T20:34:07.548Z', '2023-05-29T20:34:08.315Z', '2023-05-29T20:34:10.443Z', '2023-05-29T20:34:10.836Z', '2023-05-29T20:34:10.971Z', '2023-05-29T20:34:11.580Z', '2023-05-29T20:34:12.844Z', '2023-05-29T20:34:13.082Z', '2023-05-29T20:34:13.292Z', '2023-05-29T20:34:13.476Z', '2023-05-29T20:34:19.509Z', '2023-05-29T20:34:19.652Z', '2023-05-29T20:34:19.870Z', '2023-05-29T20:34:20.012Z', '2023-05-29T20:34:20.230Z', '2023-05-29T20:34:20.427Z', '2023-05-29T20:38:14.530Z', '2023-05-29T20:38:16.024Z', '2023-05-29T20:38:16.745Z', '2023-05-29T20:38:17.329Z', '2023-05-29T20:38:17.578Z', '2023-05-29T20:38:18.432Z', '2023-05-29T20:38:18.674Z', '2023-05-29T20:38:18.929Z', '2023-05-29T20:38:19.184Z', '2023-05-29T20:38:19.352Z', '2023-05-29T20:38:20.121Z', '2023-05-29T20:38:20.309Z', '2023-05-29T20:38:20.490Z', '2023-05-29T20:38:21.408Z', '2023-05-29T20:38:21.753Z', '2023-05-29T20:38:22.089Z', '2023-05-29T20:38:22.801Z', '2023-05-29T20:38:23.745Z', '2023-05-29T20:38:23.977Z', '2023-05-29T20:38:25.225Z', '2023-05-29T20:38:25.497Z', '2023-05-29T20:38:25.625Z', '2023-05-29T20:38:25.801Z', '2023-05-29T20:38:25.937Z', '2023-05-29T20:38:26.080Z', '2023-05-29T20:38:26.200Z', '2023-05-29T20:38:26.576Z', '2023-05-29T20:38:27.354Z', '2023-05-29T20:38:27.648Z', '2023-05-29T20:38:27.858Z', '2023-05-29T20:38:28.008Z', '2023-05-29T20:38:28.169Z', '2023-05-29T20:38:28.410Z', '2023-05-29T20:38:34.153Z', '2023-05-29T20:38:34.682Z', '2023-05-29T20:38:34.844Z', '2023-05-29T20:38:34.994Z', '2023-05-29T20:38:36.048Z', '2023-05-29T20:38:36.176Z', '2023-05-29T20:38:36.352Z', '2023-05-29T20:38:36.513Z', '2023-05-29T20:38:36.688Z', '2023-05-29T20:38:36.905Z', '2023-05-29T20:38:37.185Z', '2023-05-29T20:38:37.424Z', '2023-05-29T20:38:37.720Z', '2023-05-29T20:38:37.817Z', '2023-05-29T20:38:37.985Z', '2023-05-29T20:38:38.178Z', '2023-05-29T20:38:38.427Z', '2023-05-29T20:38:40.085Z', '2023-05-29T20:38:40.433Z', '2023-05-29T20:38:40.753Z', '2023-05-29T20:38:41.009Z', '2023-05-29T20:38:41.224Z', '2023-05-29T20:38:43.672Z', '2023-05-29T20:38:43.696Z', '2023-05-29T20:38:43.881Z', '2023-05-29T20:38:49.962Z', '2023-05-29T20:38:50.450Z', '2023-05-29T20:38:50.585Z', '2023-05-29T20:38:51.936Z', '2023-05-29T20:38:52.121Z', '2023-05-29T20:38:52.641Z', '2023-05-29T20:38:53.481Z', '2023-05-29T20:38:53.679Z', '2023-05-29T20:38:53.864Z', '2023-05-29T20:38:54.544Z', '2023-05-29T20:38:55.112Z', '2023-05-29T20:38:55.304Z', '2023-05-29T20:38:55.464Z', '2023-05-29T20:38:55.672Z', '2023-05-29T20:38:56.112Z', '2023-05-29T20:38:56.305Z', '2023-05-29T20:38:56.440Z', '2023-05-29T20:38:56.634Z', '2023-05-29T20:38:56.909Z', '2023-05-29T20:38:57.017Z', '2023-05-29T20:38:57.148Z', '2023-05-29T20:38:57.358Z', '2023-05-29T20:38:57.497Z', '2023-05-29T20:38:57.680Z', '2023-05-29T20:38:57.831Z', '2023-05-29T20:38:57.921Z', '2023-05-29T20:38:58.095Z', '2023-05-29T20:38:58.240Z', '2023-05-29T20:38:58.472Z', '2023-05-29T20:38:58.623Z', '2023-05-29T20:38:58.849Z', '2023-05-29T20:38:59.024Z', '2023-05-29T20:38:59.160Z', '2023-05-29T20:38:59.280Z', '2023-05-29T20:38:59.408Z', '2023-05-29T20:38:59.792Z', '2023-05-29T20:39:00.190Z', '2023-05-29T20:39:00.343Z', '2023-05-29T20:39:00.511Z', '2023-05-29T20:39:00.631Z', '2023-05-29T20:39:00.903Z', '2023-05-29T20:39:01.151Z', '2023-05-29T20:39:01.352Z', '2023-05-29T20:42:12.542Z', '2023-05-29T20:42:12.685Z', '2023-05-29T20:42:13.110Z', '2023-05-29T20:42:13.276Z', '2023-05-29T20:42:13.404Z', '2023-05-29T20:42:13.573Z', '2023-05-29T20:42:13.789Z', '2023-05-29T20:42:14.044Z', '2023-05-29T20:42:14.765Z', '2023-05-29T20:42:15.076Z', '2023-05-29T20:42:15.276Z', '2023-05-29T20:42:20.364Z', '2023-05-29T20:42:20.574Z', '2023-05-29T20:42:20.693Z', '2023-05-29T20:42:20.828Z', '2023-05-29T20:42:20.998Z', '2023-05-29T20:42:21.149Z', '2023-05-29T20:42:30.205Z']","To reduce mortality, cancer screening programs increase cancer incidence at early stage and decrease at late stage. As per report from 1976 to 2008, 40 years and above aged women had both early and late stage breast cancer. Screening mammography introduced in U.S which reduced the late stage cancers cases by 8 % and 1.3 million women diagnosed in past 30 years and 33 % of all breast cancers diagnosed. ",False
3087LXLJ6M1T4CPCOB4J1CIB3EX0FA,"Effect of Three Decades of Screening Mammography on Breast-Cancer Incidence

To reduce mortality, screening must detect life-threatening disease at an earlier, more curable stage. Effective cancer-screening programs therefore both increase the incidence of cancer detected at an early stage and decrease the incidence of cancer presenting at a late stage.

We used Surveillance, Epidemiology, and End Results data to examine trends from 1976 through 2008 in the incidence of early-stage breast cancer (ductal carcinoma in situ and localized disease) and late-stage breast cancer (regional and distant disease) among women 40 years of age or older.

The introduction of screening mammography in the United States has been associated with a doubling in the number of cases of early-stage breast cancer that are detected each year, from 112 to 234 cases per 100,000 women - an absolute increase of 122 cases per 100,000 women. Concomitantly, the rate at which women present with late-stage cancer has decreased by 8%, from 102 to 94 cases per 100,000 women - an absolute decrease of 8 cases per 100,000 women. With the assumption of a constant underlying disease burden, only 8 of the 122 additional early-stage cancers diagnosed were expected to progress to advanced disease. After excluding the transient excess incidence associated with hormone-replacement therapy and adjusting for trends in the incidence of breast cancer among women younger than 40 years of age, we estimated that breast cancer was overdiagnosed (i.e., tumors were detected on screening that would never have led to clinical symptoms) in 1.3 million U.S. women in the past 30 years. We estimated that in 2008, breast cancer was overdiagnosed in more than 70,000 women; this accounted for 31% of all breast cancers diagnosed.

Despite substantial increases in the number of cases of early-stage breast cancer detected, screening mammography has only marginally reduced the rate at which women present with advanced cancer. Although it is not certain which women have been affected, the imbalance suggests that there is substantial overdiagnosis, accounting for nearly a third of all newly diagnosed breast cancers, and that screening is having, at best, only a small effect on the rate of death from breast cancer.
",b e n i f i t Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace CapsLock B E N I F I T O F M E D I C I N E S Backspace Enter,"['2023-05-30T04:00:56.353Z', '2023-05-30T04:00:57.052Z', '2023-05-30T04:00:57.798Z', '2023-05-30T04:00:58.044Z', '2023-05-30T04:00:58.613Z', '2023-05-30T04:00:59.130Z', '2023-05-30T04:00:59.588Z', '2023-05-30T04:01:01.635Z', '2023-05-30T04:01:02.136Z', '2023-05-30T04:01:02.228Z', '2023-05-30T04:01:02.267Z', '2023-05-30T04:01:02.296Z', '2023-05-30T04:01:02.326Z', '2023-05-30T04:01:02.366Z', '2023-05-30T04:01:02.396Z', '2023-05-30T04:01:02.427Z', '2023-05-30T04:01:02.458Z', '2023-05-30T04:01:02.496Z', '2023-05-30T04:01:02.527Z', '2023-05-30T04:01:02.560Z', '2023-05-30T04:01:02.597Z', '2023-05-30T04:01:02.626Z', '2023-05-30T04:01:02.657Z', '2023-05-30T04:01:02.698Z', '2023-05-30T04:01:02.727Z', '2023-05-30T04:01:02.756Z', '2023-05-30T04:01:02.787Z', '2023-05-30T04:01:02.901Z', '2023-05-30T04:01:03.675Z', '2023-05-30T04:01:04.591Z', '2023-05-30T04:01:06.746Z', '2023-05-30T04:01:07.202Z', '2023-05-30T04:01:07.772Z', '2023-05-30T04:01:08.661Z', '2023-05-30T04:01:09.220Z', '2023-05-30T04:01:09.547Z', '2023-05-30T04:01:09.894Z', '2023-05-30T04:01:10.346Z', '2023-05-30T04:01:10.954Z', '2023-05-30T04:01:11.242Z', '2023-05-30T04:01:11.623Z', '2023-05-30T04:01:12.058Z', '2023-05-30T04:01:12.346Z', '2023-05-30T04:01:12.966Z', '2023-05-30T04:01:13.349Z', '2023-05-30T04:01:13.794Z', '2023-05-30T04:01:14.100Z', '2023-05-30T04:01:14.514Z', '2023-05-30T04:01:18.658Z', '2023-05-30T04:01:19.874Z', '2023-05-30T04:01:24.130Z']","BENIFIT OF MEDICINE
Medicines are chemicals or compounds used to cure, halt, or prevent disease; ease symptoms; or help in the diagnosis of illnesses. Advances in medicines have enabled doctors to cure many diseases and save livesThe benefits of medicines are the helpful effects you get when you use them, such as lowering blood pressure, curing infection, or relieving pain.Penicillin (1942) Penicillin was first developed in 1928 but started to be used in 1942. As the first official antibiotic, it marked a turning point in human history and led the way in the treatment of numerous bacterial diseases.",False
3WRBLBQ2GRTZICL7ZVA1JXIN4TX0G9,"Primary Prevention of Cardiovascular Disease with a Mediterranean Diet

Observational cohort studies and a secondary prevention trial have shown an inverse association between adherence to the Mediterranean diet and cardiovascular risk. We conducted a randomized trial of this diet pattern for the primary prevention of cardiovascular events.

In a multicenter trial in Spain, we randomly assigned participants who were at high cardiovascular risk, but with no cardiovascular disease at enrollment, to one of three diets; a Mediterranean diet supplemented with extra-virgin olive oil, a Mediterranean diet supplemented with mixed nuts, or a control diet (advice to reduce dietary fat). Participants received quarterly individual and group educational sessions and, depending on group assignment, free provision of extra-virgin olive oil, mixed nuts, or small nonfood gifts. The primary end point was the rate of major cardiovascular events (myocardial infarction, stroke, or death from cardiovascular causes). On the basis of the results of an interim analysis, the trial was stopped after a median follow-up of 4.8 years.

A total of 7447 persons were enrolled (age range, 55 to 80 years); 57% were women. The two Mediterranean-diet groups had good adherence to the intervention, according to self-reported intake and biomarker analyses. A primary end-point event occurred in 288 participants. The multivariable-adjusted hazard ratios were 0.70 (95% confidence interval (CI), 0.54 to 0.92) and 0.72 (95% CI, 0.54 to 0.96) for the group assigned to a Mediterranean diet with extra-virgin olive oil (96 events) and the group assigned to a Mediterranean diet with nuts (83 events), respectively, versus the control group (109 events). No diet-related adverse effects were reported.

Among persons at high cardiovascular risk, a Mediterranean diet supplemented with extra-virgin olive oil or nuts reduced the incidence of major cardiovascular events.
",Control C Control C Control Control Control Control V,"['2023-05-29T18:46:07.868Z', '2023-05-29T18:46:08.311Z', '2023-05-29T18:47:43.375Z', '2023-05-29T18:47:43.790Z', '2023-05-29T18:50:13.425Z', '2023-05-29T18:50:13.938Z', '2023-05-29T18:50:13.956Z', '2023-05-29T18:50:13.991Z', '2023-05-29T18:50:14.012Z']",Observational cohort studies and a secondary prevention trial have shown an inverse association between adherence to the Mediterranean diet and cardiovascular risk. We conducted a randomized trial of this diet pattern for the primary prevention of cardiovascular events.,False
3WRBLBQ2GRTZICL7ZVA1JXIN4TX0G9,"Primary Prevention of Cardiovascular Disease with a Mediterranean Diet

Observational cohort studies and a secondary prevention trial have shown an inverse association between adherence to the Mediterranean diet and cardiovascular risk. We conducted a randomized trial of this diet pattern for the primary prevention of cardiovascular events.

In a multicenter trial in Spain, we randomly assigned participants who were at high cardiovascular risk, but with no cardiovascular disease at enrollment, to one of three diets; a Mediterranean diet supplemented with extra-virgin olive oil, a Mediterranean diet supplemented with mixed nuts, or a control diet (advice to reduce dietary fat). Participants received quarterly individual and group educational sessions and, depending on group assignment, free provision of extra-virgin olive oil, mixed nuts, or small nonfood gifts. The primary end point was the rate of major cardiovascular events (myocardial infarction, stroke, or death from cardiovascular causes). On the basis of the results of an interim analysis, the trial was stopped after a median follow-up of 4.8 years.

A total of 7447 persons were enrolled (age range, 55 to 80 years); 57% were women. The two Mediterranean-diet groups had good adherence to the intervention, according to self-reported intake and biomarker analyses. A primary end-point event occurred in 288 participants. The multivariable-adjusted hazard ratios were 0.70 (95% confidence interval (CI), 0.54 to 0.92) and 0.72 (95% CI, 0.54 to 0.96) for the group assigned to a Mediterranean diet with extra-virgin olive oil (96 events) and the group assigned to a Mediterranean diet with nuts (83 events), respectively, versus the control group (109 events). No diet-related adverse effects were reported.

Among persons at high cardiovascular risk, a Mediterranean diet supplemented with extra-virgin olive oil or nuts reduced the incidence of major cardiovascular events.
",F11 CapsLock I N A M U L T I C E N T E R T R I A L I N S P I N W E R A N D O M L Y A S S I G N E D P A R T I C I P A N T S W H O W E R E A T H I G H C A A A A A A A A Backspace Backspace Backspace Backspace Backspace Backspace Backspace E Backspace R D I O V A S C U A Backspace L A E R R I C K M E D I T E R R A N E A N D E Backspace I E T S U U Backspace P P L E M E N T E D W I T H E X T R A F R E E P R O V I S I O N Q U A R T E E L Y I N D I V I D U A L A N D G R O U P E D I Backspace U C A T I O N A L S E S S I O N S A N D D E P E N D I N G O N G R O U P A S S I G N M E N T A T O T A ; Backspace Backspace Backspace R Backspace T A L O F 7 4 4 7 P R Backspace E R S O N S W E R E E N R O L L E D 5 7 5 Backspace Shift Shift Shift % W E R E W O M A N T H E T W O M E D I T E R R A N E A N D I E T G R O U P S H A D G P Backspace O O D A D H E R E N C E T O T H E I N T E R V E N T I O N A N D T H E G R O U P A S S I G N N Backspace E D T O A M E D I T E R R A N E A N D I E T W I T H N U T S 8 3 E V E N T S R E S P E C T I V E L Y V E R S U S T H E C O N T R O ; Backspace Backspace L G R O U P 1 0 9 E V E N T S E F F E C T S W E R W R E P O R T E D A M E D I T E R R A N E A N D I E T S U U Backspace P P L E M E N T E D W I T H E X T R A V I R G I N O L I V E O I L O R N U T S R E D U C E D T H E I N C I D E N C E O F M A J O R C A R D I P Backspace O V A S C U L A R E V E N T S .,"['2023-05-30T02:23:03.968Z', '2023-05-30T02:23:17.887Z', '2023-05-30T02:23:19.429Z', '2023-05-30T02:23:19.669Z', '2023-05-30T02:23:21.045Z', '2023-05-30T02:23:21.453Z', '2023-05-30T02:23:21.701Z', '2023-05-30T02:23:21.997Z', '2023-05-30T02:23:22.245Z', '2023-05-30T02:23:23.541Z', '2023-05-30T02:23:23.957Z', '2023-05-30T02:23:24.318Z', '2023-05-30T02:23:25.549Z', '2023-05-30T02:23:25.781Z', '2023-05-30T02:23:26.341Z', '2023-05-30T02:23:26.629Z', '2023-05-30T02:23:26.853Z', '2023-05-30T02:23:28.245Z', '2023-05-30T02:23:28.589Z', '2023-05-30T02:23:28.990Z', '2023-05-30T02:23:29.198Z', '2023-05-30T02:23:30.149Z', '2023-05-30T02:23:30.413Z', '2023-05-30T02:23:30.629Z', '2023-05-30T02:23:30.942Z', '2023-05-30T02:23:32.125Z', '2023-05-30T02:23:32.446Z', '2023-05-30T02:23:32.805Z', '2023-05-30T02:23:33.238Z', '2023-05-30T02:23:33.453Z', '2023-05-30T02:23:33.717Z', '2023-05-30T02:23:33.997Z', '2023-05-30T02:23:34.285Z', '2023-05-30T02:23:35.350Z', '2023-05-30T02:23:35.797Z', '2023-05-30T02:23:36.077Z', '2023-05-30T02:23:36.726Z', '2023-05-30T02:23:36.982Z', '2023-05-30T02:23:37.445Z', '2023-05-30T02:23:38.589Z', '2023-05-30T02:23:38.973Z', '2023-05-30T02:23:39.757Z', '2023-05-30T02:23:39.908Z', '2023-05-30T02:23:40.244Z', '2023-05-30T02:23:40.580Z', '2023-05-30T02:23:41.509Z', '2023-05-30T02:23:41.805Z', '2023-05-30T02:23:41.996Z', '2023-05-30T02:23:42.885Z', '2023-05-30T02:23:43.868Z', '2023-05-30T02:23:44.533Z', '2023-05-30T02:23:44.869Z', '2023-05-30T02:23:45.101Z', '2023-05-30T02:23:45.453Z', '2023-05-30T02:23:46.277Z', '2023-05-30T02:23:46.573Z', '2023-05-30T02:23:47.030Z', '2023-05-30T02:23:48.957Z', '2023-05-30T02:23:50.245Z', '2023-05-30T02:23:51.869Z', '2023-05-30T02:23:52.565Z', '2023-05-30T02:23:55.709Z', '2023-05-30T02:23:55.997Z', '2023-05-30T02:23:56.213Z', '2023-05-30T02:23:56.445Z', '2023-05-30T02:23:56.597Z', '2023-05-30T02:23:56.821Z', '2023-05-30T02:23:57.829Z', '2023-05-30T02:23:58.022Z', '2023-05-30T02:23:58.317Z', '2023-05-30T02:23:58.620Z', '2023-05-30T02:24:00.269Z', '2023-05-30T02:24:00.757Z', '2023-05-30T02:24:00.965Z', '2023-05-30T02:24:01.181Z', '2023-05-30T02:24:01.629Z', '2023-05-30T02:24:03.901Z', '2023-05-30T02:24:04.124Z', '2023-05-30T02:24:05.045Z', '2023-05-30T02:24:07.532Z', '2023-05-30T02:24:07.821Z', '2023-05-30T02:24:08.204Z', '2023-05-30T02:24:08.421Z', '2023-05-30T02:24:08.757Z', '2023-05-30T02:24:10.381Z', '2023-05-30T02:24:10.589Z', '2023-05-30T02:24:11.501Z', '2023-05-30T02:24:12.007Z', '2023-05-30T02:24:12.037Z', '2023-05-30T02:24:12.070Z', '2023-05-30T02:24:12.107Z', '2023-05-30T02:24:12.138Z', '2023-05-30T02:24:12.169Z', '2023-05-30T02:24:12.229Z', '2023-05-30T02:24:13.485Z', '2023-05-30T02:24:13.981Z', '2023-05-30T02:24:14.013Z', '2023-05-30T02:24:14.044Z', '2023-05-30T02:24:14.081Z', '2023-05-30T02:24:14.957Z', '2023-05-30T02:24:19.173Z', '2023-05-30T02:24:45.532Z', '2023-05-30T02:24:46.004Z', '2023-05-30T02:24:48.468Z', '2023-05-30T02:24:48.772Z', '2023-05-30T02:24:48.956Z', '2023-05-30T02:24:51.228Z', '2023-05-30T02:24:51.556Z', '2023-05-30T02:24:53.029Z', '2023-05-30T02:24:53.556Z', '2023-05-30T02:24:54.084Z', '2023-05-30T02:24:55.716Z', '2023-05-30T02:24:57.693Z', '2023-05-30T02:24:58.084Z', '2023-05-30T02:24:58.347Z', '2023-05-30T02:24:58.548Z', '2023-05-30T02:24:58.732Z', '2023-05-30T02:24:59.140Z', '2023-05-30T02:25:03.428Z', '2023-05-30T02:25:03.540Z', '2023-05-30T02:25:03.896Z', '2023-05-30T02:25:04.476Z', '2023-05-30T02:25:04.804Z', '2023-05-30T02:25:08.484Z', '2023-05-30T02:25:08.756Z', '2023-05-30T02:25:09.188Z', '2023-05-30T02:25:11.028Z', '2023-05-30T02:25:12.276Z', '2023-05-30T02:25:12.867Z', '2023-05-30T02:25:14.220Z', '2023-05-30T02:25:14.444Z', '2023-05-30T02:25:15.035Z', '2023-05-30T02:25:15.484Z', '2023-05-30T02:25:15.687Z', '2023-05-30T02:25:17.451Z', '2023-05-30T02:25:17.724Z', '2023-05-30T02:25:18.043Z', '2023-05-30T02:25:18.972Z', '2023-05-30T02:25:19.316Z', '2023-05-30T02:25:20.180Z', '2023-05-30T02:25:20.572Z', '2023-05-30T02:25:20.972Z', '2023-05-30T02:25:21.252Z', '2023-05-30T02:25:21.619Z', '2023-05-30T02:25:23.516Z', '2023-05-30T02:25:23.755Z', '2023-05-30T02:25:24.388Z', '2023-05-30T02:25:25.060Z', '2023-05-30T02:25:25.508Z', '2023-05-30T02:25:25.772Z', '2023-05-30T02:25:27.459Z', '2023-05-30T02:25:27.795Z', '2023-05-30T02:25:28.820Z', '2023-05-30T02:25:29.084Z', '2023-05-30T02:25:30.284Z', '2023-05-30T02:25:30.692Z', '2023-05-30T02:25:30.988Z', '2023-05-30T02:25:31.211Z', '2023-05-30T02:25:31.652Z', '2023-05-30T02:25:32.348Z', '2023-05-30T02:25:32.596Z', '2023-05-30T02:25:32.932Z', '2023-05-30T02:25:33.203Z', '2023-05-30T02:25:33.524Z', '2023-05-30T02:25:34.508Z', '2023-05-30T02:25:34.844Z', '2023-05-30T02:25:36.204Z', '2023-05-30T02:25:36.428Z', '2023-05-30T02:25:36.596Z', '2023-05-30T02:25:36.796Z', '2023-05-30T02:25:39.316Z', '2023-05-30T02:25:39.531Z', '2023-05-30T02:25:40.180Z', '2023-05-30T02:25:40.356Z', '2023-05-30T02:25:41.627Z', '2023-05-30T02:25:44.643Z', '2023-05-30T02:25:44.940Z', '2023-05-30T02:25:46.108Z', '2023-05-30T02:25:46.683Z', '2023-05-30T02:25:47.163Z', '2023-05-30T02:25:48.219Z', '2023-05-30T02:25:48.444Z', '2023-05-30T02:25:48.659Z', '2023-05-30T02:25:48.923Z', '2023-05-30T02:25:49.299Z', '2023-05-30T02:25:50.251Z', '2023-05-30T02:25:51.692Z', '2023-05-30T02:25:52.188Z', '2023-05-30T02:25:53.427Z', '2023-05-30T02:25:54.491Z', '2023-05-30T02:25:55.627Z', '2023-05-30T02:25:56.723Z', '2023-05-30T02:25:56.923Z', '2023-05-30T02:25:57.267Z', '2023-05-30T02:25:57.635Z', '2023-05-30T02:26:00.356Z', '2023-05-30T02:26:00.739Z', '2023-05-30T02:26:02.108Z', '2023-05-30T02:26:02.315Z', '2023-05-30T02:26:06.291Z', '2023-05-30T02:26:06.851Z', '2023-05-30T02:26:08.099Z', '2023-05-30T02:26:08.419Z', '2023-05-30T02:26:08.780Z', '2023-05-30T02:26:09.035Z', '2023-05-30T02:26:09.339Z', '2023-05-30T02:26:10.619Z', '2023-05-30T02:26:10.867Z', '2023-05-30T02:26:11.675Z', '2023-05-30T02:26:11.988Z', '2023-05-30T02:26:13.195Z', '2023-05-30T02:26:13.379Z', '2023-05-30T02:26:15.331Z', '2023-05-30T02:26:15.612Z', '2023-05-30T02:26:15.907Z', '2023-05-30T02:26:16.282Z', '2023-05-30T02:26:18.147Z', '2023-05-30T02:26:18.411Z', '2023-05-30T02:26:19.652Z', '2023-05-30T02:26:20.347Z', '2023-05-30T02:26:20.715Z', '2023-05-30T02:26:21.147Z', '2023-05-30T02:26:22.834Z', '2023-05-30T02:26:23.156Z', '2023-05-30T02:26:24.635Z', '2023-05-30T02:26:24.811Z', '2023-05-30T02:26:25.115Z', '2023-05-30T02:26:25.291Z', '2023-05-30T02:26:25.459Z', '2023-05-30T02:26:25.835Z', '2023-05-30T02:26:28.218Z', '2023-05-30T02:26:28.467Z', '2023-05-30T02:26:29.379Z', '2023-05-30T02:26:29.723Z', '2023-05-30T02:26:30.379Z', '2023-05-30T02:26:30.555Z', '2023-05-30T02:26:30.883Z', '2023-05-30T02:26:31.067Z', '2023-05-30T02:26:31.323Z', '2023-05-30T02:26:32.899Z', '2023-05-30T02:26:33.059Z', '2023-05-30T02:26:33.291Z', '2023-05-30T02:26:33.515Z', '2023-05-30T02:26:34.635Z', '2023-05-30T02:26:35.242Z', '2023-05-30T02:26:36.859Z', '2023-05-30T02:26:37.866Z', '2023-05-30T02:26:38.730Z', '2023-05-30T02:26:39.330Z', '2023-05-30T02:26:39.635Z', '2023-05-30T02:26:39.875Z', '2023-05-30T02:26:40.099Z', '2023-05-30T02:26:40.403Z', '2023-05-30T02:26:41.611Z', '2023-05-30T02:26:41.891Z', '2023-05-30T02:26:42.131Z', '2023-05-30T02:26:42.403Z', '2023-05-30T02:26:43.954Z', '2023-05-30T02:26:44.363Z', '2023-05-30T02:26:44.691Z', '2023-05-30T02:26:45.170Z', '2023-05-30T02:26:45.627Z', '2023-05-30T02:26:47.731Z', '2023-05-30T02:26:48.051Z', '2023-05-30T02:26:48.290Z', '2023-05-30T02:26:49.275Z', '2023-05-30T02:26:50.683Z', '2023-05-30T02:26:51.299Z', '2023-05-30T02:26:51.538Z', '2023-05-30T02:26:51.803Z', '2023-05-30T02:26:52.093Z', '2023-05-30T02:26:52.235Z', '2023-05-30T02:26:52.515Z', '2023-05-30T02:26:56.298Z', '2023-05-30T02:26:56.498Z', '2023-05-30T02:26:56.802Z', '2023-05-30T02:26:57.242Z', '2023-05-30T02:26:58.474Z', '2023-05-30T02:26:58.666Z', '2023-05-30T02:26:58.922Z', '2023-05-30T02:27:00.074Z', '2023-05-30T02:27:00.226Z', '2023-05-30T02:27:00.394Z', '2023-05-30T02:27:01.586Z', '2023-05-30T02:27:02.227Z', '2023-05-30T02:27:02.618Z', '2023-05-30T02:27:02.810Z', '2023-05-30T02:27:03.098Z', '2023-05-30T02:27:03.579Z', '2023-05-30T02:27:05.666Z', '2023-05-30T02:27:05.829Z', '2023-05-30T02:27:06.066Z', '2023-05-30T02:27:07.123Z', '2023-05-30T02:27:07.355Z', '2023-05-30T02:27:07.506Z', '2023-05-30T02:27:07.674Z', '2023-05-30T02:27:08.226Z', '2023-05-30T02:27:09.275Z', '2023-05-30T02:27:09.555Z', '2023-05-30T02:27:10.635Z', '2023-05-30T02:27:10.874Z', '2023-05-30T02:27:11.210Z', '2023-05-30T02:27:14.155Z', '2023-05-30T02:27:14.562Z', '2023-05-30T02:27:14.906Z', '2023-05-30T02:27:15.090Z', '2023-05-30T02:27:15.275Z', '2023-05-30T02:27:16.786Z', '2023-05-30T02:27:17.138Z', '2023-05-30T02:27:17.490Z', '2023-05-30T02:27:17.850Z', '2023-05-30T02:27:18.155Z', '2023-05-30T02:27:19.675Z', '2023-05-30T02:27:19.890Z', '2023-05-30T02:27:21.242Z', '2023-05-30T02:27:21.746Z', '2023-05-30T02:27:22.458Z', '2023-05-30T02:27:22.634Z', '2023-05-30T02:27:23.002Z', '2023-05-30T02:27:23.418Z', '2023-05-30T02:27:23.602Z', '2023-05-30T02:27:28.538Z', '2023-05-30T02:27:28.770Z', '2023-05-30T02:27:31.754Z', '2023-05-30T02:27:32.986Z', '2023-05-30T02:27:33.546Z', '2023-05-30T02:27:34.052Z', '2023-05-30T02:27:34.083Z', '2023-05-30T02:27:34.091Z', '2023-05-30T02:27:36.201Z', '2023-05-30T02:27:36.506Z', '2023-05-30T02:27:36.834Z', '2023-05-30T02:27:36.970Z', '2023-05-30T02:27:37.138Z', '2023-05-30T02:27:37.506Z', '2023-05-30T02:27:39.554Z', '2023-05-30T02:27:40.218Z', '2023-05-30T02:27:40.697Z', '2023-05-30T02:27:40.940Z', '2023-05-30T02:27:41.122Z', '2023-05-30T02:27:41.329Z', '2023-05-30T02:27:42.882Z', '2023-05-30T02:27:43.362Z', '2023-05-30T02:27:43.562Z', '2023-05-30T02:27:43.778Z', '2023-05-30T02:27:45.330Z', '2023-05-30T02:27:46.002Z', '2023-05-30T02:27:46.188Z', '2023-05-30T02:27:46.475Z', '2023-05-30T02:27:47.883Z', '2023-05-30T02:27:48.170Z', '2023-05-30T02:27:48.498Z', '2023-05-30T02:27:50.067Z', '2023-05-30T02:27:51.210Z', '2023-05-30T02:27:54.242Z', '2023-05-30T02:27:55.867Z', '2023-05-30T02:27:56.051Z', '2023-05-30T02:27:56.771Z', '2023-05-30T02:27:58.499Z', '2023-05-30T02:27:58.947Z', '2023-05-30T02:27:59.370Z', '2023-05-30T02:27:59.563Z', '2023-05-30T02:27:59.819Z', '2023-05-30T02:28:02.963Z', '2023-05-30T02:28:03.403Z', '2023-05-30T02:28:03.658Z', '2023-05-30T02:28:04.490Z', '2023-05-30T02:28:04.834Z', '2023-05-30T02:28:06.330Z', '2023-05-30T02:28:06.666Z', '2023-05-30T02:28:08.091Z', '2023-05-30T02:28:08.387Z', '2023-05-30T02:28:08.771Z', '2023-05-30T02:28:09.042Z', '2023-05-30T02:28:09.282Z', '2023-05-30T02:28:10.427Z', '2023-05-30T02:28:10.635Z', '2023-05-30T02:28:11.011Z', '2023-05-30T02:28:11.171Z', '2023-05-30T02:28:11.595Z', '2023-05-30T02:28:12.363Z', '2023-05-30T02:28:13.019Z', '2023-05-30T02:28:13.363Z', '2023-05-30T02:28:13.563Z', '2023-05-30T02:28:13.739Z', '2023-05-30T02:28:13.922Z', '2023-05-30T02:28:16.506Z', '2023-05-30T02:28:16.859Z', '2023-05-30T02:28:19.090Z', '2023-05-30T02:28:19.403Z', '2023-05-30T02:28:20.651Z', '2023-05-30T02:28:21.107Z', '2023-05-30T02:28:21.467Z', '2023-05-30T02:28:21.746Z', '2023-05-30T02:28:21.971Z', '2023-05-30T02:28:22.275Z', '2023-05-30T02:28:26.722Z', '2023-05-30T02:28:27.130Z', '2023-05-30T02:28:27.442Z', '2023-05-30T02:28:27.722Z', '2023-05-30T02:28:27.922Z', '2023-05-30T02:28:28.066Z', '2023-05-30T02:28:28.210Z', '2023-05-30T02:28:29.578Z', '2023-05-30T02:28:29.882Z', '2023-05-30T02:28:31.338Z', '2023-05-30T02:28:32.162Z', '2023-05-30T02:28:32.563Z', '2023-05-30T02:28:34.050Z', '2023-05-30T02:28:36.122Z', '2023-05-30T02:28:36.546Z', '2023-05-30T02:28:37.066Z', '2023-05-30T02:28:37.899Z', '2023-05-30T02:28:38.058Z', '2023-05-30T02:28:38.546Z', '2023-05-30T02:28:45.146Z', '2023-05-30T02:28:51.841Z', '2023-05-30T02:28:52.033Z', '2023-05-30T02:28:52.297Z', '2023-05-30T02:28:52.553Z', '2023-05-30T02:28:53.824Z', '2023-05-30T02:28:54.089Z', '2023-05-30T02:28:54.265Z', '2023-05-30T02:28:54.417Z', '2023-05-30T02:28:56.145Z', '2023-05-30T02:28:56.537Z', '2023-05-30T02:28:58.809Z', '2023-05-30T02:28:59.260Z', '2023-05-30T02:28:59.497Z', '2023-05-30T02:28:59.793Z', '2023-05-30T02:29:00.905Z', '2023-05-30T02:29:01.185Z', '2023-05-30T02:29:01.409Z', '2023-05-30T02:29:03.921Z', '2023-05-30T02:29:08.465Z', '2023-05-30T02:29:08.721Z', '2023-05-30T02:29:08.921Z', '2023-05-30T02:29:10.321Z', '2023-05-30T02:29:10.656Z', '2023-05-30T02:29:10.985Z', '2023-05-30T02:29:11.114Z', '2023-05-30T02:29:13.819Z', '2023-05-30T02:29:13.864Z', '2023-05-30T02:29:14.177Z', '2023-05-30T02:29:15.145Z', '2023-05-30T02:29:15.296Z', '2023-05-30T02:29:16.704Z', '2023-05-30T02:29:17.048Z', '2023-05-30T02:29:17.376Z', '2023-05-30T02:29:19.137Z', '2023-05-30T02:29:19.784Z', '2023-05-30T02:29:21.281Z', '2023-05-30T02:29:21.777Z', '2023-05-30T02:29:22.128Z', '2023-05-30T02:29:22.977Z', '2023-05-30T02:29:23.921Z', '2023-05-30T02:29:24.592Z', '2023-05-30T02:29:24.992Z', '2023-05-30T02:29:25.216Z', '2023-05-30T02:29:25.561Z', '2023-05-30T02:29:27.416Z', '2023-05-30T02:29:28.328Z', '2023-05-30T02:29:28.729Z', '2023-05-30T02:29:29.087Z', '2023-05-30T02:29:29.496Z', '2023-05-30T02:29:30.008Z', '2023-05-30T02:29:30.296Z', '2023-05-30T02:29:30.609Z', '2023-05-30T02:29:30.769Z', '2023-05-30T02:29:31.088Z', '2023-05-30T02:29:33.031Z', '2023-05-30T02:29:33.224Z', '2023-05-30T02:29:33.568Z', '2023-05-30T02:29:33.972Z', '2023-05-30T02:29:34.176Z', '2023-05-30T02:29:35.560Z', '2023-05-30T02:29:35.880Z', '2023-05-30T02:29:36.360Z', '2023-05-30T02:29:37.441Z', '2023-05-30T02:29:37.650Z', '2023-05-30T02:29:37.961Z', '2023-05-30T02:29:38.089Z', '2023-05-30T02:29:38.393Z', '2023-05-30T02:29:38.616Z', '2023-05-30T02:29:38.737Z', '2023-05-30T02:29:39.824Z', '2023-05-30T02:29:40.361Z', '2023-05-30T02:29:41.392Z', '2023-05-30T02:29:42.016Z', '2023-05-30T02:29:43.752Z', '2023-05-30T02:29:44.952Z', '2023-05-30T02:29:45.536Z', '2023-05-30T02:29:45.920Z', '2023-05-30T02:29:47.040Z', '2023-05-30T02:29:47.312Z', '2023-05-30T02:29:47.504Z', '2023-05-30T02:29:47.800Z', '2023-05-30T02:29:48.120Z', '2023-05-30T02:29:49.089Z', '2023-05-30T02:29:49.296Z', '2023-05-30T02:29:49.824Z', '2023-05-30T02:29:51.073Z', '2023-05-30T02:29:51.504Z', '2023-05-30T02:29:51.712Z', '2023-05-30T02:29:52.401Z', '2023-05-30T02:29:54.113Z', '2023-05-30T02:29:54.361Z', '2023-05-30T02:29:54.648Z', '2023-05-30T02:29:54.824Z', '2023-05-30T02:29:56.136Z', '2023-05-30T02:29:56.560Z', '2023-05-30T02:29:56.856Z', '2023-05-30T02:29:58.160Z', '2023-05-30T02:29:58.776Z', '2023-05-30T02:29:59.000Z', '2023-05-30T02:29:59.360Z', '2023-05-30T02:29:59.711Z', '2023-05-30T02:30:00.864Z', '2023-05-30T02:30:01.073Z', '2023-05-30T02:30:01.360Z', '2023-05-30T02:30:02.630Z', '2023-05-30T02:30:03.427Z', '2023-05-30T02:30:03.771Z', '2023-05-30T02:30:05.569Z', '2023-05-30T02:30:05.974Z', '2023-05-30T02:30:06.343Z', '2023-05-30T02:30:07.131Z', '2023-05-30T02:30:11.271Z', '2023-05-30T02:30:11.906Z', '2023-05-30T02:30:12.911Z', '2023-05-30T02:30:13.661Z', '2023-05-30T02:30:14.083Z', '2023-05-30T02:30:14.297Z', '2023-05-30T02:30:14.490Z', '2023-05-30T02:30:14.655Z', '2023-05-30T02:30:14.984Z', '2023-05-30T02:30:15.083Z', '2023-05-30T02:30:15.271Z', '2023-05-30T02:30:20.286Z', '2023-05-30T02:30:20.681Z', '2023-05-30T02:30:20.924Z', '2023-05-30T02:30:22.772Z', '2023-05-30T02:30:23.052Z', '2023-05-30T02:30:23.302Z', '2023-05-30T02:30:23.443Z', '2023-05-30T02:30:23.666Z', '2023-05-30T02:30:24.668Z', '2023-05-30T02:30:24.990Z', '2023-05-30T02:30:25.193Z', '2023-05-30T02:30:25.318Z', '2023-05-30T02:30:25.767Z', '2023-05-30T02:30:26.740Z', '2023-05-30T02:30:27.312Z', '2023-05-30T02:30:27.755Z', '2023-05-30T02:30:27.990Z', '2023-05-30T02:30:30.020Z', '2023-05-30T02:30:30.546Z', '2023-05-30T02:30:31.167Z', '2023-05-30T02:30:31.536Z', '2023-05-30T02:30:31.864Z', '2023-05-30T02:30:34.115Z', '2023-05-30T02:30:34.302Z', '2023-05-30T02:30:35.177Z', '2023-05-30T02:30:35.411Z', '2023-05-30T02:30:36.802Z', '2023-05-30T02:30:37.052Z', '2023-05-30T02:30:38.896Z', '2023-05-30T02:30:39.448Z', '2023-05-30T02:30:39.911Z', '2023-05-30T02:30:40.162Z', '2023-05-30T02:30:40.911Z', '2023-05-30T02:30:41.116Z', '2023-05-30T02:30:41.458Z', '2023-05-30T02:30:42.787Z', '2023-05-30T02:30:42.974Z', '2023-05-30T02:30:43.239Z', '2023-05-30T02:30:44.771Z', '2023-05-30T02:30:45.005Z', '2023-05-30T02:30:46.318Z', '2023-05-30T02:30:46.832Z', '2023-05-30T02:30:47.231Z', '2023-05-30T02:30:47.776Z', '2023-05-30T02:30:48.095Z', '2023-05-30T02:30:48.302Z', '2023-05-30T02:30:49.263Z', '2023-05-30T02:30:49.708Z', '2023-05-30T02:30:50.647Z', '2023-05-30T02:30:51.443Z', '2023-05-30T02:30:52.443Z', '2023-05-30T02:30:53.083Z', '2023-05-30T02:30:53.271Z', '2023-05-30T02:30:53.475Z', '2023-05-30T02:30:53.771Z', '2023-05-30T02:30:54.193Z', '2023-05-30T02:30:54.629Z', '2023-05-30T02:30:54.958Z', '2023-05-30T02:30:55.615Z', '2023-05-30T02:30:56.350Z', '2023-05-30T02:30:56.786Z', '2023-05-30T02:30:57.083Z', '2023-05-30T02:30:58.767Z', '2023-05-30T02:30:59.106Z', '2023-05-30T02:30:59.439Z', '2023-05-30T02:31:00.685Z', '2023-05-30T02:31:00.904Z', '2023-05-30T02:31:01.053Z', '2023-05-30T02:31:01.318Z', '2023-05-30T02:31:02.458Z', '2023-05-30T02:31:02.833Z', '2023-05-30T02:31:03.991Z', '2023-05-30T02:31:04.521Z', '2023-05-30T02:31:04.847Z', '2023-05-30T02:31:05.099Z', '2023-05-30T02:31:05.349Z', '2023-05-30T02:31:08.693Z', '2023-05-30T02:31:08.974Z', '2023-05-30T02:31:09.208Z', '2023-05-30T02:31:10.411Z', '2023-05-30T02:31:10.522Z', '2023-05-30T02:31:10.772Z', '2023-05-30T02:31:11.630Z', '2023-05-30T02:31:11.818Z', '2023-05-30T02:31:12.037Z', '2023-05-30T02:31:12.350Z', '2023-05-30T02:31:13.022Z', '2023-05-30T02:31:13.351Z', '2023-05-30T02:31:13.711Z', '2023-05-30T02:31:14.601Z', '2023-05-30T02:31:14.833Z', '2023-05-30T02:31:15.115Z', '2023-05-30T02:31:15.396Z', '2023-05-30T02:31:15.819Z', '2023-05-30T02:31:16.583Z', '2023-05-30T02:31:16.802Z', '2023-05-30T02:31:18.431Z', '2023-05-30T02:31:20.116Z', '2023-05-30T02:31:20.499Z', '2023-05-30T02:31:20.741Z', '2023-05-30T02:31:20.935Z', '2023-05-30T02:31:21.240Z', '2023-05-30T02:31:22.005Z', '2023-05-30T02:31:22.256Z', '2023-05-30T02:31:22.351Z', '2023-05-30T02:31:22.644Z', '2023-05-30T02:31:23.396Z', '2023-05-30T02:31:23.654Z', '2023-05-30T02:31:25.033Z', '2023-05-30T02:31:25.568Z', '2023-05-30T02:31:25.863Z', '2023-05-30T02:31:27.302Z', '2023-05-30T02:31:27.552Z', '2023-05-30T02:31:27.833Z', '2023-05-30T02:31:28.078Z', '2023-05-30T02:31:28.462Z', '2023-05-30T02:31:29.224Z', '2023-05-30T02:31:29.605Z', '2023-05-30T02:31:29.935Z', '2023-05-30T02:31:30.911Z', '2023-05-30T02:31:31.173Z', '2023-05-30T02:31:32.396Z', '2023-05-30T02:31:33.065Z', '2023-05-30T02:31:33.427Z', '2023-05-30T02:31:33.910Z', '2023-05-30T02:31:34.903Z', '2023-05-30T02:31:35.116Z', '2023-05-30T02:31:36.005Z', '2023-05-30T02:31:36.510Z', '2023-05-30T02:31:36.958Z', '2023-05-30T02:31:37.919Z', '2023-05-30T02:31:38.527Z', '2023-05-30T02:31:38.810Z', '2023-05-30T02:31:39.161Z', '2023-05-30T02:31:40.221Z', '2023-05-30T02:31:40.552Z', '2023-05-30T02:31:42.068Z', '2023-05-30T02:31:42.401Z', '2023-05-30T02:31:43.328Z', '2023-05-30T02:31:43.755Z', '2023-05-30T02:31:43.974Z', '2023-05-30T02:31:44.359Z', '2023-05-30T02:31:44.910Z', '2023-05-30T02:31:45.115Z', '2023-05-30T02:31:45.302Z', '2023-05-30T02:31:45.505Z', '2023-05-30T02:31:47.772Z', '2023-05-30T02:31:47.898Z', '2023-05-30T02:31:48.121Z', '2023-05-30T02:32:01.687Z']",IN A MULTICENTER TRIAL IN SPIN WE RANDOMLY ASSIGNED PARTICIPANTS WHO WERE AT HIGH CARDIOVASCULAER RICK MEDITERRANEAN DIET SUPPLEMENTED WITH EXTRA FREE PROVISION QUARTEELY INDIVIDUAL AND GROUP EDUCATIONAL SESSIONS AND DEPENDING ON GROUP ASSIGNMENT A TOTAL OF 7447 PERSONS WERE ENROLLED 57% WERE WOMAN THE TWO MEDITERRANEAN DIET GROUPS HAD GOOD ADHERENCE TO THE INTERVENTION AND THE GROUP ASSIGNED TO A MEDITERRANEAN DIET WITH NUTS 83 EVENTS RESPECTIVELY VERSUS THE CONTROL GROUP 109 EVENTS EFFECTS WERW REPORTED A MEDITERRANEAN DIET SUPPLEMENTED WITH EXTRA VIRGIN OLIVE OIL OR NUTS REDUCED THE INCIDENCE OF MAJOR CARDIOVASCULAR EVENTS .,False
3WRBLBQ2GRTZICL7ZVA1JXIN4TX0G9,"Primary Prevention of Cardiovascular Disease with a Mediterranean Diet

Observational cohort studies and a secondary prevention trial have shown an inverse association between adherence to the Mediterranean diet and cardiovascular risk. We conducted a randomized trial of this diet pattern for the primary prevention of cardiovascular events.

In a multicenter trial in Spain, we randomly assigned participants who were at high cardiovascular risk, but with no cardiovascular disease at enrollment, to one of three diets; a Mediterranean diet supplemented with extra-virgin olive oil, a Mediterranean diet supplemented with mixed nuts, or a control diet (advice to reduce dietary fat). Participants received quarterly individual and group educational sessions and, depending on group assignment, free provision of extra-virgin olive oil, mixed nuts, or small nonfood gifts. The primary end point was the rate of major cardiovascular events (myocardial infarction, stroke, or death from cardiovascular causes). On the basis of the results of an interim analysis, the trial was stopped after a median follow-up of 4.8 years.

A total of 7447 persons were enrolled (age range, 55 to 80 years); 57% were women. The two Mediterranean-diet groups had good adherence to the intervention, according to self-reported intake and biomarker analyses. A primary end-point event occurred in 288 participants. The multivariable-adjusted hazard ratios were 0.70 (95% confidence interval (CI), 0.54 to 0.92) and 0.72 (95% CI, 0.54 to 0.96) for the group assigned to a Mediterranean diet with extra-virgin olive oil (96 events) and the group assigned to a Mediterranean diet with nuts (83 events), respectively, versus the control group (109 events). No diet-related adverse effects were reported.

Among persons at high cardiovascular risk, a Mediterranean diet supplemented with extra-virgin olive oil or nuts reduced the incidence of major cardiovascular events.
",CapsLock D CapsLock e a r f r i e n d i n t h i s t o p i c a b o u t m y e Backspace Backspace Backspace Backspace b y CapsLock CapsLock p CapsLock R I M A R Y CapsLock p CapsLock R E V E N T I O N O F CapsLock c CapsLock A R D I O V A S C U L A R CapsLock d CapsLock I S E A S E . P CapsLock r i m a r y CapsLock P CapsLock r v e n t i o n o f CapsLock C CapsLock a r d i o r Backspace e v a s c u l a r d i s e a s e . Backspace CapsLock I CapsLock n t h i s t o p i c t Backspace m y s e l f t e l l b y f r i e n d . a CapsLock N D T H I S Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace . A CapsLock n d t h i s Backspace c o n v e r s a t i o n a b o u t b y CapsLock I CapsLock n t h i s t e a m c o n d u c t e d a r a n d o m z i e d t r i a l o f t h e Backspace i s t r a Backspace Backspace Backspace p Backspace f i r t Backspace s t p a t e Backspace t e r n o f CapsLock P CapsLock r e v e n t i o n o f CapsLock C CapsLock a r d i o v a s c u l a r d i s e a s e . Backspace Backspace CapsLock C CapsLock o n t r o l l e d a n Backspace d i e t f o o d a Backspace Backspace s a n d n u t s . CapsLock M CapsLock o s t o f t h i s r e Backspace Backspace d i s e a s e a f f e c t b y t h e 5 7 Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift % o f w o m e n . CapsLock A CapsLock n d t h e a g e r a n g e s o f 5 5 t o 8 0 y e a r s . Backspace CapsLock N Backspace M CapsLock o s t i m p o r t a n t t o t h e CapsLock M CapsLock e d Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace s u p p l e m e n t e d w i t h e x t r a v i r g i n o l i v e o i l o r n u t s r e d u c e d i Backspace t h e i n c i d e n c e . CapsLock S CapsLock o t h i s Backspace Backspace e s e a r e m a j o r c a r d i o v a s c u l a r v e Backspace Backspace e n e Backspace Backspace v e n t s o f t h e t o p i c .,"['2023-05-30T05:17:38.077Z', '2023-05-30T05:17:38.277Z', '2023-05-30T05:17:38.440Z', '2023-05-30T05:17:38.652Z', '2023-05-30T05:17:38.828Z', '2023-05-30T05:17:38.941Z', '2023-05-30T05:17:39.336Z', '2023-05-30T05:17:40.164Z', '2023-05-30T05:17:40.452Z', '2023-05-30T05:17:40.792Z', '2023-05-30T05:17:41.012Z', '2023-05-30T05:17:41.220Z', '2023-05-30T05:17:41.460Z', '2023-05-30T05:17:42.612Z', '2023-05-30T05:17:50.487Z', '2023-05-30T05:17:50.759Z', '2023-05-30T05:17:50.951Z', '2023-05-30T05:17:51.271Z', '2023-05-30T05:17:51.551Z', '2023-05-30T05:17:51.759Z', '2023-05-30T05:17:52.271Z', '2023-05-30T05:17:54.508Z', '2023-05-30T05:17:57.463Z', '2023-05-30T05:17:57.788Z', '2023-05-30T05:17:58.036Z', '2023-05-30T05:17:58.292Z', '2023-05-30T05:17:58.564Z', '2023-05-30T05:17:58.732Z', '2023-05-30T05:17:59.012Z', '2023-05-30T05:17:59.278Z', '2023-05-30T05:17:59.598Z', '2023-05-30T05:17:59.918Z', '2023-05-30T05:18:00.188Z', '2023-05-30T05:18:00.532Z', '2023-05-30T05:18:00.860Z', '2023-05-30T05:18:01.156Z', '2023-05-30T05:18:01.516Z', '2023-05-30T05:18:02.612Z', '2023-05-30T05:18:05.620Z', '2023-05-30T05:18:11.172Z', '2023-05-30T05:18:11.835Z', '2023-05-30T05:18:12.171Z', '2023-05-30T05:18:13.243Z', '2023-05-30T05:18:13.435Z', '2023-05-30T05:18:13.723Z', '2023-05-30T05:18:18.233Z', '2023-05-30T05:18:18.585Z', '2023-05-30T05:18:18.585Z', '2023-05-30T05:18:18.865Z', '2023-05-30T05:18:19.149Z', '2023-05-30T05:18:19.608Z', '2023-05-30T05:18:19.933Z', '2023-05-30T05:18:20.173Z', '2023-05-30T05:18:20.388Z', '2023-05-30T05:18:20.781Z', '2023-05-30T05:18:21.453Z', '2023-05-30T05:18:23.501Z', '2023-05-30T05:18:23.836Z', '2023-05-30T05:18:24.045Z', '2023-05-30T05:18:24.344Z', '2023-05-30T05:18:24.709Z', '2023-05-30T05:18:24.896Z', '2023-05-30T05:18:25.052Z', '2023-05-30T05:18:25.428Z', '2023-05-30T05:18:25.720Z', '2023-05-30T05:18:26.072Z', '2023-05-30T05:18:26.332Z', '2023-05-30T05:18:26.584Z', '2023-05-30T05:18:26.824Z', '2023-05-30T05:18:29.308Z', '2023-05-30T05:18:29.772Z', '2023-05-30T05:18:29.965Z', '2023-05-30T05:18:30.269Z', '2023-05-30T05:18:30.500Z', '2023-05-30T05:18:30.680Z', '2023-05-30T05:18:30.996Z', '2023-05-30T05:18:31.188Z', '2023-05-30T05:18:34.292Z', '2023-05-30T05:18:34.724Z', '2023-05-30T05:18:34.956Z', '2023-05-30T05:18:37.820Z', '2023-05-30T05:18:38.085Z', '2023-05-30T05:18:38.428Z', '2023-05-30T05:18:38.772Z', '2023-05-30T05:18:39.220Z', '2023-05-30T05:18:39.652Z', '2023-05-30T05:18:39.908Z', '2023-05-30T05:18:40.152Z', '2023-05-30T05:18:40.684Z', '2023-05-30T05:18:43.492Z', '2023-05-30T05:18:43.748Z', '2023-05-30T05:18:43.892Z', '2023-05-30T05:18:44.148Z', '2023-05-30T05:18:47.448Z', '2023-05-30T05:18:47.659Z', '2023-05-30T05:18:48.323Z', '2023-05-30T05:18:48.587Z', '2023-05-30T05:18:48.851Z', '2023-05-30T05:18:49.595Z', '2023-05-30T05:18:57.236Z', '2023-05-30T05:18:58.199Z', '2023-05-30T05:18:58.868Z', '2023-05-30T05:18:59.051Z', '2023-05-30T05:18:59.339Z', '2023-05-30T05:18:59.531Z', '2023-05-30T05:18:59.827Z', '2023-05-30T05:19:00.039Z', '2023-05-30T05:19:00.455Z', '2023-05-30T05:19:06.286Z', '2023-05-30T05:19:06.494Z', '2023-05-30T05:19:06.630Z', '2023-05-30T05:19:06.942Z', '2023-05-30T05:19:07.350Z', '2023-05-30T05:19:07.614Z', '2023-05-30T05:19:07.766Z', '2023-05-30T05:19:08.099Z', '2023-05-30T05:19:08.451Z', '2023-05-30T05:19:08.547Z', '2023-05-30T05:19:09.154Z', '2023-05-30T05:19:09.459Z', '2023-05-30T05:19:09.923Z', '2023-05-30T05:19:10.762Z', '2023-05-30T05:19:10.946Z', '2023-05-30T05:19:11.247Z', '2023-05-30T05:19:11.450Z', '2023-05-30T05:19:11.630Z', '2023-05-30T05:19:11.870Z', '2023-05-30T05:19:12.059Z', '2023-05-30T05:19:12.355Z', '2023-05-30T05:19:12.626Z', '2023-05-30T05:19:12.899Z', '2023-05-30T05:19:15.620Z', '2023-05-30T05:19:17.335Z', '2023-05-30T05:19:17.564Z', '2023-05-30T05:19:21.468Z', '2023-05-30T05:19:21.652Z', '2023-05-30T05:19:21.996Z', '2023-05-30T05:19:22.296Z', '2023-05-30T05:19:22.588Z', '2023-05-30T05:19:22.848Z', '2023-05-30T05:19:23.092Z', '2023-05-30T05:19:23.380Z', '2023-05-30T05:19:23.828Z', '2023-05-30T05:19:25.124Z', '2023-05-30T05:19:25.356Z', '2023-05-30T05:19:25.564Z', '2023-05-30T05:19:27.341Z', '2023-05-30T05:19:27.628Z', '2023-05-30T05:19:27.892Z', '2023-05-30T05:19:28.212Z', '2023-05-30T05:22:19.036Z', '2023-05-30T05:22:30.195Z', '2023-05-30T05:22:31.587Z', '2023-05-30T05:22:31.882Z', '2023-05-30T05:22:32.322Z', '2023-05-30T05:22:32.610Z', '2023-05-30T05:22:32.858Z', '2023-05-30T05:22:33.186Z', '2023-05-30T05:22:33.482Z', '2023-05-30T05:22:33.651Z', '2023-05-30T05:22:33.930Z', '2023-05-30T05:22:34.146Z', '2023-05-30T05:22:35.346Z', '2023-05-30T05:22:36.075Z', '2023-05-30T05:22:36.283Z', '2023-05-30T05:22:36.547Z', '2023-05-30T05:22:36.859Z', '2023-05-30T05:22:54.611Z', '2023-05-30T05:22:57.187Z', '2023-05-30T05:23:01.331Z', '2023-05-30T05:23:02.331Z', '2023-05-30T05:23:02.659Z', '2023-05-30T05:23:02.875Z', '2023-05-30T05:23:03.091Z', '2023-05-30T05:23:03.283Z', '2023-05-30T05:23:03.531Z', '2023-05-30T05:23:03.715Z', '2023-05-30T05:23:04.091Z', '2023-05-30T05:23:04.579Z', '2023-05-30T05:23:04.843Z', '2023-05-30T05:23:05.027Z', '2023-05-30T05:23:05.419Z', '2023-05-30T05:23:05.827Z', '2023-05-30T05:23:06.043Z', '2023-05-30T05:23:06.459Z', '2023-05-30T05:23:12.581Z', '2023-05-30T05:23:12.837Z', '2023-05-30T05:23:13.037Z', '2023-05-30T05:23:13.229Z', '2023-05-30T05:23:13.581Z', '2023-05-30T05:23:13.845Z', '2023-05-30T05:23:21.916Z', '2023-05-30T05:23:23.716Z', '2023-05-30T05:23:23.957Z', '2023-05-30T05:23:24.244Z', '2023-05-30T05:23:24.444Z', '2023-05-30T05:23:24.604Z', '2023-05-30T05:23:24.972Z', '2023-05-30T05:23:25.260Z', '2023-05-30T05:23:25.429Z', '2023-05-30T05:23:25.692Z', '2023-05-30T05:23:27.140Z', '2023-05-30T05:23:27.420Z', '2023-05-30T05:23:27.652Z', '2023-05-30T05:23:27.844Z', '2023-05-30T05:23:28.332Z', '2023-05-30T05:23:28.604Z', '2023-05-30T05:23:29.052Z', '2023-05-30T05:23:29.964Z', '2023-05-30T05:23:31.332Z', '2023-05-30T05:23:32.500Z', '2023-05-30T05:23:32.836Z', '2023-05-30T05:23:34.204Z', '2023-05-30T05:23:34.852Z', '2023-05-30T05:23:35.348Z', '2023-05-30T05:23:35.900Z', '2023-05-30T05:23:36.460Z', '2023-05-30T05:23:36.684Z', '2023-05-30T05:23:36.812Z', '2023-05-30T05:23:37.140Z', '2023-05-30T05:23:37.436Z', '2023-05-30T05:23:37.612Z', '2023-05-30T05:23:37.876Z', '2023-05-30T05:23:38.284Z', '2023-05-30T05:23:39.676Z', '2023-05-30T05:23:40.827Z', '2023-05-30T05:23:41.116Z', '2023-05-30T05:23:41.316Z', '2023-05-30T05:23:41.635Z', '2023-05-30T05:23:41.908Z', '2023-05-30T05:23:42.196Z', '2023-05-30T05:23:42.395Z', '2023-05-30T05:23:42.628Z', '2023-05-30T05:23:42.828Z', '2023-05-30T05:23:42.980Z', '2023-05-30T05:23:43.307Z', '2023-05-30T05:23:43.508Z', '2023-05-30T05:23:43.819Z', '2023-05-30T05:23:48.867Z', '2023-05-30T05:23:49.091Z', '2023-05-30T05:23:49.275Z', '2023-05-30T05:23:49.571Z', '2023-05-30T05:23:49.971Z', '2023-05-30T05:23:50.267Z', '2023-05-30T05:23:51.547Z', '2023-05-30T05:23:52.819Z', '2023-05-30T05:23:53.875Z', '2023-05-30T05:23:58.067Z', '2023-05-30T05:25:01.428Z', '2023-05-30T05:25:01.771Z', '2023-05-30T05:25:01.931Z', '2023-05-30T05:25:02.147Z', '2023-05-30T05:25:02.355Z', '2023-05-30T05:25:02.683Z', '2023-05-30T05:25:02.955Z', '2023-05-30T05:25:03.099Z', '2023-05-30T05:25:03.331Z', '2023-05-30T05:25:03.507Z', '2023-05-30T05:25:03.779Z', '2023-05-30T05:25:04.059Z', '2023-05-30T05:25:04.219Z', '2023-05-30T05:25:04.579Z', '2023-05-30T05:25:05.123Z', '2023-05-30T05:25:06.027Z', '2023-05-30T05:25:06.179Z', '2023-05-30T05:25:06.491Z', '2023-05-30T05:25:09.035Z', '2023-05-30T05:25:09.315Z', '2023-05-30T05:25:09.587Z', '2023-05-30T05:25:09.771Z', '2023-05-30T05:25:09.971Z', '2023-05-30T05:25:10.267Z', '2023-05-30T05:25:10.819Z', '2023-05-30T05:25:14.378Z', '2023-05-30T05:25:14.523Z', '2023-05-30T05:25:14.949Z', '2023-05-30T05:25:15.133Z', '2023-05-30T05:25:15.388Z', '2023-05-30T05:25:15.980Z', '2023-05-30T05:25:16.356Z', '2023-05-30T05:25:16.661Z', '2023-05-30T05:25:17.084Z', '2023-05-30T05:25:17.284Z', '2023-05-30T05:25:17.573Z', '2023-05-30T05:25:17.796Z', '2023-05-30T05:25:18.012Z', '2023-05-30T05:25:25.884Z', '2023-05-30T05:25:26.260Z', '2023-05-30T05:25:26.476Z', '2023-05-30T05:25:26.956Z', '2023-05-30T05:25:27.204Z', '2023-05-30T05:25:27.348Z', '2023-05-30T05:25:27.636Z', '2023-05-30T05:25:27.940Z', '2023-05-30T05:25:28.284Z', '2023-05-30T05:25:28.308Z', '2023-05-30T05:25:28.685Z', '2023-05-30T05:25:28.933Z', '2023-05-30T05:25:29.572Z', '2023-05-30T05:25:39.572Z', '2023-05-30T05:25:40.100Z', '2023-05-30T05:25:40.355Z', '2023-05-30T05:25:40.524Z', '2023-05-30T05:25:40.932Z', '2023-05-30T05:25:41.180Z', '2023-05-30T05:25:41.476Z', '2023-05-30T05:25:43.060Z', '2023-05-30T05:25:43.676Z', '2023-05-30T05:25:45.732Z', '2023-05-30T05:25:49.220Z', '2023-05-30T05:25:50.428Z', '2023-05-30T05:25:50.948Z', '2023-05-30T05:25:51.139Z', '2023-05-30T05:25:51.379Z', '2023-05-30T05:25:51.715Z', '2023-05-30T05:25:52.619Z', '2023-05-30T05:25:53.571Z', '2023-05-30T05:25:53.899Z', '2023-05-30T05:25:54.203Z', '2023-05-30T05:25:54.499Z', '2023-05-30T05:25:54.739Z', '2023-05-30T05:25:54.964Z', '2023-05-30T05:25:55.235Z', '2023-05-30T05:25:56.051Z', '2023-05-30T05:25:56.523Z', '2023-05-30T05:25:56.739Z', '2023-05-30T05:25:56.891Z', '2023-05-30T05:25:57.787Z', '2023-05-30T05:25:57.994Z', '2023-05-30T05:25:58.275Z', '2023-05-30T05:25:58.498Z', '2023-05-30T05:25:58.731Z', '2023-05-30T05:26:01.739Z', '2023-05-30T05:26:02.066Z', '2023-05-30T05:26:02.243Z', '2023-05-30T05:26:02.546Z', '2023-05-30T05:26:03.258Z', '2023-05-30T05:26:03.642Z', '2023-05-30T05:26:03.850Z', '2023-05-30T05:26:04.026Z', '2023-05-30T05:26:04.554Z', '2023-05-30T05:26:05.034Z', '2023-05-30T05:26:05.258Z', '2023-05-30T05:26:06.818Z', '2023-05-30T05:26:07.050Z', '2023-05-30T05:26:07.362Z', '2023-05-30T05:26:07.642Z', '2023-05-30T05:26:07.826Z', '2023-05-30T05:26:08.282Z', '2023-05-30T05:26:08.530Z', '2023-05-30T05:26:08.674Z', '2023-05-30T05:26:08.906Z', '2023-05-30T05:26:09.067Z', '2023-05-30T05:26:09.314Z', '2023-05-30T05:26:09.562Z', '2023-05-30T05:26:09.826Z', '2023-05-30T05:26:10.259Z', '2023-05-30T05:26:10.427Z', '2023-05-30T05:26:10.666Z', '2023-05-30T05:26:11.018Z', '2023-05-30T05:26:11.298Z', '2023-05-30T05:26:11.498Z', '2023-05-30T05:26:11.714Z', '2023-05-30T05:26:12.074Z', '2023-05-30T05:26:13.290Z', '2023-05-30T05:26:13.818Z', '2023-05-30T05:26:13.986Z', '2023-05-30T05:26:14.483Z', '2023-05-30T05:26:14.730Z', '2023-05-30T05:26:15.172Z', '2023-05-30T05:26:15.492Z', '2023-05-30T05:26:15.822Z', '2023-05-30T05:26:16.005Z', '2023-05-30T05:26:16.308Z', '2023-05-30T05:27:11.827Z', '2023-05-30T05:27:13.058Z', '2023-05-30T05:27:14.649Z', '2023-05-30T05:27:14.890Z', '2023-05-30T05:27:15.107Z', '2023-05-30T05:27:15.244Z', '2023-05-30T05:27:15.444Z', '2023-05-30T05:27:15.716Z', '2023-05-30T05:27:16.196Z', '2023-05-30T05:27:16.420Z', '2023-05-30T05:27:16.764Z', '2023-05-30T05:27:17.092Z', '2023-05-30T05:27:17.252Z', '2023-05-30T05:27:17.652Z', '2023-05-30T05:27:17.892Z', '2023-05-30T05:27:18.196Z', '2023-05-30T05:27:18.532Z', '2023-05-30T05:27:18.716Z', '2023-05-30T05:27:19.475Z', '2023-05-30T05:27:20.852Z', '2023-05-30T05:27:21.163Z', '2023-05-30T05:27:21.339Z', '2023-05-30T05:27:21.587Z', '2023-05-30T05:27:21.844Z', '2023-05-30T05:27:22.364Z', '2023-05-30T05:27:22.955Z', '2023-05-30T05:27:23.284Z', '2023-05-30T05:27:23.459Z', '2023-05-30T05:27:23.683Z', '2023-05-30T05:27:23.899Z', '2023-05-30T05:27:24.363Z', '2023-05-30T05:27:25.091Z', '2023-05-30T05:27:25.411Z', '2023-05-30T05:27:26.411Z', '2023-05-30T05:27:26.612Z', '2023-05-30T05:27:26.780Z', '2023-05-30T05:27:26.963Z', '2023-05-30T05:27:27.131Z', '2023-05-30T05:27:27.307Z', '2023-05-30T05:27:27.604Z', '2023-05-30T05:27:27.787Z', '2023-05-30T05:27:28.043Z', '2023-05-30T05:27:28.291Z', '2023-05-30T05:27:28.811Z', '2023-05-30T05:27:29.052Z', '2023-05-30T05:28:49.050Z', '2023-05-30T05:28:49.418Z', '2023-05-30T05:28:49.715Z', '2023-05-30T05:28:49.874Z', '2023-05-30T05:28:50.106Z', '2023-05-30T05:28:50.378Z', '2023-05-30T05:28:50.722Z', '2023-05-30T05:28:51.034Z', '2023-05-30T05:28:51.306Z', '2023-05-30T05:28:51.458Z', '2023-05-30T05:28:51.746Z', '2023-05-30T05:28:52.010Z', '2023-05-30T05:28:52.226Z', '2023-05-30T05:28:52.522Z', '2023-05-30T05:28:52.698Z', '2023-05-30T05:28:58.090Z', '2023-05-30T05:28:58.306Z', '2023-05-30T05:28:59.058Z', '2023-05-30T05:28:59.282Z', '2023-05-30T05:29:00.218Z', '2023-05-30T05:29:00.482Z', '2023-05-30T05:29:00.666Z', '2023-05-30T05:29:00.906Z', '2023-05-30T05:29:01.818Z', '2023-05-30T05:29:02.162Z', '2023-05-30T05:29:02.426Z', '2023-05-30T05:29:02.602Z', '2023-05-30T05:29:02.850Z', '2023-05-30T05:29:03.210Z', '2023-05-30T05:29:03.378Z', '2023-05-30T05:29:03.466Z', '2023-05-30T05:29:03.722Z', '2023-05-30T05:29:03.906Z', '2023-05-30T05:29:04.186Z', '2023-05-30T05:29:04.450Z', '2023-05-30T05:29:04.634Z', '2023-05-30T05:29:04.970Z', '2023-05-30T05:29:05.250Z', '2023-05-30T05:29:05.489Z', '2023-05-30T05:29:05.649Z', '2023-05-30T05:29:05.817Z', '2023-05-30T05:29:06.202Z', '2023-05-30T05:29:06.442Z', '2023-05-30T05:29:07.030Z', '2023-05-30T05:29:07.526Z', '2023-05-30T05:29:07.557Z', '2023-05-30T05:29:07.590Z', '2023-05-30T05:29:07.621Z', '2023-05-30T05:29:07.649Z', '2023-05-30T05:29:07.681Z', '2023-05-30T05:29:07.713Z', '2023-05-30T05:29:07.745Z', '2023-05-30T05:29:07.793Z', '2023-05-30T05:29:07.825Z', '2023-05-30T05:29:07.853Z', '2023-05-30T05:29:07.885Z', '2023-05-30T05:29:07.917Z', '2023-05-30T05:29:07.946Z', '2023-05-30T05:29:07.993Z', '2023-05-30T05:29:08.026Z', '2023-05-30T05:29:08.054Z', '2023-05-30T05:29:08.086Z', '2023-05-30T05:29:08.118Z', '2023-05-30T05:29:08.150Z', '2023-05-30T05:29:08.181Z', '2023-05-30T05:29:08.213Z', '2023-05-30T05:29:08.248Z', '2023-05-30T05:29:08.276Z', '2023-05-30T05:29:08.322Z', '2023-05-30T05:29:08.353Z', '2023-05-30T05:29:08.385Z', '2023-05-30T05:29:08.413Z', '2023-05-30T05:29:08.445Z', '2023-05-30T05:29:08.477Z', '2023-05-30T05:29:08.506Z', '2023-05-30T05:29:08.553Z', '2023-05-30T05:29:08.585Z', '2023-05-30T05:29:08.617Z', '2023-05-30T05:29:08.645Z', '2023-05-30T05:29:08.677Z', '2023-05-30T05:29:08.709Z', '2023-05-30T05:29:08.737Z', '2023-05-30T05:29:08.785Z', '2023-05-30T05:29:08.817Z', '2023-05-30T05:29:08.849Z', '2023-05-30T05:29:08.877Z', '2023-05-30T05:29:08.909Z', '2023-05-30T05:29:08.941Z', '2023-05-30T05:29:08.973Z', '2023-05-30T05:29:09.005Z', '2023-05-30T05:29:09.037Z', '2023-05-30T05:29:09.069Z', '2023-05-30T05:29:09.114Z', '2023-05-30T05:29:09.145Z', '2023-05-30T05:29:09.177Z', '2023-05-30T05:29:09.209Z', '2023-05-30T05:29:09.238Z', '2023-05-30T05:29:09.269Z', '2023-05-30T05:29:09.301Z', '2023-05-30T05:29:09.330Z', '2023-05-30T05:29:09.377Z', '2023-05-30T05:29:09.410Z', '2023-05-30T05:29:09.442Z', '2023-05-30T05:29:09.469Z', '2023-05-30T05:29:09.501Z', '2023-05-30T05:29:09.534Z', '2023-05-30T05:29:09.561Z', '2023-05-30T05:29:09.609Z', '2023-05-30T05:29:09.641Z', '2023-05-30T05:29:09.669Z', '2023-05-30T05:29:09.701Z', '2023-05-30T05:29:09.733Z', '2023-05-30T05:29:09.765Z', '2023-05-30T05:29:09.793Z', '2023-05-30T05:29:09.825Z', '2023-05-30T05:29:09.873Z', '2023-05-30T05:29:09.905Z', '2023-05-30T05:29:09.933Z', '2023-05-30T05:29:09.966Z', '2023-05-30T05:29:09.998Z', '2023-05-30T05:29:10.018Z', '2023-05-30T05:29:15.481Z', '2023-05-30T05:29:15.929Z', '2023-05-30T05:29:16.177Z', '2023-05-30T05:29:16.346Z', '2023-05-30T05:29:16.730Z', '2023-05-30T05:29:16.953Z', '2023-05-30T05:29:17.268Z', '2023-05-30T05:29:17.451Z', '2023-05-30T05:29:18.924Z', '2023-05-30T05:29:19.491Z', '2023-05-30T05:29:19.844Z', '2023-05-30T05:29:28.483Z', '2023-05-30T05:29:28.803Z', '2023-05-30T05:29:29.060Z', '2023-05-30T05:29:29.347Z', '2023-05-30T05:29:29.635Z', '2023-05-30T05:29:30.019Z', '2023-05-30T05:29:35.131Z', '2023-05-30T05:29:35.403Z', '2023-05-30T05:29:35.610Z', '2023-05-30T05:29:35.779Z', '2023-05-30T05:29:35.995Z', '2023-05-30T05:29:36.451Z', '2023-05-30T05:29:36.659Z', '2023-05-30T05:29:36.811Z', '2023-05-30T05:29:37.123Z', '2023-05-30T05:29:37.322Z', '2023-05-30T05:29:37.587Z', '2023-05-30T05:29:37.867Z', '2023-05-30T05:29:38.034Z', '2023-05-30T05:29:38.355Z', '2023-05-30T05:29:38.547Z', '2023-05-30T05:29:39.107Z', '2023-05-30T05:29:39.362Z', '2023-05-30T05:29:39.554Z', '2023-05-30T05:29:41.411Z', '2023-05-30T05:29:41.562Z', '2023-05-30T05:29:43.314Z', '2023-05-30T05:29:43.842Z', '2023-05-30T05:29:44.163Z', '2023-05-30T05:29:44.483Z', '2023-05-30T05:29:45.067Z', '2023-05-30T05:29:45.594Z', '2023-05-30T05:29:46.114Z', '2023-05-30T05:29:46.442Z', '2023-05-30T05:29:46.803Z', '2023-05-30T05:29:47.026Z', '2023-05-30T05:29:47.114Z', '2023-05-30T05:29:47.434Z', '2023-05-30T05:29:47.778Z', '2023-05-30T05:29:48.058Z', '2023-05-30T05:30:11.266Z', '2023-05-30T05:30:12.681Z', '2023-05-30T05:30:12.986Z', '2023-05-30T05:30:13.321Z', '2023-05-30T05:30:13.986Z', '2023-05-30T05:30:14.321Z', '2023-05-30T05:30:14.554Z', '2023-05-30T05:30:14.785Z', '2023-05-30T05:30:15.009Z', '2023-05-30T05:30:15.249Z', '2023-05-30T05:30:15.593Z', '2023-05-30T05:30:17.924Z', '2023-05-30T05:30:18.196Z', '2023-05-30T05:30:18.483Z', '2023-05-30T05:30:18.756Z', '2023-05-30T05:30:19.107Z', '2023-05-30T05:30:19.347Z', '2023-05-30T05:30:19.619Z', '2023-05-30T05:30:20.379Z', '2023-05-30T05:30:20.667Z', '2023-05-30T05:30:21.060Z', '2023-05-30T05:30:22.044Z', '2023-05-30T05:30:22.307Z', '2023-05-30T05:30:22.579Z', '2023-05-30T05:30:22.883Z', '2023-05-30T05:30:23.155Z', '2023-05-30T05:30:23.435Z', '2023-05-30T05:30:23.699Z', '2023-05-30T05:30:24.500Z', '2023-05-30T05:30:24.755Z', '2023-05-30T05:30:24.915Z', '2023-05-30T05:30:25.235Z', '2023-05-30T05:30:25.499Z', '2023-05-30T05:31:01.799Z', '2023-05-30T05:31:05.207Z', '2023-05-30T05:31:05.959Z', '2023-05-30T05:31:06.183Z', '2023-05-30T05:31:06.767Z', '2023-05-30T05:31:07.023Z', '2023-05-30T05:31:07.263Z', '2023-05-30T05:31:07.463Z', '2023-05-30T05:31:07.646Z', '2023-05-30T05:31:07.847Z', '2023-05-30T05:31:09.191Z', '2023-05-30T05:31:09.447Z', '2023-05-30T05:31:09.759Z', '2023-05-30T05:31:10.666Z', '2023-05-30T05:31:11.135Z', '2023-05-30T05:31:11.391Z', '2023-05-30T05:31:11.607Z', '2023-05-30T05:31:11.855Z', '2023-05-30T05:31:12.455Z', '2023-05-30T05:31:13.078Z', '2023-05-30T05:31:13.246Z', '2023-05-30T05:31:13.662Z', '2023-05-30T05:31:13.846Z', '2023-05-30T05:31:14.310Z', '2023-05-30T05:31:14.566Z', '2023-05-30T05:31:14.879Z', '2023-05-30T05:31:15.394Z', '2023-05-30T05:31:15.759Z', '2023-05-30T05:31:16.407Z', '2023-05-30T05:31:16.782Z', '2023-05-30T05:31:17.071Z', '2023-05-30T05:31:17.302Z', '2023-05-30T05:31:17.551Z', '2023-05-30T05:31:18.688Z', '2023-05-30T05:31:18.956Z', '2023-05-30T05:31:19.288Z', '2023-05-30T05:31:19.576Z', '2023-05-30T05:31:19.824Z', '2023-05-30T05:31:20.328Z', '2023-05-30T05:31:20.600Z', '2023-05-30T05:31:21.381Z', '2023-05-30T05:31:21.896Z', '2023-05-30T05:31:22.088Z', '2023-05-30T05:31:22.320Z', '2023-05-30T05:31:22.632Z', '2023-05-30T05:31:22.864Z', '2023-05-30T05:31:23.040Z', '2023-05-30T05:31:23.464Z', '2023-05-30T05:31:23.712Z', '2023-05-30T05:31:23.945Z', '2023-05-30T05:31:24.280Z', '2023-05-30T05:31:24.816Z', '2023-05-30T05:31:25.136Z', '2023-05-30T05:31:25.376Z', '2023-05-30T05:31:26.136Z', '2023-05-30T05:31:26.328Z', '2023-05-30T05:31:26.592Z', '2023-05-30T05:31:26.888Z', '2023-05-30T05:31:28.128Z', '2023-05-30T05:31:28.648Z', '2023-05-30T05:31:28.896Z', '2023-05-30T05:31:29.160Z', '2023-05-30T05:31:29.488Z', '2023-05-30T05:31:29.720Z', '2023-05-30T05:31:30.039Z', '2023-05-30T05:31:31.063Z', '2023-05-30T05:31:31.288Z', '2023-05-30T05:31:31.911Z', '2023-05-30T05:31:33.064Z', '2023-05-30T05:31:33.543Z', '2023-05-30T05:31:33.824Z', '2023-05-30T05:31:34.096Z', '2023-05-30T05:31:34.320Z', '2023-05-30T05:31:35.032Z', '2023-05-30T05:31:35.591Z', '2023-05-30T05:31:35.887Z', '2023-05-30T05:31:37.127Z', '2023-05-30T05:31:37.424Z', '2023-05-30T05:31:37.703Z', '2023-05-30T05:31:37.943Z', '2023-05-30T05:31:38.175Z', '2023-05-30T05:31:38.384Z', '2023-05-30T05:31:38.583Z', '2023-05-30T05:32:01.838Z', '2023-05-30T05:32:03.447Z', '2023-05-30T05:32:03.966Z', '2023-05-30T05:32:04.271Z', '2023-05-30T05:32:04.582Z', '2023-05-30T05:32:04.902Z', '2023-05-30T05:32:05.310Z', '2023-05-30T05:32:05.654Z', '2023-05-30T05:32:05.830Z', '2023-05-30T05:32:06.126Z', '2023-05-30T05:32:09.046Z', '2023-05-30T05:32:09.246Z', '2023-05-30T05:32:10.582Z', '2023-05-30T05:32:10.806Z', '2023-05-30T05:32:11.014Z', '2023-05-30T05:32:11.398Z', '2023-05-30T05:32:11.598Z', '2023-05-30T05:32:11.782Z', '2023-05-30T05:32:12.010Z', '2023-05-30T05:32:12.398Z', '2023-05-30T05:32:23.324Z', '2023-05-30T05:32:23.612Z', '2023-05-30T05:32:24.116Z', '2023-05-30T05:32:24.428Z', '2023-05-30T05:32:24.860Z', '2023-05-30T05:32:25.292Z', '2023-05-30T05:32:25.923Z', '2023-05-30T05:32:26.156Z', '2023-05-30T05:32:26.284Z', '2023-05-30T05:32:27.530Z', '2023-05-30T05:32:27.778Z', '2023-05-30T05:32:27.970Z', '2023-05-30T05:32:28.299Z', '2023-05-30T05:32:28.498Z', '2023-05-30T05:32:28.778Z', '2023-05-30T05:32:30.058Z', '2023-05-30T05:32:30.282Z', '2023-05-30T05:32:30.570Z', '2023-05-30T05:32:31.570Z', '2023-05-30T05:32:31.826Z', '2023-05-30T05:32:32.147Z', '2023-05-30T05:32:32.474Z', '2023-05-30T05:32:32.635Z', '2023-05-30T05:32:33.306Z', '2023-05-30T05:32:33.499Z', '2023-05-30T05:32:33.818Z', '2023-05-30T05:32:34.003Z', '2023-05-30T05:32:34.354Z', '2023-05-30T05:32:35.690Z', '2023-05-30T05:32:35.866Z', '2023-05-30T05:32:36.274Z', '2023-05-30T05:32:36.522Z', '2023-05-30T05:32:36.722Z', '2023-05-30T05:32:37.002Z', '2023-05-30T05:32:37.298Z', '2023-05-30T05:32:37.490Z', '2023-05-30T05:32:38.546Z', '2023-05-30T05:32:38.802Z', '2023-05-30T05:32:38.962Z', '2023-05-30T05:32:39.266Z', '2023-05-30T05:32:39.554Z', '2023-05-30T05:32:39.802Z', '2023-05-30T05:32:40.050Z', '2023-05-30T05:32:47.370Z', '2023-05-30T05:32:48.129Z', '2023-05-30T05:32:48.361Z', '2023-05-30T05:32:48.545Z', '2023-05-30T05:32:48.921Z', '2023-05-30T05:32:49.113Z']",In this topic myself tell by friend. And this conversation about by Primary Prevention of Cardiovascular disease. In this team conducted a randomized trial of this first pattern of Prevention of Cardiovascular disease. Controlled a diet foods and nuts. Most of this disease affect by the 57% of women. And the age ranges of 55 to 80 years. Most important supplemented with extra virgin olive oil or nuts reduced the incidence. So these are major cardiovascular events of the topic.,False
3UUSLRKAULOAO3B0I4U2SRPDZFN7D6,"Waning Protection after Fifth Dose of Acellular Pertussis Vaccine in Children

In the United States, children receive five doses of diphtheria, tetanus, and acellular pertussis (DTaP) vaccine before 7 years of age. The duration of protection after five doses of DTaP is unknown.

We assessed the risk of pertussis in children in California relative to the time since the fifth dose of DTaP from 2006 to 2011. This period included a large outbreak in 2010. We conducted a case - control study involving members of Kaiser Permanente Northern California who were vaccinated with DTaP at 47 to 84 months of age. We compared children with pertussis confirmed by a positive polymerase-chain-reaction (PCR) assay with two sets of controls; those who were PCR-negative for pertussis and closely matched controls from the general population of health-plan members. We used logistic regression to examine the risk of pertussis in relation to the duration of time since the fifth DTaP dose. Children who received whole-cell pertussis vaccine during infancy or who received any pertussis-containing vaccine after their fifth dose of DTaP were excluded.

We compared 277 children, 4 to 12 years of age, who were PCR-positive for pertussis with 3318 PCR-negative controls and 6086 matched controls. PCR-positive children were more likely to have received the fifth DTaP dose earlier than PCR-negative controls (P (0.001) or matched controls (P = 0.005). Comparison with PCR-negative controls yielded an odds ratio of 1.42 (95% confidence interval, 1.21 to 1.66), indicating that after the fifth dose of DTaP, the odds of acquiring pertussis increased by an average of 42% per year.

Protection against pertussis waned during the 5 years after the fifth dose of DTaP.
",ArrowDown ArrowDown ArrowDown ArrowDown ArrowDown ArrowDown ArrowDown ArrowDown ArrowDown ArrowDown,"['2023-05-29T18:22:49.942Z', '2023-05-29T18:22:50.421Z', '2023-05-29T18:22:50.468Z', '2023-05-29T18:22:50.500Z', '2023-05-29T18:22:50.532Z', '2023-05-29T18:22:50.563Z', '2023-05-29T18:22:50.594Z', '2023-05-29T18:22:50.626Z', '2023-05-29T18:22:50.659Z', '2023-05-29T18:22:50.689Z', '2023-05-29T18:24:58.347Z']","In the United States, children receive five doses of DTaP vaccine before 7 years of age. The duration of protection after five doses of DTaP is unknown.

A study was conducted in California to assess the risk of pertussis in children relative to the time since the fifth dose of DTaP from 2006 to 2011. The study found that children who were PCR-positive for pertussis were more likely to have received the fifth DTaP dose earlier than PCR-negative controls. Comparison with PCR-negative controls yielded an odds ratio of 1.42 (95% confidence interval, 1.21 to 1.66), indicating that after the fifth dose of DTaP, the odds of acquiring pertussis increased by an average of 42% per year.

The study's findings suggest that protection against pertussis waned during the 5 years after the fifth dose of DTaP. This suggests that children may need to receive booster doses of DTaP vaccine after the age of 7 years to maintain protection against pertussis.

 

The study included 277 children, 4 to 12 years of age, who were PCR-positive for pertussis.
The study also included 3318 PCR-negative controls and 6086 matched controls.
The study found that PCR-positive children were more likely to have received the fifth DTaP dose earlier than PCR-negative controls.
The study's findings suggest that protection against pertussis waned during the 5 years after the fifth dose of DTaP.",False
3UUSLRKAULOAO3B0I4U2SRPDZFN7D6,"Waning Protection after Fifth Dose of Acellular Pertussis Vaccine in Children

In the United States, children receive five doses of diphtheria, tetanus, and acellular pertussis (DTaP) vaccine before 7 years of age. The duration of protection after five doses of DTaP is unknown.

We assessed the risk of pertussis in children in California relative to the time since the fifth dose of DTaP from 2006 to 2011. This period included a large outbreak in 2010. We conducted a case - control study involving members of Kaiser Permanente Northern California who were vaccinated with DTaP at 47 to 84 months of age. We compared children with pertussis confirmed by a positive polymerase-chain-reaction (PCR) assay with two sets of controls; those who were PCR-negative for pertussis and closely matched controls from the general population of health-plan members. We used logistic regression to examine the risk of pertussis in relation to the duration of time since the fifth DTaP dose. Children who received whole-cell pertussis vaccine during infancy or who received any pertussis-containing vaccine after their fifth dose of DTaP were excluded.

We compared 277 children, 4 to 12 years of age, who were PCR-positive for pertussis with 3318 PCR-negative controls and 6086 matched controls. PCR-positive children were more likely to have received the fifth DTaP dose earlier than PCR-negative controls (P (0.001) or matched controls (P = 0.005). Comparison with PCR-negative controls yielded an odds ratio of 1.42 (95% confidence interval, 1.21 to 1.66), indicating that after the fifth dose of DTaP, the odds of acquiring pertussis increased by an average of 42% per year.

Protection against pertussis waned during the 5 years after the fifth dose of DTaP.
",Control v,"['2023-05-29T18:28:10.164Z', '2023-05-29T18:28:10.594Z']","The fifth dose of acellular pertussis vaccine (DTaP) is given to children in the United States before they are 7 years old. However, the duration of protection after this dose is unknown.

A study was conducted in California to assess the risk of pertussis in children relative to the time since the fifth dose of DTaP. The study found that children who received the fifth dose of DTaP earlier were more likely to develop pertussis than those who received it later. The odds of developing pertussis increased by an average of 42% per year after the fifth dose of DTaP.

These findings suggest that protection against pertussis wanes during the 5 years after the fifth dose of DTaP. This is important to keep in mind when making vaccination decisions for children.",True
3UUSLRKAULOAO3B0I4U2SRPDZFN7D6,"Waning Protection after Fifth Dose of Acellular Pertussis Vaccine in Children

In the United States, children receive five doses of diphtheria, tetanus, and acellular pertussis (DTaP) vaccine before 7 years of age. The duration of protection after five doses of DTaP is unknown.

We assessed the risk of pertussis in children in California relative to the time since the fifth dose of DTaP from 2006 to 2011. This period included a large outbreak in 2010. We conducted a case - control study involving members of Kaiser Permanente Northern California who were vaccinated with DTaP at 47 to 84 months of age. We compared children with pertussis confirmed by a positive polymerase-chain-reaction (PCR) assay with two sets of controls; those who were PCR-negative for pertussis and closely matched controls from the general population of health-plan members. We used logistic regression to examine the risk of pertussis in relation to the duration of time since the fifth DTaP dose. Children who received whole-cell pertussis vaccine during infancy or who received any pertussis-containing vaccine after their fifth dose of DTaP were excluded.

We compared 277 children, 4 to 12 years of age, who were PCR-positive for pertussis with 3318 PCR-negative controls and 6086 matched controls. PCR-positive children were more likely to have received the fifth DTaP dose earlier than PCR-negative controls (P (0.001) or matched controls (P = 0.005). Comparison with PCR-negative controls yielded an odds ratio of 1.42 (95% confidence interval, 1.21 to 1.66), indicating that after the fifth dose of DTaP, the odds of acquiring pertussis increased by an average of 42% per year.

Protection against pertussis waned during the 5 years after the fifth dose of DTaP.
",Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control c Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control v,"['2023-05-29T20:03:48.474Z', '2023-05-29T20:03:48.983Z', '2023-05-29T20:03:49.013Z', '2023-05-29T20:03:49.044Z', '2023-05-29T20:03:49.074Z', '2023-05-29T20:03:49.113Z', '2023-05-29T20:03:49.140Z', '2023-05-29T20:03:49.180Z', '2023-05-29T20:03:49.193Z', '2023-05-29T20:03:49.234Z', '2023-05-29T20:03:49.283Z', '2023-05-29T20:03:49.314Z', '2023-05-29T20:03:49.343Z', '2023-05-29T20:03:49.373Z', '2023-05-29T20:03:49.403Z', '2023-05-29T20:03:49.434Z', '2023-05-29T20:03:49.463Z', '2023-05-29T20:03:49.503Z', '2023-05-29T20:03:49.533Z', '2023-05-29T20:03:49.573Z', '2023-05-29T20:03:49.603Z', '2023-05-29T20:03:49.642Z', '2023-05-29T20:03:49.673Z', '2023-05-29T20:03:49.703Z', '2023-05-29T20:03:49.734Z', '2023-05-29T20:03:49.764Z', '2023-05-29T20:03:49.793Z', '2023-05-29T20:03:49.823Z', '2023-05-29T20:03:49.873Z', '2023-05-29T20:03:49.904Z', '2023-05-29T20:03:49.933Z', '2023-05-29T20:03:49.963Z', '2023-05-29T20:03:50.001Z', '2023-05-29T20:03:50.034Z', '2023-05-29T20:03:50.063Z', '2023-05-29T20:03:50.094Z', '2023-05-29T20:03:50.123Z', '2023-05-29T20:03:50.163Z', '2023-05-29T20:03:52.663Z', '2023-05-29T20:03:53.173Z', '2023-05-29T20:03:53.211Z', '2023-05-29T20:03:53.233Z', '2023-05-29T20:03:53.264Z', '2023-05-29T20:03:53.294Z', '2023-05-29T20:03:53.323Z', '2023-05-29T20:03:53.363Z', '2023-05-29T20:03:53.394Z', '2023-05-29T20:03:53.415Z', '2023-05-29T20:03:53.473Z', '2023-05-29T20:03:53.494Z', '2023-05-29T20:03:53.533Z', '2023-05-29T20:03:53.563Z', '2023-05-29T20:03:53.594Z', '2023-05-29T20:03:53.614Z', '2023-05-29T20:03:53.653Z', '2023-05-29T20:03:53.683Z', '2023-05-29T20:03:53.723Z', '2023-05-29T20:03:53.764Z', '2023-05-29T20:03:53.793Z', '2023-05-29T20:03:53.823Z', '2023-05-29T20:03:53.843Z']","We assessed the risk of pertussis in children in California relative to the time since the fifth dose of DTaP from 2006 to 2011. This period included a large outbreak in 2010. We conducted a case - control study involving members of Kaiser Permanente Northern California who were vaccinated with DTaP at 47 to 84 months of age. We compared children with pertussis confirmed by a positive polymerase-chain-reaction (PCR) assay with two sets of controls; those who were PCR-negative for pertussis and closely matched controls from the general population of health-plan members. We used logistic regression to examine the risk of pertussis in relation to the duration of time since the fifth DTaP dose. Children who received whole-cell pertussis vaccine during infancy or who received any pertussis-containing vaccine after their fifth dose of DTaP were excluded.
",True
36U4VBVNQOY6NO61DDIX78K1MRBUR1,"Changes in Diet and Lifestyle and Long-Term Weight Gain in Women and Men

Specific dietary and other lifestyle behaviors may affect the success of the straightforward-sounding strategy `` eat less and exercise more '' for preventing long-term weight gain.

We performed prospective investigations involving three separate cohorts that included 120,877 U.S. women and men who were free of chronic diseases and not obese at baseline, with follow-up periods from 1986 to 2006, 1991 to 2003, and 1986 to 2006. The relationships between changes in lifestyle factors and weight change were evaluated at 4-year intervals, with multivariable adjustments made for age, baseline body-mass index for each period, and all lifestyle factors simultaneously. Cohort-specific and sex-specific results were similar and were pooled with the use of an inverse-variance - weighted meta-analysis.

Within each 4-year period, participants gained an average of 3.35 lb (5th to 95th percentile,  4.1 to 12.4). On the basis of increased daily servings of individual dietary components, 4-year weight change was most strongly associated with the intake of potato chips (1.69 lb), potatoes (1.28 lb), sugar-sweetened beverages (1.00 lb), unprocessed red meats (0.95 lb), and processed meats (0.93 lb) and was inversely associated with the intake of vegetables ( 0.22 lb), whole grains ( 0.37 lb), fruits ( 0.49 lb), nuts ( 0.57 lb), and yogurt ( 0.82 lb) (P  0.005 for each comparison). Aggregate dietary changes were associated with substantial differences in weight change (3.93 lb across quintiles of dietary change). Other lifestyle factors were also independently associated with weight change (P (0.001), including physical activity ( 1.76 lb across quintiles); alcohol use (0.41 lb per drink per day), smoking (new quitters, 5.17 lb; former smokers, 0.14 lb), sleep (more weight gain with (6 or) 8 hours of sleep), and television watching (0.31 lb per hour per day).

Specific dietary and lifestyle factors are independently associated with long-term weight gain, with a substantial aggregate effect and implications for strategies to prevent obesity.
",Control c Control v,"['2023-05-29T22:14:26.554Z', '2023-05-29T22:14:26.635Z', '2023-05-29T22:16:48.762Z', '2023-05-29T22:16:48.811Z']","Men and women love to work out to release pent out frustration and to achieve weight loss. The recipe is pretty simple according to the article and they suggest workers eat less and work out more. Doctors have researched that women who work out more are prone to less diseases and same with statistics for men. Within a 4 year research, doctors have concluded that the baseline for people who don't work out is worse than people who do. It is important to realize this is a broad study and most significant changes will come from lifestyle changes from the user, etc.",True
36U4VBVNQOY6NO61DDIX78K1MRBUR1,"Changes in Diet and Lifestyle and Long-Term Weight Gain in Women and Men

Specific dietary and other lifestyle behaviors may affect the success of the straightforward-sounding strategy `` eat less and exercise more '' for preventing long-term weight gain.

We performed prospective investigations involving three separate cohorts that included 120,877 U.S. women and men who were free of chronic diseases and not obese at baseline, with follow-up periods from 1986 to 2006, 1991 to 2003, and 1986 to 2006. The relationships between changes in lifestyle factors and weight change were evaluated at 4-year intervals, with multivariable adjustments made for age, baseline body-mass index for each period, and all lifestyle factors simultaneously. Cohort-specific and sex-specific results were similar and were pooled with the use of an inverse-variance - weighted meta-analysis.

Within each 4-year period, participants gained an average of 3.35 lb (5th to 95th percentile,  4.1 to 12.4). On the basis of increased daily servings of individual dietary components, 4-year weight change was most strongly associated with the intake of potato chips (1.69 lb), potatoes (1.28 lb), sugar-sweetened beverages (1.00 lb), unprocessed red meats (0.95 lb), and processed meats (0.93 lb) and was inversely associated with the intake of vegetables ( 0.22 lb), whole grains ( 0.37 lb), fruits ( 0.49 lb), nuts ( 0.57 lb), and yogurt ( 0.82 lb) (P  0.005 for each comparison). Aggregate dietary changes were associated with substantial differences in weight change (3.93 lb across quintiles of dietary change). Other lifestyle factors were also independently associated with weight change (P (0.001), including physical activity ( 1.76 lb across quintiles); alcohol use (0.41 lb per drink per day), smoking (new quitters, 5.17 lb; former smokers, 0.14 lb), sleep (more weight gain with (6 or) 8 hours of sleep), and television watching (0.31 lb per hour per day).

Specific dietary and lifestyle factors are independently associated with long-term weight gain, with a substantial aggregate effect and implications for strategies to prevent obesity.
",Enter Enter Enter,"['2023-05-29T19:24:08.673Z', '2023-05-29T19:24:17.037Z', '2023-05-29T19:24:18.291Z']","A study of 120,877 U.S. women and men found that specific dietary and lifestyle behaviors are independently associated with long-term weight gain. The study found that people who increased their intake of potato chips, potatoes, sugar-sweetened beverages, unprocessed red meats, and processed meats gained more weight over time than those who did not increase their intake of these foods. Conversely, people who increased their intake of vegetables, whole grains, fruits, nuts, and yogurt gained less weight over time. The study also found that people who were more physically active, drank less alcohol, smoked less, slept more, and watched less television gained less weight over time.

The study's findings suggest that specific dietary and lifestyle behaviors can have a significant impact on long-term weight gain. This information can be used to develop strategies to prevent obesity and other chronic diseases that are associated with excess weight.
In a study of 120,877 U.S. women and men who were free of chronic diseases and not obese at baseline, researchers found that specific dietary and lifestyle behaviors were associated with long-term weight gain. The study found that people who increased their intake of potato chips, potatoes, sugar-sweetened beverages, unprocessed red meats, and processed meats were more likely to gain weight over time. On the other hand, people who increased their intake of vegetables, whole grains, fruits, nuts, and yogurt were less likely to gain weight. Other lifestyle factors that were associated with weight gain included physical activity, alcohol use, smoking, sleep, and television watching.

In a study of 120,877 U.S. women and men who were free of chronic diseases and not obese at baseline, researchers found that specific dietary and lifestyle behaviors were associated with long-term weight gain. The study found that people who increased their intake of potato chips, potatoes, sugar-sweetened beverages, unprocessed red meats, and processed meats were more likely to gain weight over time. On the other hand, people who increased their intake of vegetables, whole grains, fruits, nuts, and yogurt were less likely to gain weight. Other lifestyle factors that were associated with weight gain included physical activity, alcohol use, smoking, sleep, and television watching.",False
36U4VBVNQOY6NO61DDIX78K1MRBUR1,"Changes in Diet and Lifestyle and Long-Term Weight Gain in Women and Men

Specific dietary and other lifestyle behaviors may affect the success of the straightforward-sounding strategy `` eat less and exercise more '' for preventing long-term weight gain.

We performed prospective investigations involving three separate cohorts that included 120,877 U.S. women and men who were free of chronic diseases and not obese at baseline, with follow-up periods from 1986 to 2006, 1991 to 2003, and 1986 to 2006. The relationships between changes in lifestyle factors and weight change were evaluated at 4-year intervals, with multivariable adjustments made for age, baseline body-mass index for each period, and all lifestyle factors simultaneously. Cohort-specific and sex-specific results were similar and were pooled with the use of an inverse-variance - weighted meta-analysis.

Within each 4-year period, participants gained an average of 3.35 lb (5th to 95th percentile,  4.1 to 12.4). On the basis of increased daily servings of individual dietary components, 4-year weight change was most strongly associated with the intake of potato chips (1.69 lb), potatoes (1.28 lb), sugar-sweetened beverages (1.00 lb), unprocessed red meats (0.95 lb), and processed meats (0.93 lb) and was inversely associated with the intake of vegetables ( 0.22 lb), whole grains ( 0.37 lb), fruits ( 0.49 lb), nuts ( 0.57 lb), and yogurt ( 0.82 lb) (P  0.005 for each comparison). Aggregate dietary changes were associated with substantial differences in weight change (3.93 lb across quintiles of dietary change). Other lifestyle factors were also independently associated with weight change (P (0.001), including physical activity ( 1.76 lb across quintiles); alcohol use (0.41 lb per drink per day), smoking (new quitters, 5.17 lb; former smokers, 0.14 lb), sleep (more weight gain with (6 or) 8 hours of sleep), and television watching (0.31 lb per hour per day).

Specific dietary and lifestyle factors are independently associated with long-term weight gain, with a substantial aggregate effect and implications for strategies to prevent obesity.
",Control v,"['2023-05-29T18:30:11.263Z', '2023-05-29T18:30:11.703Z']","A study was conducted to investigate the relationship between changes in diet and lifestyle and long-term weight gain in women and men. The study included 120,877 U.S. adults who were free of chronic diseases and not obese at baseline. Participants were followed for an average of 16 years.

The study found that participants who made changes to their diet and lifestyle were more likely to gain weight over time. Specifically, participants who increased their intake of potato chips, potatoes, sugar-sweetened beverages, unprocessed red meats, and processed meats were more likely to gain weight. Participants who decreased their intake of vegetables, whole grains, fruits, nuts, and yogurt were also more likely to gain weight.

In addition to diet, the study also found that physical activity, smoking, alcohol use, sleep, and television watching were all associated with weight gain. Participants who were physically inactive, smoked, drank alcohol, slept less than 6 or more than 8 hours per day, or watched more than 3 hours of television per day were more likely to gain weight.

The study's findings suggest that specific dietary and lifestyle factors are independently associated with long-term weight gain. These findings have implications for strategies to prevent obesity. Public health campaigns and interventions should focus on promoting healthy eating and physical activity habits to help people maintain a healthy weight.",True
3TFJJUELSHATXA8GCWIWCUQN3ZP2CL,"A Population-Based Study of Measles, Mumps, and Rubella Vaccination and Autism

It has been suggested that vaccination against measles, mumps, and rubella (MMR) is a cause of autism.

We conducted a retrospective cohort study of all children born in Denmark from January 1991 through December 1998. The cohort was selected on the basis of data from the Danish Civil Registration System, which assigns a unique identification number to every live-born infant and new resident in Denmark. MMR-vaccination status was obtained from the Danish National Board of Health. Information on the children 's autism status was obtained from the Danish Psychiatric Central Register, which contains information on all diagnoses received by patients in psychiatric hospitals and outpatient clinics in Denmark. We obtained information on potential confounders from the Danish Medical Birth Registry, the National Hospital Registry, and Statistics Denmark.

Of the 537,303 children in the cohort (representing 2,129,864 person-years), 440,655 (82.0 percent) had received the MMR vaccine. We identified 316 children with a diagnosis of autistic disorder and 422 with a diagnosis of other autistic-spectrum disorders. After adjustment for potential confounders, the relative risk of autistic disorder in the group of vaccinated children, as compared with the unvaccinated group, was 0.92 (95 percent confidence interval, 0.68 to 1.24), and the relative risk of another autistic-spectrum disorder was 0.83 (95 percent confidence interval, 0.65 to 1.07). There was no association between the age at the time of vaccination, the time since vaccination, or the date of vaccination and the development of autistic disorder.

This study provides strong evidence against the hypothesis that MMR vaccination causes autism.
",,['2023-05-29T18:31:34.956Z'],"A study was conducted in Denmark to assess the association between MMR vaccination and autism. The study included all children born in Denmark from January 1991 through December 1998. The study found that there was no association between MMR vaccination and autism. The study's findings provide strong evidence against the hypothesis that MMR vaccination causes autism.

 

The study included 537,303 children.
Of the 537,303 children, 440,655 (82.0 percent) had received the MMR vaccine.
The study identified 316 children with a diagnosis of autistic disorder and 422 with a diagnosis of other autistic-spectrum disorders.
After adjustment for potential confounders, the relative risk of autistic disorder in the group of vaccinated children, as compared with the unvaccinated group, was 0.92 (95 percent confidence interval, 0.68 to 1.24), and the relative risk of another autistic-spectrum disorder was 0.83 (95 percent confidence interval, 0.65 to 1.07).
There was no association between the age at the time of vaccination, the time since vaccination, or the date of vaccination and the development of autistic disorder.
The study's findings are consistent with the findings of other studies that have examined the association between MMR vaccination and autism. These findings provide strong evidence against the hypothesis that MMR vaccination causes autism.",False
3TFJJUELSHATXA8GCWIWCUQN3ZP2CL,"A Population-Based Study of Measles, Mumps, and Rubella Vaccination and Autism

It has been suggested that vaccination against measles, mumps, and rubella (MMR) is a cause of autism.

We conducted a retrospective cohort study of all children born in Denmark from January 1991 through December 1998. The cohort was selected on the basis of data from the Danish Civil Registration System, which assigns a unique identification number to every live-born infant and new resident in Denmark. MMR-vaccination status was obtained from the Danish National Board of Health. Information on the children 's autism status was obtained from the Danish Psychiatric Central Register, which contains information on all diagnoses received by patients in psychiatric hospitals and outpatient clinics in Denmark. We obtained information on potential confounders from the Danish Medical Birth Registry, the National Hospital Registry, and Statistics Denmark.

Of the 537,303 children in the cohort (representing 2,129,864 person-years), 440,655 (82.0 percent) had received the MMR vaccine. We identified 316 children with a diagnosis of autistic disorder and 422 with a diagnosis of other autistic-spectrum disorders. After adjustment for potential confounders, the relative risk of autistic disorder in the group of vaccinated children, as compared with the unvaccinated group, was 0.92 (95 percent confidence interval, 0.68 to 1.24), and the relative risk of another autistic-spectrum disorder was 0.83 (95 percent confidence interval, 0.65 to 1.07). There was no association between the age at the time of vaccination, the time since vaccination, or the date of vaccination and the development of autistic disorder.

This study provides strong evidence against the hypothesis that MMR vaccination causes autism.
",Control v,"['2023-05-29T18:38:00.721Z', '2023-05-29T18:38:01.064Z']","A study was conducted in Denmark to investigate the association between MMR vaccination and autism. The study included all children born in Denmark from January 1991 through December 1998. The researchers found that there was no association between MMR vaccination and autism. The relative risk of autistic disorder in the group of vaccinated children was 0.92, and the relative risk of another autistic-spectrum disorder was 0.83. This study provides strong evidence against the hypothesis that MMR vaccination causes autism.",True
3TFJJUELSHATXA8GCWIWCUQN3ZP2CL,"A Population-Based Study of Measles, Mumps, and Rubella Vaccination and Autism

It has been suggested that vaccination against measles, mumps, and rubella (MMR) is a cause of autism.

We conducted a retrospective cohort study of all children born in Denmark from January 1991 through December 1998. The cohort was selected on the basis of data from the Danish Civil Registration System, which assigns a unique identification number to every live-born infant and new resident in Denmark. MMR-vaccination status was obtained from the Danish National Board of Health. Information on the children 's autism status was obtained from the Danish Psychiatric Central Register, which contains information on all diagnoses received by patients in psychiatric hospitals and outpatient clinics in Denmark. We obtained information on potential confounders from the Danish Medical Birth Registry, the National Hospital Registry, and Statistics Denmark.

Of the 537,303 children in the cohort (representing 2,129,864 person-years), 440,655 (82.0 percent) had received the MMR vaccine. We identified 316 children with a diagnosis of autistic disorder and 422 with a diagnosis of other autistic-spectrum disorders. After adjustment for potential confounders, the relative risk of autistic disorder in the group of vaccinated children, as compared with the unvaccinated group, was 0.92 (95 percent confidence interval, 0.68 to 1.24), and the relative risk of another autistic-spectrum disorder was 0.83 (95 percent confidence interval, 0.65 to 1.07). There was no association between the age at the time of vaccination, the time since vaccination, or the date of vaccination and the development of autistic disorder.

This study provides strong evidence against the hypothesis that MMR vaccination causes autism.
",Control v,"['2023-05-29T18:21:25.543Z', '2023-05-29T18:21:25.798Z']","This study analyzed data from 537,303 children born in Denmark between 1991 and 1998 in order to investigate any relationship between the measles, mumps, and rubella (MMR) vaccine and autism. After adjustment for potential confounders, it was found that children who had received the MMR vaccine were no more likely than those who had not to develop autistic disorder (0.92 relative risk) or any other autistic-spectrum disorder (0.83 relative risk). It was also concluded that age at time of vaccine, time since vaccine, and date of vaccine had no bearing on development of autistic disorder. This suggests that MMR vaccination is not related to autism and should not be a cause for concern.",True
30EMX9PEVK44L712YOE0RVGZ62WSKQ,"Response to a Monovalent 2009 Influenza A (H1N1) Vaccine

A novel 2009 influenza A (H1N1) virus is responsible for the first influenza pandemic in 41 years. A safe and effective vaccine is needed. A randomized, observer-blind, parallel-group trial evaluating two doses of an inactivated, split-virus 2009 H1N1 vaccine in healthy adults between the ages of 18 and 64 years is ongoing at a single site in Australia.

We evaluated the immunogenicity and safety of the vaccine after each of two scheduled doses, administered 21 days apart. A total of 240 subjects, equally divided into two age groups ((50 years and  50 years), were enrolled and underwent randomization to receive either 15 g or 30 g of hemagglutinin antigen by intramuscular injection. We measured antibody titers using hemagglutination-inhibition and microneutralization assays at baseline and 21 days after vaccination. The coprimary immunogenicity end points were the proportion of subjects with antibody titers of 1:40 or more on hemagglutination-inhibition assay, the proportion of subjects with either seroconversion or a significant increase in antibody titer, and the factor increase in the geometric mean titer.

By day 21 after the first dose, antibody titers of 1:40 or more were observed in 114 of 120 subjects (95.0%) who received the 15-g dose and in 106 of 119 subjects (89.1%) who received the 30-g dose. A similar result was observed after the second dose of vaccine. No deaths, serious adverse events, or adverse events of special interest were reported. Local discomfort (e.g., injection-site tenderness or pain) was reported by 56.3% of subjects, and systemic symptoms (e.g., headache) by 53.8% of subjects after each dose. Nearly all events were mild to moderate in intensity.

A single 15-g dose of 2009 H1N1 vaccine was immunogenic in adults, with mild-to-moderate vaccine-associated reactions.
","Control c Shift I n f l u e n z a Shift A Shift ( h 1 Backspace Backspace Shift H 1 Shift N 1 Shift ) 2 0 0 9 Shift M o n o v a l e n t Shift V a c c i n e i s a n Backspace h o m o g e n i z e d , s t e r i l e , s l i g h t l y o p a l e s c e n t s u s p e n s i o n i n a p h o s p h a t e b u f f e r e d s a l i n e . Shift Shift Shift I n Backspace Backspace Shift I t i s f o r m u l a t e d t o c o n t a i n 1 5 m c g h e m a g g l u t i n i n Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift ( Shift H A ) p e r 0 . 5 m l d o s e o f v i r u s s t r a i n . Control v Shift A Control v Control v Enter Control v Shift T h e p o s s i b l e s i d e e f f e c t s a n Enter d c o m p l i v Backspace c a t i o n s i n Shift H 1 Shift N Shift End Shift 1 i n c l u d e d Backspace s s o r e n e s s , s w e k Backspace l l i n g , a n d d i s c o l o r a t i o n a t t h e i n j e v Backspace c t i o n s i t e , h e a d a c g Backspace h e , f e v e r , n a u s e a , t i r e d n e s s a n d m u s c l e a c h e s . Enter Control Control Control Control Control v","['2023-05-29T19:54:00.991Z', '2023-05-29T19:54:01.385Z', '2023-05-29T19:56:00.526Z', '2023-05-29T19:56:00.792Z', '2023-05-29T19:56:01.413Z', '2023-05-29T19:56:02.005Z', '2023-05-29T19:56:02.334Z', '2023-05-29T19:56:02.646Z', '2023-05-29T19:56:02.966Z', '2023-05-29T19:56:03.421Z', '2023-05-29T19:56:03.662Z', '2023-05-29T19:56:03.966Z', '2023-05-29T19:56:04.181Z', '2023-05-29T19:56:04.399Z', '2023-05-29T19:56:04.750Z', '2023-05-29T19:56:06.950Z', '2023-05-29T19:56:07.494Z', '2023-05-29T19:56:07.863Z', '2023-05-29T19:56:08.879Z', '2023-05-29T19:56:09.503Z', '2023-05-29T19:56:11.526Z', '2023-05-29T19:56:11.717Z', '2023-05-29T19:56:12.543Z', '2023-05-29T19:56:12.869Z', '2023-05-29T19:56:14.078Z', '2023-05-29T19:56:14.606Z', '2023-05-29T19:56:14.909Z', '2023-05-29T19:56:15.574Z', '2023-05-29T19:56:16.118Z', '2023-05-29T19:56:16.334Z', '2023-05-29T19:56:23.826Z', '2023-05-29T19:56:24.375Z', '2023-05-29T19:56:24.586Z', '2023-05-29T19:56:24.758Z', '2023-05-29T19:56:25.134Z', '2023-05-29T19:56:25.806Z', '2023-05-29T19:56:26.334Z', '2023-05-29T19:56:26.550Z', '2023-05-29T19:56:26.814Z', '2023-05-29T19:56:27.118Z', '2023-05-29T19:56:27.374Z', '2023-05-29T19:56:27.854Z', '2023-05-29T19:56:28.054Z', '2023-05-29T19:56:28.278Z', '2023-05-29T19:56:28.723Z', '2023-05-29T19:56:28.934Z', '2023-05-29T19:56:29.230Z', '2023-05-29T19:56:29.534Z', '2023-05-29T19:56:29.662Z', '2023-05-29T19:56:29.822Z', '2023-05-29T19:56:30.062Z', '2023-05-29T19:56:30.198Z', '2023-05-29T19:56:30.366Z', '2023-05-29T19:56:30.727Z', '2023-05-29T19:56:31.022Z', '2023-05-29T19:56:31.254Z', '2023-05-29T19:56:31.453Z', '2023-05-29T19:56:33.375Z', '2023-05-29T19:56:33.718Z', '2023-05-29T19:56:33.942Z', '2023-05-29T19:56:34.078Z', '2023-05-29T19:56:34.240Z', '2023-05-29T19:56:34.502Z', '2023-05-29T19:56:35.222Z', '2023-05-29T19:56:36.471Z', '2023-05-29T19:56:40.030Z', '2023-05-29T19:56:40.374Z', '2023-05-29T19:56:40.677Z', '2023-05-29T19:56:40.950Z', '2023-05-29T19:56:41.486Z', '2023-05-29T19:56:41.653Z', '2023-05-29T19:56:41.894Z', '2023-05-29T19:56:42.191Z', '2023-05-29T19:56:44.501Z', '2023-05-29T19:56:44.806Z', '2023-05-29T19:56:45.038Z', '2023-05-29T19:56:49.046Z', '2023-05-29T19:56:49.318Z', '2023-05-29T19:56:49.782Z', '2023-05-29T19:56:49.935Z', '2023-05-29T19:56:50.439Z', '2023-05-29T19:56:50.646Z', '2023-05-29T19:56:51.206Z', '2023-05-29T19:56:51.438Z', '2023-05-29T19:56:51.758Z', '2023-05-29T19:56:53.351Z', '2023-05-29T19:56:53.854Z', '2023-05-29T19:56:54.101Z', '2023-05-29T19:56:54.341Z', '2023-05-29T19:56:54.719Z', '2023-05-29T19:56:54.926Z', '2023-05-29T19:56:55.142Z', '2023-05-29T19:56:55.576Z', '2023-05-29T19:56:55.989Z', '2023-05-29T19:56:57.223Z', '2023-05-29T19:56:57.710Z', '2023-05-29T19:56:57.917Z', '2023-05-29T19:56:58.264Z', '2023-05-29T19:57:00.710Z', '2023-05-29T19:57:00.959Z', '2023-05-29T19:57:01.247Z', '2023-05-29T19:57:01.838Z', '2023-05-29T19:57:02.143Z', '2023-05-29T19:57:02.421Z', '2023-05-29T19:57:02.799Z', '2023-05-29T19:57:11.271Z', '2023-05-29T19:57:15.358Z', '2023-05-29T19:57:15.607Z', '2023-05-29T19:57:16.118Z', '2023-05-29T19:57:16.326Z', '2023-05-29T19:57:16.815Z', '2023-05-29T19:57:17.086Z', '2023-05-29T19:57:17.406Z', '2023-05-29T19:57:17.567Z', '2023-05-29T19:57:17.854Z', '2023-05-29T19:57:18.098Z', '2023-05-29T19:57:18.391Z', '2023-05-29T19:57:18.671Z', '2023-05-29T19:57:20.126Z', '2023-05-29T19:57:21.383Z', '2023-05-29T19:57:21.847Z', '2023-05-29T19:57:22.078Z', '2023-05-29T19:57:22.334Z', '2023-05-29T19:57:22.823Z', '2023-05-29T19:57:23.997Z', '2023-05-29T19:57:24.322Z', '2023-05-29T19:57:24.590Z', '2023-05-29T19:57:27.030Z', '2023-05-29T19:57:27.638Z', '2023-05-29T19:57:27.902Z', '2023-05-29T19:57:28.064Z', '2023-05-29T19:57:28.326Z', '2023-05-29T19:57:28.728Z', '2023-05-29T19:57:28.989Z', '2023-05-29T19:57:29.302Z', '2023-05-29T19:57:29.790Z', '2023-05-29T19:57:29.958Z', '2023-05-29T19:57:34.269Z', '2023-05-29T19:57:34.472Z', '2023-05-29T19:57:34.654Z', '2023-05-29T19:57:34.871Z', '2023-05-29T19:57:36.840Z', '2023-05-29T19:57:37.286Z', '2023-05-29T19:57:37.608Z', '2023-05-29T19:57:37.799Z', '2023-05-29T19:57:38.054Z', '2023-05-29T19:57:38.302Z', '2023-05-29T19:57:38.694Z', '2023-05-29T19:57:39.478Z', '2023-05-29T19:57:40.078Z', '2023-05-29T19:57:40.694Z', '2023-05-29T19:57:41.200Z', '2023-05-29T19:57:41.231Z', '2023-05-29T19:57:41.242Z', '2023-05-29T19:57:41.494Z', '2023-05-29T19:57:44.655Z', '2023-05-29T19:57:44.841Z', '2023-05-29T19:57:45.886Z', '2023-05-29T19:57:46.223Z', '2023-05-29T19:57:46.607Z', '2023-05-29T19:57:46.902Z', '2023-05-29T19:57:47.230Z', '2023-05-29T19:57:47.369Z', '2023-05-29T19:57:47.566Z', '2023-05-29T19:57:47.870Z', '2023-05-29T19:57:48.382Z', '2023-05-29T19:57:48.566Z', '2023-05-29T19:57:48.726Z', '2023-05-29T19:57:49.121Z', '2023-05-29T19:57:49.334Z', '2023-05-29T19:57:49.534Z', '2023-05-29T19:57:49.774Z', '2023-05-29T19:57:50.015Z', '2023-05-29T19:57:50.258Z', '2023-05-29T19:57:50.647Z', '2023-05-29T19:57:52.886Z', '2023-05-29T19:57:53.567Z', '2023-05-29T19:57:53.768Z', '2023-05-29T19:57:54.086Z', '2023-05-29T19:57:54.214Z', '2023-05-29T19:57:54.438Z', '2023-05-29T19:57:54.712Z', '2023-05-29T19:57:55.024Z', '2023-05-29T19:57:55.200Z', '2023-05-29T19:57:55.471Z', '2023-05-29T19:57:55.719Z', '2023-05-29T19:57:55.920Z', '2023-05-29T19:57:56.655Z', '2023-05-29T19:57:56.831Z', '2023-05-29T19:57:57.303Z', '2023-05-29T19:57:57.542Z', '2023-05-29T19:57:58.583Z', '2023-05-29T19:57:58.823Z', '2023-05-29T19:58:00.286Z', '2023-05-29T19:58:01.065Z', '2023-05-29T19:58:01.320Z', '2023-05-29T19:58:01.656Z', '2023-05-29T19:58:01.920Z', '2023-05-29T19:58:03.776Z', '2023-05-29T19:58:03.935Z', '2023-05-29T19:58:04.319Z', '2023-05-29T19:58:04.793Z', '2023-05-29T19:58:05.145Z', '2023-05-29T19:58:05.520Z', '2023-05-29T19:58:11.695Z', '2023-05-29T19:58:11.999Z', '2023-05-29T19:58:12.269Z', '2023-05-29T19:58:12.590Z', '2023-05-29T19:58:14.191Z', '2023-05-29T19:58:14.701Z', '2023-05-29T19:58:14.730Z', '2023-05-29T19:58:14.760Z', '2023-05-29T19:58:14.789Z', '2023-05-29T19:58:14.830Z', '2023-05-29T19:58:14.859Z', '2023-05-29T19:58:14.890Z', '2023-05-29T19:58:14.929Z', '2023-05-29T19:58:14.960Z', '2023-05-29T19:58:14.990Z', '2023-05-29T19:58:15.029Z', '2023-05-29T19:58:15.060Z', '2023-05-29T19:58:15.090Z', '2023-05-29T19:58:15.119Z', '2023-05-29T19:58:15.160Z', '2023-05-29T19:58:15.194Z', '2023-05-29T19:58:15.219Z', '2023-05-29T19:58:15.255Z', '2023-05-29T19:58:16.103Z', '2023-05-29T19:58:16.355Z', '2023-05-29T19:58:16.842Z', '2023-05-29T19:58:17.462Z', '2023-05-29T19:58:20.359Z', '2023-05-29T19:58:21.039Z', '2023-05-29T19:58:21.295Z', '2023-05-29T19:58:21.566Z', '2023-05-29T19:58:21.879Z', '2023-05-29T19:58:22.663Z', '2023-05-29T19:58:22.847Z', '2023-05-29T19:58:23.126Z', '2023-05-29T19:58:24.624Z', '2023-05-29T19:58:24.943Z', '2023-05-29T19:58:25.134Z', '2023-05-29T19:58:25.599Z', '2023-05-29T19:58:27.999Z', '2023-05-29T19:58:28.214Z', '2023-05-29T19:58:28.480Z', '2023-05-29T19:58:29.335Z', '2023-05-29T19:58:29.648Z', '2023-05-29T19:58:30.135Z', '2023-05-29T19:58:30.671Z', '2023-05-29T19:58:33.055Z', '2023-05-29T19:58:35.576Z', '2023-05-29T19:58:36.096Z', '2023-05-29T19:58:36.486Z', '2023-05-29T19:58:36.952Z', '2023-05-29T19:58:37.311Z', '2023-05-29T19:58:37.543Z', '2023-05-29T19:58:37.743Z', '2023-05-29T19:58:38.007Z', '2023-05-29T19:58:38.208Z', '2023-05-29T19:58:38.504Z', '2023-05-29T19:58:38.694Z', '2023-05-29T19:58:38.984Z', '2023-05-29T19:58:44.152Z', '2023-05-29T19:59:03.279Z', '2023-05-29T19:59:03.647Z', '2023-05-29T19:59:13.287Z', '2023-05-29T19:59:13.513Z', '2023-05-29T19:59:13.799Z', '2023-05-29T19:59:38.760Z', '2023-05-29T19:59:39.049Z', '2023-05-29T19:59:43.903Z', '2023-05-29T20:00:17.679Z', '2023-05-29T20:00:18.158Z', '2023-05-29T20:01:11.702Z', '2023-05-29T20:01:13.016Z', '2023-05-29T20:01:13.415Z', '2023-05-29T20:01:18.083Z', '2023-05-29T20:01:19.137Z', '2023-05-29T20:01:19.808Z', '2023-05-29T20:01:20.072Z', '2023-05-29T20:01:20.287Z', '2023-05-29T20:01:20.496Z', '2023-05-29T20:01:50.959Z', '2023-05-29T20:01:51.351Z', '2023-05-29T20:01:51.752Z', '2023-05-29T20:01:52.044Z', '2023-05-29T20:01:52.367Z', '2023-05-29T20:01:52.527Z', '2023-05-29T20:01:53.187Z', '2023-05-29T20:01:53.415Z', '2023-05-29T20:01:53.695Z', '2023-05-29T20:01:53.870Z', '2023-05-29T20:01:54.259Z', '2023-05-29T20:01:54.616Z', '2023-05-29T20:01:55.007Z', '2023-05-29T20:01:55.271Z', '2023-05-29T20:01:55.540Z', '2023-05-29T20:01:57.039Z', '2023-05-29T20:01:57.238Z', '2023-05-29T20:01:57.648Z', '2023-05-29T20:01:57.847Z', '2023-05-29T20:01:58.127Z', '2023-05-29T20:01:58.334Z', '2023-05-29T20:01:58.511Z', '2023-05-29T20:01:58.687Z', '2023-05-29T20:01:58.831Z', '2023-05-29T20:01:59.006Z', '2023-05-29T20:01:59.407Z', '2023-05-29T20:01:59.562Z', '2023-05-29T20:02:02.120Z', '2023-05-29T20:02:03.094Z', '2023-05-29T20:02:03.215Z', '2023-05-29T20:02:08.398Z', '2023-05-29T20:02:12.942Z', '2023-05-29T20:02:13.207Z', '2023-05-29T20:02:13.416Z', '2023-05-29T20:02:13.936Z', '2023-05-29T20:02:14.207Z', '2023-05-29T20:02:14.774Z', '2023-05-29T20:02:14.993Z', '2023-05-29T20:02:15.232Z', '2023-05-29T20:02:15.624Z', '2023-05-29T20:02:16.376Z', '2023-05-29T20:02:16.864Z', '2023-05-29T20:02:17.071Z', '2023-05-29T20:02:17.279Z', '2023-05-29T20:02:17.743Z', '2023-05-29T20:02:17.943Z', '2023-05-29T20:02:18.199Z', '2023-05-29T20:02:20.823Z', '2023-05-29T20:02:20.958Z', '2023-05-29T20:02:21.856Z', '2023-05-29T20:02:22.119Z', '2023-05-29T20:02:22.350Z', '2023-05-29T20:02:22.887Z', '2023-05-29T20:02:23.311Z', '2023-05-29T20:02:24.095Z', '2023-05-29T20:02:25.815Z', '2023-05-29T20:02:25.967Z', '2023-05-29T20:02:27.382Z', '2023-05-29T20:02:27.689Z', '2023-05-29T20:02:27.720Z', '2023-05-29T20:02:28.551Z', '2023-05-29T20:02:32.623Z', '2023-05-29T20:02:34.591Z', '2023-05-29T20:02:34.831Z', '2023-05-29T20:02:35.407Z', '2023-05-29T20:02:35.898Z', '2023-05-29T20:02:36.264Z', '2023-05-29T20:02:36.678Z', '2023-05-29T20:02:36.871Z', '2023-05-29T20:02:37.083Z', '2023-05-29T20:02:38.742Z', '2023-05-29T20:02:39.199Z', '2023-05-29T20:02:41.624Z', '2023-05-29T20:02:42.943Z', '2023-05-29T20:02:43.268Z', '2023-05-29T20:02:43.711Z', '2023-05-29T20:02:43.904Z', '2023-05-29T20:02:44.423Z', '2023-05-29T20:02:44.688Z', '2023-05-29T20:02:44.951Z', '2023-05-29T20:02:45.175Z', '2023-05-29T20:02:48.222Z', '2023-05-29T20:02:49.082Z', '2023-05-29T20:02:49.296Z', '2023-05-29T20:02:49.518Z', '2023-05-29T20:02:50.118Z', '2023-05-29T20:02:50.951Z', '2023-05-29T20:02:51.343Z', '2023-05-29T20:02:51.526Z', '2023-05-29T20:02:51.752Z', '2023-05-29T20:02:51.998Z', '2023-05-29T20:02:52.223Z', '2023-05-29T20:02:52.833Z', '2023-05-29T20:02:53.551Z', '2023-05-29T20:02:54.200Z', '2023-05-29T20:02:54.423Z', '2023-05-29T20:02:54.768Z', '2023-05-29T20:02:54.976Z', '2023-05-29T20:02:55.415Z', '2023-05-29T20:02:55.847Z', '2023-05-29T20:02:55.999Z', '2023-05-29T20:02:56.533Z', '2023-05-29T20:02:56.927Z', '2023-05-29T20:02:57.239Z', '2023-05-29T20:02:57.479Z', '2023-05-29T20:03:00.374Z', '2023-05-29T20:03:00.559Z', '2023-05-29T20:03:00.711Z', '2023-05-29T20:03:02.536Z', '2023-05-29T20:03:02.736Z', '2023-05-29T20:03:03.007Z', '2023-05-29T20:03:04.927Z', '2023-05-29T20:03:05.295Z', '2023-05-29T20:03:05.687Z', '2023-05-29T20:03:05.967Z', '2023-05-29T20:03:06.239Z', '2023-05-29T20:03:06.463Z', '2023-05-29T20:03:06.655Z', '2023-05-29T20:03:06.863Z', '2023-05-29T20:03:07.882Z', '2023-05-29T20:03:08.135Z', '2023-05-29T20:03:08.327Z', '2023-05-29T20:03:08.655Z', '2023-05-29T20:03:08.880Z', '2023-05-29T20:03:09.783Z', '2023-05-29T20:03:09.999Z', '2023-05-29T20:03:10.368Z', '2023-05-29T20:03:10.791Z', '2023-05-29T20:03:10.992Z', '2023-05-29T20:03:11.246Z', '2023-05-29T20:03:11.470Z', '2023-05-29T20:03:11.696Z', '2023-05-29T20:03:11.927Z', '2023-05-29T20:03:12.351Z', '2023-05-29T20:03:12.623Z', '2023-05-29T20:03:19.662Z', '2023-05-29T20:03:20.160Z', '2023-05-29T20:03:20.471Z', '2023-05-29T20:03:20.887Z', '2023-05-29T20:03:21.063Z', '2023-05-29T20:03:21.255Z', '2023-05-29T20:03:21.400Z', '2023-05-29T20:03:21.656Z', '2023-05-29T20:03:22.047Z', '2023-05-29T20:03:23.047Z', '2023-05-29T20:03:23.447Z', '2023-05-29T20:03:23.712Z', '2023-05-29T20:03:25.175Z', '2023-05-29T20:03:28.270Z', '2023-05-29T20:03:28.416Z', '2023-05-29T20:03:28.710Z', '2023-05-29T20:03:28.775Z', '2023-05-29T20:03:29.110Z', '2023-05-29T20:03:30.175Z', '2023-05-29T20:03:31.192Z', '2023-05-29T20:03:31.863Z', '2023-05-29T20:03:32.070Z', '2023-05-29T20:03:32.279Z', '2023-05-29T20:03:32.664Z', '2023-05-29T20:03:32.856Z', '2023-05-29T20:03:33.000Z', '2023-05-29T20:03:34.878Z', '2023-05-29T20:03:35.183Z', '2023-05-29T20:03:35.591Z', '2023-05-29T20:03:36.015Z', '2023-05-29T20:03:36.414Z', '2023-05-29T20:03:36.646Z', '2023-05-29T20:03:36.842Z', '2023-05-29T20:03:37.318Z', '2023-05-29T20:03:37.711Z', '2023-05-29T20:03:37.983Z', '2023-05-29T20:03:38.158Z', '2023-05-29T20:03:39.126Z', '2023-05-29T20:03:39.343Z', '2023-05-29T20:03:40.167Z', '2023-05-29T20:03:40.551Z', '2023-05-29T20:03:40.999Z', '2023-05-29T20:03:41.832Z', '2023-05-29T20:03:42.111Z', '2023-05-29T20:03:42.696Z', '2023-05-29T20:03:42.871Z', '2023-05-29T20:03:43.330Z', '2023-05-29T20:03:43.575Z', '2023-05-29T20:03:43.761Z', '2023-05-29T20:03:43.968Z', '2023-05-29T20:03:44.192Z', '2023-05-29T20:03:44.487Z', '2023-05-29T20:03:44.903Z', '2023-05-29T20:03:45.105Z', '2023-05-29T20:03:46.769Z', '2023-05-29T20:03:49.768Z', '2023-05-29T20:03:52.864Z', '2023-05-29T20:05:01.382Z', '2023-05-29T20:05:02.806Z', '2023-05-29T20:05:03.307Z', '2023-05-29T20:05:03.337Z', '2023-05-29T20:05:03.367Z', '2023-05-29T20:05:03.396Z', '2023-05-29T20:05:03.430Z']","Influenza A (H1N1) 2009 Monovalent Vaccine  is a homogenized, sterile, slightly opalescent suspension in a phosphate buffered saline. It is formulated  to contain 15 mcg hemagglutinin (HA) per 0.5 ml dose of virus strain. Adjusted effectiveness of seasonal vaccine against pandemic (H1N1) 2009 virus was 79% (95% confidence interval 33%93%); effectiveness of monovalent vaccine was 47% and not statistically significant. Vaccine effectiveness was higher among adults. The vaccine works by causing your body to produce its own protection (antibodies) against the disease. The vaccine was effective but caused side effects.
      No deaths, serious adverse events, or adverse events of special interest were reported. Local discomfort (e.g., injection-site tenderness or pain) was reported by 56.3% of subjects, and systemic symptoms (e.g., headache) by 53.8% of subjects after each dose. Nearly all events were mild to moderate in intensity. 
The possible side effects and complications in H1N1 includes soreness, swelling, and discoloration at the injection site, headache, fever, nausea, tiredness and muscle aches.
People who have a higher risk of becoming seriously ill if infected include: Children younger than 5 years old. Adults older than age 65, younger adults, and children under age 19 who are on long-term aspirin therapy.",True
30EMX9PEVK44L712YOE0RVGZ62WSKQ,"Response to a Monovalent 2009 Influenza A (H1N1) Vaccine

A novel 2009 influenza A (H1N1) virus is responsible for the first influenza pandemic in 41 years. A safe and effective vaccine is needed. A randomized, observer-blind, parallel-group trial evaluating two doses of an inactivated, split-virus 2009 H1N1 vaccine in healthy adults between the ages of 18 and 64 years is ongoing at a single site in Australia.

We evaluated the immunogenicity and safety of the vaccine after each of two scheduled doses, administered 21 days apart. A total of 240 subjects, equally divided into two age groups ((50 years and  50 years), were enrolled and underwent randomization to receive either 15 g or 30 g of hemagglutinin antigen by intramuscular injection. We measured antibody titers using hemagglutination-inhibition and microneutralization assays at baseline and 21 days after vaccination. The coprimary immunogenicity end points were the proportion of subjects with antibody titers of 1:40 or more on hemagglutination-inhibition assay, the proportion of subjects with either seroconversion or a significant increase in antibody titer, and the factor increase in the geometric mean titer.

By day 21 after the first dose, antibody titers of 1:40 or more were observed in 114 of 120 subjects (95.0%) who received the 15-g dose and in 106 of 119 subjects (89.1%) who received the 30-g dose. A similar result was observed after the second dose of vaccine. No deaths, serious adverse events, or adverse events of special interest were reported. Local discomfort (e.g., injection-site tenderness or pain) was reported by 56.3% of subjects, and systemic symptoms (e.g., headache) by 53.8% of subjects after each dose. Nearly all events were mild to moderate in intensity.

A single 15-g dose of 2009 H1N1 vaccine was immunogenic in adults, with mild-to-moderate vaccine-associated reactions.
",Control a Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control v,"['2023-05-29T19:15:44.892Z', '2023-05-29T19:15:45.144Z', '2023-05-29T19:15:45.427Z', '2023-05-29T19:15:45.944Z', '2023-05-29T19:15:45.975Z', '2023-05-29T19:15:46.008Z', '2023-05-29T19:15:46.044Z', '2023-05-29T19:15:46.076Z', '2023-05-29T19:15:46.111Z', '2023-05-29T19:15:46.145Z', '2023-05-29T19:15:46.175Z', '2023-05-29T19:15:46.210Z', '2023-05-29T19:15:46.241Z', '2023-05-29T19:15:46.273Z', '2023-05-29T19:15:46.308Z', '2023-05-29T19:15:46.339Z', '2023-05-29T19:15:46.372Z', '2023-05-29T19:15:46.405Z', '2023-05-29T19:15:46.419Z']","A study was conducted to evaluate the immunogenicity and safety of a monovalent 2009 influenza A (H1N1) vaccine in healthy adults between the ages of 18 and 64 years. The vaccine was found to be immunogenic, with 95.0% of subjects who received a 15-g dose and 89.1% of subjects who received a 30-g dose developing antibody titers of 1:40 or more by day 21 after the first dose. No deaths, serious adverse events, or adverse events of special interest were reported. The most common side effects were local discomfort (e.g., injection-site tenderness or pain) and systemic symptoms (e.g., headache), which were mild to moderate in intensity.",True
30EMX9PEVK44L712YOE0RVGZ62WSKQ,"Response to a Monovalent 2009 Influenza A (H1N1) Vaccine

A novel 2009 influenza A (H1N1) virus is responsible for the first influenza pandemic in 41 years. A safe and effective vaccine is needed. A randomized, observer-blind, parallel-group trial evaluating two doses of an inactivated, split-virus 2009 H1N1 vaccine in healthy adults between the ages of 18 and 64 years is ongoing at a single site in Australia.

We evaluated the immunogenicity and safety of the vaccine after each of two scheduled doses, administered 21 days apart. A total of 240 subjects, equally divided into two age groups ((50 years and  50 years), were enrolled and underwent randomization to receive either 15 g or 30 g of hemagglutinin antigen by intramuscular injection. We measured antibody titers using hemagglutination-inhibition and microneutralization assays at baseline and 21 days after vaccination. The coprimary immunogenicity end points were the proportion of subjects with antibody titers of 1:40 or more on hemagglutination-inhibition assay, the proportion of subjects with either seroconversion or a significant increase in antibody titer, and the factor increase in the geometric mean titer.

By day 21 after the first dose, antibody titers of 1:40 or more were observed in 114 of 120 subjects (95.0%) who received the 15-g dose and in 106 of 119 subjects (89.1%) who received the 30-g dose. A similar result was observed after the second dose of vaccine. No deaths, serious adverse events, or adverse events of special interest were reported. Local discomfort (e.g., injection-site tenderness or pain) was reported by 56.3% of subjects, and systemic symptoms (e.g., headache) by 53.8% of subjects after each dose. Nearly all events were mild to moderate in intensity.

A single 15-g dose of 2009 H1N1 vaccine was immunogenic in adults, with mild-to-moderate vaccine-associated reactions.
",Control v,"['2023-05-29T18:22:26.433Z', '2023-05-29T18:22:26.830Z']","This study evaluated the safety and immunogenicity of a novel 2009 H1N1 influenza virus vaccine in healthy adult subjects. A single site in Australia conducted a randomized, observer-blind, parallel-group trial of two doses of the inactivated split-virus vaccine. Two age groups (50 years and over 50 years) of 120 subjects each, were given either a 15 or a 30mcg dose of hemagglutinin antigen intramuscularly. Measuring antibody titers via hemagglutination-inhibition and microneutralization assays found that the vaccine was immunogenic after both doses. No deaths, serious events, or adverse events of special interest were recorded but 56.3% of subjects experienced local discomfort and 53.8% experienced systemic symptoms such as headache, all of which were mostly mild to moderate in intensity. The results indicate that a single 15mcg dose of the 2009 H1N1 vaccine is immunogenic in adults, with only mild-to-moderate associated reactions.",True
35XW21VSVGZF5DJKJOQ16VTEV21SLT,"Association of Coffee Drinking with Total and Cause-Specific Mortality

Coffee is one of the most widely consumed beverages, but the association between coffee consumption and the risk of death remains unclear.

We examined the association of coffee drinking with subsequent total and cause-specific mortality among 229,119 men and 173,141 women in the National Institutes of Health - AARP Diet and Health Study who were 50 to 71 years of age at baseline. Participants with cancer, heart disease, and stroke were excluded. Coffee consumption was assessed once at baseline.

During 5,148,760 person-years of follow-up between 1995 and 2008, a total of 33,731 men and 18,784 women died. In age-adjusted models, the risk of death was increased among coffee drinkers. However, coffee drinkers were also more likely to smoke, and, after adjustment for tobacco-smoking status and other potential confounders, there was a significant inverse association between coffee consumption and mortality. Adjusted hazard ratios for death among men who drank coffee as compared with those who did not were as follows; 0.99 (95% confidence interval (CI), 0.95 to 1.04) for drinking less than 1 cup per day, 0.94 (95% CI, 0.90 to 0.99) for 1 cup, 0.90 (95% CI, 0.86 to 0.93) for 2 or 3 cups, 0.88 (95% CI, 0.84 to 0.93) for 4 or 5 cups, and 0.90 (95% CI, 0.85 to 0.96) for 6 or more cups of coffee per day (P (0.001 for trend); the respective hazard ratios among women were 1.01 (95% CI, 0.96 to 1.07), 0.95 (95% CI, 0.90 to 1.01), 0.87 (95% CI, 0.83 to 0.92), 0.84 (95% CI, 0.79 to 0.90), and 0.85 (95% CI, 0.78 to 0.93) (P (0.001 for trend). Inverse associations were observed for deaths due to heart disease, respiratory disease, stroke, injuries and accidents, diabetes, and infections, but not for deaths due to cancer. Results were similar in subgroups, including persons who had never smoked and persons who reported very good to excellent health at baseline.

In this large prospective study, coffee consumption was inversely associated with total and cause-specific mortality. Whether this was a causal or associational finding can not be determined from our data. (Funded by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Division of Cancer Epidemiology and Genetics.)
",g o o d,"['2023-05-29T19:18:47.765Z', '2023-05-29T19:18:47.996Z', '2023-05-29T19:18:48.156Z', '2023-05-29T19:18:48.317Z']",good,False
35XW21VSVGZF5DJKJOQ16VTEV21SLT,"Association of Coffee Drinking with Total and Cause-Specific Mortality

Coffee is one of the most widely consumed beverages, but the association between coffee consumption and the risk of death remains unclear.

We examined the association of coffee drinking with subsequent total and cause-specific mortality among 229,119 men and 173,141 women in the National Institutes of Health - AARP Diet and Health Study who were 50 to 71 years of age at baseline. Participants with cancer, heart disease, and stroke were excluded. Coffee consumption was assessed once at baseline.

During 5,148,760 person-years of follow-up between 1995 and 2008, a total of 33,731 men and 18,784 women died. In age-adjusted models, the risk of death was increased among coffee drinkers. However, coffee drinkers were also more likely to smoke, and, after adjustment for tobacco-smoking status and other potential confounders, there was a significant inverse association between coffee consumption and mortality. Adjusted hazard ratios for death among men who drank coffee as compared with those who did not were as follows; 0.99 (95% confidence interval (CI), 0.95 to 1.04) for drinking less than 1 cup per day, 0.94 (95% CI, 0.90 to 0.99) for 1 cup, 0.90 (95% CI, 0.86 to 0.93) for 2 or 3 cups, 0.88 (95% CI, 0.84 to 0.93) for 4 or 5 cups, and 0.90 (95% CI, 0.85 to 0.96) for 6 or more cups of coffee per day (P (0.001 for trend); the respective hazard ratios among women were 1.01 (95% CI, 0.96 to 1.07), 0.95 (95% CI, 0.90 to 1.01), 0.87 (95% CI, 0.83 to 0.92), 0.84 (95% CI, 0.79 to 0.90), and 0.85 (95% CI, 0.78 to 0.93) (P (0.001 for trend). Inverse associations were observed for deaths due to heart disease, respiratory disease, stroke, injuries and accidents, diabetes, and infections, but not for deaths due to cancer. Results were similar in subgroups, including persons who had never smoked and persons who reported very good to excellent health at baseline.

In this large prospective study, coffee consumption was inversely associated with total and cause-specific mortality. Whether this was a causal or associational finding can not be determined from our data. (Funded by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Division of Cancer Epidemiology and Genetics.)
",i t i s v e r y d i f f i c u l t a n d i t i s v e r y c o m p e t i v e d s a n d i s n i c e a b o u t b Backspace t h e c o f f e a n d t h e r e i s a v e r y b o Backspace a d s i t u a t i o n,"['2023-05-29T21:16:33.171Z', '2023-05-29T21:16:33.420Z', '2023-05-29T21:16:33.516Z', '2023-05-29T21:16:33.739Z', '2023-05-29T21:16:33.923Z', '2023-05-29T21:16:34.028Z', '2023-05-29T21:16:34.275Z', '2023-05-29T21:16:34.371Z', '2023-05-29T21:16:34.571Z', '2023-05-29T21:16:34.770Z', '2023-05-29T21:16:34.979Z', '2023-05-29T21:16:35.612Z', '2023-05-29T21:16:35.821Z', '2023-05-29T21:16:36.099Z', '2023-05-29T21:16:36.252Z', '2023-05-29T21:16:36.429Z', '2023-05-29T21:16:36.707Z', '2023-05-29T21:16:37.084Z', '2023-05-29T21:16:37.315Z', '2023-05-29T21:16:38.296Z', '2023-05-29T21:16:38.500Z', '2023-05-29T21:16:38.588Z', '2023-05-29T21:16:38.763Z', '2023-05-29T21:16:39.003Z', '2023-05-29T21:16:39.115Z', '2023-05-29T21:16:39.371Z', '2023-05-29T21:16:39.651Z', '2023-05-29T21:16:39.875Z', '2023-05-29T21:16:40.109Z', '2023-05-29T21:16:40.237Z', '2023-05-29T21:16:40.346Z', '2023-05-29T21:16:40.555Z', '2023-05-29T21:16:40.661Z', '2023-05-29T21:16:40.851Z', '2023-05-29T21:16:41.059Z', '2023-05-29T21:16:41.277Z', '2023-05-29T21:16:41.851Z', '2023-05-29T21:16:42.043Z', '2023-05-29T21:16:42.243Z', '2023-05-29T21:16:42.436Z', '2023-05-29T21:16:42.666Z', '2023-05-29T21:16:42.906Z', '2023-05-29T21:16:43.129Z', '2023-05-29T21:16:43.362Z', '2023-05-29T21:16:43.508Z', '2023-05-29T21:16:43.660Z', '2023-05-29T21:16:43.730Z', '2023-05-29T21:16:43.733Z', '2023-05-29T21:16:43.972Z', '2023-05-29T21:16:44.102Z', '2023-05-29T21:16:44.322Z', '2023-05-29T21:16:44.461Z', '2023-05-29T21:16:44.715Z', '2023-05-29T21:16:44.835Z', '2023-05-29T21:16:45.235Z', '2023-05-29T21:16:45.371Z', '2023-05-29T21:16:45.466Z', '2023-05-29T21:16:45.763Z', '2023-05-29T21:16:46.068Z', '2023-05-29T21:16:46.340Z', '2023-05-29T21:16:46.523Z', '2023-05-29T21:16:46.637Z', '2023-05-29T21:16:46.755Z', '2023-05-29T21:16:46.946Z', '2023-05-29T21:16:47.539Z', '2023-05-29T21:16:49.244Z', '2023-05-29T21:16:49.442Z', '2023-05-29T21:16:49.660Z', '2023-05-29T21:16:49.827Z', '2023-05-29T21:16:51.603Z', '2023-05-29T21:16:51.778Z', '2023-05-29T21:16:51.924Z', '2023-05-29T21:16:52.228Z', '2023-05-29T21:16:52.429Z', '2023-05-29T21:16:52.546Z', '2023-05-29T21:16:52.692Z', '2023-05-29T21:16:56.987Z', '2023-05-29T21:16:57.211Z', '2023-05-29T21:16:57.540Z', '2023-05-29T21:16:57.708Z', '2023-05-29T21:16:57.900Z', '2023-05-29T21:16:58.124Z', '2023-05-29T21:16:58.254Z', '2023-05-29T21:16:58.475Z', '2023-05-29T21:16:58.667Z', '2023-05-29T21:16:58.794Z', '2023-05-29T21:16:59.450Z', '2023-05-29T21:16:59.667Z', '2023-05-29T21:16:59.803Z', '2023-05-29T21:17:00.038Z', '2023-05-29T21:17:00.238Z', '2023-05-29T21:17:00.362Z', '2023-05-29T21:17:00.554Z', '2023-05-29T21:17:00.661Z', '2023-05-29T21:17:00.795Z', '2023-05-29T21:17:00.972Z', '2023-05-29T21:17:01.131Z', '2023-05-29T21:17:01.715Z', '2023-05-29T21:17:01.859Z', '2023-05-29T21:17:02.060Z', '2023-05-29T21:17:02.214Z', '2023-05-29T21:17:02.445Z', '2023-05-29T21:17:02.682Z', '2023-05-29T21:17:03.035Z', '2023-05-29T21:17:03.700Z', '2023-05-29T21:17:03.835Z', '2023-05-29T21:17:04.107Z', '2023-05-29T21:17:04.227Z', '2023-05-29T21:17:04.419Z', '2023-05-29T21:17:04.823Z', '2023-05-29T21:17:05.107Z', '2023-05-29T21:17:05.916Z', '2023-05-29T21:17:06.259Z', '2023-05-29T21:17:06.404Z', '2023-05-29T21:17:06.804Z', '2023-05-29T21:17:06.985Z', '2023-05-29T21:17:07.195Z', '2023-05-29T21:17:07.380Z']",it is very difficult and it is very competive ds  and is nice  about  the coffe and there is a very bad situation ,False
35XW21VSVGZF5DJKJOQ16VTEV21SLT,"Association of Coffee Drinking with Total and Cause-Specific Mortality

Coffee is one of the most widely consumed beverages, but the association between coffee consumption and the risk of death remains unclear.

We examined the association of coffee drinking with subsequent total and cause-specific mortality among 229,119 men and 173,141 women in the National Institutes of Health - AARP Diet and Health Study who were 50 to 71 years of age at baseline. Participants with cancer, heart disease, and stroke were excluded. Coffee consumption was assessed once at baseline.

During 5,148,760 person-years of follow-up between 1995 and 2008, a total of 33,731 men and 18,784 women died. In age-adjusted models, the risk of death was increased among coffee drinkers. However, coffee drinkers were also more likely to smoke, and, after adjustment for tobacco-smoking status and other potential confounders, there was a significant inverse association between coffee consumption and mortality. Adjusted hazard ratios for death among men who drank coffee as compared with those who did not were as follows; 0.99 (95% confidence interval (CI), 0.95 to 1.04) for drinking less than 1 cup per day, 0.94 (95% CI, 0.90 to 0.99) for 1 cup, 0.90 (95% CI, 0.86 to 0.93) for 2 or 3 cups, 0.88 (95% CI, 0.84 to 0.93) for 4 or 5 cups, and 0.90 (95% CI, 0.85 to 0.96) for 6 or more cups of coffee per day (P (0.001 for trend); the respective hazard ratios among women were 1.01 (95% CI, 0.96 to 1.07), 0.95 (95% CI, 0.90 to 1.01), 0.87 (95% CI, 0.83 to 0.92), 0.84 (95% CI, 0.79 to 0.90), and 0.85 (95% CI, 0.78 to 0.93) (P (0.001 for trend). Inverse associations were observed for deaths due to heart disease, respiratory disease, stroke, injuries and accidents, diabetes, and infections, but not for deaths due to cancer. Results were similar in subgroups, including persons who had never smoked and persons who reported very good to excellent health at baseline.

In this large prospective study, coffee consumption was inversely associated with total and cause-specific mortality. Whether this was a causal or associational finding can not be determined from our data. (Funded by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Division of Cancer Epidemiology and Genetics.)
",Enter Enter,"['2023-05-29T21:01:35.110Z', '2023-05-29T21:01:35.328Z']","
A study of 229,119 men and 173,141 women in the National Institutes of Health - AARP Diet and Health Study found that coffee drinkers had a lower risk of death than non-coffee drinkers. The risk of death was reduced by 10% for every additional cup of coffee consumed per day. The inverse association between coffee consumption and mortality was observed for all causes of death, except cancer. The study also found that the inverse association was stronger in people who had never smoked and in people who reported very good to excellent health at baseline. The authors concluded that coffee consumption may be associated with a lower risk of death, but more research is needed to confirm these findings.",False
3MIVREZQVHJS8RMP6KPVWV1YOEBQKZ,"Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Rosiglitazone is widely used to treat patients with type 2 diabetes mellitus, but its effect on cardiovascular morbidity and mortality has not been determined.

We conducted searches of the published literature, the Web site of the Food and Drug Administration, and a clinical-trials registry maintained by the drug manufacturer (GlaxoSmithKline). Criteria for inclusion in our meta-analysis included a study duration of more than 24 weeks, the use of a randomized control group not receiving rosiglitazone, and the availability of outcome data for myocardial infarction and death from cardiovascular causes. Of 116 potentially relevant studies, 42 trials met the inclusion criteria. We tabulated all occurrences of myocardial infarction and death from cardiovascular causes.

Data were combined by means of a fixed-effects model. In the 42 trials, the mean age of the subjects was approximately 56 years, and the mean baseline glycated hemoglobin level was approximately 8.2%. In the rosiglitazone group, as compared with the control group, the odds ratio for myocardial infarction was 1.43 (95% confidence interval (CI), 1.03 to 1.98; P = 0.03), and the odds ratio for death from cardiovascular causes was 1.64 (95% CI, 0.98 to 2.74; P = 0.06).

Rosiglitazone was associated with a significant increase in the risk of myocardial infarction and with an increase in the risk of death from cardiovascular causes that had borderline significance. Our study was limited by a lack of access to original source data, which would have enabled time-to-event analysis. Despite these limitations, patients and providers should consider the potential for serious adverse cardiovascular effects of treatment with rosiglitazone for type 2 diabetes.
","Control C R CapsLock o s i g l i t a z o n e i s w i d e l y u s e d t o t r e a t p a t i e n t s w i t h t y p e 2 d i a b e t e s m e l l i t u s , b u t i t e f f e c t s o n c a r d i o v a s c u l a r m o r b i d i t y a n d m o r t a l i t y Backspace Shift d r u g s a r e w i d e l y u s e d t o l o e Backspace w e r b ; Backspace l o o d s u g a r Backspace Backspace Backspace Backspace Backspace Backspace g l u c o s e l e v e l i n p a t i e n t s w i t h t y p e 2 d i a b e t e s m e l l i t u s . Shift I n Shift U S Backspace , t h r e e s u c h a g e n t s a r e t h e r e , t r i g l i t a z o n e , w h i c h w a s r e m o v e d f r Backspace o o m m a r r k e t b e c a o Backspace u s e o f h e p o t Backspace Backspace a t o t o x i t y , a n d t w o o t h e r c u r r e n t l y a v a i l a b l e a g e n t s , r o s i g l i t a z o n e Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift ( Shift A n Backspace v a n d i a Backspace , Shift Shift Shift Shift Shift Shift Shift Shift G l a z Backspace x o Shift S m i t h Shift K l i n e Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift ) a n d p i o g l i t a z o n e Shift ( * Shift A Backspace Backspace Backspace Shift ( A c t o s Shift R Backspace Backspace , Shift t a k e d a Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift ) Backspace Shift T . CapsLock CapsLock Shift Shift Shift Shift Shift Shift Shift A r e c e m Backspace n t l y p u b l i z e d Backspace Backspace Backspace c i z e d m e t a - a n a l y s i s o f 4 2 c l i n i c a l t r i a l s i c l u d e s r o s i g l i t a z o n e w a s a s s o s Backspace c i a t e d w i t h a n a p p r o x i m a t e l y 4 3 Shift % i n c r e a s e d r i s k o f Backspace Backspace Backspace Backspace k f o r m y o c a r d i a l i n f a r c t i o n a n d a n a p p r o x i m a t e l y 6 4 Shift % i n c r e a s e d r i s k o f c a r d i o v a s c u l a r r i s k . r d e a t h Backspace c o n c Backspace Control Control v Control Control v Backspace . Shift t h e Backspace Backspace Backspace Backspace Shift t h e s i d e e f f e c t s o f r o s i g l i t a Backspace Backspace Shift T h Enter z o n e ; Backspace Shift : Shift A d d o m i a n o t Backspace r Shift S t o m a c h p a i n Backspace Backspace d Backspace b d Backspace Backspace n a l , Shift D Backspace Shift D e c r e a s e a m o u n t o f u r i n e , f l u s h e d o r d r y s k i n , i n c r e a s e d t h i r s t , i i r Insert Insert Backspace Backspace r r e g u k Backspace l a r h e a r t b e a t , Backspace e t c . Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Enter Control v Backspace Shift CapsLock Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift a Backspace A Enter Shift i Backspace Shift Shift i Backspace I Shift N S U S Backspace Backspace Backspace Backspace Backspace Backspace CapsLock i CapsLock Backspace I CapsLock n Shift S u s c e p t i b l e p a t i e n t s , r o s i g l i t a z o n e t h e r a p h y m a y b e c a p a b l e o f p r o v o k i n g n Backspace m y o c a r d i a l i n f r a c t i o n o r d e a t h f r o n Backspace m c a r d i o v a s c u l a r c a u s e s a f t e r s h o r t t e r m e x p o s u r e , Backspace . Shift I b Backspace m Backspace n Shift C o n t r a s t , l o n g t e r m t h e r a p i e s t h a t i m p o r o v e c a r d i o v a s c u l a r o u t c o m e s s u c h a s s t a t i n s a n d a n t i h y p e r t e n s i v e d r u g s .","['2023-05-29T19:22:39.271Z', '2023-05-29T19:22:39.521Z', '2023-05-29T19:24:24.146Z', '2023-05-29T19:24:24.891Z', '2023-05-29T19:24:28.051Z', '2023-05-29T19:24:28.386Z', '2023-05-29T19:24:28.930Z', '2023-05-29T19:24:33.067Z', '2023-05-29T19:24:33.682Z', '2023-05-29T19:24:33.987Z', '2023-05-29T19:24:34.314Z', '2023-05-29T19:24:34.746Z', '2023-05-29T19:24:35.906Z', '2023-05-29T19:24:36.442Z', '2023-05-29T19:24:36.787Z', '2023-05-29T19:24:37.066Z', '2023-05-29T19:24:44.601Z', '2023-05-29T19:24:45.354Z', '2023-05-29T19:24:45.577Z', '2023-05-29T19:24:45.810Z', '2023-05-29T19:24:46.674Z', '2023-05-29T19:24:47.026Z', '2023-05-29T19:24:47.466Z', '2023-05-29T19:24:47.649Z', '2023-05-29T19:24:48.114Z', '2023-05-29T19:24:48.474Z', '2023-05-29T19:24:48.754Z', '2023-05-29T19:24:49.025Z', '2023-05-29T19:24:49.490Z', '2023-05-29T19:24:49.698Z', '2023-05-29T19:24:49.930Z', '2023-05-29T19:24:51.482Z', '2023-05-29T19:24:51.850Z', '2023-05-29T19:24:52.329Z', '2023-05-29T19:24:52.618Z', '2023-05-29T19:24:52.985Z', '2023-05-29T19:24:53.209Z', '2023-05-29T19:24:53.473Z', '2023-05-29T19:24:53.786Z', '2023-05-29T19:24:54.154Z', '2023-05-29T19:24:55.306Z', '2023-05-29T19:24:58.905Z', '2023-05-29T19:24:59.249Z', '2023-05-29T19:24:59.497Z', '2023-05-29T19:25:00.129Z', '2023-05-29T19:25:00.321Z', '2023-05-29T19:25:00.593Z', '2023-05-29T19:25:01.001Z', '2023-05-29T19:25:01.178Z', '2023-05-29T19:25:01.393Z', '2023-05-29T19:25:03.177Z', '2023-05-29T19:25:03.585Z', '2023-05-29T19:25:03.945Z', '2023-05-29T19:25:04.185Z', '2023-05-29T19:25:04.465Z', '2023-05-29T19:25:04.809Z', '2023-05-29T19:25:05.017Z', '2023-05-29T19:25:05.506Z', '2023-05-29T19:25:06.609Z', '2023-05-29T19:25:09.016Z', '2023-05-29T19:25:09.841Z', '2023-05-29T19:25:10.928Z', '2023-05-29T19:25:11.729Z', '2023-05-29T19:25:12.105Z', '2023-05-29T19:25:12.376Z', '2023-05-29T19:25:12.656Z', '2023-05-29T19:25:12.928Z', '2023-05-29T19:25:13.168Z', '2023-05-29T19:25:13.249Z', '2023-05-29T19:25:13.608Z', '2023-05-29T19:25:15.193Z', '2023-05-29T19:25:15.633Z', '2023-05-29T19:25:15.880Z', '2023-05-29T19:25:16.264Z', '2023-05-29T19:25:16.457Z', '2023-05-29T19:25:16.713Z', '2023-05-29T19:25:17.113Z', '2023-05-29T19:25:17.385Z', '2023-05-29T19:25:17.664Z', '2023-05-29T19:25:18.560Z', '2023-05-29T19:25:19.273Z', '2023-05-29T19:25:22.913Z', '2023-05-29T19:25:23.305Z', '2023-05-29T19:25:23.594Z', '2023-05-29T19:25:23.866Z', '2023-05-29T19:25:24.147Z', '2023-05-29T19:25:24.433Z', '2023-05-29T19:25:24.689Z', '2023-05-29T19:25:25.034Z', '2023-05-29T19:25:25.275Z', '2023-05-29T19:25:25.457Z', '2023-05-29T19:25:25.729Z', '2023-05-29T19:25:26.290Z', '2023-05-29T19:25:26.674Z', '2023-05-29T19:25:26.873Z', '2023-05-29T19:25:28.114Z', '2023-05-29T19:25:28.859Z', '2023-05-29T19:25:29.154Z', '2023-05-29T19:25:29.362Z', '2023-05-29T19:25:29.722Z', '2023-05-29T19:25:29.849Z', '2023-05-29T19:25:30.050Z', '2023-05-29T19:25:30.282Z', '2023-05-29T19:25:30.762Z', '2023-05-29T19:25:31.002Z', '2023-05-29T19:25:31.458Z', '2023-05-29T19:25:31.649Z', '2023-05-29T19:25:31.889Z', '2023-05-29T19:25:32.169Z', '2023-05-29T19:25:32.633Z', '2023-05-29T19:25:32.985Z', '2023-05-29T19:25:33.233Z', '2023-05-29T19:25:35.577Z', '2023-05-29T19:25:36.266Z', '2023-05-29T19:25:36.930Z', '2023-05-29T19:25:37.210Z', '2023-05-29T19:25:38.106Z', '2023-05-29T19:25:40.257Z', '2023-05-29T19:25:40.562Z', '2023-05-29T19:25:40.930Z', '2023-05-29T19:25:41.417Z', '2023-05-29T19:25:41.834Z', '2023-05-29T19:25:42.057Z', '2023-05-29T19:25:42.713Z', '2023-05-29T19:25:43.242Z', '2023-05-29T19:25:43.601Z', '2023-05-29T19:25:44.041Z', '2023-05-29T19:25:44.312Z', '2023-05-29T19:25:44.697Z', '2023-05-29T19:25:44.961Z', '2023-05-29T19:25:45.410Z', '2023-05-29T19:25:45.633Z', '2023-05-29T19:25:45.849Z', '2023-05-29T19:25:46.225Z', '2023-05-29T19:25:46.473Z', '2023-05-29T19:25:46.881Z', '2023-05-29T19:25:47.097Z', '2023-05-29T19:25:47.689Z', '2023-05-29T19:26:23.611Z', '2023-05-29T19:27:13.521Z', '2023-05-29T19:27:13.857Z', '2023-05-29T19:27:14.097Z', '2023-05-29T19:27:14.640Z', '2023-05-29T19:27:14.960Z', '2023-05-29T19:27:15.152Z', '2023-05-29T19:27:15.361Z', '2023-05-29T19:27:15.529Z', '2023-05-29T19:27:15.736Z', '2023-05-29T19:27:15.944Z', '2023-05-29T19:27:16.298Z', '2023-05-29T19:27:16.480Z', '2023-05-29T19:27:16.833Z', '2023-05-29T19:27:17.273Z', '2023-05-29T19:27:17.825Z', '2023-05-29T19:27:18.008Z', '2023-05-29T19:27:18.504Z', '2023-05-29T19:27:18.873Z', '2023-05-29T19:27:19.320Z', '2023-05-29T19:27:19.633Z', '2023-05-29T19:27:20.016Z', '2023-05-29T19:27:20.393Z', '2023-05-29T19:27:20.881Z', '2023-05-29T19:27:21.704Z', '2023-05-29T19:27:22.360Z', '2023-05-29T19:27:22.768Z', '2023-05-29T19:27:23.088Z', '2023-05-29T19:27:23.288Z', '2023-05-29T19:27:23.618Z', '2023-05-29T19:27:24.610Z', '2023-05-29T19:27:25.097Z', '2023-05-29T19:27:25.466Z', '2023-05-29T19:27:25.929Z', '2023-05-29T19:27:26.690Z', '2023-05-29T19:27:27.106Z', '2023-05-29T19:27:27.602Z', '2023-05-29T19:27:28.497Z', '2023-05-29T19:27:28.898Z', '2023-05-29T19:27:29.131Z', '2023-05-29T19:27:29.314Z', '2023-05-29T19:27:29.497Z', '2023-05-29T19:27:29.746Z', '2023-05-29T19:27:29.873Z', '2023-05-29T19:27:30.201Z', '2023-05-29T19:27:30.530Z', '2023-05-29T19:27:30.657Z', '2023-05-29T19:27:30.977Z', '2023-05-29T19:27:35.649Z', '2023-05-29T19:27:35.834Z', '2023-05-29T19:27:36.017Z', '2023-05-29T19:27:36.193Z', '2023-05-29T19:27:36.362Z', '2023-05-29T19:27:36.890Z', '2023-05-29T19:27:38.538Z', '2023-05-29T19:27:38.849Z', '2023-05-29T19:27:39.369Z', '2023-05-29T19:27:39.657Z', '2023-05-29T19:27:40.074Z', '2023-05-29T19:27:40.600Z', '2023-05-29T19:27:40.849Z', '2023-05-29T19:27:41.249Z', '2023-05-29T19:27:41.585Z', '2023-05-29T19:27:42.242Z', '2023-05-29T19:27:42.449Z', '2023-05-29T19:27:42.697Z', '2023-05-29T19:27:42.817Z', '2023-05-29T19:27:45.353Z', '2023-05-29T19:27:45.609Z', '2023-05-29T19:27:45.906Z', '2023-05-29T19:27:46.145Z', '2023-05-29T19:27:46.361Z', '2023-05-29T19:27:46.650Z', '2023-05-29T19:27:46.785Z', '2023-05-29T19:27:47.072Z', '2023-05-29T19:27:47.481Z', '2023-05-29T19:27:47.689Z', '2023-05-29T19:27:48.065Z', '2023-05-29T19:27:48.449Z', '2023-05-29T19:27:48.649Z', '2023-05-29T19:27:49.227Z', '2023-05-29T19:27:49.713Z', '2023-05-29T19:27:50.041Z', '2023-05-29T19:27:50.377Z', '2023-05-29T19:27:50.592Z', '2023-05-29T19:27:50.873Z', '2023-05-29T19:27:51.146Z', '2023-05-29T19:27:51.321Z', '2023-05-29T19:27:51.801Z', '2023-05-29T19:27:52.088Z', '2023-05-29T19:27:52.329Z', '2023-05-29T19:27:52.937Z', '2023-05-29T19:27:53.384Z', '2023-05-29T19:27:53.601Z', '2023-05-29T19:27:53.938Z', '2023-05-29T19:27:54.073Z', '2023-05-29T19:27:54.329Z', '2023-05-29T19:27:54.505Z', '2023-05-29T19:27:54.761Z', '2023-05-29T19:27:54.890Z', '2023-05-29T19:27:59.521Z', '2023-05-29T19:28:00.041Z', '2023-05-29T19:28:04.473Z', '2023-05-29T19:28:04.712Z', '2023-05-29T19:28:05.088Z', '2023-05-29T19:28:05.256Z', '2023-05-29T19:28:05.537Z', '2023-05-29T19:28:05.864Z', '2023-05-29T19:28:06.088Z', '2023-05-29T19:28:06.256Z', '2023-05-29T19:28:08.545Z', '2023-05-29T19:28:08.864Z', '2023-05-29T19:28:09.161Z', '2023-05-29T19:28:09.377Z', '2023-05-29T19:28:09.897Z', '2023-05-29T19:28:10.232Z', '2023-05-29T19:28:11.465Z', '2023-05-29T19:28:11.776Z', '2023-05-29T19:28:12.193Z', '2023-05-29T19:28:12.584Z', '2023-05-29T19:28:16.160Z', '2023-05-29T19:28:17.223Z', '2023-05-29T19:28:17.559Z', '2023-05-29T19:28:23.915Z', '2023-05-29T19:28:24.163Z', '2023-05-29T19:28:24.490Z', '2023-05-29T19:28:24.730Z', '2023-05-29T19:28:24.898Z', '2023-05-29T19:28:25.195Z', '2023-05-29T19:28:25.402Z', '2023-05-29T19:28:26.522Z', '2023-05-29T19:28:27.769Z', '2023-05-29T19:28:28.217Z', '2023-05-29T19:28:28.466Z', '2023-05-29T19:28:28.626Z', '2023-05-29T19:28:28.773Z', '2023-05-29T19:28:28.995Z', '2023-05-29T19:28:29.282Z', '2023-05-29T19:28:29.658Z', '2023-05-29T19:28:30.202Z', '2023-05-29T19:28:30.578Z', '2023-05-29T19:28:30.769Z', '2023-05-29T19:28:31.114Z', '2023-05-29T19:28:31.338Z', '2023-05-29T19:28:31.667Z', '2023-05-29T19:28:31.962Z', '2023-05-29T19:28:32.202Z', '2023-05-29T19:28:32.210Z', '2023-05-29T19:28:32.490Z', '2023-05-29T19:28:32.634Z', '2023-05-29T19:28:38.506Z', '2023-05-29T19:28:39.121Z', '2023-05-29T19:28:39.330Z', '2023-05-29T19:28:40.009Z', '2023-05-29T19:28:40.371Z', '2023-05-29T19:28:40.962Z', '2023-05-29T19:28:43.826Z', '2023-05-29T19:28:44.202Z', '2023-05-29T19:28:44.377Z', '2023-05-29T19:28:44.705Z', '2023-05-29T19:28:45.186Z', '2023-05-29T19:28:45.482Z', '2023-05-29T19:28:45.738Z', '2023-05-29T19:28:52.634Z', '2023-05-29T19:28:53.297Z', '2023-05-29T19:29:00.305Z', '2023-05-29T19:29:00.569Z', '2023-05-29T19:29:00.857Z', '2023-05-29T19:29:01.288Z', '2023-05-29T19:29:01.713Z', '2023-05-29T19:29:03.049Z', '2023-05-29T19:29:04.256Z', '2023-05-29T19:29:04.496Z', '2023-05-29T19:29:04.697Z', '2023-05-29T19:29:04.961Z', '2023-05-29T19:29:05.240Z', '2023-05-29T19:29:05.409Z', '2023-05-29T19:29:05.888Z', '2023-05-29T19:29:06.113Z', '2023-05-29T19:29:06.489Z', '2023-05-29T19:29:06.825Z', '2023-05-29T19:29:07.016Z', '2023-05-29T19:29:07.273Z', '2023-05-29T19:29:07.529Z', '2023-05-29T19:29:07.722Z', '2023-05-29T19:29:21.664Z', '2023-05-29T19:29:40.530Z', '2023-05-29T19:29:41.076Z', '2023-05-29T19:29:47.146Z', '2023-05-29T19:29:47.442Z', '2023-05-29T19:29:47.650Z', '2023-05-29T19:29:47.849Z', '2023-05-29T19:29:47.986Z', '2023-05-29T19:29:48.290Z', '2023-05-29T19:29:48.874Z', '2023-05-29T19:29:49.258Z', '2023-05-29T19:29:49.498Z', '2023-05-29T19:29:49.706Z', '2023-05-29T19:29:51.769Z', '2023-05-29T19:29:52.203Z', '2023-05-29T19:29:52.345Z', '2023-05-29T19:29:52.593Z', '2023-05-29T19:29:52.850Z', '2023-05-29T19:29:53.097Z', '2023-05-29T19:29:53.881Z', '2023-05-29T19:29:54.298Z', '2023-05-29T19:29:54.505Z', '2023-05-29T19:29:54.706Z', '2023-05-29T19:29:55.018Z', '2023-05-29T19:29:55.305Z', '2023-05-29T19:29:55.721Z', '2023-05-29T19:29:55.977Z', '2023-05-29T19:29:56.650Z', '2023-05-29T19:29:56.873Z', '2023-05-29T19:29:57.282Z', '2023-05-29T19:29:57.513Z', '2023-05-29T19:30:00.921Z', '2023-05-29T19:30:04.770Z', '2023-05-29T19:30:05.529Z', '2023-05-29T19:30:06.681Z', '2023-05-29T19:30:06.913Z', '2023-05-29T19:30:07.362Z', '2023-05-29T19:30:07.753Z', '2023-05-29T19:30:08.081Z', '2023-05-29T19:30:08.738Z', '2023-05-29T19:30:09.081Z', '2023-05-29T19:30:09.417Z', '2023-05-29T19:30:09.625Z', '2023-05-29T19:30:11.105Z', '2023-05-29T19:30:11.330Z', '2023-05-29T19:30:11.465Z', '2023-05-29T19:30:11.601Z', '2023-05-29T19:30:11.985Z', '2023-05-29T19:30:12.169Z', '2023-05-29T19:30:12.521Z', '2023-05-29T19:30:12.889Z', '2023-05-29T19:30:13.249Z', '2023-05-29T19:30:13.649Z', '2023-05-29T19:30:18.825Z', '2023-05-29T19:30:20.040Z', '2023-05-29T19:30:20.441Z', '2023-05-29T19:30:20.688Z', '2023-05-29T19:30:20.888Z', '2023-05-29T19:30:21.041Z', '2023-05-29T19:30:21.353Z', '2023-05-29T19:30:21.673Z', '2023-05-29T19:30:22.201Z', '2023-05-29T19:30:22.697Z', '2023-05-29T19:30:22.864Z', '2023-05-29T19:30:23.065Z', '2023-05-29T19:30:23.521Z', '2023-05-29T19:30:23.832Z', '2023-05-29T19:30:24.225Z', '2023-05-29T19:30:24.715Z', '2023-05-29T19:30:25.098Z', '2023-05-29T19:30:26.874Z', '2023-05-29T19:30:27.146Z', '2023-05-29T19:30:27.274Z', '2023-05-29T19:30:27.426Z', '2023-05-29T19:30:29.842Z', '2023-05-29T19:30:30.067Z', '2023-05-29T19:30:30.275Z', '2023-05-29T19:30:30.699Z', '2023-05-29T19:30:31.043Z', '2023-05-29T19:30:31.307Z', '2023-05-29T19:30:31.482Z', '2023-05-29T19:30:31.650Z', '2023-05-29T19:30:31.914Z', '2023-05-29T19:30:32.099Z', '2023-05-29T19:30:32.426Z', '2023-05-29T19:30:32.819Z', '2023-05-29T19:30:32.987Z', '2023-05-29T19:30:37.794Z', '2023-05-29T19:30:44.234Z', '2023-05-29T19:30:44.705Z', '2023-05-29T19:30:44.889Z', '2023-05-29T19:30:45.058Z', '2023-05-29T19:30:49.810Z', '2023-05-29T19:30:50.145Z', '2023-05-29T19:30:50.434Z', '2023-05-29T19:30:50.787Z', '2023-05-29T19:30:51.042Z', '2023-05-29T19:30:51.265Z', '2023-05-29T19:30:51.674Z', '2023-05-29T19:30:51.986Z', '2023-05-29T19:30:52.201Z', '2023-05-29T19:31:03.483Z', '2023-05-29T19:31:03.996Z', '2023-05-29T19:31:04.027Z', '2023-05-29T19:31:04.059Z', '2023-05-29T19:31:04.089Z', '2023-05-29T19:31:04.121Z', '2023-05-29T19:31:04.152Z', '2023-05-29T19:31:04.183Z', '2023-05-29T19:31:04.214Z', '2023-05-29T19:31:04.245Z', '2023-05-29T19:31:04.292Z', '2023-05-29T19:31:04.323Z', '2023-05-29T19:31:04.354Z', '2023-05-29T19:31:04.383Z', '2023-05-29T19:31:04.413Z', '2023-05-29T19:31:04.446Z', '2023-05-29T19:31:04.491Z', '2023-05-29T19:31:04.522Z', '2023-05-29T19:31:04.552Z', '2023-05-29T19:31:04.583Z', '2023-05-29T19:31:04.614Z', '2023-05-29T19:31:04.645Z', '2023-05-29T19:31:04.676Z', '2023-05-29T19:31:04.722Z', '2023-05-29T19:31:04.753Z', '2023-05-29T19:31:04.784Z', '2023-05-29T19:31:04.815Z', '2023-05-29T19:31:04.846Z', '2023-05-29T19:31:04.877Z', '2023-05-29T19:31:04.906Z', '2023-05-29T19:31:04.952Z', '2023-05-29T19:31:04.982Z', '2023-05-29T19:31:05.013Z', '2023-05-29T19:31:05.044Z', '2023-05-29T19:31:05.076Z', '2023-05-29T19:31:05.107Z', '2023-05-29T19:31:05.137Z', '2023-05-29T19:31:05.183Z', '2023-05-29T19:31:05.213Z', '2023-05-29T19:31:05.245Z', '2023-05-29T19:31:05.274Z', '2023-05-29T19:31:05.307Z', '2023-05-29T19:31:05.339Z', '2023-05-29T19:31:05.369Z', '2023-05-29T19:31:05.414Z', '2023-05-29T19:31:05.445Z', '2023-05-29T19:31:05.476Z', '2023-05-29T19:31:05.498Z', '2023-05-29T19:31:06.914Z', '2023-05-29T19:31:07.265Z', '2023-05-29T19:31:08.194Z', '2023-05-29T19:31:09.073Z', '2023-05-29T19:31:09.585Z', '2023-05-29T19:31:09.801Z', '2023-05-29T19:31:09.992Z', '2023-05-29T19:31:10.330Z', '2023-05-29T19:31:10.794Z', '2023-05-29T19:31:11.026Z', '2023-05-29T19:31:11.449Z', '2023-05-29T19:31:12.593Z', '2023-05-29T19:31:14.369Z', '2023-05-29T19:31:14.705Z', '2023-05-29T19:31:15.097Z', '2023-05-29T19:31:15.599Z', '2023-05-29T19:31:15.646Z', '2023-05-29T19:31:15.678Z', '2023-05-29T19:31:15.709Z', '2023-05-29T19:31:15.741Z', '2023-05-29T19:31:15.773Z', '2023-05-29T19:31:15.804Z', '2023-05-29T19:31:15.834Z', '2023-05-29T19:31:18.577Z', '2023-05-29T19:31:18.758Z', '2023-05-29T19:31:19.105Z', '2023-05-29T19:31:19.856Z', '2023-05-29T19:31:20.241Z', '2023-05-29T19:31:20.561Z', '2023-05-29T19:31:20.896Z', '2023-05-29T19:31:21.129Z', '2023-05-29T19:31:21.656Z', '2023-05-29T19:31:21.945Z', '2023-05-29T19:31:22.313Z', '2023-05-29T19:31:22.642Z', '2023-05-29T19:31:23.897Z', '2023-05-29T19:31:24.297Z', '2023-05-29T19:31:26.315Z', '2023-05-29T19:31:26.570Z', '2023-05-29T19:31:26.851Z', '2023-05-29T19:31:27.257Z', '2023-05-29T19:31:29.378Z', '2023-05-29T19:31:29.885Z', '2023-05-29T19:31:29.916Z', '2023-05-29T19:31:29.948Z', '2023-05-29T19:31:29.980Z', '2023-05-29T19:31:30.013Z', '2023-05-29T19:31:30.045Z', '2023-05-29T19:31:30.076Z', '2023-05-29T19:31:30.126Z', '2023-05-29T19:31:30.155Z', '2023-05-29T19:31:30.187Z', '2023-05-29T19:31:30.217Z', '2023-05-29T19:31:30.248Z', '2023-05-29T19:31:30.281Z', '2023-05-29T19:31:30.312Z', '2023-05-29T19:31:30.343Z', '2023-05-29T19:31:30.374Z', '2023-05-29T19:31:30.420Z', '2023-05-29T19:31:30.434Z', '2023-05-29T19:31:46.930Z', '2023-05-29T19:31:53.865Z', '2023-05-29T19:31:54.000Z', '2023-05-29T19:31:54.345Z', '2023-05-29T19:31:54.441Z', '2023-05-29T19:31:54.938Z', '2023-05-29T19:31:55.241Z', '2023-05-29T19:31:57.425Z', '2023-05-29T19:32:00.977Z', '2023-05-29T19:32:01.473Z', '2023-05-29T19:32:01.745Z', '2023-05-29T19:32:02.138Z', '2023-05-29T19:32:02.424Z', '2023-05-29T19:32:02.761Z', '2023-05-29T19:32:03.105Z', '2023-05-29T19:32:03.401Z', '2023-05-29T19:32:03.688Z', '2023-05-29T19:32:05.352Z', '2023-05-29T19:32:05.601Z', '2023-05-29T19:32:06.065Z', '2023-05-29T19:32:06.076Z', '2023-05-29T19:32:06.977Z', '2023-05-29T19:32:07.448Z', '2023-05-29T19:32:10.080Z', '2023-05-29T19:32:10.264Z', '2023-05-29T19:32:10.441Z', '2023-05-29T19:32:11.728Z', '2023-05-29T19:32:11.936Z', '2023-05-29T19:32:12.537Z', '2023-05-29T19:32:16.896Z', '2023-05-29T19:32:17.344Z', '2023-05-29T19:32:17.760Z', '2023-05-29T19:32:18.024Z', '2023-05-29T19:32:18.368Z', '2023-05-29T19:32:18.632Z', '2023-05-29T19:32:18.888Z', '2023-05-29T19:32:25.832Z', '2023-05-29T19:32:26.698Z', '2023-05-29T19:32:28.196Z', '2023-05-29T19:32:28.498Z', '2023-05-29T19:32:28.755Z', '2023-05-29T19:32:29.354Z', '2023-05-29T19:32:29.682Z', '2023-05-29T19:32:29.865Z', '2023-05-29T19:32:30.146Z', '2023-05-29T19:32:30.435Z', '2023-05-29T19:32:31.395Z', '2023-05-29T19:32:31.903Z', '2023-05-29T19:32:31.934Z', '2023-05-29T19:32:31.965Z', '2023-05-29T19:32:31.994Z', '2023-05-29T19:32:32.040Z', '2023-05-29T19:32:32.071Z', '2023-05-29T19:32:32.102Z', '2023-05-29T19:32:32.132Z', '2023-05-29T19:32:32.163Z', '2023-05-29T19:32:32.194Z', '2023-05-29T19:32:32.225Z', '2023-05-29T19:32:32.270Z', '2023-05-29T19:32:32.302Z', '2023-05-29T19:32:32.331Z', '2023-05-29T19:32:32.361Z', '2023-05-29T19:32:32.393Z', '2023-05-29T19:32:32.402Z', '2023-05-29T19:32:40.001Z', '2023-05-29T19:32:40.434Z', '2023-05-29T19:32:40.657Z', '2023-05-29T19:32:44.378Z', '2023-05-29T19:32:49.929Z', '2023-05-29T19:33:54.939Z', '2023-05-29T19:33:55.027Z', '2023-05-29T19:33:56.018Z', '2023-05-29T19:33:56.520Z', '2023-05-29T19:33:56.549Z', '2023-05-29T19:33:56.579Z', '2023-05-29T19:33:56.610Z', '2023-05-29T19:33:56.650Z', '2023-05-29T19:33:56.680Z', '2023-05-29T19:33:56.705Z', '2023-05-29T19:33:57.929Z', '2023-05-29T19:33:58.345Z', '2023-05-29T19:33:58.538Z', '2023-05-29T19:33:58.857Z', '2023-05-29T19:33:59.050Z', '2023-05-29T19:33:59.578Z', '2023-05-29T19:34:00.491Z', '2023-05-29T19:34:00.905Z', '2023-05-29T19:34:01.169Z', '2023-05-29T19:34:01.522Z', '2023-05-29T19:34:02.169Z', '2023-05-29T19:34:02.833Z', '2023-05-29T19:34:06.369Z', '2023-05-29T19:34:06.817Z', '2023-05-29T19:34:07.121Z', '2023-05-29T19:34:07.506Z', '2023-05-29T19:34:07.745Z', '2023-05-29T19:34:09.785Z', '2023-05-29T19:34:10.121Z', '2023-05-29T19:34:10.369Z', '2023-05-29T19:34:17.242Z', '2023-05-29T19:34:17.449Z', '2023-05-29T19:34:20.137Z', '2023-05-29T19:34:21.217Z', '2023-05-29T19:34:21.649Z', '2023-05-29T19:34:22.177Z', '2023-05-29T19:34:22.441Z', '2023-05-29T19:34:22.657Z', '2023-05-29T19:34:24.353Z', '2023-05-29T19:34:25.145Z', '2023-05-29T19:34:25.377Z', '2023-05-29T19:34:25.656Z', '2023-05-29T19:34:25.865Z', '2023-05-29T19:34:26.113Z', '2023-05-29T19:34:26.968Z', '2023-05-29T19:34:29.065Z', '2023-05-29T19:34:29.344Z', '2023-05-29T19:34:29.472Z', '2023-05-29T19:34:29.738Z', '2023-05-29T19:34:30.219Z', '2023-05-29T19:34:30.563Z', '2023-05-29T19:34:30.915Z', '2023-05-29T19:34:31.035Z', '2023-05-29T19:34:32.794Z', '2023-05-29T19:34:33.290Z', '2023-05-29T19:34:33.762Z', '2023-05-29T19:34:34.042Z', '2023-05-29T19:34:34.570Z', '2023-05-29T19:34:34.810Z', '2023-05-29T19:34:35.922Z', '2023-05-29T19:34:36.427Z', '2023-05-29T19:34:36.867Z', '2023-05-29T19:34:37.130Z', '2023-05-29T19:34:37.362Z', '2023-05-29T19:34:37.587Z', '2023-05-29T19:34:37.930Z', '2023-05-29T19:34:38.148Z', '2023-05-29T19:34:38.418Z', '2023-05-29T19:34:45.003Z', '2023-05-29T19:34:45.490Z', '2023-05-29T19:34:45.674Z', '2023-05-29T19:34:46.210Z', '2023-05-29T19:34:46.378Z', '2023-05-29T19:34:46.553Z', '2023-05-29T19:34:46.714Z', '2023-05-29T19:34:48.298Z', '2023-05-29T19:34:57.561Z', '2023-05-29T19:34:58.321Z', '2023-05-29T19:34:58.794Z', '2023-05-29T19:34:59.169Z', '2023-05-29T19:34:59.682Z', '2023-05-29T19:34:59.897Z', '2023-05-29T19:35:00.185Z', '2023-05-29T19:35:00.561Z', '2023-05-29T19:35:02.019Z', '2023-05-29T19:35:02.313Z', '2023-05-29T19:35:02.635Z', '2023-05-29T19:35:03.106Z', '2023-05-29T19:35:03.378Z', '2023-05-29T19:35:05.025Z', '2023-05-29T19:35:05.489Z', '2023-05-29T19:35:05.746Z', '2023-05-29T19:35:06.098Z', '2023-05-29T19:35:06.890Z', '2023-05-29T19:35:07.418Z', '2023-05-29T19:35:07.945Z', '2023-05-29T19:35:08.257Z', '2023-05-29T19:35:08.577Z', '2023-05-29T19:35:09.529Z', '2023-05-29T19:35:10.281Z', '2023-05-29T19:35:10.490Z', '2023-05-29T19:35:10.673Z', '2023-05-29T19:35:10.921Z', '2023-05-29T19:35:11.057Z', '2023-05-29T19:35:11.345Z', '2023-05-29T19:35:11.497Z', '2023-05-29T19:35:11.921Z', '2023-05-29T19:35:12.113Z', '2023-05-29T19:35:14.211Z', '2023-05-29T19:35:14.753Z', '2023-05-29T19:35:15.137Z', '2023-05-29T19:35:15.369Z', '2023-05-29T19:35:15.601Z', '2023-05-29T19:35:15.872Z', '2023-05-29T19:35:16.081Z', '2023-05-29T19:35:16.553Z', '2023-05-29T19:35:17.400Z', '2023-05-29T19:35:17.721Z', '2023-05-29T19:35:18.032Z', '2023-05-29T19:35:18.275Z', '2023-05-29T19:35:18.553Z', '2023-05-29T19:35:18.737Z', '2023-05-29T19:35:18.897Z', '2023-05-29T19:35:19.121Z', '2023-05-29T19:35:19.281Z', '2023-05-29T19:35:19.586Z', '2023-05-29T19:35:19.777Z', '2023-05-29T19:35:22.016Z', '2023-05-29T19:35:22.577Z', '2023-05-29T19:35:23.249Z', '2023-05-29T19:35:23.753Z', '2023-05-29T19:35:29.233Z', '2023-05-29T19:35:29.432Z', '2023-05-29T19:35:29.746Z', '2023-05-29T19:35:30.002Z', '2023-05-29T19:35:30.490Z', '2023-05-29T19:35:30.890Z', '2023-05-29T19:35:32.043Z', '2023-05-29T19:35:32.906Z', '2023-05-29T19:35:33.161Z', '2023-05-29T19:35:35.010Z', '2023-05-29T19:35:35.227Z', '2023-05-29T19:35:36.562Z', '2023-05-29T19:35:37.307Z', '2023-05-29T19:35:37.562Z', '2023-05-29T19:35:37.977Z', '2023-05-29T19:35:38.298Z', '2023-05-29T19:35:38.513Z', '2023-05-29T19:35:38.802Z', '2023-05-29T19:35:39.033Z', '2023-05-29T19:35:39.258Z', '2023-05-29T19:35:39.466Z', '2023-05-29T19:35:39.713Z', '2023-05-29T19:35:39.977Z', '2023-05-29T19:35:40.514Z', '2023-05-29T19:35:40.674Z', '2023-05-29T19:35:40.858Z', '2023-05-29T19:35:41.121Z', '2023-05-29T19:35:41.434Z', '2023-05-29T19:35:41.801Z', '2023-05-29T19:35:44.802Z', '2023-05-29T19:35:44.985Z', '2023-05-29T19:35:45.171Z', '2023-05-29T19:35:45.338Z', '2023-05-29T19:35:46.947Z', '2023-05-29T19:35:47.202Z', '2023-05-29T19:35:47.545Z', '2023-05-29T19:35:48.049Z', '2023-05-29T19:35:48.265Z', '2023-05-29T19:35:48.745Z', '2023-05-29T19:35:50.387Z', '2023-05-29T19:35:50.811Z', '2023-05-29T19:35:51.218Z', '2023-05-29T19:35:51.609Z', '2023-05-29T19:35:51.826Z', '2023-05-29T19:35:51.954Z', '2023-05-29T19:35:52.162Z', '2023-05-29T19:35:52.577Z', '2023-05-29T19:35:52.769Z', '2023-05-29T19:35:52.938Z', '2023-05-29T19:35:53.537Z', '2023-05-29T19:35:54.145Z', '2023-05-29T19:35:54.418Z', '2023-05-29T19:35:54.873Z', '2023-05-29T19:35:55.089Z', '2023-05-29T19:35:55.250Z', '2023-05-29T19:35:55.713Z', '2023-05-29T19:35:57.594Z', '2023-05-29T19:35:58.137Z', '2023-05-29T19:35:58.352Z', '2023-05-29T19:35:58.632Z', '2023-05-29T19:35:59.105Z', '2023-05-29T19:35:59.361Z', '2023-05-29T19:35:59.753Z', '2023-05-29T19:36:00.177Z', '2023-05-29T19:36:00.497Z', '2023-05-29T19:36:00.746Z', '2023-05-29T19:36:00.898Z', '2023-05-29T19:36:01.353Z', '2023-05-29T19:36:01.609Z', '2023-05-29T19:36:02.081Z', '2023-05-29T19:36:02.249Z', '2023-05-29T19:36:02.560Z', '2023-05-29T19:36:02.809Z', '2023-05-29T19:36:03.298Z', '2023-05-29T19:36:03.728Z', '2023-05-29T19:36:04.474Z', '2023-05-29T19:36:04.672Z', '2023-05-29T19:36:04.896Z', '2023-05-29T19:36:05.145Z', '2023-05-29T19:36:05.601Z', '2023-05-29T19:36:06.000Z', '2023-05-29T19:36:07.065Z', '2023-05-29T19:36:08.017Z', '2023-05-29T19:36:08.290Z', '2023-05-29T19:36:08.961Z', '2023-05-29T19:36:09.177Z', '2023-05-29T19:36:10.489Z', '2023-05-29T19:36:11.168Z', '2023-05-29T19:36:11.408Z', '2023-05-29T19:36:11.770Z', '2023-05-29T19:36:12.040Z', '2023-05-29T19:36:12.265Z', '2023-05-29T19:36:12.553Z', '2023-05-29T19:36:12.784Z', '2023-05-29T19:36:12.984Z', '2023-05-29T19:36:13.192Z', '2023-05-29T19:36:13.441Z', '2023-05-29T19:36:13.713Z', '2023-05-29T19:36:14.160Z', '2023-05-29T19:36:14.296Z', '2023-05-29T19:36:14.489Z', '2023-05-29T19:36:14.776Z', '2023-05-29T19:36:18.185Z', '2023-05-29T19:36:18.729Z', '2023-05-29T19:36:19.080Z', '2023-05-29T19:36:20.688Z', '2023-05-29T19:36:20.840Z', '2023-05-29T19:36:21.081Z', '2023-05-29T19:36:21.280Z', '2023-05-29T19:36:21.784Z', '2023-05-29T19:36:21.992Z', '2023-05-29T19:36:22.402Z', '2023-05-29T19:36:22.608Z', '2023-05-29T19:36:22.833Z', '2023-05-29T19:36:23.072Z', '2023-05-29T19:36:23.544Z', '2023-05-29T19:36:23.920Z', '2023-05-29T19:36:24.176Z', '2023-05-29T19:36:24.432Z', '2023-05-29T19:36:24.721Z', '2023-05-29T19:36:24.968Z', '2023-05-29T19:36:25.529Z', '2023-05-29T19:36:25.696Z', '2023-05-29T19:36:25.920Z', '2023-05-29T19:36:26.968Z', '2023-05-29T19:36:33.745Z', '2023-05-29T19:36:34.009Z', '2023-05-29T19:36:34.298Z', '2023-05-29T19:36:34.521Z', '2023-05-29T19:36:34.665Z', '2023-05-29T19:36:34.929Z', '2023-05-29T19:36:35.169Z', '2023-05-29T19:36:48.753Z', '2023-05-29T19:36:49.250Z', '2023-05-29T19:36:49.657Z', '2023-05-29T19:36:49.954Z', '2023-05-29T19:36:50.360Z', '2023-05-29T19:36:53.385Z', '2023-05-29T19:39:41.891Z', '2023-05-29T19:39:42.392Z', '2023-05-29T19:39:42.410Z', '2023-05-29T19:40:18.737Z', '2023-05-29T19:40:19.237Z', '2023-05-29T19:40:19.257Z', '2023-05-29T19:40:22.385Z', '2023-05-29T19:40:23.512Z', '2023-05-29T19:40:57.426Z', '2023-05-29T19:40:57.745Z', '2023-05-29T19:40:58.025Z', '2023-05-29T19:40:58.178Z', '2023-05-29T19:40:58.385Z', '2023-05-29T19:40:59.450Z', '2023-05-29T19:40:59.953Z', '2023-05-29T19:41:00.145Z', '2023-05-29T19:41:00.377Z', '2023-05-29T19:41:02.953Z', '2023-05-29T19:41:03.161Z', '2023-05-29T19:41:03.401Z', '2023-05-29T19:41:03.666Z', '2023-05-29T19:41:03.818Z', '2023-05-29T19:41:04.017Z', '2023-05-29T19:41:04.161Z', '2023-05-29T19:41:04.529Z', '2023-05-29T19:41:04.913Z', '2023-05-29T19:41:05.114Z', '2023-05-29T19:41:05.393Z', '2023-05-29T19:41:05.769Z', '2023-05-29T19:41:06.049Z', '2023-05-29T19:41:06.217Z', '2023-05-29T19:41:06.337Z', '2023-05-29T19:41:06.536Z', '2023-05-29T19:41:06.770Z', '2023-05-29T19:41:07.017Z', '2023-05-29T19:41:07.137Z', '2023-05-29T19:41:07.554Z', '2023-05-29T19:41:07.953Z', '2023-05-29T19:41:08.186Z', '2023-05-29T19:41:08.505Z', '2023-05-29T19:41:09.090Z', '2023-05-29T19:41:09.346Z', '2023-05-29T19:41:11.617Z', '2023-05-29T19:41:13.216Z', '2023-05-29T19:41:13.753Z', '2023-05-29T19:41:14.177Z', '2023-05-29T19:41:14.553Z', '2023-05-29T19:41:14.825Z', '2023-05-29T19:41:21.040Z', '2023-05-29T19:41:21.225Z', '2023-05-29T19:41:22.385Z', '2023-05-29T19:41:22.745Z', '2023-05-29T19:41:23.017Z', '2023-05-29T19:41:26.496Z', '2023-05-29T19:41:32.432Z', '2023-05-29T19:41:32.889Z', '2023-05-29T19:41:33.208Z', '2023-05-29T19:41:33.552Z', '2023-05-29T19:41:35.104Z', '2023-05-29T19:41:36.376Z', '2023-05-29T19:41:36.729Z', '2023-05-29T19:41:37.008Z', '2023-05-29T19:41:39.793Z', '2023-05-29T19:41:40.354Z', '2023-05-29T19:41:40.818Z', '2023-05-29T19:41:41.146Z', '2023-05-29T19:41:42.250Z', '2023-05-29T19:41:42.609Z', '2023-05-29T19:41:42.922Z', '2023-05-29T19:41:43.170Z', '2023-05-29T19:41:43.433Z', '2023-05-29T19:41:43.529Z', '2023-05-29T19:41:43.761Z', '2023-05-29T19:41:44.153Z', '2023-05-29T19:41:44.697Z', '2023-05-29T19:41:45.466Z', '2023-05-29T19:41:45.690Z', '2023-05-29T19:41:46.553Z', '2023-05-29T19:41:46.778Z', '2023-05-29T19:41:46.993Z', '2023-05-29T19:41:47.369Z', '2023-05-29T19:41:47.866Z', '2023-05-29T19:41:48.138Z', '2023-05-29T19:41:48.322Z', '2023-05-29T19:41:49.034Z', '2023-05-29T19:41:49.322Z', '2023-05-29T19:41:49.578Z', '2023-05-29T19:41:49.929Z', '2023-05-29T19:41:50.049Z', '2023-05-29T19:41:50.242Z', '2023-05-29T19:41:50.490Z', '2023-05-29T19:41:54.993Z', '2023-05-29T19:41:55.178Z', '2023-05-29T19:41:56.937Z', '2023-05-29T19:41:58.641Z', '2023-05-29T19:41:59.137Z', '2023-05-29T19:41:59.361Z', '2023-05-29T19:42:02.697Z', '2023-05-29T19:42:02.873Z', '2023-05-29T19:42:03.329Z', '2023-05-29T19:42:03.969Z', '2023-05-29T19:42:04.081Z', '2023-05-29T19:42:07.969Z', '2023-05-29T19:42:09.249Z', '2023-05-29T19:42:10.857Z', '2023-05-29T19:42:11.265Z', '2023-05-29T19:42:12.705Z', '2023-05-29T19:42:13.241Z', '2023-05-29T19:42:13.473Z', '2023-05-29T19:42:13.729Z', '2023-05-29T19:42:14.145Z', '2023-05-29T19:42:14.408Z', '2023-05-29T19:42:14.633Z', '2023-05-29T19:42:14.922Z', '2023-05-29T19:42:14.944Z', '2023-05-29T19:42:15.281Z', '2023-05-29T19:42:16.528Z', '2023-05-29T19:42:16.810Z', '2023-05-29T19:42:17.024Z', '2023-05-29T19:42:17.313Z', '2023-05-29T19:42:17.585Z', '2023-05-29T19:42:17.849Z', '2023-05-29T19:42:18.152Z', '2023-05-29T19:42:18.440Z', '2023-05-29T19:42:18.729Z', '2023-05-29T19:42:19.121Z', '2023-05-29T19:42:19.361Z', '2023-05-29T19:42:19.665Z', '2023-05-29T19:42:19.840Z', '2023-05-29T19:42:20.072Z', '2023-05-29T19:42:20.336Z', '2023-05-29T19:42:20.690Z', '2023-05-29T19:42:21.185Z', '2023-05-29T19:42:22.856Z', '2023-05-29T19:42:23.361Z', '2023-05-29T19:42:24.874Z', '2023-05-29T19:42:25.168Z', '2023-05-29T19:42:25.480Z', '2023-05-29T19:42:25.792Z', '2023-05-29T19:42:26.168Z', '2023-05-29T19:42:26.361Z', '2023-05-29T19:42:26.609Z', '2023-05-29T19:42:26.952Z', '2023-05-29T19:42:27.376Z', '2023-05-29T19:42:27.624Z', '2023-05-29T19:42:27.896Z', '2023-05-29T19:42:28.088Z', '2023-05-29T19:42:28.352Z', '2023-05-29T19:42:28.633Z', '2023-05-29T19:42:28.880Z', '2023-05-29T19:42:29.104Z', '2023-05-29T19:42:29.312Z', '2023-05-29T19:42:29.520Z', '2023-05-29T19:42:29.840Z', '2023-05-29T19:42:30.121Z', '2023-05-29T19:42:32.688Z', '2023-05-29T19:42:32.960Z', '2023-05-29T19:42:33.369Z', '2023-05-29T19:42:33.640Z', '2023-05-29T19:42:33.864Z', '2023-05-29T19:42:34.144Z', '2023-05-29T19:42:34.329Z', '2023-05-29T19:42:34.520Z', '2023-05-29T19:42:34.713Z', '2023-05-29T19:42:34.945Z', '2023-05-29T19:42:35.225Z', '2023-05-29T19:42:35.448Z', '2023-05-29T19:42:35.664Z', '2023-05-29T19:42:36.064Z', '2023-05-29T19:42:36.360Z', '2023-05-29T19:42:36.632Z', '2023-05-29T19:42:38.208Z', '2023-05-29T19:42:39.048Z', '2023-05-29T19:42:40.563Z', '2023-05-29T19:42:40.746Z', '2023-05-29T19:42:41.395Z', '2023-05-29T19:42:42.450Z', '2023-05-29T19:42:42.674Z', '2023-05-29T19:42:44.002Z', '2023-05-29T19:42:44.794Z', '2023-05-29T19:42:45.874Z', '2023-05-29T19:42:46.035Z', '2023-05-29T19:42:46.250Z', '2023-05-29T19:42:46.714Z', '2023-05-29T19:42:46.979Z', '2023-05-29T19:42:47.290Z', '2023-05-29T19:42:48.114Z', '2023-05-29T19:42:48.473Z', '2023-05-29T19:42:48.715Z', '2023-05-29T19:42:49.058Z', '2023-05-29T19:42:49.482Z', '2023-05-29T19:42:50.578Z', '2023-05-29T19:42:51.026Z', '2023-05-29T19:42:51.289Z', '2023-05-29T19:42:51.474Z', '2023-05-29T19:42:51.697Z', '2023-05-29T19:42:52.193Z', '2023-05-29T19:42:52.362Z', '2023-05-29T19:42:52.730Z', '2023-05-29T19:42:52.930Z', '2023-05-29T19:42:56.212Z', '2023-05-29T19:43:00.138Z', '2023-05-29T19:43:00.481Z', '2023-05-29T19:43:00.690Z', '2023-05-29T19:43:00.898Z', '2023-05-29T19:43:01.225Z', '2023-05-29T19:43:01.801Z', '2023-05-29T19:44:56.586Z', '2023-05-29T19:44:57.098Z', '2023-05-29T19:44:57.129Z', '2023-05-29T19:44:57.160Z', '2023-05-29T19:44:57.190Z', '2023-05-29T19:44:57.222Z', '2023-05-29T19:44:57.253Z', '2023-05-29T19:44:57.284Z', '2023-05-29T19:44:57.332Z', '2023-05-29T19:44:57.365Z', '2023-05-29T19:44:57.396Z', '2023-05-29T19:44:57.429Z', '2023-05-29T19:44:57.462Z', '2023-05-29T19:44:57.489Z', '2023-05-29T19:44:57.520Z', '2023-05-29T19:44:57.551Z', '2023-05-29T19:44:57.582Z', '2023-05-29T19:44:57.614Z', '2023-05-29T19:44:57.661Z', '2023-05-29T19:44:57.693Z', '2023-05-29T19:44:57.723Z', '2023-05-29T19:44:57.754Z', '2023-05-29T19:44:57.787Z', '2023-05-29T19:44:57.818Z', '2023-05-29T19:44:57.849Z', '2023-05-29T19:44:57.880Z', '2023-05-29T19:44:57.912Z', '2023-05-29T19:44:57.958Z', '2023-05-29T19:44:57.989Z', '2023-05-29T19:44:58.021Z', '2023-05-29T19:44:58.053Z', '2023-05-29T19:44:58.083Z', '2023-05-29T19:44:58.117Z', '2023-05-29T19:44:58.673Z', '2023-05-29T19:44:59.979Z', '2023-05-29T19:45:00.450Z', '2023-05-29T19:45:05.554Z', '2023-05-29T19:45:05.913Z', '2023-05-29T19:45:06.490Z', '2023-05-29T19:45:07.930Z', '2023-05-29T19:45:08.431Z', '2023-05-29T19:45:08.476Z', '2023-05-29T19:45:08.507Z', '2023-05-29T19:45:08.538Z', '2023-05-29T19:45:08.569Z', '2023-05-29T19:45:08.602Z', '2023-05-29T19:45:08.633Z', '2023-05-29T19:45:08.664Z', '2023-05-29T19:45:08.695Z', '2023-05-29T19:45:08.728Z', '2023-05-29T19:45:08.773Z', '2023-05-29T19:45:08.804Z', '2023-05-29T19:45:08.819Z', '2023-05-29T19:45:10.449Z', '2023-05-29T19:45:11.089Z', '2023-05-29T19:45:32.401Z', '2023-05-29T19:46:05.386Z', '2023-05-29T19:46:05.794Z', '2023-05-29T19:46:09.961Z', '2023-05-29T19:46:14.874Z', '2023-05-29T19:46:15.373Z', '2023-05-29T19:46:15.387Z', '2023-05-29T19:46:16.793Z', '2023-05-29T19:46:17.722Z', '2023-05-29T19:46:18.402Z', '2023-05-29T19:46:19.057Z', '2023-05-29T19:46:19.290Z', '2023-05-29T19:46:19.553Z', '2023-05-29T19:46:19.825Z', '2023-05-29T19:46:19.945Z', '2023-05-29T19:46:42.560Z', '2023-05-29T19:46:42.769Z', '2023-05-29T19:46:42.984Z', '2023-05-29T19:46:43.192Z', '2023-05-29T19:46:43.393Z', '2023-05-29T19:46:43.576Z', '2023-05-29T19:46:45.577Z', '2023-05-29T19:46:45.858Z', '2023-05-29T19:46:46.530Z', '2023-05-29T19:46:47.216Z', '2023-05-29T19:46:48.440Z', '2023-05-29T19:46:49.611Z', '2023-05-29T19:46:50.083Z', '2023-05-29T19:46:50.754Z', '2023-05-29T19:46:51.363Z', '2023-05-29T19:46:51.596Z', '2023-05-29T19:46:52.938Z', '2023-05-29T19:46:53.106Z', '2023-05-29T19:46:56.218Z', '2023-05-29T19:46:56.563Z', '2023-05-29T19:46:57.186Z', '2023-05-29T19:46:57.842Z', '2023-05-29T19:46:58.219Z', '2023-05-29T19:46:58.578Z', '2023-05-29T19:46:58.972Z', '2023-05-29T19:46:59.378Z', '2023-05-29T19:47:04.858Z', '2023-05-29T19:47:05.610Z', '2023-05-29T19:47:05.834Z', '2023-05-29T19:47:06.105Z', '2023-05-29T19:47:06.538Z', '2023-05-29T19:47:06.761Z', '2023-05-29T19:47:07.042Z', '2023-05-29T19:47:07.442Z', '2023-05-29T19:47:07.633Z', '2023-05-29T19:47:08.442Z', '2023-05-29T19:47:09.386Z', '2023-05-29T19:47:10.209Z', '2023-05-29T19:47:11.081Z', '2023-05-29T19:47:11.338Z', '2023-05-29T19:47:11.561Z', '2023-05-29T19:47:12.073Z', '2023-05-29T19:47:12.561Z', '2023-05-29T19:47:12.850Z', '2023-05-29T19:47:13.209Z', '2023-05-29T19:47:13.457Z', '2023-05-29T19:47:13.793Z', '2023-05-29T19:47:14.057Z', '2023-05-29T19:47:14.385Z', '2023-05-29T19:47:14.729Z', '2023-05-29T19:47:16.434Z', '2023-05-29T19:47:16.785Z', '2023-05-29T19:47:17.001Z', '2023-05-29T19:47:17.313Z', '2023-05-29T19:47:17.513Z', '2023-05-29T19:47:17.737Z', '2023-05-29T19:47:18.089Z', '2023-05-29T19:47:18.705Z', '2023-05-29T19:47:18.937Z', '2023-05-29T19:47:19.225Z', '2023-05-29T19:47:19.505Z', '2023-05-29T19:47:19.657Z', '2023-05-29T19:47:19.913Z', '2023-05-29T19:47:20.209Z', '2023-05-29T19:47:20.465Z', '2023-05-29T19:47:20.617Z', '2023-05-29T19:47:21.001Z', '2023-05-29T19:47:22.065Z', '2023-05-29T19:47:22.473Z', '2023-05-29T19:47:22.608Z', '2023-05-29T19:47:23.272Z', '2023-05-29T19:47:23.466Z', '2023-05-29T19:47:23.793Z', '2023-05-29T19:47:24.153Z', '2023-05-29T19:47:24.497Z', '2023-05-29T19:47:24.633Z', '2023-05-29T19:47:25.025Z', '2023-05-29T19:47:25.441Z', '2023-05-29T19:47:26.513Z', '2023-05-29T19:47:27.329Z', '2023-05-29T19:47:27.745Z', '2023-05-29T19:47:28.001Z', '2023-05-29T19:47:28.418Z', '2023-05-29T19:47:28.841Z', '2023-05-29T19:47:29.064Z', '2023-05-29T19:47:29.257Z', '2023-05-29T19:47:29.505Z', '2023-05-29T19:47:29.809Z', '2023-05-29T19:47:31.017Z', '2023-05-29T19:47:32.305Z', '2023-05-29T19:47:33.073Z', '2023-05-29T19:47:33.497Z', '2023-05-29T19:47:33.922Z', '2023-05-29T19:47:34.320Z', '2023-05-29T19:47:34.728Z', '2023-05-29T19:47:34.968Z', '2023-05-29T19:47:35.128Z', '2023-05-29T19:47:35.361Z', '2023-05-29T19:47:35.809Z', '2023-05-29T19:47:36.009Z', '2023-05-29T19:47:36.160Z', '2023-05-29T19:47:36.416Z', '2023-05-29T19:47:36.689Z', '2023-05-29T19:47:36.929Z', '2023-05-29T19:47:37.321Z', '2023-05-29T19:47:37.520Z', '2023-05-29T19:47:37.672Z', '2023-05-29T19:47:37.865Z', '2023-05-29T19:47:45.425Z', '2023-05-29T19:47:46.000Z', '2023-05-29T19:47:46.201Z', '2023-05-29T19:47:46.528Z', '2023-05-29T19:47:47.656Z', '2023-05-29T19:47:48.416Z', '2023-05-29T19:47:48.976Z', '2023-05-29T19:47:49.248Z', '2023-05-29T19:47:49.528Z', '2023-05-29T19:47:49.713Z', '2023-05-29T19:47:49.866Z', '2023-05-29T19:47:50.065Z', '2023-05-29T19:47:50.337Z', '2023-05-29T19:47:50.601Z', '2023-05-29T19:47:50.953Z', '2023-05-29T19:47:51.186Z', '2023-05-29T19:47:51.786Z', '2023-05-29T19:47:52.194Z', '2023-05-29T19:47:53.025Z', '2023-05-29T19:47:53.506Z', '2023-05-29T19:47:55.049Z', '2023-05-29T19:47:56.481Z', '2023-05-29T19:47:56.633Z', '2023-05-29T19:47:56.865Z', '2023-05-29T19:47:57.065Z', '2023-05-29T19:47:57.569Z', '2023-05-29T19:47:57.777Z', '2023-05-29T19:47:58.121Z', '2023-05-29T19:47:58.305Z', '2023-05-29T19:47:58.570Z', '2023-05-29T19:47:58.833Z', '2023-05-29T19:47:59.249Z', '2023-05-29T19:47:59.673Z', '2023-05-29T19:47:59.882Z', '2023-05-29T19:48:00.161Z', '2023-05-29T19:48:00.473Z', '2023-05-29T19:48:00.705Z', '2023-05-29T19:48:00.809Z', '2023-05-29T19:48:01.073Z', '2023-05-29T19:48:01.473Z', '2023-05-29T19:48:01.689Z', '2023-05-29T19:48:01.865Z', '2023-05-29T19:48:03.225Z', '2023-05-29T19:48:04.041Z', '2023-05-29T19:48:04.337Z', '2023-05-29T19:48:04.569Z', '2023-05-29T19:48:04.841Z', '2023-05-29T19:48:05.042Z', '2023-05-29T19:48:05.825Z', '2023-05-29T19:48:07.121Z', '2023-05-29T19:48:07.488Z', '2023-05-29T19:48:07.865Z', '2023-05-29T19:48:08.489Z', '2023-05-29T19:48:08.689Z', '2023-05-29T19:48:08.945Z', '2023-05-29T19:48:09.209Z', '2023-05-29T19:48:09.457Z', '2023-05-29T19:48:09.640Z', '2023-05-29T19:48:10.160Z', '2023-05-29T19:48:10.384Z', '2023-05-29T19:48:10.697Z', '2023-05-29T19:48:11.024Z', '2023-05-29T19:48:11.905Z', '2023-05-29T19:48:14.577Z', '2023-05-29T19:48:14.793Z', '2023-05-29T19:48:15.256Z', '2023-05-29T19:48:15.609Z', '2023-05-29T19:48:15.801Z', '2023-05-29T19:48:16.641Z', '2023-05-29T19:48:18.241Z', '2023-05-29T19:48:19.089Z', '2023-05-29T19:48:26.520Z', '2023-05-29T19:48:26.888Z', '2023-05-29T19:48:28.136Z', '2023-05-29T19:48:28.856Z', '2023-05-29T19:48:29.279Z', '2023-05-29T19:48:30.264Z', '2023-05-29T19:48:30.656Z', '2023-05-29T19:48:31.392Z', '2023-05-29T19:48:31.616Z', '2023-05-29T19:48:31.960Z', '2023-05-29T19:48:32.864Z', '2023-05-29T19:48:33.144Z', '2023-05-29T19:48:33.528Z', '2023-05-29T19:48:33.849Z', '2023-05-29T19:48:34.208Z', '2023-05-29T19:48:34.408Z', '2023-05-29T19:48:34.791Z', '2023-05-29T19:48:37.696Z', '2023-05-29T19:48:37.960Z', '2023-05-29T19:48:38.216Z', '2023-05-29T19:48:38.416Z', '2023-05-29T19:48:38.688Z', '2023-05-29T19:48:39.017Z', '2023-05-29T19:48:39.257Z', '2023-05-29T19:48:39.488Z', '2023-05-29T19:48:39.728Z', '2023-05-29T19:48:39.896Z', '2023-05-29T19:48:40.328Z', '2023-05-29T19:48:40.560Z', '2023-05-29T19:48:40.832Z', '2023-05-29T19:48:41.039Z', '2023-05-29T19:48:41.354Z', '2023-05-29T19:48:41.535Z', '2023-05-29T19:48:41.720Z', '2023-05-29T19:48:42.200Z', '2023-05-29T19:48:45.104Z', '2023-05-29T19:48:45.600Z', '2023-05-29T19:48:45.816Z', '2023-05-29T19:48:47.944Z', '2023-05-29T19:48:48.911Z', '2023-05-29T19:48:49.168Z', '2023-05-29T19:48:49.328Z', '2023-05-29T19:48:49.504Z', '2023-05-29T19:48:49.802Z', '2023-05-29T19:48:50.161Z', '2023-05-29T19:48:50.409Z', '2023-05-29T19:48:50.673Z', '2023-05-29T19:48:50.696Z', '2023-05-29T19:48:51.321Z', '2023-05-29T19:48:51.513Z', '2023-05-29T19:48:51.994Z', '2023-05-29T19:48:52.266Z', '2023-05-29T19:48:52.633Z', '2023-05-29T19:48:58.233Z', '2023-05-29T19:48:58.514Z', '2023-05-29T19:48:58.721Z', '2023-05-29T19:48:58.921Z', '2023-05-29T19:48:59.129Z', '2023-05-29T19:48:59.641Z', '2023-05-29T19:48:59.841Z', '2023-05-29T19:49:00.313Z', '2023-05-29T19:49:00.489Z', '2023-05-29T19:49:00.745Z', '2023-05-29T19:49:00.994Z', '2023-05-29T19:49:01.465Z', '2023-05-29T19:49:01.818Z', '2023-05-29T19:49:02.024Z', '2023-05-29T19:49:02.361Z', '2023-05-29T19:49:02.648Z', '2023-05-29T19:49:02.977Z', '2023-05-29T19:49:03.242Z', '2023-05-29T19:49:03.520Z', '2023-05-29T19:49:03.835Z', '2023-05-29T19:49:04.345Z', '2023-05-29T19:49:04.601Z', '2023-05-29T19:49:05.033Z', '2023-05-29T19:49:05.217Z', '2023-05-29T19:49:05.464Z', '2023-05-29T19:49:05.681Z', '2023-05-29T19:49:05.905Z', '2023-05-29T19:49:06.305Z', '2023-05-29T19:49:06.528Z', '2023-05-29T19:49:06.761Z', '2023-05-29T19:49:06.954Z', '2023-05-29T19:49:07.098Z', '2023-05-29T19:49:09.082Z', '2023-05-29T19:49:09.594Z', '2023-05-29T19:49:09.851Z', '2023-05-29T19:49:10.009Z', '2023-05-29T19:49:10.153Z', '2023-05-29T19:49:10.657Z', '2023-05-29T19:49:10.921Z', '2023-05-29T19:49:11.129Z', '2023-05-29T19:49:12.779Z', '2023-05-29T19:49:13.009Z', '2023-05-29T19:49:13.449Z', '2023-05-29T19:49:13.993Z', '2023-05-29T19:49:14.274Z', '2023-05-29T19:49:14.472Z', '2023-05-29T19:49:14.609Z', '2023-05-29T19:49:14.944Z', '2023-05-29T19:49:15.425Z', '2023-05-29T19:49:15.960Z', '2023-05-29T19:49:16.185Z', '2023-05-29T19:49:18.912Z', '2023-05-29T19:49:19.217Z', '2023-05-29T19:49:19.416Z', '2023-05-29T19:49:19.664Z', '2023-05-29T19:49:19.811Z', '2023-05-29T19:49:20.129Z', '2023-05-29T19:49:20.432Z', '2023-05-29T19:49:20.792Z', '2023-05-29T19:49:21.168Z', '2023-05-29T19:49:21.392Z', '2023-05-29T19:49:23.944Z', '2023-05-29T19:49:24.944Z', '2023-05-29T19:49:25.161Z', '2023-05-29T19:49:25.640Z', '2023-05-29T19:49:25.929Z', '2023-05-29T19:49:26.216Z', '2023-05-29T19:49:53.322Z']","drugs are widely used to lower blood glucose level in patients with type 2 diabetes mellitus. In US, three such agents are there,troglitazone , which was removed from marrket because of hepatotoxity, and two  other currently  available agents,rosiglitazone (Avandia, GlaxoSmithKline)and pioglitazone (Actos ,Takeda).A recently publicized meta -analysis of 42 clinical trials concludes  rosiglitazone was associated with an approximately 43% increased risk for myocardial infarction and an approximately 64% increased risk of cardiovascular death.the mechanism of action of rosiglitazone is by activation of the intracellular receptor class of the peroxisome proliferator-activated receptors (PPARs), specifically PPAR. Rosiglitazone is a selective ligand of PPAR, and has no PPAR-binding action.Mechanisms which lead to cardiac complications after cocaine, amphetamine or ecstasy use are: vessel damage, prothrombotic effect and direct myocardial injury. 
The side effects of rosiglitazone: Abdominal or Stomach pain, Decrease amount of urine, flushed or dry skin, increased thirst, irregular heartbeat etc.
As compared with placebo or with other antidiabetic regimens, treatment with rosiglitazone was associated with a significant increase in the risk of myocardial infarction and with an increase in the risk of death from cardiovascular causes that was of borderline significance.
In Susceptible patients, rosiglitazone theraphy may be  capable of provoking myocardial infraction or death from cardiovascular causes after short term exposure.In Contrast, long term therapies that imporove  cardiovascular outcomes such as statins and antihypertensive drugs.",True
3MIVREZQVHJS8RMP6KPVWV1YOEBQKZ,"Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Rosiglitazone is widely used to treat patients with type 2 diabetes mellitus, but its effect on cardiovascular morbidity and mortality has not been determined.

We conducted searches of the published literature, the Web site of the Food and Drug Administration, and a clinical-trials registry maintained by the drug manufacturer (GlaxoSmithKline). Criteria for inclusion in our meta-analysis included a study duration of more than 24 weeks, the use of a randomized control group not receiving rosiglitazone, and the availability of outcome data for myocardial infarction and death from cardiovascular causes. Of 116 potentially relevant studies, 42 trials met the inclusion criteria. We tabulated all occurrences of myocardial infarction and death from cardiovascular causes.

Data were combined by means of a fixed-effects model. In the 42 trials, the mean age of the subjects was approximately 56 years, and the mean baseline glycated hemoglobin level was approximately 8.2%. In the rosiglitazone group, as compared with the control group, the odds ratio for myocardial infarction was 1.43 (95% confidence interval (CI), 1.03 to 1.98; P = 0.03), and the odds ratio for death from cardiovascular causes was 1.64 (95% CI, 0.98 to 2.74; P = 0.06).

Rosiglitazone was associated with a significant increase in the risk of myocardial infarction and with an increase in the risk of death from cardiovascular causes that had borderline significance. Our study was limited by a lack of access to original source data, which would have enabled time-to-event analysis. Despite these limitations, patients and providers should consider the potential for serious adverse cardiovascular effects of treatment with rosiglitazone for type 2 diabetes.
",Control Control Control Control Control Control Control Control c Control c i t i s a m e d i c a l r e a l a t e r Backspace Backspace Backspace Backspace a t e d i n f o r m a t i o n m o s t i m p o r t a n t a n a Backspace Backspace Backspace Backspace Backspace i n f o r m a t i o n s o a Backspace i t o l s m y o t h e r f r i e n d Backspace s s h a r e t h r Backspace Backspace Backspace t j h Backspace Backspace h e i n f o r m a t i o n m u Backspace y f r Backspace Backspace Backspace Backspace Backspace Backspace Backspace n m r r a Backspace Backspace Backspace Backspace Backspace Backspace Backspace n h i i j o h n Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace a i j o h n d o y o u t h i n g Backspace Backspace Backspace Backspace Backspace Backspace n o t h a t Control c Control Control v Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Control z Control z Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Control c Control Control v,"['2023-05-30T01:04:58.326Z', '2023-05-30T01:04:58.782Z', '2023-05-30T01:04:58.853Z', '2023-05-30T01:04:58.969Z', '2023-05-30T01:04:58.971Z', '2023-05-30T01:04:58.971Z', '2023-05-30T01:04:58.972Z', '2023-05-30T01:04:59.732Z', '2023-05-30T01:04:59.733Z', '2023-05-30T01:05:12.121Z', '2023-05-30T01:05:12.392Z', '2023-05-30T01:06:58.874Z', '2023-05-30T01:06:59.702Z', '2023-05-30T01:06:59.706Z', '2023-05-30T01:06:59.802Z', '2023-05-30T01:07:00.118Z', '2023-05-30T01:07:00.860Z', '2023-05-30T01:07:01.922Z', '2023-05-30T01:07:01.929Z', '2023-05-30T01:07:02.230Z', '2023-05-30T01:07:02.594Z', '2023-05-30T01:07:02.935Z', '2023-05-30T01:07:03.329Z', '2023-05-30T01:07:03.831Z', '2023-05-30T01:07:03.901Z', '2023-05-30T01:07:04.292Z', '2023-05-30T01:07:04.850Z', '2023-05-30T01:07:04.953Z', '2023-05-30T01:07:05.112Z', '2023-05-30T01:07:05.519Z', '2023-05-30T01:07:05.894Z', '2023-05-30T01:07:05.993Z', '2023-05-30T01:07:06.781Z', '2023-05-30T01:07:06.870Z', '2023-05-30T01:07:06.876Z', '2023-05-30T01:07:07.665Z', '2023-05-30T01:07:07.871Z', '2023-05-30T01:07:08.041Z', '2023-05-30T01:07:08.231Z', '2023-05-30T01:07:10.326Z', '2023-05-30T01:07:11.526Z', '2023-05-30T01:07:11.538Z', '2023-05-30T01:07:11.963Z', '2023-05-30T01:07:12.776Z', '2023-05-30T01:07:14.219Z', '2023-05-30T01:07:14.678Z', '2023-05-30T01:07:15.220Z', '2023-05-30T01:07:17.821Z', '2023-05-30T01:07:18.424Z', '2023-05-30T01:07:18.431Z', '2023-05-30T01:07:18.436Z', '2023-05-30T01:07:18.967Z', '2023-05-30T01:07:19.621Z', '2023-05-30T01:07:20.395Z', '2023-05-30T01:07:20.402Z', '2023-05-30T01:07:20.410Z', '2023-05-30T01:07:22.933Z', '2023-05-30T01:07:23.183Z', '2023-05-30T01:07:23.623Z', '2023-05-30T01:07:24.164Z', '2023-05-30T01:07:24.264Z', '2023-05-30T01:07:24.776Z', '2023-05-30T01:07:25.283Z', '2023-05-30T01:07:25.646Z', '2023-05-30T01:07:26.277Z', '2023-05-30T01:07:26.752Z', '2023-05-30T01:07:26.969Z', '2023-05-30T01:07:27.271Z', '2023-05-30T01:07:27.699Z', '2023-05-30T01:07:28.024Z', '2023-05-30T01:07:28.697Z', '2023-05-30T01:07:28.767Z', '2023-05-30T01:07:29.088Z', '2023-05-30T01:07:29.265Z', '2023-05-30T01:07:30.330Z', '2023-05-30T01:07:30.584Z', '2023-05-30T01:07:30.823Z', '2023-05-30T01:07:31.054Z', '2023-05-30T01:07:31.488Z', '2023-05-30T01:07:32.152Z', '2023-05-30T01:07:32.968Z', '2023-05-30T01:07:33.718Z', '2023-05-30T01:07:33.766Z', '2023-05-30T01:07:34.104Z', '2023-05-30T01:07:35.102Z', '2023-05-30T01:07:35.109Z', '2023-05-30T01:07:35.150Z', '2023-05-30T01:07:36.489Z', '2023-05-30T01:07:37.184Z', '2023-05-30T01:07:37.305Z', '2023-05-30T01:07:37.782Z', '2023-05-30T01:07:38.510Z', '2023-05-30T01:07:38.516Z', '2023-05-30T01:07:38.726Z', '2023-05-30T01:07:38.984Z', '2023-05-30T01:07:39.732Z', '2023-05-30T01:07:40.281Z', '2023-05-30T01:07:40.888Z', '2023-05-30T01:07:41.277Z', '2023-05-30T01:07:43.513Z', '2023-05-30T01:07:44.232Z', '2023-05-30T01:07:45.533Z', '2023-05-30T01:07:45.539Z', '2023-05-30T01:07:46.492Z', '2023-05-30T01:07:46.764Z', '2023-05-30T01:07:47.191Z', '2023-05-30T01:07:47.561Z', '2023-05-30T01:07:48.198Z', '2023-05-30T01:07:49.546Z', '2023-05-30T01:07:49.904Z', '2023-05-30T01:07:50.155Z', '2023-05-30T01:07:50.894Z', '2023-05-30T01:07:50.903Z', '2023-05-30T01:07:51.141Z', '2023-05-30T01:07:51.581Z', '2023-05-30T01:07:51.832Z', '2023-05-30T01:07:52.502Z', '2023-05-30T01:07:52.912Z', '2023-05-30T01:07:53.253Z', '2023-05-30T01:07:53.677Z', '2023-05-30T01:07:53.995Z', '2023-05-30T01:07:55.373Z', '2023-05-30T01:07:56.278Z', '2023-05-30T01:07:56.862Z', '2023-05-30T01:07:57.285Z', '2023-05-30T01:07:57.776Z', '2023-05-30T01:07:58.054Z', '2023-05-30T01:07:59.064Z', '2023-05-30T01:07:59.746Z', '2023-05-30T01:08:02.031Z', '2023-05-30T01:08:02.234Z', '2023-05-30T01:08:02.330Z', '2023-05-30T01:08:03.288Z', '2023-05-30T01:08:03.756Z', '2023-05-30T01:08:04.394Z', '2023-05-30T01:08:05.289Z', '2023-05-30T01:08:05.958Z', '2023-05-30T01:08:06.926Z', '2023-05-30T01:08:06.942Z', '2023-05-30T01:08:07.867Z', '2023-05-30T01:08:08.053Z', '2023-05-30T01:08:09.639Z', '2023-05-30T01:08:09.771Z', '2023-05-30T01:08:10.036Z', '2023-05-30T01:08:11.450Z', '2023-05-30T01:08:11.830Z', '2023-05-30T01:08:12.247Z', '2023-05-30T01:08:12.664Z', '2023-05-30T01:08:13.086Z', '2023-05-30T01:08:13.386Z', '2023-05-30T01:08:13.484Z', '2023-05-30T01:08:14.426Z', '2023-05-30T01:08:15.849Z', '2023-05-30T01:08:16.134Z', '2023-05-30T01:08:17.276Z', '2023-05-30T01:08:17.465Z', '2023-05-30T01:08:31.034Z', '2023-05-30T01:08:31.255Z', '2023-05-30T01:08:31.950Z', '2023-05-30T01:08:32.698Z', '2023-05-30T01:08:32.707Z', '2023-05-30T01:08:33.000Z', '2023-05-30T01:08:33.498Z', '2023-05-30T01:08:47.768Z', '2023-05-30T01:08:48.589Z', '2023-05-30T01:08:48.672Z', '2023-05-30T01:08:48.706Z', '2023-05-30T01:08:48.764Z', '2023-05-30T01:08:49.030Z', '2023-05-30T01:08:49.337Z', '2023-05-30T01:08:50.873Z', '2023-05-30T01:08:51.111Z', '2023-05-30T01:08:51.884Z', '2023-05-30T01:08:52.086Z', '2023-05-30T01:08:52.379Z', '2023-05-30T01:08:53.159Z', '2023-05-30T01:08:53.461Z', '2023-05-30T01:08:54.421Z', '2023-05-30T01:08:55.061Z', '2023-05-30T01:08:55.069Z', '2023-05-30T01:08:55.095Z', '2023-05-30T01:08:55.373Z', '2023-05-30T01:08:56.071Z', '2023-05-30T01:08:56.078Z', '2023-05-30T01:09:00.474Z', '2023-05-30T01:09:00.751Z', '2023-05-30T01:09:07.334Z', '2023-05-30T01:09:07.786Z', '2023-05-30T01:09:07.927Z', '2023-05-30T01:09:08.246Z', '2023-05-30T01:09:08.729Z', '2023-05-30T01:09:09.052Z', '2023-05-30T01:09:09.841Z', '2023-05-30T01:09:10.406Z', '2023-05-30T01:09:10.412Z', '2023-05-30T01:09:14.074Z', '2023-05-30T01:09:14.083Z', '2023-05-30T01:09:14.232Z', '2023-05-30T01:09:14.446Z', '2023-05-30T01:09:14.584Z', '2023-05-30T01:09:14.776Z', '2023-05-30T01:09:15.037Z', '2023-05-30T01:09:15.563Z', '2023-05-30T01:09:16.415Z', '2023-05-30T01:09:16.785Z', '2023-05-30T01:09:17.096Z', '2023-05-30T01:09:17.529Z', '2023-05-30T01:09:18.015Z', '2023-05-30T01:09:18.652Z', '2023-05-30T01:09:19.108Z', '2023-05-30T01:09:19.324Z', '2023-05-30T01:09:20.666Z', '2023-05-30T01:09:22.189Z', '2023-05-30T01:09:22.218Z', '2023-05-30T01:09:22.931Z', '2023-05-30T01:09:23.610Z', '2023-05-30T01:09:23.837Z', '2023-05-30T01:09:24.106Z', '2023-05-30T01:09:24.794Z', '2023-05-30T01:09:24.805Z', '2023-05-30T01:09:25.161Z', '2023-05-30T01:09:25.504Z', '2023-05-30T01:09:27.065Z', '2023-05-30T01:09:28.838Z', '2023-05-30T01:09:29.147Z', '2023-05-30T01:09:29.425Z', '2023-05-30T01:09:29.591Z', '2023-05-30T01:09:29.893Z', '2023-05-30T01:09:30.507Z', '2023-05-30T01:09:31.418Z', '2023-05-30T01:09:32.180Z', '2023-05-30T01:09:32.900Z', '2023-05-30T01:09:33.389Z', '2023-05-30T01:09:34.170Z', '2023-05-30T01:09:34.480Z', '2023-05-30T01:09:35.129Z', '2023-05-30T01:09:35.386Z', '2023-05-30T01:09:50.924Z', '2023-05-30T01:09:51.290Z', '2023-05-30T01:09:56.322Z', '2023-05-30T01:09:57.066Z', '2023-05-30T01:09:57.116Z', '2023-05-30T01:09:57.126Z', '2023-05-30T01:10:01.403Z', '2023-05-30T01:10:01.968Z', '2023-05-30T01:10:01.980Z', '2023-05-30T01:10:01.993Z', '2023-05-30T01:10:02.015Z', '2023-05-30T01:10:02.046Z', '2023-05-30T01:10:02.121Z', '2023-05-30T01:10:02.133Z', '2023-05-30T01:10:02.279Z', '2023-05-30T01:10:02.329Z', '2023-05-30T01:10:02.358Z', '2023-05-30T01:10:02.368Z', '2023-05-30T01:10:02.382Z', '2023-05-30T01:10:02.392Z', '2023-05-30T01:10:02.403Z', '2023-05-30T01:10:02.414Z', '2023-05-30T01:10:02.554Z', '2023-05-30T01:10:02.563Z', '2023-05-30T01:10:02.579Z', '2023-05-30T01:10:02.590Z', '2023-05-30T01:10:02.613Z', '2023-05-30T01:10:02.622Z', '2023-05-30T01:10:02.643Z', '2023-05-30T01:10:02.702Z', '2023-05-30T01:10:02.713Z', '2023-05-30T01:10:02.890Z', '2023-05-30T01:10:02.901Z', '2023-05-30T01:10:03.083Z', '2023-05-30T01:10:03.149Z', '2023-05-30T01:10:03.163Z', '2023-05-30T01:10:03.184Z', '2023-05-30T01:10:03.198Z', '2023-05-30T01:10:03.214Z', '2023-05-30T01:10:03.229Z', '2023-05-30T01:10:03.244Z', '2023-05-30T01:10:03.255Z', '2023-05-30T01:10:03.267Z', '2023-05-30T01:10:03.278Z', '2023-05-30T01:10:03.304Z', '2023-05-30T01:10:03.320Z', '2023-05-30T01:10:03.342Z', '2023-05-30T01:10:03.356Z', '2023-05-30T01:10:03.367Z', '2023-05-30T01:10:03.378Z', '2023-05-30T01:10:03.396Z', '2023-05-30T01:10:03.423Z', '2023-05-30T01:10:03.461Z', '2023-05-30T01:10:03.495Z', '2023-05-30T01:10:03.524Z', '2023-05-30T01:10:03.553Z', '2023-05-30T01:10:03.592Z', '2023-05-30T01:10:03.635Z', '2023-05-30T01:10:03.756Z', '2023-05-30T01:10:03.767Z', '2023-05-30T01:10:03.791Z', '2023-05-30T01:10:03.801Z', '2023-05-30T01:10:03.813Z', '2023-05-30T01:10:03.823Z', '2023-05-30T01:10:03.883Z', '2023-05-30T01:10:03.950Z', '2023-05-30T01:10:03.965Z', '2023-05-30T01:10:03.977Z', '2023-05-30T01:10:03.993Z', '2023-05-30T01:10:04.013Z', '2023-05-30T01:10:04.050Z', '2023-05-30T01:10:04.086Z', '2023-05-30T01:10:04.178Z', '2023-05-30T01:10:04.201Z', '2023-05-30T01:10:04.946Z', '2023-05-30T01:10:05.260Z', '2023-05-30T01:10:06.586Z', '2023-05-30T01:10:07.065Z', '2023-05-30T01:10:07.945Z', '2023-05-30T01:10:08.451Z', '2023-05-30T01:10:08.479Z', '2023-05-30T01:10:08.519Z', '2023-05-30T01:10:08.549Z', '2023-05-30T01:10:08.600Z', '2023-05-30T01:10:08.613Z', '2023-05-30T01:10:08.644Z', '2023-05-30T01:10:08.679Z', '2023-05-30T01:10:08.710Z', '2023-05-30T01:10:08.742Z', '2023-05-30T01:10:08.776Z', '2023-05-30T01:10:08.809Z', '2023-05-30T01:10:08.863Z', '2023-05-30T01:10:08.903Z', '2023-05-30T01:10:08.965Z', '2023-05-30T01:10:09.015Z', '2023-05-30T01:10:09.028Z', '2023-05-30T01:10:09.041Z', '2023-05-30T01:10:09.054Z', '2023-05-30T01:10:09.078Z', '2023-05-30T01:10:09.111Z', '2023-05-30T01:10:09.148Z', '2023-05-30T01:10:09.174Z', '2023-05-30T01:10:09.205Z', '2023-05-30T01:10:09.237Z', '2023-05-30T01:10:09.269Z', '2023-05-30T01:10:09.314Z', '2023-05-30T01:10:09.339Z', '2023-05-30T01:10:09.374Z', '2023-05-30T01:10:09.400Z', '2023-05-30T01:10:09.437Z', '2023-05-30T01:10:09.468Z', '2023-05-30T01:10:09.501Z', '2023-05-30T01:10:09.547Z', '2023-05-30T01:10:09.569Z', '2023-05-30T01:10:09.608Z', '2023-05-30T01:10:09.675Z', '2023-05-30T01:10:09.699Z', '2023-05-30T01:10:09.731Z', '2023-05-30T01:10:09.764Z', '2023-05-30T01:10:09.804Z', '2023-05-30T01:10:09.840Z', '2023-05-30T01:10:09.878Z', '2023-05-30T01:10:09.910Z', '2023-05-30T01:10:09.934Z', '2023-05-30T01:10:09.970Z', '2023-05-30T01:10:10.015Z', '2023-05-30T01:10:10.038Z', '2023-05-30T01:10:10.063Z', '2023-05-30T01:10:10.108Z', '2023-05-30T01:10:10.162Z', '2023-05-30T01:10:10.176Z', '2023-05-30T01:10:10.274Z', '2023-05-30T01:10:10.293Z', '2023-05-30T01:10:10.306Z', '2023-05-30T01:10:10.319Z', '2023-05-30T01:10:10.335Z', '2023-05-30T01:10:10.442Z', '2023-05-30T01:10:10.459Z', '2023-05-30T01:10:10.471Z', '2023-05-30T01:10:10.484Z', '2023-05-30T01:10:10.501Z', '2023-05-30T01:10:10.539Z', '2023-05-30T01:10:10.639Z', '2023-05-30T01:10:10.659Z', '2023-05-30T01:10:10.682Z', '2023-05-30T01:10:10.697Z', '2023-05-30T01:10:10.716Z', '2023-05-30T01:10:10.735Z', '2023-05-30T01:10:10.756Z', '2023-05-30T01:10:10.790Z', '2023-05-30T01:10:10.830Z', '2023-05-30T01:10:10.868Z', '2023-05-30T01:10:10.892Z', '2023-05-30T01:10:10.919Z', '2023-05-30T01:10:10.955Z', '2023-05-30T01:10:10.987Z', '2023-05-30T01:10:11.021Z', '2023-05-30T01:10:11.073Z', '2023-05-30T01:10:11.089Z', '2023-05-30T01:10:11.123Z', '2023-05-30T01:10:11.151Z', '2023-05-30T01:10:11.224Z', '2023-05-30T01:10:11.283Z', '2023-05-30T01:10:11.296Z', '2023-05-30T01:10:11.309Z', '2023-05-30T01:10:11.333Z', '2023-05-30T01:10:11.352Z', '2023-05-30T01:10:11.398Z', '2023-05-30T01:10:11.419Z', '2023-05-30T01:10:11.494Z', '2023-05-30T01:10:11.507Z', '2023-05-30T01:10:11.527Z', '2023-05-30T01:10:11.627Z', '2023-05-30T01:10:11.643Z', '2023-05-30T01:10:11.676Z', '2023-05-30T01:10:11.689Z', '2023-05-30T01:10:11.703Z', '2023-05-30T01:10:11.816Z', '2023-05-30T01:10:11.830Z', '2023-05-30T01:10:11.846Z', '2023-05-30T01:10:11.861Z', '2023-05-30T01:10:11.874Z', '2023-05-30T01:10:11.901Z', '2023-05-30T01:10:11.939Z', '2023-05-30T01:10:11.952Z', '2023-05-30T01:10:12.004Z', '2023-05-30T01:10:12.063Z', '2023-05-30T01:10:12.082Z', '2023-05-30T01:10:12.122Z', '2023-05-30T01:10:12.136Z', '2023-05-30T01:10:12.152Z', '2023-05-30T01:10:12.219Z', '2023-05-30T01:10:12.237Z', '2023-05-30T01:10:12.256Z', '2023-05-30T01:10:12.281Z', '2023-05-30T01:10:12.330Z', '2023-05-30T01:10:12.349Z', '2023-05-30T01:10:12.421Z', '2023-05-30T01:10:12.436Z', '2023-05-30T01:10:12.530Z', '2023-05-30T01:10:12.552Z', '2023-05-30T01:10:12.573Z', '2023-05-30T01:10:12.614Z', '2023-05-30T01:10:12.630Z', '2023-05-30T01:10:12.656Z', '2023-05-30T01:10:12.673Z', '2023-05-30T01:10:12.702Z', '2023-05-30T01:10:12.724Z', '2023-05-30T01:10:12.739Z', '2023-05-30T01:10:12.769Z', '2023-05-30T01:10:12.816Z', '2023-05-30T01:10:12.857Z', '2023-05-30T01:10:12.878Z', '2023-05-30T01:10:12.908Z', '2023-05-30T01:10:12.935Z', '2023-05-30T01:10:12.971Z', '2023-05-30T01:10:13.122Z', '2023-05-30T01:10:13.242Z', '2023-05-30T01:10:13.263Z', '2023-05-30T01:10:13.278Z', '2023-05-30T01:10:13.297Z', '2023-05-30T01:10:13.315Z', '2023-05-30T01:10:13.334Z', '2023-05-30T01:10:13.364Z', '2023-05-30T01:10:13.389Z', '2023-05-30T01:10:13.437Z', '2023-05-30T01:10:13.517Z', '2023-05-30T01:10:13.547Z', '2023-05-30T01:10:13.573Z', '2023-05-30T01:10:13.602Z', '2023-05-30T01:10:13.621Z', '2023-05-30T01:10:13.648Z', '2023-05-30T01:10:13.669Z', '2023-05-30T01:10:13.694Z', '2023-05-30T01:10:13.782Z', '2023-05-30T01:10:13.798Z', '2023-05-30T01:10:13.819Z', '2023-05-30T01:10:13.840Z', '2023-05-30T01:10:13.859Z', '2023-05-30T01:10:13.878Z', '2023-05-30T01:10:13.898Z', '2023-05-30T01:10:13.932Z', '2023-05-30T01:10:13.949Z', '2023-05-30T01:10:13.964Z', '2023-05-30T01:10:13.984Z', '2023-05-30T01:10:14.058Z', '2023-05-30T01:10:14.092Z', '2023-05-30T01:10:14.115Z', '2023-05-30T01:10:14.132Z', '2023-05-30T01:10:14.175Z', '2023-05-30T01:10:14.199Z', '2023-05-30T01:10:14.265Z', '2023-05-30T01:10:14.286Z', '2023-05-30T01:10:14.313Z', '2023-05-30T01:10:14.332Z', '2023-05-30T01:10:14.355Z', '2023-05-30T01:10:14.380Z', '2023-05-30T01:10:14.447Z', '2023-05-30T01:10:14.465Z', '2023-05-30T01:10:14.482Z', '2023-05-30T01:10:14.502Z', '2023-05-30T01:10:14.523Z', '2023-05-30T01:10:14.542Z', '2023-05-30T01:10:14.559Z', '2023-05-30T01:10:14.596Z', '2023-05-30T01:10:14.688Z', '2023-05-30T01:10:14.704Z', '2023-05-30T01:10:14.765Z', '2023-05-30T01:10:15.268Z', '2023-05-30T01:10:15.298Z', '2023-05-30T01:10:15.329Z', '2023-05-30T01:10:15.405Z', '2023-05-30T01:10:15.447Z', '2023-05-30T01:10:15.468Z', '2023-05-30T01:10:15.642Z', '2023-05-30T01:10:15.884Z', '2023-05-30T01:10:16.100Z', '2023-05-30T01:10:16.282Z', '2023-05-30T01:10:16.505Z', '2023-05-30T01:10:16.720Z', '2023-05-30T01:10:16.924Z', '2023-05-30T01:10:17.136Z', '2023-05-30T01:10:17.369Z', '2023-05-30T01:10:17.592Z', '2023-05-30T01:10:17.816Z', '2023-05-30T01:10:18.044Z', '2023-05-30T01:10:18.440Z', '2023-05-30T01:10:18.846Z', '2023-05-30T01:10:18.870Z', '2023-05-30T01:10:19.005Z', '2023-05-30T01:10:19.242Z', '2023-05-30T01:10:19.894Z', '2023-05-30T01:10:19.927Z', '2023-05-30T01:10:19.970Z', '2023-05-30T01:10:20.219Z', '2023-05-30T01:10:20.410Z', '2023-05-30T01:10:20.966Z', '2023-05-30T01:10:20.990Z', '2023-05-30T01:10:21.250Z', '2023-05-30T01:10:21.394Z', '2023-05-30T01:10:21.593Z', '2023-05-30T01:10:21.834Z', '2023-05-30T01:10:22.047Z', '2023-05-30T01:10:22.283Z', '2023-05-30T01:10:22.522Z', '2023-05-30T01:10:22.755Z', '2023-05-30T01:10:23.021Z', '2023-05-30T01:10:23.231Z', '2023-05-30T01:10:23.899Z', '2023-05-30T01:10:24.206Z', '2023-05-30T01:10:39.371Z', '2023-05-30T01:10:39.746Z', '2023-05-30T01:10:44.411Z', '2023-05-30T01:10:45.161Z', '2023-05-30T01:10:45.191Z']","it is a medical realated information most importan information so i  tols my other friends share the information hai john do you no thatMyocardial Infarction and Death from Cardiovascular Causes

Rosiglitazone is widely used to treat patients with type 2 diabetes mellitus, but its effect on cardiovascular morbidity and mortality has not been determined.

We conducted searches of the published literature, the Web site of the Food and Drug Administration, and a clinical-trials registry maintained by the drug manufacturer (GlaxoSmithKline). Criteria for inclusion in our meta-analysis included a study duration of more than 24 weeks, the use of a randomized control group not receiving rosiglitazone, and the availability of outcome data for myocardial infarction and death from cardiovascular causes. Of 116 potentially relevant studies, 42 trials met the inclusion criteria. We tabulated all occurrences of myocardial infarction and death from cardiovascular causes.

Data were combined by means of a fixed-effects model. In the 42 trials, the mean age of the subjects was approximately 56 years, and the mean baseline glycated hemoglobin level was approximately 8.2%. In the rosiglitazone group, as compared with the control group, the odds ratio for myocardial infarction was 1.43 (95% confidence interval (CI), 1.03 to 1.98; P = 0.03), and the odds ratio for death from cardiovascular causes was 1.64 (95% CI, 0.98 to 2.74; P = 0.06).

Rosiglitazone was associated with a significant increase in the risk of myocardial infarction and with an increase in the risk of death from cardiovascular causes that had borderline significance. Our study was limited by a lack of access to original source data, which would have enabled time-to-event analysis. Despite these limitations, patients and providers should consider the potential for serious adverse cardiovascular effects of treatment with rosiglitazone for type 2 diabetes.",True
3MIVREZQVHJS8RMP6KPVWV1YOEBQKZ,"Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Rosiglitazone is widely used to treat patients with type 2 diabetes mellitus, but its effect on cardiovascular morbidity and mortality has not been determined.

We conducted searches of the published literature, the Web site of the Food and Drug Administration, and a clinical-trials registry maintained by the drug manufacturer (GlaxoSmithKline). Criteria for inclusion in our meta-analysis included a study duration of more than 24 weeks, the use of a randomized control group not receiving rosiglitazone, and the availability of outcome data for myocardial infarction and death from cardiovascular causes. Of 116 potentially relevant studies, 42 trials met the inclusion criteria. We tabulated all occurrences of myocardial infarction and death from cardiovascular causes.

Data were combined by means of a fixed-effects model. In the 42 trials, the mean age of the subjects was approximately 56 years, and the mean baseline glycated hemoglobin level was approximately 8.2%. In the rosiglitazone group, as compared with the control group, the odds ratio for myocardial infarction was 1.43 (95% confidence interval (CI), 1.03 to 1.98; P = 0.03), and the odds ratio for death from cardiovascular causes was 1.64 (95% CI, 0.98 to 2.74; P = 0.06).

Rosiglitazone was associated with a significant increase in the risk of myocardial infarction and with an increase in the risk of death from cardiovascular causes that had borderline significance. Our study was limited by a lack of access to original source data, which would have enabled time-to-event analysis. Despite these limitations, patients and providers should consider the potential for serious adverse cardiovascular effects of treatment with rosiglitazone for type 2 diabetes.
",Enter Shift Backspace Backspace Backspace Shift Shift h a s b e e n f o u n d t o p r o d u c e a n i n c r e a d Backspace e d Backspace Backspace s e d r i s k o f h e a r t a t t a c k a n d d e a t h b y t h i s s t u d y . Shift T h e s t u d y w a s l i m i t e d b y n o Backspace Backspace l a c k o f a c c e s s Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace d i r e c t a c c e s s t o m e d i c a l r e c o r d s w h i c h c o u l d h a v e i m p r o v e d t h e a c c u r a c y o f t h e r e s u l t s . ArrowUp ArrowUp ArrowDown ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowLeft ArrowRight f o r p a t i e n t s w i t h Shift T y p e Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift I I Shift D i a b e t e s Control Control c Control v,"['2023-05-29T18:19:45.898Z', '2023-05-29T18:19:45.922Z', '2023-05-29T18:19:46.554Z', '2023-05-29T18:19:46.754Z', '2023-05-29T18:19:46.946Z', '2023-05-29T18:20:08.773Z', '2023-05-29T18:39:08.394Z', '2023-05-29T18:39:09.106Z', '2023-05-29T18:39:13.387Z', '2023-05-29T18:39:13.555Z', '2023-05-29T18:39:13.787Z', '2023-05-29T18:39:13.923Z', '2023-05-29T18:39:14.139Z', '2023-05-29T18:39:14.267Z', '2023-05-29T18:39:14.467Z', '2023-05-29T18:39:14.627Z', '2023-05-29T18:39:14.827Z', '2023-05-29T18:39:15.091Z', '2023-05-29T18:39:15.243Z', '2023-05-29T18:39:15.475Z', '2023-05-29T18:39:15.691Z', '2023-05-29T18:39:15.875Z', '2023-05-29T18:39:16.051Z', '2023-05-29T18:39:16.283Z', '2023-05-29T18:39:16.451Z', '2023-05-29T18:39:16.659Z', '2023-05-29T18:39:17.995Z', '2023-05-29T18:39:18.227Z', '2023-05-29T18:39:18.427Z', '2023-05-29T18:39:18.603Z', '2023-05-29T18:39:18.859Z', '2023-05-29T18:39:19.011Z', '2023-05-29T18:39:19.299Z', '2023-05-29T18:39:19.483Z', '2023-05-29T18:39:19.700Z', '2023-05-29T18:39:19.851Z', '2023-05-29T18:39:20.059Z', '2023-05-29T18:39:20.283Z', '2023-05-29T18:39:20.523Z', '2023-05-29T18:39:20.691Z', '2023-05-29T18:39:20.931Z', '2023-05-29T18:39:21.131Z', '2023-05-29T18:39:21.667Z', '2023-05-29T18:39:22.011Z', '2023-05-29T18:39:22.443Z', '2023-05-29T18:39:22.668Z', '2023-05-29T18:39:22.900Z', '2023-05-29T18:39:23.540Z', '2023-05-29T18:39:24.500Z', '2023-05-29T18:39:25.340Z', '2023-05-29T18:39:25.572Z', '2023-05-29T18:39:25.780Z', '2023-05-29T18:39:26.012Z', '2023-05-29T18:39:27.436Z', '2023-05-29T18:39:27.628Z', '2023-05-29T18:39:27.924Z', '2023-05-29T18:39:28.708Z', '2023-05-29T18:39:28.924Z', '2023-05-29T18:39:29.100Z', '2023-05-29T18:39:29.268Z', '2023-05-29T18:39:29.412Z', '2023-05-29T18:39:29.644Z', '2023-05-29T18:39:29.756Z', '2023-05-29T18:39:30.012Z', '2023-05-29T18:39:30.252Z', '2023-05-29T18:39:30.484Z', '2023-05-29T18:39:30.748Z', '2023-05-29T18:39:30.948Z', '2023-05-29T18:39:31.148Z', '2023-05-29T18:39:31.357Z', '2023-05-29T18:39:31.517Z', '2023-05-29T18:39:31.797Z', '2023-05-29T18:39:32.021Z', '2023-05-29T18:39:32.205Z', '2023-05-29T18:39:32.373Z', '2023-05-29T18:39:32.557Z', '2023-05-29T18:39:32.765Z', '2023-05-29T18:39:32.973Z', '2023-05-29T18:39:33.141Z', '2023-05-29T18:39:33.373Z', '2023-05-29T18:39:33.661Z', '2023-05-29T18:39:34.005Z', '2023-05-29T18:39:34.189Z', '2023-05-29T18:39:34.493Z', '2023-05-29T18:39:36.893Z', '2023-05-29T18:39:37.125Z', '2023-05-29T18:39:37.333Z', '2023-05-29T18:39:37.517Z', '2023-05-29T18:39:37.645Z', '2023-05-29T18:39:37.861Z', '2023-05-29T18:39:38.013Z', '2023-05-29T18:39:38.173Z', '2023-05-29T18:39:38.317Z', '2023-05-29T18:39:38.589Z', '2023-05-29T18:39:38.798Z', '2023-05-29T18:39:39.325Z', '2023-05-29T18:39:39.517Z', '2023-05-29T18:39:40.262Z', '2023-05-29T18:39:40.502Z', '2023-05-29T18:39:40.758Z', '2023-05-29T18:39:40.942Z', '2023-05-29T18:39:41.238Z', '2023-05-29T18:39:41.398Z', '2023-05-29T18:39:41.678Z', '2023-05-29T18:39:44.534Z', '2023-05-29T18:39:44.902Z', '2023-05-29T18:39:45.166Z', '2023-05-29T18:39:45.462Z', '2023-05-29T18:39:45.710Z', '2023-05-29T18:39:45.950Z', '2023-05-29T18:39:46.134Z', '2023-05-29T18:39:46.431Z', '2023-05-29T18:39:46.686Z', '2023-05-29T18:39:47.014Z', '2023-05-29T18:39:47.294Z', '2023-05-29T18:39:47.526Z', '2023-05-29T18:39:47.742Z', '2023-05-29T18:39:47.958Z', '2023-05-29T18:39:48.110Z', '2023-05-29T18:39:48.366Z', '2023-05-29T18:39:48.599Z', '2023-05-29T18:39:48.766Z', '2023-05-29T18:39:48.975Z', '2023-05-29T18:39:49.158Z', '2023-05-29T18:39:49.487Z', '2023-05-29T18:39:50.071Z', '2023-05-29T18:39:50.335Z', '2023-05-29T18:39:50.863Z', '2023-05-29T18:39:51.552Z', '2023-05-29T18:39:52.639Z', '2023-05-29T18:39:52.847Z', '2023-05-29T18:39:53.159Z', '2023-05-29T18:39:53.311Z', '2023-05-29T18:39:53.527Z', '2023-05-29T18:39:53.695Z', '2023-05-29T18:39:53.855Z', '2023-05-29T18:39:54.015Z', '2023-05-29T18:39:54.175Z', '2023-05-29T18:39:54.439Z', '2023-05-29T18:39:54.623Z', '2023-05-29T18:39:54.839Z', '2023-05-29T18:39:55.111Z', '2023-05-29T18:39:55.303Z', '2023-05-29T18:39:55.559Z', '2023-05-29T18:39:56.463Z', '2023-05-29T18:39:56.767Z', '2023-05-29T18:39:56.975Z', '2023-05-29T18:39:57.183Z', '2023-05-29T18:39:57.399Z', '2023-05-29T18:39:57.615Z', '2023-05-29T18:39:57.855Z', '2023-05-29T18:39:58.079Z', '2023-05-29T18:39:59.536Z', '2023-05-29T18:39:59.952Z', '2023-05-29T18:40:00.168Z', '2023-05-29T18:40:00.304Z', '2023-05-29T18:40:00.544Z', '2023-05-29T18:40:00.792Z', '2023-05-29T18:40:01.040Z', '2023-05-29T18:40:01.232Z', '2023-05-29T18:40:01.408Z', '2023-05-29T18:40:01.680Z', '2023-05-29T18:40:01.880Z', '2023-05-29T18:40:02.120Z', '2023-05-29T18:40:02.384Z', '2023-05-29T18:40:02.576Z', '2023-05-29T18:40:02.800Z', '2023-05-29T18:40:05.544Z', '2023-05-29T18:40:05.848Z', '2023-05-29T18:40:16.866Z', '2023-05-29T18:40:17.922Z', '2023-05-29T18:40:18.098Z', '2023-05-29T18:40:18.322Z', '2023-05-29T18:40:18.530Z', '2023-05-29T18:40:18.730Z', '2023-05-29T18:40:19.002Z', '2023-05-29T18:40:19.162Z', '2023-05-29T18:40:19.370Z', '2023-05-29T18:40:19.530Z', '2023-05-29T18:40:19.762Z', '2023-05-29T18:40:20.002Z', '2023-05-29T18:40:20.146Z', '2023-05-29T18:40:20.290Z', '2023-05-29T18:40:20.498Z', '2023-05-29T18:40:20.754Z', '2023-05-29T18:40:20.938Z', '2023-05-29T18:40:21.162Z', '2023-05-29T18:40:21.306Z', '2023-05-29T18:40:21.546Z', '2023-05-29T18:40:21.738Z', '2023-05-29T18:40:21.898Z', '2023-05-29T18:40:22.114Z', '2023-05-29T18:40:22.306Z', '2023-05-29T18:40:22.450Z', '2023-05-29T18:40:22.690Z', '2023-05-29T18:40:22.922Z', '2023-05-29T18:40:23.106Z', '2023-05-29T18:40:23.218Z', '2023-05-29T18:40:23.442Z', '2023-05-29T18:40:23.602Z', '2023-05-29T18:40:23.738Z', '2023-05-29T18:40:23.954Z', '2023-05-29T18:40:24.074Z', '2023-05-29T18:40:26.146Z', '2023-05-29T18:40:26.386Z', '2023-05-29T18:40:26.667Z', '2023-05-29T18:40:26.859Z', '2023-05-29T18:40:26.987Z', '2023-05-29T18:40:27.187Z', '2023-05-29T18:40:27.467Z', '2023-05-29T18:40:28.091Z', '2023-05-29T18:40:28.323Z', '2023-05-29T18:40:28.491Z', '2023-05-29T18:40:28.659Z', '2023-05-29T18:40:28.875Z', '2023-05-29T18:40:29.035Z', '2023-05-29T18:40:33.963Z', '2023-05-29T18:40:34.331Z', '2023-05-29T18:40:34.515Z', '2023-05-29T18:40:34.699Z', '2023-05-29T18:40:34.883Z', '2023-05-29T18:40:35.300Z', '2023-05-29T18:40:35.588Z', '2023-05-29T18:40:35.884Z', '2023-05-29T18:40:36.108Z', '2023-05-29T18:40:36.332Z', '2023-05-29T18:40:36.476Z', '2023-05-29T18:40:36.636Z', '2023-05-29T18:40:36.771Z', '2023-05-29T18:40:36.940Z', '2023-05-29T18:40:37.100Z', '2023-05-29T18:40:37.268Z', '2023-05-29T18:40:37.396Z', '2023-05-29T18:40:37.628Z', '2023-05-29T18:40:37.860Z', '2023-05-29T18:40:38.868Z', '2023-05-29T18:40:39.140Z', '2023-05-29T18:40:39.308Z', '2023-05-29T18:40:39.620Z', '2023-05-29T18:40:39.788Z', '2023-05-29T18:40:39.988Z', '2023-05-29T18:40:50.733Z', '2023-05-29T18:40:51.101Z', '2023-05-29T18:40:52.885Z', '2023-05-29T18:40:53.325Z', '2023-05-29T18:40:53.832Z', '2023-05-29T18:40:53.863Z', '2023-05-29T18:40:53.895Z', '2023-05-29T18:40:53.926Z', '2023-05-29T18:40:53.973Z', '2023-05-29T18:40:54.005Z', '2023-05-29T18:40:54.037Z', '2023-05-29T18:40:54.068Z', '2023-05-29T18:40:54.100Z', '2023-05-29T18:40:54.131Z', '2023-05-29T18:40:54.161Z', '2023-05-29T18:40:54.193Z', '2023-05-29T18:40:54.225Z', '2023-05-29T18:40:54.256Z', '2023-05-29T18:40:54.288Z', '2023-05-29T18:40:54.335Z', '2023-05-29T18:40:54.367Z', '2023-05-29T18:40:54.398Z', '2023-05-29T18:40:54.430Z', '2023-05-29T18:40:54.460Z', '2023-05-29T18:40:54.493Z', '2023-05-29T18:40:54.525Z', '2023-05-29T18:40:54.555Z', '2023-05-29T18:40:54.586Z', '2023-05-29T18:40:54.632Z', '2023-05-29T18:40:54.664Z', '2023-05-29T18:40:54.695Z', '2023-05-29T18:40:54.726Z', '2023-05-29T18:40:54.758Z', '2023-05-29T18:40:54.790Z', '2023-05-29T18:40:54.821Z', '2023-05-29T18:40:54.852Z', '2023-05-29T18:40:54.883Z', '2023-05-29T18:40:54.929Z', '2023-05-29T18:40:54.959Z', '2023-05-29T18:40:54.990Z', '2023-05-29T18:40:55.022Z', '2023-05-29T18:40:55.054Z', '2023-05-29T18:40:55.087Z', '2023-05-29T18:40:55.118Z', '2023-05-29T18:40:55.149Z', '2023-05-29T18:40:55.180Z', '2023-05-29T18:40:55.212Z', '2023-05-29T18:40:55.259Z', '2023-05-29T18:40:55.290Z', '2023-05-29T18:40:55.320Z', '2023-05-29T18:40:55.351Z', '2023-05-29T18:40:55.382Z', '2023-05-29T18:40:55.413Z', '2023-05-29T18:40:55.444Z', '2023-05-29T18:40:55.490Z', '2023-05-29T18:40:55.520Z', '2023-05-29T18:40:55.550Z', '2023-05-29T18:40:55.582Z', '2023-05-29T18:40:55.611Z', '2023-05-29T18:40:55.641Z', '2023-05-29T18:40:56.517Z', '2023-05-29T18:41:02.134Z', '2023-05-29T18:41:03.822Z', '2023-05-29T18:41:04.182Z', '2023-05-29T18:41:04.334Z', '2023-05-29T18:41:04.470Z', '2023-05-29T18:41:04.670Z', '2023-05-29T18:41:04.838Z', '2023-05-29T18:41:05.182Z', '2023-05-29T18:41:05.358Z', '2023-05-29T18:41:05.566Z', '2023-05-29T18:41:05.862Z', '2023-05-29T18:41:06.190Z', '2023-05-29T18:41:06.566Z', '2023-05-29T18:41:06.751Z', '2023-05-29T18:41:06.943Z', '2023-05-29T18:41:07.119Z', '2023-05-29T18:41:07.279Z', '2023-05-29T18:41:07.415Z', '2023-05-29T18:41:07.623Z', '2023-05-29T18:41:07.839Z', '2023-05-29T18:41:07.959Z', '2023-05-29T18:41:08.191Z', '2023-05-29T18:41:08.375Z', '2023-05-29T18:41:08.583Z', '2023-05-29T18:41:08.807Z', '2023-05-29T18:41:09.223Z', '2023-05-29T18:41:09.737Z', '2023-05-29T18:41:09.767Z', '2023-05-29T18:41:09.798Z', '2023-05-29T18:41:09.828Z', '2023-05-29T18:41:09.858Z', '2023-05-29T18:41:09.888Z', '2023-05-29T18:41:09.936Z', '2023-05-29T18:41:09.967Z', '2023-05-29T18:41:09.999Z', '2023-05-29T18:41:10.031Z', '2023-05-29T18:41:10.063Z', '2023-05-29T18:41:10.098Z', '2023-05-29T18:41:10.127Z', '2023-05-29T18:41:10.158Z', '2023-05-29T18:41:10.191Z', '2023-05-29T18:41:10.221Z', '2023-05-29T18:41:10.252Z', '2023-05-29T18:41:10.256Z', '2023-05-29T18:41:10.527Z', '2023-05-29T18:41:10.920Z', '2023-05-29T18:41:11.151Z', '2023-05-29T18:41:11.295Z', '2023-05-29T18:41:11.463Z', '2023-05-29T18:41:11.759Z', '2023-05-29T18:41:12.295Z', '2023-05-29T18:41:12.455Z', '2023-05-29T18:41:12.711Z', '2023-05-29T18:41:12.975Z', '2023-05-29T18:41:13.522Z', '2023-05-29T18:41:34.906Z', '2023-05-29T18:41:35.418Z', '2023-05-29T18:41:35.442Z', '2023-05-29T18:48:27.024Z', '2023-05-29T18:48:27.520Z']",Rosiglitazone has been found to produce an increased risk of heart attack and death for patients with Type II Diabetes by this study. The study was conducted by way of meta-analysis. The study used 116 study results from 42 different trials. This data was accessed by the researchers and aligned by various comorbidities than cross-sectioned by use of the drug. Results of the study were somewhat limited by lack of direct access to patient medical records which could have improved the accuracy of the results and identified other pertinent data which might have affected the conclusions in a minor way.,True
3FCO4VKOZ4YFG9P0EZ5MY97YZRO7EZ,"Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer

Adjuvant therapy with an aromatase inhibitor improves outcomes, as compared with tamoxifen, in postmenopausal women with hormone-receptor - positive breast cancer.

In two phase 3 trials, we randomly assigned premenopausal women with hormone-receptor - positive early breast cancer to the aromatase inhibitor exemestane plus ovarian suppression or tamoxifen plus ovarian suppression for a period of 5 years. Suppression of ovarian estrogen production was achieved with the use of the gonadotropin-releasing-hormone agonist triptorelin, oophorectomy, or ovarian irradiation. The primary analysis combined data from 4690 patients in the two trials.

After a median follow-up of 68 months, disease-free survival at 5 years was 91.1% in the exemestane - ovarian suppression group and 87.3% in the tamoxifen - ovarian suppression group (hazard ratio for disease recurrence, second invasive cancer, or death, 0.72; 95% confidence interval (CI), 0.60 to 0.85; P (0.001). The rate of freedom from breast cancer at 5 years was 92.8% in the exemestane - ovarian suppression group, as compared with 88.8% in the tamoxifen - ovarian suppression group (hazard ratio for recurrence, 0.66; 95% CI, 0.55 to 0.80; P (0.001). With 194 deaths (4.1% of the patients), overall survival did not differ significantly between the two groups (hazard ratio for death in the exemestane - ovarian suppression group, 1.14; 95% CI, 0.86 to 1.51; P = 0.37). Selected adverse events of grade 3 or 4 were reported for 30.6% of the patients in the exemestane - ovarian suppression group and 29.4% of those in the tamoxifen - ovarian suppression group, with profiles similar to those for postmenopausal women.

In premenopausal women with hormone-receptor - positive early breast cancer, adjuvant treatment with exemestane plus ovarian suppression, as compared with tamoxifen plus ovarian suppression, significantly reduced recurrence.
",Control Control Control c c c Control v,"['2023-05-29T18:47:06.245Z', '2023-05-29T18:47:06.719Z', '2023-05-29T18:47:06.759Z', '2023-05-29T18:47:06.776Z', '2023-05-29T18:47:07.008Z', '2023-05-29T18:47:07.208Z', '2023-05-29T18:48:14.383Z', '2023-05-29T18:48:14.800Z']","
In this study, adjuvant therapy with exemestane plus ovarian suppression was found to be superior to tamoxifen plus ovarian suppression for premenopausal women with hormone-receptor-positive early breast cancer. After a median follow-up of 68 months, disease-free survival at 5 years was 91.1% in the exemestane - ovarian suppression group, as compared with 87.3% in the tamoxifen - ovarian suppression group. Additionally, the rate of freedom from breast cancer at 5 years was 92.8% in the exemestane - ovarian suppression group, as compared with 88.8% in the tamoxifen - ovarian suppression group. While there was no significant difference in overall survival, the study showed that premenopausal women with hormone-receptor-positive breast cancer may experience a reduced risk of recurrence by opting for exemestane plus ovarian suppression as their adjuvant therapy.",True
3FCO4VKOZ4YFG9P0EZ5MY97YZRO7EZ,"Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer

Adjuvant therapy with an aromatase inhibitor improves outcomes, as compared with tamoxifen, in postmenopausal women with hormone-receptor - positive breast cancer.

In two phase 3 trials, we randomly assigned premenopausal women with hormone-receptor - positive early breast cancer to the aromatase inhibitor exemestane plus ovarian suppression or tamoxifen plus ovarian suppression for a period of 5 years. Suppression of ovarian estrogen production was achieved with the use of the gonadotropin-releasing-hormone agonist triptorelin, oophorectomy, or ovarian irradiation. The primary analysis combined data from 4690 patients in the two trials.

After a median follow-up of 68 months, disease-free survival at 5 years was 91.1% in the exemestane - ovarian suppression group and 87.3% in the tamoxifen - ovarian suppression group (hazard ratio for disease recurrence, second invasive cancer, or death, 0.72; 95% confidence interval (CI), 0.60 to 0.85; P (0.001). The rate of freedom from breast cancer at 5 years was 92.8% in the exemestane - ovarian suppression group, as compared with 88.8% in the tamoxifen - ovarian suppression group (hazard ratio for recurrence, 0.66; 95% CI, 0.55 to 0.80; P (0.001). With 194 deaths (4.1% of the patients), overall survival did not differ significantly between the two groups (hazard ratio for death in the exemestane - ovarian suppression group, 1.14; 95% CI, 0.86 to 1.51; P = 0.37). Selected adverse events of grade 3 or 4 were reported for 30.6% of the patients in the exemestane - ovarian suppression group and 29.4% of those in the tamoxifen - ovarian suppression group, with profiles similar to those for postmenopausal women.

In premenopausal women with hormone-receptor - positive early breast cancer, adjuvant treatment with exemestane plus ovarian suppression, as compared with tamoxifen plus ovarian suppression, significantly reduced recurrence.
",g o o d,"['2023-05-29T22:19:23.068Z', '2023-05-29T22:19:23.618Z', '2023-05-29T22:19:23.819Z', '2023-05-29T22:19:24.412Z']",good,False
3FCO4VKOZ4YFG9P0EZ5MY97YZRO7EZ,"Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer

Adjuvant therapy with an aromatase inhibitor improves outcomes, as compared with tamoxifen, in postmenopausal women with hormone-receptor - positive breast cancer.

In two phase 3 trials, we randomly assigned premenopausal women with hormone-receptor - positive early breast cancer to the aromatase inhibitor exemestane plus ovarian suppression or tamoxifen plus ovarian suppression for a period of 5 years. Suppression of ovarian estrogen production was achieved with the use of the gonadotropin-releasing-hormone agonist triptorelin, oophorectomy, or ovarian irradiation. The primary analysis combined data from 4690 patients in the two trials.

After a median follow-up of 68 months, disease-free survival at 5 years was 91.1% in the exemestane - ovarian suppression group and 87.3% in the tamoxifen - ovarian suppression group (hazard ratio for disease recurrence, second invasive cancer, or death, 0.72; 95% confidence interval (CI), 0.60 to 0.85; P (0.001). The rate of freedom from breast cancer at 5 years was 92.8% in the exemestane - ovarian suppression group, as compared with 88.8% in the tamoxifen - ovarian suppression group (hazard ratio for recurrence, 0.66; 95% CI, 0.55 to 0.80; P (0.001). With 194 deaths (4.1% of the patients), overall survival did not differ significantly between the two groups (hazard ratio for death in the exemestane - ovarian suppression group, 1.14; 95% CI, 0.86 to 1.51; P = 0.37). Selected adverse events of grade 3 or 4 were reported for 30.6% of the patients in the exemestane - ovarian suppression group and 29.4% of those in the tamoxifen - ovarian suppression group, with profiles similar to those for postmenopausal women.

In premenopausal women with hormone-receptor - positive early breast cancer, adjuvant treatment with exemestane plus ovarian suppression, as compared with tamoxifen plus ovarian suppression, significantly reduced recurrence.
","Meta c Meta c c Meta v Shift I t i s Backspace Backspace Backspace r e m a i n s u n c l e a r t h e e f f e c t o f ArrowRight Backspace a Meta x Backspace , Meta v Backspace Backspace Backspace . Shift I n a c l i n c Backspace i c a l Backspace t w o p h a s e Shift I I I t r i a l s , f o Backspace Backspace t h e s t u d y i n v e s t i g a t e d Meta c Meta c Meta v . Shift T Backspace Shift T h e r e s u l t s s h o w e d t h a t Meta c Meta Meta v o v e r Meta c a Meta v .","['2023-05-29T18:28:39.047Z', '2023-05-29T18:28:39.059Z', '2023-05-29T18:28:39.886Z', '2023-05-29T18:28:40.137Z', '2023-05-29T18:28:40.324Z', '2023-05-29T18:28:41.795Z', '2023-05-29T18:28:41.923Z', '2023-05-29T18:28:43.211Z', '2023-05-29T18:28:43.394Z', '2023-05-29T18:28:43.606Z', '2023-05-29T18:28:43.727Z', '2023-05-29T18:28:43.793Z', '2023-05-29T18:28:44.010Z', '2023-05-29T18:28:44.262Z', '2023-05-29T18:28:44.600Z', '2023-05-29T18:28:44.791Z', '2023-05-29T18:28:44.925Z', '2023-05-29T18:28:45.081Z', '2023-05-29T18:28:45.156Z', '2023-05-29T18:28:45.644Z', '2023-05-29T18:28:45.795Z', '2023-05-29T18:28:45.924Z', '2023-05-29T18:28:46.084Z', '2023-05-29T18:28:46.217Z', '2023-05-29T18:28:46.300Z', '2023-05-29T18:28:46.464Z', '2023-05-29T18:28:46.675Z', '2023-05-29T18:28:46.884Z', '2023-05-29T18:28:47.444Z', '2023-05-29T18:28:47.851Z', '2023-05-29T18:28:47.975Z', '2023-05-29T18:28:48.099Z', '2023-05-29T18:28:48.279Z', '2023-05-29T18:28:48.439Z', '2023-05-29T18:28:48.592Z', '2023-05-29T18:28:48.713Z', '2023-05-29T18:28:48.807Z', '2023-05-29T18:28:49.956Z', '2023-05-29T18:28:50.194Z', '2023-05-29T18:28:50.357Z', '2023-05-29T18:28:50.464Z', '2023-05-29T18:28:50.688Z', '2023-05-29T18:28:50.868Z', '2023-05-29T18:28:51.061Z', '2023-05-29T18:28:51.249Z', '2023-05-29T18:28:51.478Z', '2023-05-29T18:28:52.164Z', '2023-05-29T18:28:52.720Z', '2023-05-29T18:28:53.154Z', '2023-05-29T18:28:54.739Z', '2023-05-29T18:29:02.093Z', '2023-05-29T18:29:02.330Z', '2023-05-29T18:29:05.480Z', '2023-05-29T18:29:06.225Z', '2023-05-29T18:29:06.346Z', '2023-05-29T18:29:06.533Z', '2023-05-29T18:29:06.677Z', '2023-05-29T18:29:12.103Z', '2023-05-29T18:29:13.896Z', '2023-05-29T18:29:14.077Z', '2023-05-29T18:29:14.861Z', '2023-05-29T18:29:44.753Z', '2023-05-29T18:29:44.980Z', '2023-05-29T18:29:45.068Z', '2023-05-29T18:29:45.260Z', '2023-05-29T18:29:45.371Z', '2023-05-29T18:29:45.492Z', '2023-05-29T18:29:45.661Z', '2023-05-29T18:29:46.046Z', '2023-05-29T18:29:46.189Z', '2023-05-29T18:29:46.417Z', '2023-05-29T18:29:46.602Z', '2023-05-29T18:29:46.797Z', '2023-05-29T18:29:47.621Z', '2023-05-29T18:29:47.869Z', '2023-05-29T18:29:48.000Z', '2023-05-29T18:29:48.168Z', '2023-05-29T18:29:48.205Z', '2023-05-29T18:29:48.326Z', '2023-05-29T18:29:54.324Z', '2023-05-29T18:29:54.894Z', '2023-05-29T18:29:55.070Z', '2023-05-29T18:29:55.196Z', '2023-05-29T18:29:56.586Z', '2023-05-29T18:29:56.828Z', '2023-05-29T18:29:56.937Z', '2023-05-29T18:29:57.091Z', '2023-05-29T18:29:57.212Z', '2023-05-29T18:29:57.477Z', '2023-05-29T18:29:57.715Z', '2023-05-29T18:29:57.843Z', '2023-05-29T18:29:57.995Z', '2023-05-29T18:29:58.169Z', '2023-05-29T18:29:58.310Z', '2023-05-29T18:29:58.556Z', '2023-05-29T18:29:58.719Z', '2023-05-29T18:29:58.858Z', '2023-05-29T18:29:59.294Z', '2023-05-29T18:30:00.367Z', '2023-05-29T18:30:00.472Z', '2023-05-29T18:30:00.620Z', '2023-05-29T18:30:01.286Z', '2023-05-29T18:30:15.642Z', '2023-05-29T18:30:15.812Z', '2023-05-29T18:30:16.204Z', '2023-05-29T18:30:16.388Z', '2023-05-29T18:30:17.035Z', '2023-05-29T18:30:17.192Z', '2023-05-29T18:30:17.316Z', '2023-05-29T18:30:17.475Z', '2023-05-29T18:30:18.406Z', '2023-05-29T18:30:18.585Z', '2023-05-29T18:30:18.801Z', '2023-05-29T18:30:18.969Z', '2023-05-29T18:30:19.070Z', '2023-05-29T18:30:19.332Z', '2023-05-29T18:30:20.692Z', '2023-05-29T18:30:20.867Z', '2023-05-29T18:30:21.010Z', '2023-05-29T18:30:21.730Z', '2023-05-29T18:30:22.301Z', '2023-05-29T18:30:23.008Z', '2023-05-29T18:30:23.069Z', '2023-05-29T18:30:23.327Z', '2023-05-29T18:30:23.494Z', '2023-05-29T18:30:23.630Z', '2023-05-29T18:30:23.750Z', '2023-05-29T18:30:23.926Z', '2023-05-29T18:30:24.030Z', '2023-05-29T18:30:31.220Z', '2023-05-29T18:30:31.373Z', '2023-05-29T18:30:31.978Z', '2023-05-29T18:30:32.266Z', '2023-05-29T18:30:36.523Z', '2023-05-29T18:30:36.615Z', '2023-05-29T18:30:49.591Z', '2023-05-29T18:30:55.023Z', '2023-05-29T18:30:55.296Z', '2023-05-29T18:30:57.956Z', '2023-05-29T18:30:58.440Z', '2023-05-29T18:31:11.735Z', '2023-05-29T18:31:12.066Z', '2023-05-29T18:31:12.271Z', '2023-05-29T18:31:12.448Z', '2023-05-29T18:31:12.612Z', '2023-05-29T18:31:12.750Z', '2023-05-29T18:31:13.055Z', '2023-05-29T18:31:13.138Z', '2023-05-29T18:31:13.320Z', '2023-05-29T18:31:13.436Z', '2023-05-29T18:31:13.577Z', '2023-05-29T18:31:13.740Z', '2023-05-29T18:31:13.953Z', '2023-05-29T18:31:14.092Z', '2023-05-29T18:31:14.291Z', '2023-05-29T18:31:14.412Z', '2023-05-29T18:31:14.528Z', '2023-05-29T18:31:14.666Z', '2023-05-29T18:31:14.780Z', '2023-05-29T18:31:15.003Z', '2023-05-29T18:31:15.121Z', '2023-05-29T18:31:15.239Z', '2023-05-29T18:31:15.361Z', '2023-05-29T18:31:15.413Z', '2023-05-29T18:31:15.512Z', '2023-05-29T18:31:15.612Z', '2023-05-29T18:31:34.894Z', '2023-05-29T18:31:35.035Z', '2023-05-29T18:31:37.953Z', '2023-05-29T18:31:38.298Z', '2023-05-29T18:31:38.507Z', '2023-05-29T18:31:40.605Z', '2023-05-29T18:31:40.890Z', '2023-05-29T18:31:41.076Z', '2023-05-29T18:31:41.251Z', '2023-05-29T18:31:41.382Z', '2023-05-29T18:31:41.542Z', '2023-05-29T18:31:47.912Z', '2023-05-29T18:31:48.056Z', '2023-05-29T18:31:51.117Z', '2023-05-29T18:31:51.619Z', '2023-05-29T18:31:51.819Z', '2023-05-29T18:31:51.918Z', '2023-05-29T18:31:53.820Z']","It remains unclear the effect of adjuvant therapy with an aromatase inhibitor in postmenopausal women with hormone-receptor - positive breast cancer, as compared with tamoxifen. Two clinical phase III trials investigated premenopausal women with hormone-receptor - positive early breast cancer to the aromatase inhibitor exemestane plus ovarian suppression or tamoxifen plus ovarian suppression for a period of 5 years. The results showed that disease-free survival at 5 years was 91.1% in the exemestane - ovarian suppression group and 87.3% in the tamoxifen - ovarian suppression group over a median follow-up of 68 months.
",False
367O8HRHKGTJ75CZDWRKKER39G74SD,"Global Sodium Consumption and Death from Cardiovascular Causes

High sodium intake increases blood pressure, a risk factor for cardiovascular disease, but the effects of sodium intake on global cardiovascular mortality are uncertain.

We collected data from surveys on sodium intake as determined by urinary excretion and diet in persons from 66 countries (accounting for 74.1% of adults throughout the world), and we used these data to quantify the global consumption of sodium according to age, sex, and country. The effects of sodium on blood pressure, according to age, race, and the presence or absence of hypertension, were calculated from data in a new meta-analysis of 107 randomized interventions, and the effects of blood pressure on cardiovascular mortality, according to age, were calculated from a meta-analysis of cohorts. Cause-specific mortality was derived from the Global Burden of Disease Study 2010. Using comparative risk assessment, we estimated the cardiovascular effects of current sodium intake, as compared with a reference intake of 2.0 g of sodium per day, according to age, sex, and country.

In 2010, the estimated mean level of global sodium consumption was 3.95 g per day, and regional mean levels ranged from 2.18 to 5.51 g per day. Globally, 1.65 million annual deaths from cardiovascular causes (95% uncertainty interval (confidence interval), 1.10 million to 2.22 million) were attributed to sodium intake above the reference level; 61.9% of these deaths occurred in men and 38.1% occurred in women. These deaths accounted for nearly 1 of every 10 deaths from cardiovascular causes (9.5%). Four of every 5 deaths (84.3%) occurred in low - and middle-income countries, and 2 of every 5 deaths (40.4%) were premature (before 70 years of age). The rate of death from cardiovascular causes associated with sodium intake above the reference level was highest in the country of Georgia and lowest in Kenya.

In this modeling study, 1.65 million deaths from cardiovascular causes that occurred in 2010 were attributed to sodium consumption above a reference level of 2.0 g per day.
",g o d Backspace o d,"['2023-05-29T22:19:05.563Z', '2023-05-29T22:19:06.128Z', '2023-05-29T22:19:07.274Z', '2023-05-29T22:19:08.585Z', '2023-05-29T22:19:09.410Z', '2023-05-29T22:19:10.283Z']",good,False
367O8HRHKGTJ75CZDWRKKER39G74SD,"Global Sodium Consumption and Death from Cardiovascular Causes

High sodium intake increases blood pressure, a risk factor for cardiovascular disease, but the effects of sodium intake on global cardiovascular mortality are uncertain.

We collected data from surveys on sodium intake as determined by urinary excretion and diet in persons from 66 countries (accounting for 74.1% of adults throughout the world), and we used these data to quantify the global consumption of sodium according to age, sex, and country. The effects of sodium on blood pressure, according to age, race, and the presence or absence of hypertension, were calculated from data in a new meta-analysis of 107 randomized interventions, and the effects of blood pressure on cardiovascular mortality, according to age, were calculated from a meta-analysis of cohorts. Cause-specific mortality was derived from the Global Burden of Disease Study 2010. Using comparative risk assessment, we estimated the cardiovascular effects of current sodium intake, as compared with a reference intake of 2.0 g of sodium per day, according to age, sex, and country.

In 2010, the estimated mean level of global sodium consumption was 3.95 g per day, and regional mean levels ranged from 2.18 to 5.51 g per day. Globally, 1.65 million annual deaths from cardiovascular causes (95% uncertainty interval (confidence interval), 1.10 million to 2.22 million) were attributed to sodium intake above the reference level; 61.9% of these deaths occurred in men and 38.1% occurred in women. These deaths accounted for nearly 1 of every 10 deaths from cardiovascular causes (9.5%). Four of every 5 deaths (84.3%) occurred in low - and middle-income countries, and 2 of every 5 deaths (40.4%) were premature (before 70 years of age). The rate of death from cardiovascular causes associated with sodium intake above the reference level was highest in the country of Georgia and lowest in Kenya.

In this modeling study, 1.65 million deaths from cardiovascular causes that occurred in 2010 were attributed to sodium consumption above a reference level of 2.0 g per day.
",Control v Backspace,"['2023-05-29T19:18:36.185Z', '2023-05-29T19:18:36.574Z', '2023-05-29T19:22:08.766Z']","High sodium intake increases blood pressure, which is a risk factor for cardiovascular disease.
A study of sodium intake and cardiovascular mortality in 66 countries found that 1.65 million deaths from cardiovascular causes in 2010 were attributed to sodium intake above a reference level of 2.0 g per day.
The majority of these deaths (84.3%) occurred in low- and middle-income countries.
The rate of death from cardiovascular causes associated with sodium intake above the reference level was highest in Georgia and lowest in Kenya.
",True
367O8HRHKGTJ75CZDWRKKER39G74SD,"Global Sodium Consumption and Death from Cardiovascular Causes

High sodium intake increases blood pressure, a risk factor for cardiovascular disease, but the effects of sodium intake on global cardiovascular mortality are uncertain.

We collected data from surveys on sodium intake as determined by urinary excretion and diet in persons from 66 countries (accounting for 74.1% of adults throughout the world), and we used these data to quantify the global consumption of sodium according to age, sex, and country. The effects of sodium on blood pressure, according to age, race, and the presence or absence of hypertension, were calculated from data in a new meta-analysis of 107 randomized interventions, and the effects of blood pressure on cardiovascular mortality, according to age, were calculated from a meta-analysis of cohorts. Cause-specific mortality was derived from the Global Burden of Disease Study 2010. Using comparative risk assessment, we estimated the cardiovascular effects of current sodium intake, as compared with a reference intake of 2.0 g of sodium per day, according to age, sex, and country.

In 2010, the estimated mean level of global sodium consumption was 3.95 g per day, and regional mean levels ranged from 2.18 to 5.51 g per day. Globally, 1.65 million annual deaths from cardiovascular causes (95% uncertainty interval (confidence interval), 1.10 million to 2.22 million) were attributed to sodium intake above the reference level; 61.9% of these deaths occurred in men and 38.1% occurred in women. These deaths accounted for nearly 1 of every 10 deaths from cardiovascular causes (9.5%). Four of every 5 deaths (84.3%) occurred in low - and middle-income countries, and 2 of every 5 deaths (40.4%) were premature (before 70 years of age). The rate of death from cardiovascular causes associated with sodium intake above the reference level was highest in the country of Georgia and lowest in Kenya.

In this modeling study, 1.65 million deaths from cardiovascular causes that occurred in 2010 were attributed to sodium consumption above a reference level of 2.0 g per day.
",Control c Control v Control c Control v Control c Alt Alt Control v Backspace Backspace Backspace Backspace Backspace,"['2023-05-29T23:32:16.638Z', '2023-05-29T23:32:16.667Z', '2023-05-29T23:32:18.612Z', '2023-05-29T23:32:18.790Z', '2023-05-29T23:32:30.735Z', '2023-05-29T23:32:30.956Z', '2023-05-29T23:32:32.417Z', '2023-05-29T23:32:32.575Z', '2023-05-29T23:32:53.921Z', '2023-05-29T23:32:54.352Z', '2023-05-29T23:32:54.525Z', '2023-05-29T23:32:55.981Z', '2023-05-29T23:32:58.775Z', '2023-05-29T23:32:58.896Z', '2023-05-29T23:33:03.977Z', '2023-05-29T23:33:06.032Z', '2023-05-29T23:33:09.026Z', '2023-05-29T23:33:09.961Z', '2023-05-29T23:33:10.584Z', '2023-05-29T23:33:11.970Z']","We collected data from surveys on sodium intake as determined by urinary excretion and diet in persons from 66 countries (accounting for 74.1% of adults throughout the world), and we used these data to quantify the global consumption of sodium according to age, sex, and country.Cause-specific mortality was derived from the Global Burden of Disease Study 2010. Using comparative risk assessment, we estimated the cardiovascular effects of current sodium intake, as compared with a reference intake of 2.0 g of sodium per day, according to age, sex, and country.Four of every 5 deaths occurred in low - and middle-income countries, and 2 of every 5 deaths  were premature .
",True
